ENZYMES WITH RUVC DOMAINS

BACKGROUND

Cas enzymes along with their associated Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) guide ribonucleic acids (RNAs) appear to be a pervasive (˜45% of bacteria, ˜84% of archaea) component of prokaryotic immune systems, serving to protect such microorganisms against non-self nucleic acids, such as infectious viruses and plasmids by CRISPR-RNA guided nucleic acid cleavage. While the deoxyribonucleic acid (DNA) elements encoding CRISPR RNA elements may be relatively conserved in structure and length, their CRISPR-associated (Cas) proteins are highly diverse, containing a wide variety of nucleic acid-interacting domains. While CRISPR DNA elements have been observed as early as 1987, the programmable endonuclease cleavage ability of CRISPR/Cas complexes has only been recognized relatively recently, leading to the use of recombinant CRISPR/Cas systems in diverse DNA manipulation and gene editing applications.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Feb. 22, 2024, is named 55921-731_301.xml and is 26,079,403 bytes in size.

SUMMARY

In some aspects, the present disclosure provides for a method of disrupting a Beta-2-Microglobulin (B2M) locus in a cell, comprising contacting to the cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the B2M locus, wherein the region of the B2M locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6387-6468. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 6305-6386. In some embodiments, the region of the B2M locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6388, 6399, 6401, 6403, 6410, 6413, 6421, 6446, and 6448.

In some aspects, the present disclosure provides for a method of editing a T Cell Receptor Alpha Constant (TRAC) locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the TRAC locus, wherein the region of the TRAC locus comprises a targeting sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6509-6548 or 6805. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 6469-6508 or 6804. In some embodiments, the region of the TRAC locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6517, 6520, and 6523.

In some aspects, the present disclosure provides for a method of disrupting a Hypoxanthine Phosphoribosyltransferase 1 (HPRT) locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the HPRT locus, wherein the region of the HPRT locus comprises a targeting sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6616-6682. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6549-6615. In some embodiments, the region of the HPRT locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6619, 6634, 6673, 6675, and 6679.

In some aspects, the present disclosure provides for a method of editing a T Cell Receptor Beta Constant 1 or T Cell Receptor Beta Constant 2 (TRBC1/2) locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the TRBC1/2 locus, wherein the region of the TRBC1/2 locus comprises a targeting sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6722-6760 or 6782-6802. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6683-6721 and 6761-6781. In some embodiments, the region of the TRBC1/2 locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6734, 6753, 6790, and 6800.

In some aspects, the present disclosure provides for a method of editing an Hydroxyacid Oxidase 1 (HAO1) locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the HAO1 locus, wherein the region of the HAO1 locus comprises a targeting sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 11802-11820. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the region of the HAO1 locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 11806, 11813, 11816, and 11819.

In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA comprises (i) a 2′-O-methyl nucleotide; (ii) a 2′-fluoro nucleotide; or (iii) a phosphorothioate bond; wherein the RNA-guided endonuclease has at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 421-431 or a variant thereof. In some embodiments, the RNA-guided endonuclease comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 421.

In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an endonuclease having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 421-431 or a variant thereof; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence, wherein the system has reduced immunogenicity when administered to a human subject compared to an equivalent system comprising a Cas9 enzyme. In some embodiments, the Cas9 enzyme is an SpCas9 enzyme. In some embodiments, the immunogenicity is antibody immunogenicity. In some embodiments, the engineered guide RNA comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of any one of SEQ ID NOs: 5466-5467 and 11160-11162. In some embodiments, the engineered nuclease has at least about 75% sequence identity at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 421 or 423 or a variant thereof.

In some aspects, the present disclosure provides for a method of editing a locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease or a nucleic acid encoding the RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the RNA-guided endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the locus; wherein the cell is a peripheral blood mononuclear cell (PBMC), a hematopoietic stem cell (HSC), or an induced pluripotent stem cell (iPSC). In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the RNA-guided endonuclease has at least about 75% sequence identity at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 421 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 6804, 6806, and 6808. In some embodiments, the nucleic acid encoding the RNA-guided endonuclease comprises a sequence comprising at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 6803 or a variant thereof. In some embodiments, the region of the locus comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 nucleotides of any one of SEQ ID NOs: 6805, 6807, and 6809.

In some aspects, the present disclosure provides for a method of editing a CD2 Molecule (CD2) locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the CD2 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 6853-6894; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to the non-degenerate nucleotides of any one of SEQ ID NOs: 6811-6852. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the RNA-guided endonuclease comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 421-431. In some embodiments, the RNA-guided endonuclease comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 421, or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to the non-degenerate nucleotides of any one of SEQ ID NOs: 6813, 6841, 6843-6847, 6852, or 6852. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 6A. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6855, 6883, 6885-6889, 6892, or 6984.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 6811-6852. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 6A.

In some aspects, the present disclosure provides for a method of editing a CD5 Molecule (CD5) locus in a cell comprising contacting to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the CD5 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotide complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID Nos: 6959-7022; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity the non-degenerate nucleotides of any one of SEQ ID NOs: 5466 or 6895-6958. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the RNA-guided endonuclease comprises an endonuclease comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 421-431 or a variant thereof. In some embodiments, the RNA-guided endonuclease comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 421. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity the non-degenerate nucleotides of any one of SEQ ID NOs: 6897, 6904, 6906, 6911, 6928, 6930, 6932, 6934, 6938, 6945, 6950, 6952, and 6958. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modification recited in any of the guide RNAs recited in Table 7A. In some embodiments, the engineered guide RNA is configured to hybridize to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6961, 6968, 6970, 6975, 6992, 6994, 6996, 6998, 7002, 7009, 7014, 7016, and 7022.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 6895-6958. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 7A.

In some aspects, the present disclosure provides for a method of editing an RNA locus in a cell, comprising contacting to the cell: (a) an RNA-guided endonuclease comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244, or a variant thereof; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the RNA locus, wherein the RNA locus does not comprise bacterial or microbial RNA. In some embodiments, the guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466 or SEQ ID NO: 5539.

In some aspects, the present disclosure provides for a method of disrupting a Fas Cell Surface Death Receptor (FAS) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the human FAS locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7057-7090; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7023-7056. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 7059, 7061, 7069, 7070, 7076, 7080, 7083, 7084, 7085, or 7088. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 7025, 7027, 7035, 7036, 7042, 7046, 7049-7051, or 7054. In some embodiments, the guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 8.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7023-7056. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 8.

In some aspects, the present disclosure provides for a method of disrupting a Programmed Cell Death 1 (PD-1) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the human PD-1 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7129-7166; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7091-7128. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 7135, 7137, 7146, 7149, 7152, 7156, 7160, 7161, 7164, 7165, or 7166. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 7097, 7099, 7108, 7111, 7114, 7118, 7122, 7123, 7126, 7127, or 7128. In some embodiments, the guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 9.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7091-7128. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 9.

In some aspects, the present disclosure provides for a method of disrupting an human Rosa26 (hRosa26) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the hRosa26 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7199-7230; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7167-7198. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 7205-7206, 7215, 7220, 7223, or 7225. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 7173, 7174, 7183, 7188, 7191, or 7193. In some embodiments, the guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 10.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7167-7198. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 10.

In some aspects, the present disclosure provides for a method of disrupting an T Cell Receptor Alpha Constant (TRAC) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the TRAC locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7235-7238, 7248-7256, 7270, or 7278-7284; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7231-7234, 7239-7247, 7269, or 7271-7277. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 1512, 1756, 11711-11713, or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5473, 5475, 11145, 11714, or 11715. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 7235-7238, 7248-7256, 7270, or 7278-7284. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 7231-7234, 7239-7244, 7269, or 7271-7277. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 11.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7231-7234, 7239-7247, 7269, or 7271-7277. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 11.

In some aspects, the present disclosure provides for a method of disrupting an Adeno-Associated Virus Integration Site 1 (AAVS1) locus in a cell, comprising introducing to the cell: (a) a class 2, type II Cas endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the AAVS1 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7261-7264 or 7267-7268; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7257-7260 or 7265-7266. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 1756 or 11711, or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5475 or 11715. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 7261-7263 or 7267-7268. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 7257-7260 or 7265-7266. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 12.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 7257-7260 or 7265-7266. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 12.

In some aspects, the present disclosure provides for a method of disrupting an Hydroxyacid Oxidase 1 (HAO-1) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the HAO-1 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11773-11793. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 11773, 11780, 11786, or 11787. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421, or a variant thereof.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a spacer sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11773-11793 and a scaffold sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 5466.

In some aspects, the present disclosure provides for a method of disrupting a human G Protein-Coupled Receptor 146 (GPR146) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the GPR146 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11406-11437; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11374-11405. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of SEQ ID NO: 11425. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to SEQ ID NO: 11393. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 15.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a spacer sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11374-11405. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 15.

In some aspects, the present disclosure provides for a method of disrupting a mouse G Protein-Coupled Receptor 146 (GPR146) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the GPR146 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11473-11507; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11438-11472. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 2242, or a variant thereof. In some embodiments, the RNA-guided endonuclease further comprises an HNH domain. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 5466. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 11482, 11488, or 11490. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to SEQ ID NO: 11447, 11453, or 11455. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 16.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a spacer sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11438-11472. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 16.

In some aspects, the present disclosure provides for a method of disrupting a T Cell Receptor Alpha Constant (TRAC) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the TRAC locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11516-11517; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11514-11515. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 11153. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 11516. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 11716, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to SEQ ID NO: 11514. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 17.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a spacer sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11514-11515. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 17.

In some aspects, the present disclosure provides for a method of disrupting an Adeno-Associated Virus Integration Site 1 (AAVS1) locus in a cell, comprising introducing to the cell: (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a region of the AAVS1 locus, wherein the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 18-22 consecutive nucleotides complementary to a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11511-11513; or wherein the engineered guide RNA comprises a nucleotide sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11508-11510. In some embodiments, the RNA-guided endonuclease is a class 2, type II Cas endonuclease. In some embodiments, the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of SEQ ID NO: 11717. In some embodiments, the engineered guide RNA comprises or is configured to hybridize to a sequence having at least 80% identity to at least 18 consecutive nucleotides of SEQ ID NO: 11511. In some embodiments, the RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 914, or a variant thereof. In some embodiments, the guide RNA comprises a sequence having at least 80% identity to SEQ ID NO: 11508. In some embodiments, the engineered guide RNA further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 17.

In some aspects, the present disclosure provides for an isolated RNA molecule comprising a spacer sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any one of SEQ ID NOs: 11508-11510. In some embodiments, the RNA molecule further comprises a pattern of nucleotide modifications recited in any of the guide RNAs recited in Table 17.

In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an endonuclease having at least at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to a PI domain of any of the Cas effector protein sequences described herein, or a variant thereof; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence, wherein the engineered guide RNA comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to non-degenerate nucleotides of any of the sgRNA sequences described herein. In some embodiments, the endonuclease further comprises a RuvCIII domain or a HNH domain having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to RuvCIII domains or HNH domains of any of the Cas effector nucleases described herein. In some embodiments, the endonuclease is configured to have selectivity for any of the PAM sequences described herein. In some embodiments, the endonuclease further comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to any of the Cas effector sequences described herein.

In some aspects, the present disclosure provides for use of any of the methods described herein for disrupting a B2M locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting a TRAC locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein for disrupting an HPRT locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein for disrupting a TRBC1/2 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting an HAO-1 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting a CD2 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting a CD5 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting a FAS locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting a PD-1 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting an hRosa26 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting an AAVS1 locus in a cell.

In some aspects, the present disclosure provides for use of any of the methods described herein or any of the RNA molecules described herein for disrupting a GPR146 locus in a cell.

In some aspects, the present disclosure provides for an engineered nuclease system, comprising: (a) an endonuclease comprising a RuvC_III domain and an HNH domain, wherein the endonuclease is derived from an uncultivated microorganism, wherein the endonuclease is a class 2, type II Cas endonuclease; and (b) an engineered guide ribonucleic acid structure configured to form a complex with the endonuclease comprising: (i) a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a tracr ribonucleic acid sequence configured to bind to the endonuclease. In some embodiments, the RuvC_III domain comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, or at least 98% sequence identity to any one of SEQ ID NOs: 1827-3637.

In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an endonuclease comprising a RuvC_III domain having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, or at least 98% sequence identity to any one of SEQ ID NOs: 1827-3637; and (b) an engineered guide ribonucleic acid structure configured to form a complex with the endonuclease comprising: (i) a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a tracr ribonucleic acid sequence configured to bind to the endonuclease.

In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an endonuclease configured to bind to a protospacer adjacent motif (PAM) sequence comprising SEQ ID NOs: 5512-5537, wherein the endonuclease is a class 2, type II Cas endonuclease; and (b) an engineered guide ribonucleic acid structure configured to form a complex with the endonuclease comprising: (i) a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a tracr ribonucleic acid sequence configured to bind to the endonuclease.

In some embodiments, the endonuclease is derived from an uncultivated microorganism. In some embodiments, the endonuclease has not been engineered to bind to a different PAM sequence. In some embodiments, the endonuclease is not a Cas9 endonuclease, a Cas14 endonuclease, a Cas12a endonuclease, a Cas12b endonuclease, a Cas 12c endonuclease, a Cas12d endonuclease, a Cas12e endonuclease, a Cas13a endonuclease, a Cas13b endonuclease, a Cas13c endonuclease, or a Cas 13d endonuclease. In some embodiments, the endonuclease has less than 80% identity to a Cas9 endonuclease. In some embodiments, the endonuclease further comprises an HNH domain. In some embodiments, the tracr ribonucleic acid sequence comprises a sequence with at least 80% sequence identity to about 60 to 90 consecutive nucleotides selected from any one of SEQ ID NOs: 5476-5511 and SEQ ID NO: 5538.

In some aspects, the present disclosure provides for an engineered nuclease system comprising, (a) an engineered guide ribonucleic acid structure comprising: (i) a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a tracr ribonucleic acid sequence configured to bind to an endonuclease, wherein the tracr ribonucleic acid sequence comprises a sequence with at least 80% sequence identity to about 60 to 90 consecutive nucleotides selected from any one of SEQ ID NOs: 5476-5511 and SEQ ID NO: 5538; and (b) a class 2, type II Cas endonuclease configured to bind to the engineered guide ribonucleic acid. In some embodiments, the endonuclease is configured to bind to a protospacer adjacent motif (PAM) sequence selected from the group comprising SEQ ID NOs: 5512-5537.

In some embodiments, the engineered guide ribonucleic acid structure comprises at least two ribonucleic acid polynucleotides. In some embodiments, the engineered guide ribonucleic acid structure comprises one ribonucleic acid polynucleotide comprising the guide ribonucleic acid sequence and the tracr ribonucleic acid sequence.

In some embodiments, the guide ribonucleic acid sequence is complementary to a prokaryotic, bacterial, archaeal, eukaryotic, fungal, plant, mammalian, or human genomic sequence. In some embodiments, the guide ribonucleic acid sequence is 15-24 nucleotides in length. In some embodiments, the endonuclease comprises one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of the endonuclease. In some embodiments, the NLS comprises a sequence selected from SEQ ID NOs: 5597-5612.

In some embodiments, the engineered nuclease system further comprises a single- or double-stranded DNA repair template comprising from 5′ to 3′: a first homology arm comprising a sequence of at least 20 nucleotides 5′ to the target deoxyribonucleic acid sequence, a synthetic DNA sequence of at least 10 nucleotides, and a second homology arm comprising a sequence of at least 20 nucleotides 3′ to the target sequence. In some embodiments, the first or second homology arm comprises a sequence of at least 40, 80, 120, 150, 200, 300, 500, or 1,000 nucleotides.

In some embodiments, the system further comprises a source of Mg2+.

In some embodiments, the endonuclease and the tracr ribonucleic acid sequence are derived from distinct bacterial species within a same phylum. In some embodiments, the endonuclease is derived from a bacterium belonging to a genus Dermabacter. In some embodiments, the endonuclease is derived from a bacterium belonging to Phylum Verrucomicrobia, Phylum Candidatus Peregrinibacteria, or Phylum Candidatus Melainabacteria. In some embodiments, the endonuclease is derived from a bacterium comprising a 16S rRNA gene having at least 90% identity to any one of SEQ ID NOs: 5592-5595.

In some embodiments, the HNH domain comprises a sequence with at least 70% or at least 80% identity to any one of SEQ ID NOs: 5638-5460. In some embodiments, the endonuclease comprises SEQ ID NOs: 1-1826 or a variant thereof having at least 55% identity thereto. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1827-1830 or SEQ ID NOs: 1827-2140.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 3638-3641 or SEQ ID NOs: 3638-3954. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5615-5632. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1-4 or SEQ ID NOs: 1-319.

In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 5461-5464, SEQ ID NOs: 5476-5479, or SEQ ID NOs: 5476-5489. In some embodiments, the guide RNA structure comprises an RNA sequence predicted to comprise a hairpin consisting of a stem and a loop, wherein the stem comprises at least 10, at least 12 or at least 14 base-paired ribonucleotides, and an asymmetric bulge within 4 base pairs of the loop.

In some embodiments, the endonuclease is configured to bind to a PAM comprising a sequence selected from the group consisting of SEQ ID NOs: 5512-5515 or SEQ ID NOs: 5527-5530.

In some embodiments: (a) the endonuclease comprises a sequence at least 70%, at least 80%, or at least 90% identical to SEQ ID NO: 1827; (b) the guide RNA structure comprises a sequence at least 70%, at least 80%, or at least 90% identical to at least one of SEQ ID NO: 5461 or SEQ ID NO: 5476; and (c) the endonuclease is configured to bind to a PAM comprising SEQ ID NO: 5512 or SEQ ID NO: 5527. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, at least 80%, or at least 90% identical to SEQ ID NO: 1828; (b) the guide RNA structure comprises a sequence at least 70%, at least 80%, or at least 90% identical to at least one of SEQ ID NO: 5462 or SEQ ID NO: 5477; and (c) the endonuclease is configured to bind to a PAM comprising SEQ ID NO: 5513 or SEQ ID NO: 5528. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, at least 80%, or at least 90% identical to SEQ ID NO: 1829; (b) the guide RNA structure comprises a sequence at least 70%, at least 80%, or at least 90% identical to at least one of SEQ ID NO: 5463 or SEQ ID NO: 5478; and (c) the endonuclease is configured to bind to a PAM comprising SEQ ID NO: 5514 or SEQ ID NO: 5529. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, at least 80%, or at least 90% identical to SEQ ID NO: 1830; (b) the guide RNA structure comprises a sequence at least 70%, at least 80%, or at least 90% identical to at least one of SEQ ID NO: 5464 or SEQ ID NO: 5479; and (c) the endonuclease is configured to bind to a PAM comprising SEQ ID NO: 5515 or SEQ ID NO: 5530.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 2141-2142 or SEQ ID NOs: 2141-2241. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 3955-3956 or SEQ ID NOs: 3955-4055. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5632-5638. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 320-321 or SEQ ID NOs: 320-420. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5465, SEQ ID NOs: 5490-5491 or SEQ ID NOs: 5490-5494. In some embodiments, the guide RNA structure comprises a tracr ribonucleic acid sequence comprising a hairpin comprising at least 8, at least 10, or at least 12 base-paired ribonucleotides. In some embodiments, the endonuclease is configured to bind to a PAM comprising a sequence selected from the group consisting of SEQ ID NOs: 5516 and SEQ ID NOs: 5531. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2141; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5490; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5531. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2142; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5465 or SEQ ID NO: 5491; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5516.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 2245-2246. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 4059-4060. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5639-5648. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 424-425. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 5498-5499 and SEQ ID NO: 5539. In some embodiments, the guide RNA structure comprises a guide ribonucleic acid sequence predicted to comprise a hairpin with an uninterrupted base-paired region comprising at least 8 nucleotides of a guide ribonucleic acid sequence and at least 8 nucleotides of a tracr ribonucleic acid sequence, and wherein the tracr ribonucleic acid sequence comprises, from 5′ to 3′, a first hairpin and a second hairpin, wherein the first hairpin has a longer stem than the second hairpin.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 2242-2244 or SEQ ID NOs: 2247-2249. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 4056-4058 and SEQ ID NOs 4061-4063. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5639-5648. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 421-423 or SEQ ID NOs: 426-428. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 5466-5467, SEQ ID NOs: 5495-5497, SEQ ID NO: 5500-5502, and SEQ ID NO: 5539. In some embodiments, the guide RNA structure comprises a guide ribonucleic acid sequence predicted to comprise a hairpin with an uninterrupted base-paired region comprising at least 8 nucleotides of a guide ribonucleic acid sequence and at least 8 nucleotides of a tracr ribonucleic acid sequence, and wherein the tracr ribonucleic acid sequence comprises, from 5′ to 3′, a first hairpin and a second hairpin, wherein the first hairpin has a longer stem than the second hairpin. In some embodiments, the endonuclease is configured to binding to a PAM comprising a sequence selected from the group consisting of SEQ ID NOs: 5517-5518 or SEQ ID NOs: 5532-5534. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2247; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5500; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5517 or SEQ ID NO: 5532. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2248; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5501; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5518 or SEQ ID NOs: 5533. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2249; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5502; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5534.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2253 or SEQ ID NOs: 2253-2481. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 4067 or SEQ ID NOs: 4067-4295. In some embodiments, the endonuclease comprises a peptide motif according to SEQ ID NO: 5649. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 432 or SEQ ID NOs: 432-660. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5468 or SEQ ID NO: 5503. In some embodiments, the endonuclease is configured to binding to a PAM comprising a sequence selected from the group consisting of SEQ ID NOs: 5519. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2253; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5468 or SEQ ID NO: 5503; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5519.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 2482-2489. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 4296-4303. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of or SEQ ID NOs: 661-668. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of or SEQ ID NOs: 2490-2498. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 4304-4312. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 669-677. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5504.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2499 or SEQ ID NOs: 2499-2750. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 4313 or SEQ ID NOs: 4313-4564. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5650-5667. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 678 or SEQ ID NOs: 678-929. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5469 or SEQ ID NO: 5505. In some embodiments, the endonuclease is configured to binding to a PAM comprising SEQ ID NOs: 5520 or SEQ ID NOs: 5535. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2499; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5469 or SEQ ID NO: 5505; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5520 or SEQ ID NO: 5535.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2751 or SEQ ID NOs: 2751-2913. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 4565 or SEQ ID NOs: 4565-4727. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5668-5678. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 930 or SEQ ID NOs: 930-1092. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5470 or SEQ ID NOs: 5506. In some embodiments, the endonuclease is configured to binding to a PAM comprising a sequence selected from the group consisting of SEQ ID NOs: 5521 or SEQ ID NOs: 5536. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2751; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5470 or SEQ ID NO: 5506; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5521 or SEQ ID NO: 5536.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2914 or SEQ ID NOs: 2914-3174. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 4728 or SEQ ID NOs: 4728-4988. In some embodiments, the endonuclease comprises at least 1, at least 2, or at least 3 peptide motifs selected from the group consisting of SEQ ID NOs: 5676-5678. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1093 or SEQ ID NOs: 1093-1353. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5471, SEQ ID NO: 5507, and SEQ ID NOs: 5540-5542. In some embodiments, the guide RNA structure comprises a tracr ribonucleic acid sequence predicted to comprise at least two hairpins comprising less than 5 base-paired ribonucleotides. In some embodiments, the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5522. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 2914; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5471 or SEQ ID NO: 5507; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5522.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 3175 or SEQ ID NOs: 3175-3330. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 4989 or SEQ ID NOs: 4989-5146. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5679-5686. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1354 or SEQ ID NOs: 1354-1511. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 5472 or SEQ ID NOs: 5508. In some embodiments, the endonuclease is configured to binding to a PAM comprising a sequence selected from the group consisting of SEQ ID NO: 5523 or SEQ ID NO: 5537. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 3175; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5472 or SEQ ID NO: 5508; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5523 or SEQ ID NO: 5537.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 3331 or SEQ ID NOs: 3331-3474. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 5147 or SEQ ID NOs: 5147-5290. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5674-5675 and SEQ ID NOs: 5687-5693. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1512 or SEQ ID NOs: 1512-1655. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5473 or SEQ ID NO: 5509. In some embodiments, the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5524. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 3331; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5473 or SEQ ID NO: 5509; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5524.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 3475 or SEQ ID NOs: 3475-3568. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5291 or SEQ ID NOs: 5291-5389. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5694-5699. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1656 or SEQ ID NOs: 1656-1755. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5474 or SEQ ID NO: 5510. In some embodiments, the endonuclease is configured to binding to a PAM comprising SEQ ID NOs: 5525. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 3475; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5474 or SEQ ID NO: 5510; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5525.

In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 3569 or SEQ ID NOs: 3569-3637. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 5390 or SEQ ID NOs: 5390-5460. In some embodiments, the endonuclease comprises at least 1, at least 2, at least 3, at least 4, or at least 5 peptide motifs selected from the group consisting of SEQ ID NOs: 5700-5717. In some embodiments, the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1756 or SEQ ID NOs: 1756-1826. In some embodiments, the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5475 or SEQ ID NOs: 5511. In some embodiments, the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5526. In some embodiments: (a) the endonuclease comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 3569; (b) the guide RNA structure comprises a sequence at least 70%, 80%, or 90% identical to SEQ ID NO: 5475 or SEQ ID NO: 5511; and (c) the endonuclease is configured to binding to a PAM comprising SEQ ID NO: 5526. In some embodiments, the sequence identity is determined by a BLASTP, CLUSTALW, MUSCLE, MAFFT, or CLUSTALW with the parameters of the Smith-Waterman homology search algorithm. In some embodiments, the sequence identity is determined by the BLASTP homology search algorithm using parameters of a wordlength (W) of 3, an expectation (E) of 10, and a BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1, and using a conditional compositional score matrix adjustment.

In some aspects, the present disclosure provides for an engineered guide ribonucleic acid polynucleotide comprising: (a) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a target sequence in a target DNA molecule; and (b) a protein-binding segment comprising two complementary stretches of nucleotides that hybridize to form a double-stranded RNA (dsRNA) duplex, wherein the two complementary stretches of nucleotides are covalently linked to one another with intervening nucleotides, and wherein the engineered guide ribonucleic acid polynucleotide is configured to forming a complex with an endonuclease comprising a RuvC_III domain having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, or at least 98% sequence identity to any one of SEQ ID NOs: 1827-3637 and targeting the complex to the target sequence of the target DNA molecule. In some embodiments, the DNA-targeting segment is positioned 5′ of both of the two complementary stretches of nucleotides.

In some embodiments: (a) the protein binding segment comprises a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, or at least 98% identity to a sequence selected from the group consisting of SEQ ID NOs: 5476-5479 or SEQ ID NOs: 5476-5489; (b) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to a sequence selected from the group consisting of (SEQ ID NOs: 5490-5491 or SEQ ID NOs: 5490-5494) and SEQ ID NO: 5538; (c) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 5498-5499; (d) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 5495-5497 and SEQ ID NOs: 5500-5502; (e) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5503; (f) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5504; (g) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NOs: 5505; (h) protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5506; (i) protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5507; (j) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5508; (k) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5509; (1) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5510; or (m) the protein binding segment comprises a sequence having at least 70%, at least 80%, or at least 90% identity to SEQ ID NO: 5511.

In some embodiments: (a) the guide ribonucleic acid polynucleotide comprises an RNA sequence comprising a hairpin comprising a stem and a loop, wherein the stem comprises at least 10, at least 12, or at least 14 base-paired ribonucleotides, and an asymmetric bulge within 4 base pairs of the loop; (b) the guide ribonucleic acid polynucleotide comprises a tracr ribonucleic acid sequence predicted to comprise a hairpin comprising at least 8, at least 10, or at least 12 base-paired ribonucleotides; (c) the guide ribonucleic acid polynucleotide comprises a guide ribonucleic acid sequence predicted to comprise a hairpin with an uninterrupted base-paired region comprising at least 8 nucleotides of a guide ribonucleic acid sequence and at least 8 nucleotides of a tracr ribonucleic acid sequence, and wherein the tracr ribonucleic acid sequence comprises, from 5′ to 3′, a first hairpin and a second hairpin, wherein the first hairpin has a longer stem than the second hairpin; or (d) the guide ribonucleic acid polynucleotide comprises a tracr ribonucleic acid sequence predicted to comprise at least two hairpins comprising less than 5 base-paired ribonucleotides.

In some aspects, the present disclosure provides for a deoxyribonucleic acid polynucleotide encoding any of the engineered guide ribonucleic acid polynucleotides described herein.

In some aspects, the present disclosure provides for a nucleic acid comprising an engineered nucleic acid sequence optimized for expression in an organism, wherein the nucleic acid encodes a class 2, type II Cas endonuclease comprising a RuvC_III domain and an HNH domain, and wherein the endonuclease is derived from an uncultivated microorganism.

In some aspects, the present disclosure provides for a nucleic acid comprising an engineered nucleic acid sequence optimized for expression in an organism, wherein the nucleic acid encodes an endonuclease comprising a RuvC_III domain having at least 70% sequence identity to any one of SEQ ID NOs: 1827-3637. In some embodiments, the endonuclease comprises an HNH domain having at least 70% or at least 80% sequence identity to any one of SEQ ID NOs: 3638-5460. In some embodiments, the endonuclease comprises SEQ ID NOs: 5572-5591 or a variant thereof having at least 70% sequence identity thereto. In some embodiments, the endonuclease comprises a sequence encoding one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of the endonuclease. In some embodiments, the NLS comprises a sequence selected from SEQ ID NOs: 5597-5612.

In some embodiments, the organism is prokaryotic, bacterial, eukaryotic, fungal, plant, mammalian, rodent, or human. In some embodiments, the organism is E. coli, and: (a) the nucleic acid sequence has at least 70%, 80%, or 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 5572-5575; (b) the nucleic acid sequence has at least 70%, 80%, or 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 5576-5577; (c) the nucleic acid sequence has at least 70%, 80%, or 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 5578-5580; (d) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5581; (e) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5582; (f) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5583; (g) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5584; (h) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5585; (i) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5586; or (j) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5587. In some embodiments, the organism is human, and: (a) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5588 or SEQ ID NO: 5589; or (b) the nucleic acid sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 5590 or SEQ ID NO: 5591.

In some aspects, the present disclosure provides for a vector comprising a nucleic acid sequence encoding a class 2, type II Cas endonuclease comprising a RuvC_III domain and an HNH domain, wherein the endonuclease is derived from an uncultivated microorganism.

In some aspects, the present disclosure provides for a vector comprising the any of the nucleic acids described herein. In some embodiments, the vector further comprises a nucleic acid encoding an engineered guide ribonucleic acid structure configured to form a complex with the endonuclease comprising: (a) a guide ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (b) a tracr ribonucleic acid sequence configured to binding to the endonuclease. In some embodiments, the vector is a plasmid, a minicircle, a CELiD, an adeno-associated virus (AAV) derived virion, or a lentivirus.

In some aspects, the present disclosure provides for a cell comprising any of the vectors described herein.

In some aspects, the present disclosure provides for a method of manufacturing an endonuclease, comprising cultivating any of the cells described herein.

In some embodiments, the class 2, type II Cas endonuclease is not a Cas9 endonuclease, a Cas14 endonuclease, a Cas12a endonuclease, a Cas12b endonuclease, a Cas 12c endonuclease, a Cas12d endonuclease, a Cas12e endonuclease, a Cas13a endonuclease, a Cas13b endonuclease, a Cas13c endonuclease, or a Cas 13d endonuclease. In some embodiments, the class 2, type II Cas endonuclease is derived from an uncultivated microorganism. In some embodiments, the double-stranded deoxyribonucleic acid polynucleotide is a eukaryotic, plant, fungal, mammalian, rodent, or human double-stranded deoxyribonucleic acid polynucleotide.

In some embodiments: (a) the PAM comprises a sequence selected from the group consisting of SEQ ID NOs: 5512-5515 and SEQ ID NOs: 5527-5530; (b) the PAM comprises SEQ ID NO: 5516 or SEQ ID NO: 5531; (c) the PAM comprises SEQ ID NO: 5539; (d) the PAM comprises SEQ ID NO: 5517 or SEQ ID NO: 5518; (e) the PAM comprises SEQ ID NO: 5519; (f) the PAM comprises SEQ ID NO: 5520 or SEQ ID NO: 5535; (g) the PAM comprises SEQ ID NO: 5521 or SEQ ID NO: 5536; (h) the PAM comprises SEQ ID NO: 5522; (i) the PAM comprises SEQ ID NO: 5523 or SEQ ID NO: 5537; (j) the PAM comprises SEQ ID NO: 5524; (k) the PAM comprises SEQ ID NO: 5525; or (1) the PAM comprises SEQ ID NO: 5526.

In some aspects, the present disclosure provides for a method of modifying a target nucleic acid locus, the method comprising delivering to the target nucleic acid locus any of the engineered nuclease systems described herein, wherein the endonuclease is configured to form a complex with the engineered guide ribonucleic acid structure, and wherein the complex is configured such that upon binding of the complex to the target nucleic acid locus, the complex modifies the target nucleic locus. In some embodiments, modifying the target nucleic acid locus comprises binding, nicking, cleaving, or marking the target nucleic acid locus. In some embodiments, the target nucleic acid locus comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). In some embodiments, the target nucleic acid comprises genomic DNA, viral DNA, viral RNA, or bacterial DNA. In some embodiments, the target nucleic acid locus is in vitro. In some embodiments, the target nucleic acid locus is within a cell. In some embodiments, the cell is a prokaryotic cell, a bacterial cell, a eukaryotic cell, a fungal cell, a plant cell, an animal cell, a mammalian cell, a rodent cell, a primate cell, or a human cell.

In some embodiments, delivering the engineered nuclease system to the target nucleic acid locus comprises delivering any of the nucleic acids described herein or any of the vectors described herein. In some embodiments, delivering the engineered nuclease system to the target nucleic acid locus comprises delivering a nucleic acid comprising an open reading frame encoding the endonuclease. In some embodiments, the nucleic acid comprises a promoter to which the open reading frame encoding the endonuclease is operably linked. In some embodiments, the engineered nuclease system to the target nucleic acid locus comprises delivering a capped mRNA containing the open reading frame encoding the endonuclease. In some embodiments, the engineered nuclease system to the target nucleic acid locus comprises delivering a translated polypeptide. In some embodiments, the engineered nuclease system to the target nucleic acid locus comprises delivering a deoxyribonucleic acid (DNA) encoding the engineered guide ribonucleic acid structure operably linked to a ribonucleic acid (RNA) pol III promoter. In some embodiments, the endonuclease induces a single-stranded break or a double-stranded break at or proximal to the target locus.

In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an endonuclease comprising a sequence having at least 75% sequence identity to any one of SEQ ID NOs: 5718-5846 or 6257; and (b) an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease comprising: (i) a ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a ribonucleic acid sequence configured to bind to said endonuclease. In some aspects, the present disclosure provides for an engineered nuclease system comprising: (a) an endonuclease configured to bind to a protospacer adjacent motif (PAM) sequence comprising SEQ ID NOs: 5847-5861 or 6258-6278, wherein said endonuclease is a class 2, type II Cas endonuclease; and (b) an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease comprising: (i) a ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a ribonucleic acid sequence configured to bind to said endonuclease. In some embodiments, said endonuclease is derived from an uncultivated microorganism. In some embodiments, said endonuclease has not been engineered to bind to a different PAM sequence. In some embodiments, said endonuclease is not a Cas9 endonuclease, a Cas14 endonuclease, a Cas12a endonuclease, a Cas12b endonuclease, a Cas 12c endonuclease, a Cas12d endonuclease, a Cas12e endonuclease, a Cas13a endonuclease, a Cas13b endonuclease, a Cas13c endonuclease, or a Cas 13d endonuclease. In some embodiments, said endonuclease has less than 80% identity to a Cas9 endonuclease. In some embodiments, said ribonucleic acid sequence comprises a sequence with at least 80% sequence identity to (a) any one of SEQ ID NOs: 5886-5887, 5891, 5893, or 5894; or (b) the non-degenerate nucleotides of any one of SEQ ID NOs: 5862-5885, 5888-5890, 5892, 5895-5896, or 6279-6301. In some aspects, the present disclosure provides for an engineered nuclease system comprising, (a) an engineered guide ribonucleic acid structure comprising: (i) a ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (ii) a ribonucleic acid sequence configured to bind to an endonuclease, wherein said ribonucleic acid sequence comprises a sequence with at least 80% sequence identity (a) any one of SEQ ID NOs: 5886-5887, 5891, 5893, or 5894; or (b) the non-degenerate nucleotides of any one of SEQ ID NOs: 5862-5885, 5888-5890, 5892, 5895-5896, or 6279-6301; and a class 2, type II Cas endonuclease configured to bind to said engineered guide ribonucleic acid. In some embodiments, endonuclease is configured to bind to a protospacer adjacent motif (PAM) sequence selected from the group comprising SEQ ID NOs: 5847-5861 or 6258-6278. In some embodiments, said guide ribonucleic acid sequence is 15-24 nucleotides in length or 19-24 nucleotides in length. In some embodiments, said endonuclease comprises one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of said endonuclease. In some embodiments, said NLS comprises a sequence selected from SEQ ID NOs: 5597-5612. In some embodiments, the system further comprises a single- or double-stranded DNA repair template comprising from 5′ to 3′: a first homology arm comprising a sequence of at least 20 nucleotides 5′ to said target deoxyribonucleic acid sequence, a synthetic DNA sequence of at least 10 nucleotides, and a second homology arm comprising a sequence of at least 20 nucleotides 3′ to said target sequence. In some embodiments, said first or second homology arm comprises a sequence of at least 40, 80, 120, 150, 200, 300, 500, or 1,000 nucleotides. In some embodiments, said sequence identity is determined by a BLASTP, CLUSTALW, MUSCLE, MAFFT, or CLUSTALW with the parameters of the Smith-Waterman homology search algorithm. In some embodiments, said sequence identity is determined by said BLASTP homology search algorithm using parameters of a wordlength (W) of 3, an expectation (E) of 10, and a BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1, and using a conditional compositional score matrix adjustment.

In some aspects, the present disclosure provides for a deoxyribonucleic acid polynucleotide encoding any of the engineered guide ribonucleic acid polynucleotides described herein.

In some aspects, the present disclosure provides for a nucleic acid comprising an engineered nucleic acid sequence optimized for expression in an organism, wherein said nucleic acid encodes an endonuclease comprising a sequence having at least 75% sequence identity to any one of SEQ ID NOs: 5718-5846 or 6257. In some embodiments, said endonuclease comprises a sequence encoding one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of said endonuclease. In some embodiments, said NLS comprises a sequence selected from SEQ ID NOs: 5597-5612. In some embodiments, said organism is prokaryotic, bacterial, eukaryotic, fungal, plant, mammalian, rodent, or human.

In some aspects, the present disclosure provides for a vector comprising any of the nucleic acids described herein. In some embodiments, the vector further comprises a nucleic acid encoding an engineered guide ribonucleic acid structure configured to form a complex with said endonuclease comprising: (a) a ribonucleic acid sequence configured to hybridize to a target deoxyribonucleic acid sequence; and (b) a ribonucleic acid sequence configured to bind to said endonuclease. In some embodiments, the vector is a plasmid, a minicircle, a CELiD, an adeno-associated virus (AAV) derived virion, or a lentivirus.

In some aspects, the present disclosure provides for a cell comprising any of the vectors described herein

In some aspects, the present disclosure provides for a method of manufacturing an endonuclease, comprising cultivating any of the cells described herein.

In some aspects, the present disclosure provides for a method for binding, cleaving, marking, or modifying a double-stranded deoxyribonucleic acid polynucleotide, comprising: contacting said double-stranded deoxyribonucleic acid polynucleotide with a class 2, type II Cas endonuclease in complex with an engineered guide ribonucleic acid structure configured to bind to said endonuclease and said double-stranded deoxyribonucleic acid polynucleotide; wherein said double-stranded deoxyribonucleic acid polynucleotide comprises a protospacer adjacent motif (PAM); and wherein said PAM comprises a sequence selected from the group consisting of SEQ ID NOs: 5847-5861 or 6258-6278. In some embodiments, said double-stranded deoxyribonucleic acid polynucleotide comprises a first strand comprising a sequence complementary to a sequence of said engineered guide ribonucleic acid structure and a second strand comprising said PAM. In some embodiments, said PAM is directly adjacent to the 3′ end of said sequence complementary to said sequence of said engineered guide ribonucleic acid structure. In some embodiments, said class 2, type II Cas endonuclease is not a Cas9 endonuclease, a Cas14 endonuclease, a Cas12a endonuclease, a Cas12b endonuclease, a Cas 12c endonuclease, a Cas12d endonuclease, a Cas12e endonuclease, a Cas13a endonuclease, a Cas13b endonuclease, a Cas13c endonuclease, or a Cas 13d endonuclease. In some embodiments, said double-stranded deoxyribonucleic acid polynucleotide is a eukaryotic, plant, fungal, mammalian, rodent, or human double-stranded deoxyribonucleic acid polynucleotide.

In some aspects, the present disclosure provides for a method of modifying a target nucleic acid locus, said method comprising delivering to said target nucleic acid locus any of the engineered nuclease systems described herein, wherein said endonuclease is configured to form a complex with said engineered guide ribonucleic acid structure, and wherein said complex is configured such that upon binding of said complex to said target nucleic acid locus, said complex modifies said target nucleic locus. In some embodiments, said target nucleic acid locus comprises binding, nicking, cleaving, or marking said target nucleic acid locus. In some embodiments, said target nucleic acid locus comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). In some embodiments, said target nucleic acid comprises genomic DNA, viral DNA, viral RNA, or bacterial DNA. In some embodiments, said target nucleic acid locus is in vitro. In some embodiments, said target nucleic acid locus is within a cell. In some embodiments, said cell is a prokaryotic cell, a bacterial cell, a eukaryotic cell, a fungal cell, a plant cell, an animal cell, a mammalian cell, a rodent cell, a primate cell, or a human cell. In some embodiments, said engineered nuclease system to said target nucleic acid locus comprises delivering any of the nucleic acids described herein or any of the vectors described herein. In some embodiments, delivering said engineered nuclease system to said target nucleic acid locus comprises delivering a nucleic acid comprising an open reading frame encoding said endonuclease. In some embodiments, said nucleic acid comprises a promoter to which said open reading frame encoding said endonuclease is operably linked. In some embodiments, delivering said engineered nuclease system to said target nucleic acid locus comprises delivering a capped mRNA containing said open reading frame encoding said endonuclease. In some embodiments, delivering said engineered nuclease system to said target nucleic acid locus comprises delivering a translated polypeptide. In some embodiments, delivering said engineered nuclease system to said target nucleic acid locus comprises delivering a deoxyribonucleic acid (DNA) encoding said engineered guide ribonucleic acid structure operably linked to a ribonucleic acid (RNA) pol III promoter. In some embodiments, said endonuclease induces a single-stranded break or a double-stranded break at or proximal to said target locus.

In some aspects, the present disclosure provides for a method of editing a TRAC locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said TRAC locus, wherein said engineered guide RNA comprises a targeting sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides of any one of SEQ ID NOs: 5950-5958 or 5959-5965. In some embodiments, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 5950-5958 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO:421. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 5959-5965 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 5953-5957. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 5960-5961 or 5963-5964.

In some aspects, the present disclosure provides for a method of editing a TRBC locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said TRBC locus, wherein said engineered guide RNA comprises a targeting sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides of any one of SEQ ID NOs: 5966-6004 or 6005-6025. In some embodiments, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 5966-6004 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 421. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6005-6025 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 5970, 5971, 5983, or 5984. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6006, 6010, 6011, or 6012.

In some aspects, the present disclosure provides for a method of editing a GR (NR3C1) locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said GR (NR3C1) locus, wherein said engineered guide RNA comprises a targeting sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides consecutive nucleotides of any one of SEQ ID NOs: 6026-6090 or 6091-6121. In some embodiments, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6026-6090 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 421. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6091-6121 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6027-6028, 6029, 6038, 6043, 6049, 6076, 6080, 6081, or 6086. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6092, 6115, or 6119.

In some aspects, the present disclosure provides for a method of editing an AAVS1 locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said AAVS1 locus, wherein said engineered guide RNA comprises a targeting sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides of any one of SEQ ID NOs: 6122-6152. In some embodiments, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6122, 6125-6126, 6128, 6131, 6133, 6136, 6141, 6143, or 6148.

In some aspects, the present disclosure provides for a method of editing an TIGIT locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said TIGIT locus, wherein said engineered guide RNA comprises a targeting sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides of any one of SEQ ID NOs: 6153-6181. In some embodiments, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some embodiments, said RNA-guided endonuclease comprises a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 66155, 6159, 616, or 6172.

In some aspects, the present disclosure provides for a method of editing an CD38 locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said CD38 locus, wherein said engineered guide RNA comprises a targeting sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides of any one of SEQ ID NOs: 6182-6248 or 6249-6256. In some embodiments, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6182-6248 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 421. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6249-6256 and said endonuclease comprises a sequence having at least 75% identity to SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6182-6183, 6189, 6191, 6208, 6210, 6211, or 6215. In some embodiments, said engineered guide RNA comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of SEQ ID NO: 6251.

In some embodiments of any of the methods for editing particular loci in cells above, said cell is a peripheral blood mononuclear cell, a T-cell, an NK cell, a hematopoietic stem cell (HSCT), or a B-cell, or any combination thereof.

In some aspects, the present disclosure provides for an engineered guide ribonucleic acid polynucleotide comprising: (a) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a target sequence in a target DNA molecule; and (b) a protein-binding segment comprising two complementary stretches of nucleotides that hybridize to form a double-stranded RNA (dsRNA) duplex, wherein said two complementary stretches of nucleotides are covalently linked to one another with intervening nucleotides, and wherein said engineered guide ribonucleic acid polynucleotide is configured to form a complex with a class 2, type II Cas endonuclease and target said complex to said target sequence of said target DNA molecule, wherein said DNA-targeting segment comprises a sequence having at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to at least 19, at least 20, at least 21, at least 22, at least 23, or at least 24 consecutive nucleotides of any one of SEQ ID NOs: 5950-5965, 5966-6025, 6026-6121, 6122-6152, 6153-6181, or 6182-6256. In some embodiments, said protein-binding segment comprises a sequence having at least 85% identity to any one of SEQ ID NOs: 5466 or 6304.

In some aspects, the present disclosure provides for a system for generating an edited immune cell, comprising: (a) an RNA-guided endonuclease; (b) an engineered guide ribonucleic acid polynucleotide according to claim 97 configured to bind said RNA-guided endonuclease; and (c) a single- or double-stranded DNA repair template comprising first and second homology arms flanking a sequence encoding a chimeric antigen receptor (CAR). In some embodiments, said cell is a peripheral blood mononuclear cell, a T-cell, an NK cell, a hematopoietic stem cell (HSCT), or a B-cell, or any combination thereof. In some aspects, said RNA-guided endonuclease is a class II, type II Cas endonuclease. In some aspects, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some aspects, said RNA-guided endonuclease further comprises an HNH domain. In some aspects, said RNA-guided endonuclease comprises a sequence having at least 75% identity, at least 80% identity, at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, or at least 100% identity to SEQ ID NO: 421 or SEQ ID NO: 423.

Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.

In some aspects, the present disclosure provides for a method of editing a B2M locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said B2M locus, wherein said region of said B2M locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6387-6468. In some embodiments, said RNA-guided endonuclease is a Cas endonuclease. In some embodiments, said Cas endonuclease is a class 2, type II Cas endonuclease. In some embodiments, said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421. In some embodiments, said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6305-6386. In some embodiments, said region of said B2M locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6388, 6399, 6401, 6403, 6410, 6413, 6421, 6446, and 6448. In some embodiments, said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6306, 6317, 6319, 6321, 6328, 6331, 6339, 6364, and 6366.

In some aspects, the present disclosure provides for a method of editing a HPRT locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said HPRT locus, wherein said region of said HPRT locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6616-6682. In some embodiments, said RNA-guided endonuclease is a Cas endonuclease. In some embodiments, said Cas endonuclease is a class 2, type II Cas endonuclease. In some embodiments, said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6549-6615. In some embodiments, said region of said HPRT locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6619, 6634, 6673, 6675, and 6679. In some embodiments, said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6552, 6567, 6606, 6608, and 6612.

In some aspects, the present disclosure provides for a method of editing a TRBC1/2 locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said TRBC1/2 locus, wherein said region of said TRBC1/2 locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6722-6760 or 6782-6802. In some embodiments, said RNA-guided endonuclease is a Cas endonuclease. In some embodiments, said Cas endonuclease is a class 2, type II Cas endonuclease. In some embodiments, said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421 or SEQ ID NO: 423. In some embodiments, said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6683-6721 and 6761-6781. In some embodiments, said region of said TRBC1/2 locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6734, 6753, 6790, and 6800. In some embodiments, said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6695, 6714, 6769, and 6779.

In some aspects, the present disclosure provides for a method of editing a HAO1 locus in a cell, comprising contacting to said cell (a) an RNA-guided endonuclease; and (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said HAO1 locus, wherein said region of said HAO1 locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 11802-11820. In some embodiments, said RNA-guided endonuclease is a Cas endonuclease. In some embodiments, said Cas endonuclease is a class 2, type II Cas endonuclease. In some embodiments, said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431. In some embodiments, said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242. In some embodiments, said RNA-guided endonuclease further comprises an HNH domain. In some embodiments, said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421. In some embodiments, said region of said HAO1 locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 11806, 11813, 11816, and 11819. In some embodiments, said cell is a peripheral blood mononuclear cell (PBMC). In some embodiments, said cell is a T-cell or a precursor thereof or a hematopoietic stem cell (HSC).

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

FIG. 1 depicts the gene editing outcomes at the DNA level for B2M.

FIG. 2A and FIG. 2B depicts the gene editing outcomes at the DNA level for mouse TRAC.

FIG. 3 depicts the gene editing outcomes at the DNA level for HPRT.

FIG. 4 depicts the flow cytometry results for gene editing of human TRBC1/2.

FIG. 5 depicts the results of a guide screen in Hepa1-6 cells; guides were delivered as mRNA and gRNA using lipofectamine Messenger Max.

FIG. 6 depicts analysis of gene-editing outcomes by NGS for mRNA electroporation in T cells.

FIG. 7 depicts ELISA results from a screen performed at a serum dilution of 1:50 to detect antibodies against MG-3-6 and MG3-8 (n=50). Tetanus toxoid was used as the positive control due to wide-spread vaccination against this antigen. Serum samples above the dashed line were considered antibody-positive; the line represents the mean absorbance of the negative control (human albumin) plus two standard deviations from the mean. *P<0.05, **P<0.01, ****P<0.0001 as determined by an unpaired Student's t-test; ns, not significant.

FIG. 8 depicts the gene editing outcomes at the DNA and cell-surface protein level for TRAC in human peripheral blood B cells.

FIG. 9 depicts the gene editing outcomes at the DNA level for TRAC in hematopoietic stem cells.

FIG. 10 depicts the gene editing outcomes at the DNA and cell-surface protein level for TRAC in induced pluripotent stem cells (iPSCs) for MG3-6 delivered as a ribonucleoprotein.

FIG. 11 depicts the gene editing outcomes at the DNA level for TRAC in induced pluripotent stem cells (iPSCs) for MG3-6 delivered as mRNA.

FIG. 12 depicts the gene editing outcomes at the DNA level for CD2 in primary T cells.

FIG. 13 depicts the gene editing outcomes at the DNA level for CD5 in primary T cells.

FIG. 14 depicts targeted RNA cleavage by MG3-6 and MG3-8.

FIG. 15 depicts the gene editing outcomes at the DNA level for FAS in T cells.

FIG. 16 depicts the gene editing outcomes at the DNA level for PD-1 in T cells.

FIG. 17 depicts the gene editing outcomes at the DNA level for hRosa26 in T cells.

FIG. 18 depicts the gene editing outcomes at the DNA level for TRAC and AAVS1 in K562 cells.

FIG. 19 depicts the activity of chemically modified MG3-6 human HAO-1 guides in Hep3B cells when delivered as mRNA and gRNA using Lipofectamine Messenger Max.

FIG. 20 depicts the gene editing outcomes at the DNA level for human GPR146 in Hep3B cells.

FIG. 21 depicts the gene editing outcomes at the DNA level for mouse GPR146 in Hepa1-6 cells.

FIG. 22 depicts the gene editing outcomes at the DNA level for mouse GPR146 in primary mouse hepatocytes.

FIG. 23 depicts the gene editing outcomes at the DNA level for TRAC and AAVS1 in K562 cells.

FIG. 24 depicts phylogenetic analysis of nucleases from the MG3 and MG150 families. PAM SeqLogo representations are shown for some active candidates. Reference SaCas9 and SpyCas9 sequences were included.

FIG. 25 depicts phylogenetic analysis of nucleases from the MG15 family. Active candidates are highlighted with circles. Reference SaCas9, SpyCas9, and AcCas9 sequences were included as outgroup.

FIG. 26 depicts SeqLogos of the PAMs for MG123-1, MG124-2, MG 125-1 and MG125-2.

FIG. 27 depicts SeqLogos of the PAMs for MG125-3, MG125-4, MG125-5, and MG150-5.

FIG. 28 depicts SeqLogos of the PAMs for MG150-6, MG150-7, MG150-8, and MG150-9.

FIG. 29 depicts SeqLogos of the PAMs for MG3-18, MG3-89, MG3-90, and MG3-91.

FIG. 30 depicts SeqLogos of the PAMs for MG3-92, MG3-93, MG3-95, and MG3-96.

FIG. 31 depicts SeqLogos of the PAMs for MG3-103, MG15-130, MG15-146, and MG15-164.

FIG. 32 depicts SeqLogos of the PAMs for MG15-166, MG15-171, MG15-172, and MG15-174.

FIG. 33 depicts SeqLogos of the PAMs for MG15-184, MG15-187, MG15-191, and MG15-193.

FIG. 34 depicts SeqLogos of the PAMs for MG15-195, MG15-217, MG15-218, and MG15-219.

FIG. 35 depicts a SeqLogo of the PAM for MG15-177.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

The Sequence Listing filed herewith provides exemplary polynucleotide and polypeptide sequences for use in methods, compositions and systems according to the disclosure. Below are exemplary descriptions of sequences therein.

MG1

SEQ ID NOs: 1-319 and 7285-7293 show the full-length peptide sequences of MG1 nucleases.

SEQ ID NOs: 1827-2140 show the peptide sequences of RuvC_III domains of MG1 nucleases above.

SEQ ID NOs: 3638-3955 show the peptide of HNH domains of MG1 nucleases above.

SEQ ID NOs: 5476-5479 show the nucleotide sequences of MG1 tracrRNAs derived from the same loci as MG1 nucleases above (e.g., same loci as SEQ ID NO:1-4, respectively).

SEQ ID NOs: 5461-5464 and 11130 show the nucleotide sequences of sgRNAs engineered to function with an MG1 nuclease (e.g., SEQ ID NO:1-4, respectively), where Ns denote nucleotides of a targeting sequence.

SEQ ID NOs: 5572-5575 show nucleotide sequences for E. coli codon-optimized coding sequences for MG1 family enzymes (SEQ ID NOs: 1-4).

SEQ ID NOs: 5588-5589 show nucleotide sequences for human codon-optimized coding sequences for MG1 family enzymes (SEQ ID NOs: 1 and 3).

SEQ ID NOs: 5616-5632 show peptide motifs characteristic of MG1 family enzymes.

SEQ ID NOs: 9192-9255 show the peptide sequences of PAM-interacting domains of MG1 nucleases.

SEQ ID NOs: 11229-11269 show the nucleotide sequences of target sites of MG1 nucleases.

MG2

SEQ ID NOs: 320-420 and 7294-7358 show the full-length peptide sequences of MG2 nucleases.

SEQ ID NOs: 2141-2241 show the peptide sequences of RuvC_III domains of MG2 nucleases above.

SEQ ID NOs: 3955-4055 show the peptide of HNH domains of MG2 nucleases above.

SEQ ID NOs: 5490-5494 and 11159 show the nucleotide sequences of MG2 tracrRNAs derived from the same loci as MG2 nucleases above (e.g., same loci as SEQ ID NOs: 320, 321, 323, 325, and 326, respectively).

SEQ ID NO: 5465 shows the nucleotide sequence of an sgRNA engineered to function with an MG2 nuclease (e.g., SEQ ID NO: 321 above).

SEQ ID NOs: 5572-5575 show nucleotide sequences for E. coli codon-optimized coding sequences for MG2 family enzymes.

SEQ ID NOs: 5631-5638 show peptide sequences characteristic of MG2 family enzymes.

SEQ ID NOs: 9256-9322 show the peptide sequences of PAM-interacting domains of MG2 nucleases.

SEQ ID NOs: 11270-11275 show the nucleotide sequences of target sites of MG2 nucleases.

MG3

SEQ ID NOs: 421-431 show the full-length peptide sequences of MG3 nucleases.

SEQ ID NO: 6803 shows the nucleotide sequence of an MG3-6 nuclease containing 5′ UTR, NLS, CDS, NLS, 3′ UTR, and polyA tail.

SEQ ID NOs: 2242-2252 show the peptide sequences of RuvC_III domains of MG3 nucleases above.

SEQ ID NOs: 4056-4066 show the peptide of HNH domains of MG3 nucleases above.

SEQ ID NOs: 5495-5502 and 11160-11162 show the nucleotide sequences of MG3 tracrRNAs derived from the same loci as MG3 nucleases above (e.g., same loci as SEQ ID NOs: 421-428, respectively).

SEQ ID NOs: 5466-5467, 11131, and 11567-11576 show the nucleotide sequences of sgRNAs engineered to function with MG3 nucleases (e.g., SEQ ID NOs: 421-423).

SEQ ID NOs: 5578-5580 show nucleotide sequences for E. coli codon-optimized coding sequences for MG3 family enzymes.

SEQ ID NOs: 5639-5648 show peptide sequences characteristic of MG3 family enzymes.

SEQ ID NOs: 9323-9329 show the peptide sequences of PAM-interacting domains of MG3 nucleases.

SEQ ID NOs: 11108 and 11530-11538 show the nucleotide sequences of single guide PAMs of MG3 nucleases.

SEQ ID NOs: 11276-11294 show the nucleotide sequences of target sites of MG1 nucleases.

SEQ ID NO: 11373 shows the nucleotide sequence of a DNA sequence encoding MG3-6 mRNA.

MG3a

SEQ ID NOs: 7369-7375 show the full-length peptide sequences of MG3a nucleases.

SEQ ID NOs: 11099 show the peptide sequences of PAM-interacting domains of MG3a nucleases.

MG3b

SEQ ID NOs: 7376-7390 show the full-length peptide sequences of MG3b nucleases.

SEQ ID NOs: 11100-11107 show the peptide sequences of PAM-interacting domains of MG3b nucleases.

MG4

SEQ ID NOs: 432-660 and 7391-7535 show the full-length peptide sequences of MG4 nucleases.

SEQ ID NOs: 2253-2481 show the peptide sequences of RuvC_III domains of MG4 nucleases above.

SEQ ID NOs: 4067-4295 show the peptide of HNH domains of MG4 nucleases above.

SEQ ID NO: 5503 shows the nucleotide sequences of an MG4 tracrRNA derived from the same loci as MG4 nucleases above.

SEQ ID NO: 5468 shows the nucleotide sequence of sgRNAs engineered to function with an MG4 nuclease.

SEQ ID NO: 5649 shows a peptide sequence characteristic of MG4 family enzymes.

SEQ ID NOs: 9330-9485 show the peptide sequences of PAM-interacting domains of MG4 nucleases.

SEQ ID NOs: 11295-11303 show the nucleotide sequences of target sites of MG4 nucleases.

MG5

SEQ ID NOs: 7536-7583 show the full-length peptide sequences of MG5 nucleases.

SEQ ID NOs: 9486-9526 show the peptide sequences of PAM-interacting domains of MG5 nucleases.

MG6

SEQ ID NOs: 661-668 and 7584-7587 show the full-length peptide sequences of MG6 nucleases.

SEQ ID NOs: 2482-2489 show the peptide sequences of RuvC_III domains of MG6 nucleases above.

SEQ ID NOs: 4296-4303 show the peptide of HNH domains of MG3 nucleases above.

SEQ ID NOs: 9527-9531 show the peptide sequences of PAM-interacting domains of MG6 nucleases.

MG7

SEQ ID NOs: 669-677 show the full-length peptide sequences of MG7 nucleases.

SEQ ID NOs: 2490-2498 show the peptide sequences of RuvC_III domains of MG7 nucleases above.

SEQ ID NOs: 4304-4312 show the peptide of HNH domains of MG3 nucleases above.

SEQ ID NO: 5504 shows the nucleotide sequence of an MG7 tracrRNA derived from the same loci as MG7 nucleases above.

SEQ ID NOs: 9532-9535 show the peptide sequences of PAM-interacting domains of MG7 nucleases.

MG14

SEQ ID NOs: 678-929 and 7588-7597 show the full-length peptide sequences of MG14 nucleases.

SEQ ID NOs: 2499-2750 show the peptide sequences of RuvC_III domains of MG14 nucleases above.

SEQ ID NOs: 4313-4564 show the peptide of HNH domains of MG14 nucleases above.

SEQ ID NOs: 5505 and 11163-11167 show nucleotide sequences of MG14 tracrRNAs derived from the same loci as MG14 nucleases above.

SEQ ID NO: 5581 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG14 family enzyme.

SEQ ID NOs: 5650-5667 show peptide sequences characteristic of MG14 family enzymes.

SEQ ID NOs: 9536-9611 show the peptide sequences of PAM-interacting domains of MG14 nucleases.

SEQ ID NOs: 11109-11113 show the nucleotide sequences of single guide PAMs of MG14 nucleases.

SEQ ID NOs: 11132-11136 shows the nucleotide sequence of sgRNAs engineered to function with an MG14 nuclease.

SEQ ID NOs: 11304-11312 show the nucleotide sequences of target sites of MG14 nucleases.

MG15

SEQ ID NOs: 930-1092, 7598-7622, and 11593-11616 show the full-length peptide sequences of MG15 nucleases.

SEQ ID NOs: 2751-2913 show the peptide sequences of RuvC_III domains of MG15 nucleases above.

SEQ ID NOs: 4565-4727 show the peptide of HNH domains of MG15 nucleases above.

SEQ ID NOs: 5506 and 11168-11172 show nucleotide sequences of MG15 tracrRNAs derived from the same loci as MG15 nucleases above.

SEQ ID NOs: 5470 and 11577-11592 show the nucleotide sequences of sgRNAs engineered to function with MG15 nucleases.

SEQ ID NO: 5582 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG15 family enzyme.

SEQ ID NOs: 5668-5675 show peptide sequences characteristic of MG15 family enzymes.

SEQ ID NOs: 9612-9671 show the peptide sequences of PAM-interacting domains of MG15 nucleases.

SEQ ID NOs: 11539-11554 show the nucleotide sequences of single guide PAMs of MG15 nucleases.

MG16

SEQ ID NOs: 1093-1353 and 7623-7698 show the full-length peptide sequences of MG16 nucleases.

SEQ ID NOs: 2914-3174 show the peptide sequences of RuvC_III domains of MG16 nucleases above.

SEQ ID NOs: 4728-4988 show the peptide of HNH domains of MG16 nucleases above.

SEQ ID NOs: 5507 and 11173-11174 show nucleotide sequences of MG16 tracrRNAs derived from the same loci as MG16 nucleases above.

SEQ ID NOs: 5471 and 11137 show nucleotide sequences of sgRNAs engineered to function with an MG16 nuclease.

SEQ ID NO: 5583 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG16 family enzyme.

SEQ ID NOs: 5676-5678 show peptide sequences characteristic of MG16 family enzymes.

SEQ ID NOs: 9672-9842 show the peptide sequences of PAM-interacting domains of MG16 nucleases.

SEQ ID NO: 11114 shows the nucleotide sequence of a single guide PAM of an MG16 nuclease.

SEQ ID NOs: 11313-11320 show the nucleotide sequences of target sites of MG16 nucleases.

MG17

SEQ ID NOs: 7699-7715 show the full-length peptide sequences of MG17 nucleases.

SEQ ID NOs: 9843-9856 show the peptide sequences of PAM-interacting domains of MG17 nucleases.

SEQ ID NO: 11115 shows the nucleotide sequence of a single guide PAM of an MG17 nuclease.

SEQ ID NO: 11138 shows the nucleotide sequence of an sgRNA engineered to function with an MG17 nuclease.

SEQ ID NO: 11175 shows the nucleotide sequence of an MG17 tracrRNA derived from the same loci as MG17 nucleases above.

MG18

SEQ ID NOs: 1354-1511 show the full-length peptide sequences of MG18 nucleases.

SEQ ID NOs: 3175-3330 show the peptide sequences of RuvC_III domains of MG18 nucleases above.

SEQ ID NOs: 4989-5146 show the peptide of HNH domains of MG18 nucleases above.

SEQ ID NO: 5508 shows the nucleotide sequences of MG18 tracrRNA derived from the same loci as MG18 nucleases above.

SEQ ID NOs: 5472 shows the nucleotide sequence of an sgRNA engineered to function with an MG18 nuclease.

SEQ ID NO: 5584 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG18 family enzyme.

SEQ ID NOs: 5679-5686 show peptide sequences characteristic of MG18 family enzymes.

SEQ ID NOs: 9857-9891 show the peptide sequences of PAM-interacting domains of MG18 nucleases.

SEQ ID NOs: 11321-11327 show the nucleotide sequences of target sites of MG18 nucleases.

MG21

SEQ ID NOs: 1512-1655 and 7716-7733 show the full-length peptide sequences of MG21 nucleases.

SEQ ID NOs: 3331-3474 show the peptide sequences of RuvC_III domains of MG21 nucleases above.

SEQ ID NOs: 5147-5290 show the peptide of HNH domains of MG21 nucleases above.

SEQ ID NOs: 5509 and 11176-11178 show nucleotide sequences of MG21 tracrRNAs derived from the same loci as MG21 nucleases above.

SEQ ID NOs: 5473 and 11139 show nucleotide sequences of sgRNAs engineered to function with an MG21 nuclease.

SEQ ID NO: 5585 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG21 family enzyme.

SEQ ID NOs: 5687-5692 and 5674-5675 show peptide sequences characteristic of MG21 family enzymes.

SEQ ID NOs: 9892-9951 show the peptide sequences of PAM-interacting domains of MG21 nucleases.

SEQ ID NO: 11116 shows the nucleotide sequence of a single guide PAM of an MG21 nuclease.

SEQ ID NOs: 11328-11336 show the nucleotide sequences of target sites of MG21 nucleases.

MG22

SEQ ID NOs: 1656-1755 show the full-length peptide sequences of MG22 nucleases.

SEQ ID NOs: 3475-3568 show the peptide sequences of RuvC_III domains of MG22 nucleases above.

SEQ ID NOs: 5291-5389 show the peptide of HNH domains of MG22 nucleases above.

SEQ ID NOs: 5510 and 11179-11180 show nucleotide sequences of MG22 tracrRNAs derived from the same loci as MG22 nucleases above.

SEQ ID NOs: 5474 shows the nucleotide sequence of an sgRNAs engineered to function with an MG22 nuclease.

SEQ ID NO: 5586 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG22 family enzyme.

SEQ ID NOs: 5694-5699 show peptide sequences characteristic of MG22 family enzymes.

SEQ ID NOs: 9952-9982 show the peptide sequences of PAM-interacting domains of MG22 nucleases.

SEQ ID NOs: 11337-11344 show the nucleotide sequences of target sites of MG22 nucleases.

MG23

SEQ ID NOs: 1756-1826 and 7734-7735 show the full-length peptide sequences of MG23 nucleases.

SEQ ID NOs: 3569-3637 show the peptide sequences of RuvC_III domains of MG23 nucleases above.

SEQ ID NOs: 5390-5460 show the peptide of HNH domains of MG23 nucleases above.

SEQ ID NOs: 5511 and 11181-11182 show nucleotide sequences of MG23 tracrRNAs derived from the same loci as MG23 nucleases above.

SEQ ID NOs: 5475 and 11140 show nucleotide sequences of sgRNAs engineered to function with an MG23 nuclease.

SEQ ID NO: 5587 shows a nucleotide sequence for an E. coli codon-optimized coding sequences for an MG23 family enzyme.

SEQ ID NOs: 5700-5717 show peptide sequences characteristic of MG23 family enzymes.

SEQ ID NOs: 9983-10004 show the peptide sequences of PAM-interacting domains of MG23 nucleases.

SEQ ID NOs: 11345-11351 show the nucleotide sequences of target sites of MG23 nucleases.

MG24

SEQ ID NOs: 7736-8027 show the full-length peptide sequences of MG24 nucleases.

SEQ ID NOs: 10005-10162 show the peptide sequences of PAM-interacting domains of MG24 nucleases.

MG25

SEQ ID NOs: 8028-8091 show the full-length peptide sequences of MG25 nucleases.

SEQ ID NOs: 10163-10211 show the peptide sequences of PAM-interacting domains of MG25 nucleases.

MG38

SEQ ID NOs: 8092-8095 show the full-length peptide sequences of MG38 nucleases.

SEQ ID NOs: 10212-10214 show the peptide sequences of PAM-interacting domains of MG38 nucleases.

MG40

SEQ ID NOs: 5718-5750 and 8096-8163 show the full-length peptide sequences of MG40 nucleases.

SEQ ID NOs: 5847-5852 show protospacer adjacent motifs associated with MG 40 nucleases.

SEQ ID NOs: 5862-5873 show the nucleotide sequence of an sgRNA engineered to function with an MG40 nuclease.

SEQ ID NOs: 10215-10263 show the peptide sequences of PAM-interacting domains of MG40 nucleases.

SEQ ID NOs: 11183-11188 show nucleotide sequences of MG40 tracrRNAs derived from the same loci as MG40 nucleases above.

MG41

SEQ ID NOs: 8164-8286 show the full-length peptide sequences of MG41 nucleases.

SEQ ID NOs: 10264-10304 show the peptide sequences of PAM-interacting domains of MG41 nucleases.

MG42

SEQ ID NOs: 8287-8356 show the full-length peptide sequences of MG42 nucleases.

SEQ ID NOs: 10305-10355 show the peptide sequences of PAM-interacting domains of MG42 nucleases.

MG43

SEQ ID NOs: 8357-8453 show the full-length peptide sequences of MG43 nucleases.

SEQ ID NOs: 10356-10412 show the peptide sequences of PAM-interacting domains of MG43 nucleases.

SEQ ID NO: 11117 shows the nucleotide sequence of a single guide PAM of an MG43 nuclease.

SEQ ID NO: 11141 shows the nucleotide sequence of an sgRNA engineered to function with an MG43 nuclease.

SEQ ID NO: 11189 shows the nucleotide sequence of an MG43 tracrRNA derived from the same loci as MG43 nucleases above.

MG44

SEQ ID NOs: 8454-8496 show the full-length peptide sequences of MG44 nucleases.

SEQ ID NOs: 10413-10555 show the peptide sequences of PAM-interacting domains of MG44 nucleases.

SEQ ID NO: 11190 shows the nucleotide sequence of an MG44 tracrRNA derived from the same loci as MG44 nucleases above.

MG46

SEQ ID NOs: 8497-8634 show the full-length peptide sequences of MG46 nucleases.

SEQ ID NOs: 10556-10633 show the peptide sequences of PAM-interacting domains of MG46 nucleases.

SEQ ID NO: 11191 shows the nucleotide sequence of an MG46 tracrRNA derived from the same loci as MG46 nucleases above.

MG47

SEQ ID NOs: 5751-5768 and 8635-8664 show the full-length peptide sequences of MG47 nucleases.

SEQ ID NOs: 5853-5854 show protospacer adjacent motifs associated with MG47 nucleases.

SEQ ID NOs: 5878-5881 show the nucleotide sequence of an sgRNA engineered to function with an MG47 nuclease.

SEQ ID NOs: 10634-10656 show the peptide sequences of PAM-interacting domains of MG47 nucleases.

SEQ ID NOs: 11192-11193 show nucleotide sequences of MG47 tracrRNAs derived from the same loci as MG47 nucleases above.

MG48

SEQ ID NOs: 5769-5804 and 8665 show the full-length peptide sequences of MG48 nucleases.

SEQ ID NOs: 5855-5856 show protospacer adjacent motifs associated with MG48 nucleases.

SEQ ID NOs: 5886, 5890, 5893, and 11194 show the nucleotide sequences of MG48 tracrRNA derived from the same loci as MG48 nucleases above

SEQ ID NOs: 5887, 5891 and 5894 show CRISPR repeats associated with MG48 nucleases described herein.

SEQ ID NOs: 5888-5889, 5892 and 5895-5896 show putative sgRNA designed to function with an MG48 nuclease.

SEQ ID NOs: 10657-10662 show the peptide sequences of PAM-interacting domains of MG48 nucleases.

SEQ ID NOs: 11142-11143 show nucleotide sequences of sgRNAs engineered to function with an MG48 nuclease.

MG49

SEQ ID NOs: 5805-5823 and 8666-8677 show the full-length peptide sequences of MG49 nucleases.

SEQ ID NOs: 5857-5858 show protospacer adjacent motifs associated with MG49 nucleases.

SEQ ID NOs: 5862-5873 show the nucleotide sequence of an sgRNA engineered to function with an MG40 nuclease.

SEQ ID NOs: 5876-5877 show the nucleotide sequence of an sgRNA engineered to function with an MG49 nuclease.

SEQ ID NOs: 10663-10675 show the peptide sequences of PAM-interacting domains of MG49 nucleases.

SEQ ID NOs: 11195-11196 show nucleotide sequences of MG49 tracrRNAs derived from the same loci as MG49 nucleases above.

MG50

SEQ ID NOs: 5824-5826 and 8678-8682 show the full-length peptide sequences of MG50 nucleases.

SEQ ID NO: 5859 shows a protospacer adjacent motif associated with MG50 nucleases.

SEQ ID NOs: 5884-5885 show the nucleotide sequence of an sgRNA engineered to function with an MG50 nuclease.

SEQ ID NOs: 10676-10682 show the peptide sequences of PAM-interacting domains of MG50 nucleases.

SEQ ID NO: 11197 shows the nucleotide sequence of an MG50 tracrRNA derived from the same loci as MG50 nucleases above.

MG51

SEQ ID NOs: 5827-5830 and 8683-8705 show the full-length peptide sequences of MG51 nucleases.

SEQ ID NO: 5860 shows a protospacer adjacent motif associated with MG51 nucleases.

SEQ ID NOs: 5882-5883 show the nucleotide sequence of an sgRNA engineered to function with an MG51 nuclease.

SEQ ID NOs: 10683-10704 show the peptide sequences of PAM-interacting domains of MG51 nucleases.

SEQ ID NO: 11198 shows the nucleotide sequence of an MG51 tracrRNA derived from the same loci as MG51 nucleases above.

MG52

SEQ ID NOs: 5831-5846 and 8706 show the full-length peptide sequences of MG52 nucleases.

SEQ ID NO: 5861 shows a protospacer adjacent motif associated with MG52 nucleases.

SEQ ID NOs: 5874-5875 show the nucleotide sequence of an sgRNA engineered to function with an MG52 nuclease.

SEQ ID NOs: 10705-10710 show the peptide sequences of PAM-interacting domains of MG52 nucleases.

SEQ ID NO: 11199 shows the nucleotide sequence of an MG52 tracrRNA derived from the same loci as MG52 nucleases above.

MG71

SEQ ID NOs: 10711-10712 show the peptide sequences of PAM-interacting domains of MG71 nucleases.

SEQ ID NOs: 11144-11145 show nucleotide sequences of sgRNAs engineered to function with an MG71 nuclease.

SEQ ID NOs: 11200-11201 show nucleotide sequences of MG71 tracrRNAs derived from the same loci as MG71 nucleases above.

MG72

SEQ ID NO: 11202 shows the nucleotide sequence of an MG72 tracrRNA derived from the same loci as MG72 nucleases above.

MG73

SEQ ID NOs: 10713-10718 show the peptide sequences of PAM-interacting domains of MG73 nucleases.

SEQ ID NOs: 11203-11204 show nucleotide sequences of MG73 tracrRNAs derived from the same loci as MG73 nucleases above.

MG74

SEQ ID NOs: 10719-10732 show the peptide sequences of PAM-interacting domains of MG74 nucleases.

SEQ ID NO: 11205 shows the nucleotide sequence of an MG74 tracrRNA derived from the same loci as MG74 nucleases above.

MG86

SEQ ID NOs: 8707-8737 show the full-length peptide sequences of MG86 nucleases.

SEQ ID NOs: 10733-10791 show the peptide sequences of PAM-interacting domains of MG86 nucleases.

SEQ ID NO: 11118 shows the nucleotide sequence of a single guide PAM of an MG86 nuclease.

SEQ ID NOs: 11206-11207 show nucleotide sequences of MG86 tracrRNAs derived from the same loci as MG86 nucleases above.

MG87

SEQ ID NOs: 8738-8747 show the full-length peptide sequences of MG87 nucleases.

SEQ ID NOs: 10792-10828 show the peptide sequences of PAM-interacting domains of MG87 nucleases.

SEQ ID NOs: 11208-11210 show nucleotide sequences of MG87 tracrRNAs derived from the same loci as MG87 nucleases above.

MG88

SEQ ID NOs: 10829-10841 show the peptide sequences of PAM-interacting domains of MG88 nucleases.

SEQ ID NOs: 11211-11213 show nucleotide sequences of MG88 tracrRNAs derived from the same loci as MG88 nucleases above.

MG89

SEQ ID NOs: 10842-10854 show the peptide sequences of PAM-interacting domains of MG89 nucleases.

SEQ ID NOs: 11214-11215 show nucleotide sequences of MG89 tracrRNAs derived from the same loci as MG89 nucleases above.

MG94

SEQ ID NOs: 8748-8781 show the full-length peptide sequences of MG94 nucleases.

SEQ ID NOs: 10855-10860 show the peptide sequences of PAM-interacting domains of MG94 nucleases.

SEQ ID NOs: 11119-11120 show the nucleotide sequences of single guide PAMs of MG94 nucleases.

SEQ ID NOs: 11146-11147 show nucleotide sequences of sgRNAs engineered to function with an MG94 nuclease.

SEQ ID NOs: 11216-11217 show nucleotide sequences of MG94 tracrRNAs derived from the same loci as MG94 nucleases above.

MG95

SEQ ID NOs: 8782-8785 show the full-length peptide sequences of MG95 nucleases.

SEQ ID NOs: 10861-10863 show the peptide sequences of PAM-interacting domains of MG95 nucleases.

SEQ ID NOs: 11121-11122 show the nucleotide sequences of single guide PAMs of MG95 nucleases.

SEQ ID NOs: 11148-11149 show nucleotide sequences of sgRNAs engineered to function with an MG95 nuclease.

SEQ ID NOs: 11218-11219 show nucleotide sequences of MG95 tracrRNAs derived from the same loci as MG95 nucleases above.

MG96

SEQ ID NOs: 8786-8814 show the full-length peptide sequences of MG96 nucleases.

SEQ ID NOs: 10864-10884 show the peptide sequences of PAM-interacting domains of MG96 nucleases.

SEQ ID NO: 11123 shows the nucleotide sequence of a single guide PAM of an MG96 nuclease.

SEQ ID NO: 11150 shows the nucleotide sequence of an sgRNA engineered to function with an MG96 nuclease.

SEQ ID NO: 11220 shows the nucleotide sequence of an MG96 tracrRNA derived from the same loci as MG96 nucleases above.

MG97

SEQ ID NOs: 8815-8818 show the full-length peptide sequences of MG97 nucleases.

SEQ ID NOs: 10885-10887 show the peptide sequences of PAM-interacting domains of MG97 nucleases.

MG98

SEQ ID NOs: 8819-8959 show the full-length peptide sequences of MG98 nucleases.

SEQ ID NOs: 10888-10936 show the peptide sequences of PAM-interacting domains of MG98 nucleases.

SEQ ID NOs: 11124-11125 show the nucleotide sequences of single guide PAMs of MG98 nucleases.

SEQ ID NOs: 11151-11152 show nucleotide sequences of sgRNAs engineered to function with an MG98 nuclease.

SEQ ID NOs: 11221-11222 show nucleotide sequences of MG98 tracrRNAs derived from the same loci as MG98 nucleases above.

MG99

SEQ ID NO: 11153 shows the nucleotide sequence of an sgRNA engineered to function with an MG99 nuclease.

SEQ ID NO: 11223 shows the nucleotide sequence of an MG99 tracrRNA derived from the same loci as MG99 nucleases above.

MG100

SEQ ID NOs: 8960-9036 show the full-length peptide sequences of MG100 nucleases.

SEQ ID NOs: 10937-10991 show the peptide sequences of PAM-interacting domains of MG100 nucleases.

SEQ ID NO: 11126 shows the nucleotide sequence of a single guide PAM of an MG100 nuclease.

SEQ ID NOs: 11154-11155 show nucleotide sequences of sgRNAs engineered to function with an MG100 nuclease.

SEQ ID NOs: 11224-11225 show nucleotide sequences of MG100 tracrRNAs derived from the same loci as MG100 nucleases above.

MG111

SEQ ID NOs: 9037-9126 show the full-length peptide sequences of MG111 nucleases.

SEQ ID NOs: 10992-11046 show the peptide sequences of PAM-interacting domains of MG111 nucleases.

SEQ ID NOs: 11127-11128 show the nucleotide sequences of single guide PAMs of MG111 nucleases.

SEQ ID NOs: 11156-11157 show nucleotide sequences of sgRNAs engineered to function with an MG111 nuclease.

SEQ ID NOs: 11226-11227 show nucleotide sequences of MG111 tracrRNAs derived from the same loci as MG111 nucleases above.

MG112

SEQ ID NOs: 9127-9149 show the full-length peptide sequences of MG112 nucleases.

SEQ ID NOs: 11047-11062 show the peptide sequences of PAM-interacting domains of MG112 nucleases.

MG116

SEQ ID NOs: 9150-9191 show the full-length peptide sequences of MG116 nucleases.

SEQ ID NOs: 11063-11098 show the peptide sequences of PAM-interacting domains of MG116 nucleases.

SEQ ID NO: 11129 shows the nucleotide sequence of a single guide PAM of an MG116 nuclease.

SEQ ID NO: 11158 shows the nucleotide sequence of an sgRNA engineered to function with an MG116 nuclease.

SEQ ID NO: 11228 shows the nucleotide sequence of an MG116 tracrRNA derived from the same loci as MG116 nucleases above.

MG123

SEQ ID NOs: 11617-11624 show the full-length peptide sequences of MG123 nucleases.

SEQ ID NO: 11518 shows the nucleotide sequence of a single guide PAM of an MG123 nuclease.

SEQ ID NO: 11555 shows the nucleotide sequence of an sgRNA engineered to function with an MG123 nuclease.

MG124

SEQ ID NOs: 11625-11626 show the full-length peptide sequences of MG124 nucleases.

SEQ ID NO: 11519 shows the nucleotide sequence of a single guide PAM of an MG124 nuclease.

SEQ ID NO: 11556 shows the nucleotide sequence of an sgRNA engineered to function with an MG124 nuclease.

MG125

SEQ ID NOs: 11627-11707 show the full-length peptide sequences of MG125 nucleases.

SEQ ID NOs: 11520-11524 show the nucleotide sequences of single guide PAMs of MG125 nucleases.

SEQ ID NOs: 11557-11561 show the nucleotide sequences of sgRNAs engineered to function with MG125 nucleases.

MG150

SEQ ID NOs: 7359-7368 and 11708-11710 show the full-length peptide sequences of MG150 nucleases.

SEQ ID NOs: 11525-11529 show the nucleotide sequences of single guide PAMs of MG150 nucleases.

SEQ ID NOs: 11562-11566 show the nucleotide sequences of sgRNAs engineered to function with MG150 nucleases.

B2M Targeting

SEQ ID NOs: 6305-6386 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target B2M.

SEQ ID NOs: 6387-6468 show the DNA sequences of B2M target sites.

TRAC Targeting

SEQ ID NOs: 6469-6508 and 6804 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target TRAC.

SEQ ID NOs: 6509-6548 and 6805 show the DNA sequences of TRAC target sites. HPRT Targeting

SEQ ID NOs: 6549-6615 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target HPRT.

SEQ ID NOs: 6616-6682 show the DNA sequences of HPRT target sites.

MG3-6 TRBC1/2 Targeting

SEQ ID NOs: 6683-6721 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target TRBC1/2.

SEQ ID NOs: 6722-6760 show the DNA sequences of TRBC1/2 target sites.

MG3-8 TRBC1/2 Targeting

SEQ ID NOs: 6761-6781 show the nucleotide sequences of sgRNAs engineered to function with an MG3-8 nuclease in order to target TRBC1/2.

SEQ ID NOs: 6782-6802 show the DNA sequences of TRBC1/2 target sites.

MG3-6 CD2 Targeting

SEQ ID NOs: 6811-6852 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target CD2.

SEQ ID NOs: 6853-6894 show the DNA sequences of CD2 target sites.

MG3-6 CD5 Targeting

SEQ ID NOs: 6895-6958 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target CD5.

SEQ ID NOs: 6959-7022 show the DNA sequences of CD5 target sites.

MG3-6 FAS Targeting

SEQ ID NOs: 7023-7056 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target FAS.

SEQ ID NOs: 7057-7090 show the DNA sequences of FAS target sites.

MG3-6 PD-1 Targeting

SEQ ID NOs: 7091-7128 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target PD-1.

SEQ ID NOs: 7129-7166 show the DNA sequences of PD-1 target sites.

MG3-6 hRosa26 Targeting

SEQ ID NOs: 7167-7198 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target hRosa26.

SEQ ID NOs: 7199-7230 show the DNA sequences of hRosa26 target sites.

MG21-1 TRAC Targeting

SEQ ID NOs: 7231-7234 show the nucleotide sequences of sgRNAs engineered to function with an MG21-1 nuclease in order to target TRAC.

SEQ ID NOs: 7235-7238 show the DNA sequences of TRAC target sites.

MG23-1 TRAC Targeting

SEQ ID NOs: 7239-7247 show the nucleotide sequences of sgRNAs engineered to function with an MG23-1 nuclease in order to target TRAC.

SEQ ID NOs: 7248-7256 show the DNA sequences of TRAC target sites.

MG14-241 AAVS1 Targeting

SEQ ID NOs: 11508-11510 show the nucleotide sequences of sgRNAs engineered to function with an MG14-241 nuclease in order to target AAVS1.

SEQ ID NOs: 11511-11513 show the DNA sequences of AAVS1 target sites.

MG23-1 AAVS1 Targeting

SEQ ID NOs: 7257-7260 show the nucleotide sequences of sgRNAs engineered to function with an MG23-1 nuclease in order to target AAVS1.

SEQ ID NOs: 7261-7264 show the DNA sequences of AAVS1 target sites.

MG71-2 AAVS1 Targeting

SEQ ID NOs: 7265-7266 show the nucleotide sequences of sgRNAs engineered to function with an MG71-2 nuclease in order to target AAVS1.

SEQ ID NOs: 7267-7268 show the DNA sequences of AAVS1 target sites.

MG73-1 TRAC Targeting

SEQ ID NO: 7269 shows the nucleotide sequence of an sgRNA engineered to function with an MG73-1 nuclease in order to target TRAC.

SEQ ID NO: 7270 shows the DNA sequence of a TRAC target site.

MG89-2 TRAC Targeting

SEQ ID NOs: 7271-7277 show the nucleotide sequences of sgRNAs engineered to function with an MG89-2 nuclease in order to target TRAC.

SEQ ID NOs: 7278-7284 show the DNA sequences of TRAC target sites.

MG99-1 TRAC Targeting

SEQ ID NOs: 11514-11515 show the nucleotide sequences of sgRNAs engineered to function with an MG99-1 nuclease in order to target TRAC.

SEQ ID NOs: 11516-11517 show the DNA sequences of TRAC target sites.

MG3-6 Human HAO-1 Targeting

SEQ ID NOs: 11352-11372 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target human HAO-1.

MG3-6 human GPR146 Targeting

SEQ ID NOs: 11374-11405 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target human GPR146.

SEQ ID NOs: 11406-11437 show the DNA sequences of human GPR146 target sites.

MG3-6 mouse GPR146 Targeting

SEQ ID NOs: 11438-11472 show the nucleotide sequences of sgRNAs engineered to function with an MG3-6 nuclease in order to target mouse GPR146.

SEQ ID NOs: 11473-11507 show the DNA sequences of mouse GPR146 target sites.

DETAILED DESCRIPTION

While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

The practice of some methods disclosed herein employ, unless otherwise indicated, techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA. See for example Sambrook and Green, Molecular Cloning: A Laboratory Manual, 4^thEdition (2012); the series Current Protocols in Molecular Biology (F. M. Ausubel, et al. eds.); the series Methods In Enzymology (Academic Press, Inc.), PCR 2: A Practical Approach (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6^thEdition (R. I. Freshney, ed. (2010)) (which is entirely incorporated by reference herein).

As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”.

The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within one or more than one standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value.

As used herein, a “cell” generally refers to a biological cell. A cell may be the basic structural, functional or biological unit of a living organism. A cell may originate from any organism having one or more cells. Some non-limiting examples include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g., cells from plant crops, fruits, vegetables, grains, soy bean, corn, maize, wheat, seeds, tomatoes, rice, cassava, sugarcane, pumpkin, hay, potatoes, cotton, Cannabis, tobacco, flowering plants, conifers, gymnosperms, ferns, clubmosses, hornworts, liverworts, mosses), an algal cell, (e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like), seaweeds (e.g., kelp), a fungal cell (e.g., a yeast cell, a cell from a mushroom), an animal cell, a cell from an invertebrate animal (e.g., fruit fly, cnidarian, echinoderm, nematode, etc.), a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal), a cell from a mammal (e.g., a pig, a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, a human, etc.), and etcetera. Sometimes a cell is not originating from a natural organism (e.g., a cell can be a synthetically made, sometimes termed an artificial cell).

The term “nucleotide,” as used herein, generally refers to a base-sugar-phosphate combination. A nucleotide may comprise a synthetic nucleotide. A nucleotide may comprise a synthetic nucleotide analog. Nucleotides may be monomeric units of a nucleic acid sequence (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)). The term nucleotide may include ribonucleoside triphosphates adenosine triphosphate (ATP), uridine triphosphate (UTP), cytosine triphosphate (CTP), guanosine triphosphate (GTP) and deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives may include, for example, [αS]dATP, 7-deaza-dGTP and 7-deaza-dATP, and nucleotide derivatives that confer nuclease resistance on the nucleic acid molecule containing them. The term nucleotide as used herein may refer to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrative examples of dideoxyribonucleoside triphosphates may include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. A nucleotide may be unlabeled or detectably labeled, such as using moieties comprising optically detectable moieties (e.g., fluorophores). Labeling may also be carried out with quantum dots. Detectable labels may include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels. Fluorescent labels of nucleotides may include but are not limited fluorescein, 5-carboxyfluorescein (FAM), 2′7′-dimethoxy-4′5-dichloro-6-carboxyfluorescein (JOE), rhodamine, 6-carboxyrhodamine (R6G), N,N,N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4′dimethylaminophenylazo) benzoic acid (DABCYL), Cascade Blue, Oregon Green, Texas Red, Cyanine and 5-(2′-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS). Specific examples of fluorescently labeled nucleotides can include [R6G]dUTP, [TAMRA]dUTP, [RI 10]dCTP, [R6G]dCTP, [TAMRA]dCTP, [JOE]ddATP, [R6G]ddATP, [FAM]ddCTP, [R110]ddCTP, [TAMRA]ddGTP, [ROX]ddTTP, [dR6G]ddATP, [dR110]ddCTP, [dTAMRA]ddGTP, and [dROX]ddTTP available from Perkin Elmer, Foster City, Calif; FluoroLink DeoxyNucleotides, FluoroLink Cy3-dCTP, FluoroLink Cy5-dCTP, FluoroLink Fluor X-dCTP, FluoroLink Cy3-dUTP, and FluoroLink Cy5-dUTP available from Amersham, Arlington Heights, Ill.; Fluorescein-15-dATP, Fluorescein-12-dUTP, Tetramethyl-rodamine-6-dUTP, IR770-9-dATP, Fluorescein-12-ddUTP, Fluorescein-12-UTP, and Fluorescein-15-2′-dATP available from Boehringer Mannheim, Indianapolis, Ind.; and Chromosome Labeled Nucleotides, BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP, BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade Blue-7-UTP, Cascade Blue-7-dUTP, fluorescein-12-UTP, fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine Green-5-UTP, Rhodamine Green-5-dUTP, tetramethylrhodamine-6-UTP, tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP, and Texas Red-12-dUTP available from Molecular Probes, Eugene, Oreg. Nucleotides can also be labeled or marked by chemical modification. A chemically-modified single nucleotide can be biotin-dNTP. Some non-limiting examples of biotinylated dNTPs can include, biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP), biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP), and biotin-dUTP (e.g., biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP).

The terms “polynucleotide,” “oligonucleotide,” and “nucleic acid” are used interchangeably to generally refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof, either in single-, double-, or multi-stranded form. A polynucleotide may be exogenous or endogenous to a cell. A polynucleotide may exist in a cell-free environment. A polynucleotide may be a gene or fragment thereof. A polynucleotide may be DNA. A polynucleotide may be RNA. A polynucleotide may have any three-dimensional structure and may perform any function. A polynucleotide may comprise one or more analogs (e.g., altered backbone, sugar, or nucleobase). If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to the sugar), thiol containing nucleotides, biotin linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudourdine, dihydrouridine, queuosine, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes, and primers. The sequence of nucleotides may be interrupted by non-nucleotide components.

The terms “transfection” or “transfected” generally refer to introduction of a nucleic acid into a cell by non-viral or viral-based methods. The nucleic acid molecules may be gene sequences encoding complete proteins or functional portions thereof. See, e.g., Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 18.1-18.88.

The terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein to generally refer to a polymer of at least two amino acid residues joined by peptide bond(s). This term does not connote a specific length of polymer, nor is it intended to imply or distinguish whether the peptide is produced using recombinant techniques, chemical or enzymatic synthesis, or is naturally occurring. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers comprising at least one modified amino acid. In some cases, the polymer may be interrupted by non-amino acids. The terms include amino acid chains of any length, including full length proteins, and proteins with or without secondary or tertiary structure (e.g., domains). The terms also encompass an amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulation such as conjugation with a labeling component. The terms “amino acid” and “amino acids,” as used herein, generally refer to natural and non-natural amino acids, including, but not limited to, modified amino acids and amino acid analogues. Modified amino acids may include natural amino acids and non-natural amino acids, which have been chemically modified to include a group or a chemical moiety not naturally present on the amino acid. Amino acid analogues may refer to amino acid derivatives. The term “amino acid” includes both D-amino acids and L-amino acids.

As used herein, the “non-native” can generally refer to a nucleic acid or polypeptide sequence that is not found in a native nucleic acid or protein. Non-native may refer to affinity tags. Non-native may refer to fusions. Non-native may refer to a naturally occurring nucleic acid or polypeptide sequence that comprises mutations, insertions or deletions. A non-native sequence may exhibit or encode for an activity (e.g., enzymatic activity, methyltransferase activity, acetyltransferase activity, kinase activity, ubiquitinating activity, etc.) that may also be exhibited by the nucleic acid or polypeptide sequence to which the non-native sequence is fused. A non-native nucleic acid or polypeptide sequence may be linked to a naturally-occurring nucleic acid or polypeptide sequence (or a variant thereof) by genetic engineering to generate a chimeric nucleic acid or polypeptide sequence encoding a chimeric nucleic acid or polypeptide.

The term “promoter”, as used herein, generally refers to the regulatory DNA region which controls transcription or expression of a gene, and which may be located adjacent to or overlapping a nucleotide or region of nucleotides at which RNA transcription is initiated. A promoter may contain specific DNA sequences which bind protein factors, often referred to as transcription factors, which facilitate binding of RNA polymerase to the DNA leading to gene transcription. A ‘basal promoter’, also referred to as a ‘core promoter’, may generally refer to a promoter that contains all the basic elements to promote transcriptional expression of an operably linked polynucleotide. Eukaryotic basal promoters often contain a TATA-box or a CAAT box.

The term “expression”, as used herein, generally refers to the process by which a nucleic acid sequence or a polynucleotide is transcribed from a DNA template (such as into mRNA or other RNA transcript) or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as “gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.

As used herein, “operably linked”, “operable linkage”, “operatively linked”, or grammatical equivalents thereof generally refer to juxtaposition of genetic elements, e.g., a promoter, an enhancer, a polyadenylation sequence, etc., wherein the elements are in a relationship permitting them to operate in the expected manner. For instance, a regulatory element, which may comprise promoter or enhancer sequences, is operatively linked to a coding region if the regulatory element helps initiate transcription of the coding sequence. There may be intervening residues between the regulatory element and coding region so long as this functional relationship is maintained.

A “vector” as used herein, generally refers to a macromolecule or association of macromolecules that comprises or associates with a polynucleotide and which may be used to mediate delivery of the polynucleotide to a cell. Examples of vectors include plasmids, viral vectors, liposomes, and other gene delivery vehicles. The vector generally comprises genetic elements, e.g., regulatory elements, operatively linked to a gene to facilitate expression of the gene in a target.

As used herein, “an expression cassette” and “a nucleic acid cassette” are used interchangeably generally to refer to a combination of nucleic acid sequences or elements that are expressed together or are operably linked for expression. In some cases, an expression cassette refers to the combination of regulatory elements and a gene or genes to which they are operably linked for expression.

A “functional fragment” of a DNA or protein sequence generally refers to a fragment that retains a biological activity (either functional or structural) that is substantially similar to a biological activity of the full-length DNA or protein sequence. A biological activity of a DNA sequence may be its ability to influence expression in a manner attributed to the full-length sequence.

As used herein, an “engineered” object generally indicates that the object has been modified by human intervention. According to non-limiting examples: a nucleic acid may be modified by changing its sequence to a sequence that does not occur in nature; a nucleic acid may be modified by ligating it to a nucleic acid that it does not associate with in nature such that the ligated product possesses a function not present in the original nucleic acid; an engineered nucleic acid may synthesized in vitro with a sequence that does not exist in nature; a protein may be modified by changing its amino acid sequence to a sequence that does not exist in nature; an engineered protein may acquire a new function or property. An “engineered” system comprises at least one engineered component.

As used herein, “synthetic” and “artificial” are used interchangeably to refer to a protein or a domain thereof that has low sequence identity (e.g., less than 50% sequence identity, less than 25% sequence identity, less than 10% sequence identity, less than 5% sequence identity, less than 1% sequence identity) to a naturally occurring human protein. For example, VPR and VP64 domains are synthetic transactivation domains.

The term “tracrRNA” or “tracr sequence”, as used herein, can generally refer to a nucleic acid with at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% sequence identity or sequence similarity to a wild type exemplary tracrRNA sequence (e.g., a tracrRNA from S. pyogenes S. aureus, etc or SEQ ID NOs: 5476-5511). tracrRNA can refer to a nucleic acid with at most about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% sequence identity or sequence similarity to a wild type exemplary tracrRNA sequence (e.g., a tracrRNA from S. pyogenes S. aureus, etc). tracrRNA may refer to a modified form of a tracrRNA that can comprise a nucleotide change such as a deletion, insertion, or substitution, variant, mutation, or chimera. A tracrRNA may refer to a nucleic acid that can be at least about 60% identical to a wild type exemplary tracrRNA (e.g., a tracrRNA from S. pyogenes S. aureus, etc) sequence over a stretch of at least 6 contiguous nucleotides. For example, a tracrRNA sequence can be at least about 60% identical, at least about 65% identical, at least about 70% identical, at least about 75% identical, at least about 80% identical, at least about 85% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, or 100% identical to a wild type exemplary tracrRNA (e.g., a tracrRNA from S. pyogenes S. aureus, etc) sequence over a stretch of at least 6 contiguous nucleotides. Type II tracrRNA sequences can be predicted on a genome sequence by identifying regions with complementarity to part of the repeat sequence in an adjacent CRISPR array.

As used herein, a “guide nucleic acid” can generally refer to a nucleic acid that may hybridize to another nucleic acid. A guide nucleic acid may be RNA. A guide nucleic acid may be DNA. The guide nucleic acid may be programmed to bind to a sequence of nucleic acid site-specifically. The nucleic acid to be targeted, or the target nucleic acid, may comprise nucleotides. The guide nucleic acid may comprise nucleotides. A portion of the target nucleic acid may be complementary to a portion of the guide nucleic acid. The strand of a double-stranded target polynucleotide that is complementary to and hybridizes with the guide nucleic acid may be called the complementary strand. The strand of the double-stranded target polynucleotide that is complementary to the complementary strand, and therefore may not be complementary to the guide nucleic acid may be called noncomplementary strand. A guide nucleic acid may comprise a polynucleotide chain and can be called a “single guide nucleic acid.” A guide nucleic acid may comprise two polynucleotide chains and may be called a “double guide nucleic acid.” If not otherwise specified, the term “guide nucleic acid” may be inclusive, referring to both single guide nucleic acids and double guide nucleic acids. A guide nucleic acid may comprise a segment that can be referred to as a “nucleic acid-targeting segment” or a “nucleic acid-targeting sequence.” A nucleic acid-targeting segment may comprise a sub-segment that may be referred to as a “protein binding segment” or “protein binding sequence” or “Cas protein binding segment”.

The term “sequence identity” or “percent identity” in the context of two or more nucleic acids or polypeptide sequences, generally refers to two (e.g., in a pairwise alignment) or more (e.g., in a multiple sequence alignment) sequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a local or global comparison window, as measured using a sequence comparison algorithm. Suitable sequence comparison algorithms for polypeptide sequences include, e.g., BLASTP using parameters of a wordlength (W) of 3, an expectation I of 10, and the BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1, and using a conditional compositional score matrix adjustment for polypeptide sequences longer than 30 residues; BLASTP using parameters of a wordlength (W) of 2, an expectation (E) of 1000000, and the PAM30 scoring matrix setting gap costs at 9 to open gaps and 1 to extend gaps for sequences of less than 30 residues (these are the default parameters for BLASTP in the BLAST suite available at https://blast.ncbi.nlm.nih.gov); CLUSTALW with parameters of; the Smith-Waterman homology search algorithm with parameters of a match of 2, a mismatch of −1, and a gap of −1; MUSCLE with default parameters; MAFFT with parameters retree of 2 and maxiterations of 1000; Novafold with default parameters; HMMER hmmalign with default parameters.

Included in the current disclosure are variants of any of the enzymes described herein with one or more conservative amino acid substitutions. Such conservative substitutions can be made in the amino acid sequence of a polypeptide without disrupting the three-dimensional structure or function of the polypeptide. Conservative substitutions can be accomplished by substituting amino acids with similar hydrophobicity, polarity, and R chain length for one another. Additionally or alternatively, by comparing aligned sequences of homologous proteins from different species, conservative substitutions can be identified by locating amino acid residues that have been mutated between species (e.g. non-conserved residues) without altering the basic functions of the encoded proteins. Such conservatively substituted variants may include variants with at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% identity to any one of the endonuclease protein sequences described herein (e.g. MG1, MG2, MG3, MG3a, MG3b, MG4, MG5, MG6, MG7, MG14, MG15, MG16, MG17, MG18, MG21, MG22, MG23, MG24, MG25, MG38, MG40, MG41, MG42, MG43, MG44, MG46, MG47, MG48, MG49, MG50, MG51, MG52, MG71, MG72, MG73, MG74, MG86, MG87, MG88, MG89, MG94, MG95, MG96, MG97, MG98, MG99, MG100, MG111, MG112, MG116, MG123, MG124, MG125, or MG150 family endonucleases described herein). In some embodiments, such conservatively substituted variants are functional variants. Such functional variants can encompass sequences with substitutions such that the activity of critical active site residues of the endonuclease are not disrupted. In some embodiments, a functional variant of any of the proteins described herein lacks substitution of at least one conserved or functional residue.

Conservative substitution tables providing functionally similar amino acids are available from a variety of references (see, for e.g., Creighton, Proteins: Structures and Molecular Properties (W H Freeman & Co.; 2nd edition (December 1993)). The following eight groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
- 7) Serine (S), Threonine (T); and
- 8) Cysteine (C), Methionine (M)

Also included in the current disclosure are variants of any of the nucleic acid sequences described herein with one or more substitutions. Such variants may include variants with at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of the nucleic acid sequences described herein.

As used herein, the term “RuvC_III domain” generally refers to a third discontinuous segment of a RuvC endonuclease domain (the RuvC nuclease domain being comprised of three discontiguous segments, RuvC_I, RuvC_II, and RuvC_III). A RuvC domain or segments thereof can generally be identified by alignment to documented domain sequences, structural alignment to proteins with annotated domains, or by comparison to Hidden Markov Models (HMMs) built based on documented domain sequences (e.g., Pfam HMM PF18541 for RuvC_III).

As used herein, the term “HNH domain” generally refers to an endonuclease domain having characteristic histidine and asparagine residues. An HNH domain can generally be identified by alignment to documented domain sequences, structural alignment to proteins with annotated domains, or by comparison to Hidden Markov Models (HMMs) built based on documented domain sequences (e.g., Pfam HMM PF01844 for domain HNH).

Overview

The discovery of new Cas enzymes with unique functionality and structure may offer the potential to further disrupt deoxyribonucleic acid (DNA) editing technologies, improving speed, specificity, functionality, and ease of use. Relative to the predicted prevalence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems in microbes and the sheer diversity of microbial species, relatively few functionally characterized CRISPR/Cas enzymes exist in the literature. This is partly because a huge number of microbial species may not be readily cultivated in laboratory conditions. Metagenomic sequencing from natural environmental niches that represent large numbers of microbial species may offer the potential to drastically increase the number of new CRISPR/Cas systems documented and speed the discovery of new oligonucleotide editing functionalities. A recent example of the fruitfulness of such an approach is demonstrated by the 2016 discovery of CasX/CasY CRISPR systems from metagenomic analysis of natural microbial communities.

CRISPR/Cas systems are RNA-directed nuclease complexes that have been described to function as an adaptive immune system in microbes. In their natural context, CRISPR/Cas systems occur in CRISPR (clustered regularly interspaced short palindromic repeats) operons or loci, which generally comprise two parts: (i) an array of short repetitive sequences (30-40 bp) separated by equally short spacer sequences, which encode the RNA-based targeting element; and (ii) ORFs encoding the Cas encoding the nuclease polypeptide directed by the RNA-based targeting element alongside accessory proteins/enzymes. Efficient nuclease targeting of a particular target nucleic acid sequence generally requires both (i) complementary hybridization between the first 6-8 nucleic acids of the target (the target seed) and the crRNA guide; and (ii) the presence of a protospacer-adjacent motif (PAM) sequence within a defined vicinity of the target seed (the PAM usually being a sequence not commonly represented within the host genome). Depending on the exact function and organization of the system, CRISPR-Cas systems are commonly organized into 2 classes, 5 types and 16 subtypes based on shared functional characteristics and evolutionary similarity.

Class I CRISPR-Cas systems have large, multisubunit effector complexes, and comprise Types I, III, and IV.

Type I CRISPR-Cas systems are considered of moderate complexity in terms of components. In Type I CRISPR-Cas systems, the array of RNA-targeting elements is transcribed as a long precursor crRNA (pre-crRNA) that is processed at repeat elements to liberate short, mature crRNAs that direct the nuclease complex to nucleic acid targets when they are followed by a suitable short consensus sequence called a protospacer-adjacent motif (PAM). This processing occurs via an endoribonuclease subunit (Cas6) of a large endonuclease complex called Cascade, which also comprises a nuclease (Cas3) protein component of the crRNA-directed nuclease complex. Cas I nucleases function primarily as DNA nucleases.

Type III CRISPR systems may be characterized by the presence of a central nuclease, known as Cas10, alongside a repeat-associated mysterious protein (RAMP) that comprises Csm or Cmr protein subunits. Like in Type I systems, the mature crRNA is processed from a pre-crRNA using a Cas6-like enzyme. Unlike type I and II systems, type III systems appear to target and cleave DNA-RNA duplexes (such as DNA strands being used as templates for an RNA polymerase).

Type IV CRISPR-Cas systems possess an effector complex that consists of a highly reduced large subunit nuclease (csf1), two genes for RAMP proteins of the Cas5 (csf3) and Cas7 (csf2) groups, and, in some cases, a gene for a predicted small subunit; such systems are commonly found on endogenous plasmids.

Class II CRISPR-Cas systems generally have single-polypeptide multidomain nuclease effectors, and comprise Types II, V and VI.

Type II CRISPR-Cas systems are considered the simplest in terms of components. In Type II CRISPR-Cas systems, the processing of the CRISPR array into mature crRNAs does not require the presence of a special endonuclease subunit, but rather a small trans-encoded crRNA (tracrRNA) with a region complementary to the array repeat sequence; the tracrRNA interacts with both its corresponding effector nuclease (e.g. Cas9) and the repeat sequence to form a precursor dsRNA structure, which is cleaved by endogenous RNAse III to generate a mature effector enzyme loaded with both tracrRNA and crRNA. Cas II nucleases are known as DNA nucleases. Type 2 effectors generally exhibit a structure consisting of a RuvC-like endonuclease domain that adopts the RNase H fold with an unrelated HNH nuclease domain inserted within the folds of the RuvC-like nuclease domain. The RuvC-like domain is responsible for the cleavage of the target (e.g., crRNA complementary) DNA strand, while the HNH domain is responsible for cleavage of the displaced DNA strand.

Type V CRISPR-Cas systems are characterized by a nuclease effector (e.g. Cas12) structure similar to that of Type II effectors, comprising a RuvC-like domain. Similar to Type II, most (but not all) Type V CRISPR systems use a tracrRNA to process pre-crRNAs into mature crRNAs; however, unlike Type II systems which requires RNAse III to cleave the pre-crRNA into multiple crRNAs, type V systems are capable of using the effector nuclease itself to cleave pre-crRNAs. Like Type-II CRISPR-Cas systems, Type V CRISPR-Cas systems are again known as DNA nucleases. Unlike Type II CRISPR-Cas systems, some Type V enzymes (e.g., Cas12a) appear to have a robust single-stranded nonspecific deoxyribonuclease activity that is activated by the first crRNA directed cleavage of a double-stranded target sequence.

Type VI CRIPSR-Cas systems have RNA-guided RNA endonucleases. Instead of RuvC-like domains, the single polypeptide effector of Type VI systems (e.g. Cas13) comprises two HEPN ribonuclease domains. Differing from both Type II and V systems, Type VI systems also appear to not require a tracrRNA for processing of pre-crRNA into crRNA. Similar to type V systems, however, some Type VI systems (e.g., C2C2) appear to possess robust single-stranded nonspecific nuclease (ribonuclease) activity activated by the first crRNA directed cleavage of a target RNA.

Because of their simpler architecture, Class II CRISPR-Cas have been most widely adopted for engineering and development as designer nuclease/genome editing applications.

One of the early adaptations of such a system for in vitro use can be found in Jinek et al. (Science. 2012 Aug. 17; 337(6096):816-21, which is entirely incorporated herein by reference). The Jinek study first described a system that involved (i) recombinantly-expressed, purified full-length Cas9 (e.g., a Class II, Type II Cas enzyme) isolated from S. pyogenes SF370, (ii) purified mature ˜42 nt crRNA bearing a ˜20 nt 5′ sequence complementary to the target DNA sequence desired to be cleaved followed by a 3′ tracr-binding sequence (the whole crRNA being in vitro transcribed from a synthetic DNA template carrying a T7 promoter sequence); (iii) purified tracrRNA in vitro transcribed from a synthetic DNA template carrying a T7 promoter sequence, and (iv) Mg2+. Jinek later described an improved, engineered system wherein the crRNA of (ii) is joined to the 5′ end of (iii) by a linker (e.g., GAAA) to form a single fused synthetic guide RNA (sgRNA) capable of directing Cas9 to a target by itself.

Mali et al. (Science. 2013 Feb. 15; 339(6121): 823-826.), which is entirely incorporated herein by reference, later adapted this system for use in mammalian cells by providing DNA vectors encoding (i) an ORF encoding codon-optimized Cas9 (e.g., a Class II, Type II Cas enzyme) under a suitable mammalian promoter with a C-terminal nuclear localization sequence (e.g., SV40 NLS) and a suitable polyadenylation signal (e.g., TK pA signal); and (ii) an ORF encoding an sgRNA (having a 5′ sequence beginning with G followed by 20 nt of a complementary targeting nucleic acid sequence joined to a 3′ tracr-binding sequence, a linker, and the tracrRNA sequence) under a suitable Polymerase III promoter (e.g., the U6 promoter).

MG Enzymes

In one aspect, the present disclosure provides for an engineered nuclease system discovered through metagenomic sequencing. In some cases, the metagenomic sequencing is conducted on samples. In some cases, the samples may be collected by a variety of environments. Such environments may be a human microbiome, an animal microbiome, environments with high temperatures, environments with low temperatures. Such environments may include sediment.

MG3 Enzymes

In one aspect, the present disclosure provides for an engineered nuclease system comprising (a) an endonuclease. In some cases, the endonuclease is a Cas endonuclease. In some cases, the endonuclease is a Type II, Class II Cas endonuclease. The endonuclease may comprise a RuvC_III domain, wherein said RuvC_III domain has at least about 70% sequence identity to any one of SEQ ID NOs: 2242-2251. In some cases, the endonuclease may comprise a RuvC_III domain, wherein the RuvC_III domain has at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% identity to any one of SEQ ID NOs: 2242-2251. In some cases, the endonuclease may comprise a RuvC_III domain, wherein the substantially identical to any one of SEQ ID NOs: 2242-2251. The endonuclease may comprise a RuvC_III domain having at least about 70% sequence identity to any one of SEQ ID NOs: 2242-2244. In some cases, the endonuclease may comprise a RuvC_III domain having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% identity to any one of SEQ ID NOs: 2242-2244. In some cases, the endonuclease may comprise a RuvC_III domain substantially identical to any one of SEQ ID NOs: 2242-2244.

The endonuclease may comprise an HNH domain having at least about 70% identity to any one of SEQ ID NOs: 4056-4066. In some cases, the endonuclease may comprise an HNH domain having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 4056-4066. The endonuclease may comprise an HNH domain substantially identical to any one of SEQ ID NOs: 4056-4066. The endonuclease may comprise an HNH domain having at least about 70% identity to any one of SEQ ID NOs: 4056-4058. In some cases, the endonuclease may comprise an HNH domain having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 4056-4058. The endonuclease may comprise an HNH domain substantially identical to any one of SEQ ID NOs: 4056-4058.

In some cases, the endonuclease may comprise a variant having at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 421-431. In some cases, the endonuclease may be substantially identical to any one of SEQ ID NOs: 421-431. In some cases, the endonuclease may comprise a variant having at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs:421-423. In some cases, the endonuclease may be substantially identical to any one of SEQ ID NOs: 421-423.

In some cases, the endonuclease may comprise a variant having one or more nuclear localization sequences (NLSs). The NLS may be proximal to the N- or C-terminus of said endonuclease. The NLS may be appended N-terminal or C-terminal to any one of SEQ ID NOs: 421-431, or to a variant having at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 421-431. The NLS may be an SV40 large T antigen NLS. The NLS may be a c-myc NLS. The NLS can comprise a sequence with at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99% identity to any one of SEQ ID NOs: 5593-5608. The NLS can comprise a sequence substantially identical to any one of SEQ ID NOs: 5593-5608.

In some cases, sequence identity may be determined by the BLASTP, CLUSTALW, MUSCLE, MAFFT, Novafold, or CLUSTALW with the parameters of the Smith-Waterman homology search algorithm. The sequence identity may be determined by the BLASTP algorithm using parameters of a wordlength (W) of 3, an expectation (E) of 10, and using a BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1, and using a conditional compositional score matrix adjustment.

In some cases, the system above may comprise (b) at least one engineered synthetic guide ribonucleic acid (sgRNA) capable of forming a complex with the endonuclease bearing a 5′ targeting region complementary to a desired cleavage sequence. In some cases, the 5′ targeting region may comprises a PAM sequence compatible with the endonuclease. In some cases, the 5′ most nucleotide of the targeting region may be G. In some cases, the 5′ targeting region may be 15-23 nucleotides in length. The guide sequence and the tracr sequence may be supplied as separate ribonucleic acids (RNAs) or a single ribonucleic acid (RNA). The guide RNA may comprise a crRNA tracrRNA binding sequence 3′ to the targeting region. The guide RNA may comprise a tracrRNA sequence preceded by a 4-nucleotide linker 3′ to the crRNA tracrRNA binding region. The sgRNA may comprise, from 5′ to 3′: a non-natural guide nucleic acid sequence capable of hybridizing to a target sequence in a cell; and a tracr sequence. In some cases, the non-natural guide nucleic acid sequence and the tracr sequence are covalently linked.

In some cases, the tracr sequence may have a particular sequence. The tracr sequence may have at least about 80% to at least about 60-100 (e.g., at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, or at least about 90) consecutive nucleotides of a natural tracrRNA sequence. The tracr sequence may have at least about 80% sequence identity to at least about 60-100 (e.g., at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, or at least about 90) consecutive nucleotides of any one of SEQ ID NOs: 5495-5502. In some cases, the tracrRNA may have at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to at least about 60-90 (e.g., at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, or at least about 90) consecutive nucleotides of any one of SEQ ID NOs: 5495-5502. In some cases, the tracrRNA may be substantially identical to at least about 60-100 (e.g., at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, or at least about 90) consecutive nucleotides of any one of SEQ ID NOs: 5495-5502. The tracrRNA may comprise any of SEQ ID NOs: 5495-5502.

In some cases, the at least one engineered synthetic guide ribonucleic acid (sgRNA) capable of forming a complex with the endonuclease may comprise a sequence having at least about 80% identity to any one of SEQ ID NOs: 5466-5467. The sgRNA may comprise a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 5466-5467. The sgRNA may comprise a sequence substantially identical to any one of SEQ ID NOs: 5466-5467.

In some cases, the system above may comprise two different sgRNAs targeting a first region and a second region for cleavage in a target DNA locus, wherein the second region is 3′ to the first region. In some cases, the system above may comprise a single- or double-stranded DNA repair template comprising from 5′ to 3′: a first homology arm comprising a sequence of at least about 20 (e.g., at least about 40, 80, 120, 150, 200, 300, 500, or 1 kb) nucleotides 5′ to the first region, a synthetic DNA sequence of at least about 10 nucleotides, and a second homology arm comprising a sequence of at least about 20 (e.g., at least about 40, 80, 120, 150, 200, 300, 500, or 1 kb) nucleotides 3′ to the second region.

In another aspect, the present disclosure provides a method for modifying a target nucleic acid locus of interest. The method may comprise delivering to the target nucleic acid locus any of the non-natural systems disclosed herein, including an enzyme and at least one synthetic guide RNA (sgRNA) disclosed herein. The enzyme may form a complex with the at least one sgRNA, and upon binding of the complex to the target nucleic acid locus of interest, may modify the target nucleic acid locus of interest. Delivering the enzyme to said locus may comprise transfecting a cell with the system or nucleic acids encoding the system. Delivering the nuclease to said locus may comprise electroporating a cell with the system or nucleic acids encoding the system. Delivering the nuclease to said locus may comprise incubating the system in a buffer with a nucleic acid comprising the locus of interest. In some cases, the target nucleic acid locus comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The target nucleic acid locus may comprise genomic DNA, viral DNA, viral RNA, or bacterial DNA. The target nucleic acid locus may be within a cell. The target nucleic acid locus may be in vitro. The target nucleic acid locus may be within a eukaryotic cell or a prokaryotic cell. The cell may be an animal cell, a human cell, bacterial cell, archaeal cell, or a plant cell. The enzyme may induce a single or double-stranded break at or proximal to the target locus of interest.

In cases where the target nucleic acid locus may be within a cell, the enzyme may be supplied as a nucleic acid containing an open reading frame encoding the enzyme having a RuvC_III domain having at least about 75% (e.g., at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%) identity to any one of SEQ ID NOs: 2242-2251. The deoxyribonucleic acid (DNA) containing an open reading frame encoding said endonuclease may comprise a sequence substantially identical to any of SEQ ID NOs: 5578-5580 or at variant having at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 5578-5580. In some cases, the nucleic acid comprises a promoter to which the open reading frame encoding the endonuclease is operably linked. The promoter may be a CMV, EF1a, SV40, PGK1, Ubc, human beta actin, CAG, TRE, or CaMKIIa promoter. The endonuclease may be supplied as a capped mRNA containing said open reading frame encoding said endonuclease. The endonuclease may be supplied as a translated polypeptide. The at least one engineered sgRNA may be supplied as deoxyribonucleic acid (DNA) containing a gene sequence encoding said at least one engineered sgRNA operably linked to a ribonucleic acid (RNA) pol III promoter. In some cases, the organism may be eukaryotic. In some cases, the organism may be fungal. In some cases, the organism may be human.

Systems of the present disclosure may be used for various applications, such as, for example, nucleic acid editing (e.g., gene editing), binding to a nucleic acid molecule (e.g., sequence-specific binding). Such systems may be used, for example, for addressing (e.g., removing or replacing) a genetically inherited mutation that may cause a disease in a subject, inactivating a gene in order to ascertain its function in a cell, as a diagnostic tool to detect disease-causing genetic elements (e.g. via cleavage of reverse-transcribed viral RNA or an amplified DNA sequence encoding a disease-causing mutation), as deactivated enzymes in combination with a probe to target and detect a specific nucleotide sequence (e.g. sequence encoding antibiotic resistance int bacteria), to render viruses inactive or incapable of infecting host cells by targeting viral genomes, to add genes or amend metabolic pathways to engineer organisms to produce valuable small molecules, macromolecules, or secondary metabolites, to establish a gene drive element for evolutionary selection, to detect cell perturbations by foreign small molecules and nucleotides as a biosensor.

EXAMPLES
Example 1—Metagenomic Analysis for New Proteins

Metagenomic samples were collected from sediment, soil and animal. Deoxyribonucleic acid (DNA) was extracted with a Zymobiomics DNA mini-prep kit and sequenced on an Illumina HiSeq® 2500. Samples were collected with consent of property owners. Additional raw sequence data from public sources included animal microbiomes, sediment, soil, hot springs, hydrothermal vents, marine, peat bogs, permafrost, and sewage sequences. Metagenomic sequence data was searched using Hidden Markov Models generated based on documented Cas protein sequences including type II Cas effector proteins to identify new Cas effectors. Novel effector proteins identified by the search were aligned to documented proteins to identify potential active sites. This metagenomic workflow resulted in delineation of the families of class II, type II CRISPR endonucleases described herein.

Example 2—(General Protocol) PAM Sequence Identification/Confirmation for the Endonucleases Described Herein

PAM sequences were determined by sequencing plasmids containing randomly-generated PAM sequences that can be cleaved by putative endonucleases expressed in an E. coli lysate-based expression system (myTXTL, Arbor Biosciences). In this system, an E. coli codon optimized nucleotide sequence was transcribed and translated from a PCR fragment under control of a T7 promoter. A second PCR fragment with a tracr sequence under a T7 promoter and a minimal CRISPR array composed of a T7 promoter followed by a repeat-spacer-repeat sequence was transcribed in the same reaction. Successful expression of the endonuclease and tracr sequence in the TXTL system followed by CRISPR array processing provided active in vitro CRISPR nuclease complexes.

A library of target plasmids containing a spacer sequence matching that in the minimal array followed by 8N mixed bases (putative PAM sequences) was incubated with the output of the TXTL reaction. After 1-3 hr, the reaction was stopped and the DNA was recovered via a DNA clean-up kit, e.g., Zymo DCC, AMPure XP beads, QiaQuick etc. Adapter sequences were blunt-end ligated to DNA with active PAM sequences that had been cleaved by the endonuclease, whereas DNA that had not been cleaved was inaccessible for ligation. DNA segments comprising active PAM sequences were then amplified by PCR with primers specific to the library and the adapter sequence. The PCR amplification products were resolved on a gel to identify amplicons that corresponded to cleavage events. The amplified segments of the cleavage reaction were also used as template for preparation of an NGS library. Sequencing this resulting library, which was a subset of the starting 8N library, revealed the sequences which contain the correct PAM for the active CRISPR complex. For PAM testing with a single RNA construct, the same procedure was repeated except that an in vitro transcribed RNA was added along with the plasmid library and the tracr/minimal CRISPR array template was omitted. For endonucleases where NGS libraries were prepared, seqLogo (see e.g., Huber et al. Nat Methods. 2015 February; 12(2):115-21) representations were constructed. The seqLogo module used to construct these representations takes the position weight matrix of a DNA sequence motif (e.g. a PAM sequence) and plots the corresponding sequence logo as introduced by Schneider and Stephens (see e.g. Schneider et al. Nucleic Acids Res. 1990 Oct. 25; 18(20):6097-100. The characters representing the sequence in the seqLogo representations have been stacked on top of each other for each position in the aligned sequences (e.g. PAM sequences). The height of each letter is proportional to its frequency, and the letters have been sorted so the most common one is on top.

Example 3—(General Protocol) RNA Folding of tracrRNA and sgRNA Structures

Folded structures of guide RNA sequences at 37° C. were computed using the method of Andronescu et al. Bioinformatics. 2007 Jul. 1; 23(13):i19-28, which is incorporated by reference herein in its entirety.

Example 4—(General Protocol) In Vitro Cleavage Efficiency of MG CRISPR Complexes

Endonucleases were expressed as His-tagged fusion proteins from an inducible T7 promoter in a protease deficient E. coli B strain. Cells expressing the His-tagged proteins were lysed by sonication and the His-tagged proteins were purified by Ni-NTA affinity chromatography on a HisTrap FF column (GE Lifescience) on an AKTA Avant FPLC (GE Lifescience). The eluate was resolved by SDS-PAGE on acrylamide gels (Bio-Rad) and stained with InstantBlue Ultrafast coomassie (Sigma-Aldrich). Purity was determined using densitometry of the protein band with ImageLab software (Bio-Rad). Purified endonucleases were dialyzed into a storage buffer composed of 50 mM Tris-HCl, 300 mM NaCl, 1 mM TCEP, 5% glycerol; pH 7.5 and stored at −80° C.

Target DNAs containing spacer sequences and PAM sequences (determined e.g., as in Example 2) were constructed by DNA synthesis. A single representative PAM was chosen for testing when the PAM had degenerate bases. The target DNAs comprised 2200 bp of linear DNA derived from a plasmid via PCR amplification with a PAM and spacer located 700 bp from one end. Successful cleavage resulted in fragments of 700 and 1500 bp. The target DNA, in vitro transcribed single RNA, and purified recombinant protein were combined in cleavage buffer (10 mM Tris, 100 mM NaCl, 10 mM MgCl₂) with an excess of protein and RNA and incubated for 5 minutes to 3 hours, usually 1 hr. The reaction was stopped via addition of RNAse A and incubation at 60 minutes. The reaction was then resolved on a 1.2% TAE agarose gel and the fraction of cleaved target DNA is quantified in ImageLab software.

Example 5—(General Protocol) Testing of Genome Cleavage Activity of MG CRISPR Complexes in E. coli

E. coli lacks the capacity to efficiently repair double-stranded DNA breaks. Thus, cleavage of genomic DNA can be a lethal event. Exploiting this phenomenon, endonuclease activity was tested in E. coli by recombinantly expressing an endonuclease and a tracrRNA in a target strain with spacer/target and PAM sequences integrated into its genomic DNA.

In this assay, the PAM sequence is specific for the endonuclease being tested as determined by the methods described in Example 2. sgRNA sequences were determined based upon the sequence and predicted structure of the tracrRNA. Repeat-anti-repeat pairings of 8-12 bp (generally 10 bp) were chosen, starting from the 5′ end of the repeat. The remaining 3′ end of the repeat and 5′ end of the tracrRNA were replaced with a tetraloop. Generally, the tetraloop was GAAA, but other tetraloops can be used, particularly if the GAAA sequence is predicted to interfere with folding. In these cases, a TTCG tetraloop was used.

Engineered strains with PAM sequences integrated into their genomic DNA were transformed with DNA encoding the endonuclease. Transformants were then made chemocompetent and transformed with 50 ng of single guide RNAs either specific to the target sequence (“on target”), or non-specific to the target (“non target”). After heat shock, transformations were recovered in SOC for 2 hrs at 37° C. Nuclease efficiency was then determined by a 5-fold dilution series grown on induction media. Colonies were quantified from the dilution series in triplicate.

Example 6a—(General protocol) Testing of Genome Cleavage Activity of MG CRISPR Complexes in Mammalian Cells

To show targeting and cleavage activity in mammalian cells, the MG Cas effector protein sequences were tested in two mammalian expression vectors: (a) one with a C-terminal SV40 NLS and a 2A-GFP tag, and (b) one with no GFP tag and two SV40 NLS sequences, one on the N-terminus and one on the C-terminus. In some instances, nucleotide sequences encoding the endonucleases were codon-optimized for expression in mammalian cells.

The corresponding single guide RNA sequence (sgRNA) with targeting sequence attached is cloned into a second mammalian expression vector. The two plasmids are cotransfected into HEK293T cells. 72 hr after co-transfection of the expression plasmid and a sgRNA targeting plasmid into HEK293T cells, the DNA is extracted and used for the preparation of an NGS-library. Percent NHEJ is measured via indels in the sequencing of the target site to demonstrate the targeting efficiency of the enzyme in mammalian cells. At least 10 different target sites were chosen to test each protein's activity.

Example 6b—(General Protocol) Testing of Genome Cleavage Activity of MG CRISPR Complexes in Mammalian Cells

To show targeting and cleavage activity in mammalian cells, the MG Cas effector protein sequences were cloned into two mammalian expression vector: (a) one with flanking N and C-terminal SV40 NLS sequences, a C-terminal His tag, and a 2A-GFP tag at the C terminus after the His tag (Backbone 1), and (b) one with flanking NLS sequences and C-terminal His tag but no T2A GFP tag (Backbone 2). In some instances, nucleotide sequences encoding the endonucleases were the native sequence, codon-optimized for expression in E. coli, or codon-optimized for expression in mammalian cells.

The corresponding single guide RNA sequence (sgRNA) with targeting sequence attached was cloned into a second mammalian expression vector. The two plasmids were cotransfected into HEK293T cells. 72 hr after co-transfection of the expression plasmid and a sgRNA targeting plasmid into HEK293T cells, the DNA was extracted and used for the preparation of an NGS-library. Percent NHEJ was measured via indels in the sequencing of the target site to demonstrate the targeting efficiency of the enzyme in mammalian cells. About 7-12 different target sites were chosen for testing each protein's activity. An arbitrary threshold of 5% indels was used to identify active candidates.

Example 7—Gene Editing Outcomes at the DNA Level for B2M

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (106 pmol protein/160 pmol guide) (SEQ ID NOs: 6305-6386) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 6387-6468). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 1).

TABLE 1A

Guide sequences used in Example 7

SEQ

ID

NO:
Entity Name
Sequence

6305
MG3-6-B2M-sgRNA-A1
mC*mG*mC*rUrArCrUrCrUrCrUrCrUrUrUrCrUrGrGrCrCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6306
MG3-6-B2M-sgRNA-B1
mA*mG*mA*rGrArCrUrCrArCrGrCrUrGrGrArUrArGrCrCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6307
MG3-6-B2M-sgRNA-C1
mG*mA*mG*rArGrArGrUrArGrCrGrCrGrArGrCrArCrArGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6308
MG3-6-B2M-sgRNA-D1
mC*mC*mC*rGrArUrArUrUrCrCrUrCrArGrGrUrArCrUrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6309
MG3-6-B2M-sgRNA-E1
mA*mU*mU*rCrCrUrCrArGrGrUrArCrUrCrCrArArArGrArUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6310
MG3-6-B2M-sgRNA-F1
mA*mA*mU*rUrUrCrCrUrGrArArUrUrGrCrUrArUrGrUrGrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6311
MG3-6-B2M-sgRNA-G1
mG*mA*mG*rArArUrUrGrArArArArArGrUrGrGrArGrCrArUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6312
MG3-6-B2M-sgRNA-H1
mG*mC*mA*rUrUrCrArGrArCrUrUrGrUrCrUrUrUrCrArGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6313
MG3-6-B2M-sgRNA-A2
mA*mG*mA*rCrUrUrArCrCrCrCrArCrUrUrArArCrUrArUrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6314
MG3-6-B2M-sgRNA-B2
mU*mU*mC*rArGrUrGrUrArGrUrArCrArArGrArGrArUrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6315
MG3-6-B2M-sgRNA-C2
mA*mG*mU*rUrCrUrCrCrUrUrGrGrUrGrGrCrCrCrGrCrCrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6316
MG3-6-B2M-sgRNA-D2
mG*mU*mG*rGrCrCrCrGrCrCrGrUrGrGrGrGrCrUrArGrUrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6317
MG3-6-B2M-sgRNA-E2
mC*mC*mG*rCrCrGrUrGrGrGrGrCrUrArGrUrCrCrArGrGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

6318
MG3-6-B2M-sgRNA-F2
mG*mC*mC*rCrCrUrUrUrCrGrGrCrGrGrGrGrArGrCrArGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6319
MG3-6-B2M-sgRNA-G2
mG*mA*mC*rCrUrUrUrGrGrCrCrUrArCrGrGrCrGrArCrGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6320
MG3-6-B2M-sgRNA-H2
mG*mC*mG*rUrCrGrArUrArArGrCrGrUrCrArGrArGrCrGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6321
MG3-6-B2M-sgRNA-A3
mC*mG*mU*rCrArGrArGrCrGrCrCrGrArGrGrUrUrGrGrGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6322
MG3-6-B2M-sgRNA-B3
mG*mG*mG*rUrUrUrCrUrCrUrUrCrCrGrCrUrCrUrUrUrCrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6323
MG3-6-B2M-sgRNA-C3
mG*mC*mG*rCrArGrCrUrGrGrArGrUrGrGrGrGrGrArCrGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6324
MG3-6-B2M-sgRNA-D3
mG*mC*mU*rCrGrUrCrCrCrArArArGrGrCrGrCrGrGrCrGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6325
MG3-6-B2M-sgRNA-E3
mU*mG*mU*rGrArArCrGrCrGrUrGrGrArGrGrGrGrCrGrCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6326
MG3-6-B2M-sgRNA-F3
mG*mU*mC*rUrGrCrUrGrCrGrGrCrUrCrUrGrCrUrUrCrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6327
MG3-6-B2M-sgRNA-G3
mG*mC*mU*rUrCrCrCrUrUrArGrArCrUrGrGrArGrArGrCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6328
MG3-6-B2M-sgRNA-H3
mA*mA*mG*rUrUrCrGrCrArUrGrUrCrCrUrArGrCrArCrCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6329
MG3-6-B2M-sgRNA-A4
mU*mC*mC*rUrArGrCrArCrCrUrCrUrGrGrGrUrCrUrArUrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6330
MG3-6-B2M-sgRNA-B4
mC*mC*mU*rCrCrCrCrArCrGrGrUrGrUrGrGrCrCrCrCrArCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6331
MG3-6-B2M-sgRNA-C4
mA*mA*mG*rGrGrArArGrCrArGrArGrCrCrGrCrArGrCrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

6332
MG3-6-B2M-sgRNA-D4
mG*mC*mU*rUrArCrCrCrGrGrGrCrGrArCrGrCrCrUrCrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUmU*mU*mU

6333
MG3-6-B2M-sgRNA-E4
mC*mU*mC*rCrArGrCrUrGrCrGrCrUrGrGrGrGrGrArGrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6334
MG3-6-B2M-sgRNA-F4
mU*mU*mG*rUrCrCrCrGrArCrCrCrUrCrCrCrGrUrCrGrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6335
MG3-6-B2M-sgRNA-G4
mG*mA*mC*rCrCrUrCrCrCrGrUrCrGrCrCrGrUrArGrGrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6336
MG3-6-B2M-sgRNA-H4
mG*mU*mG*rCrGrCrArCrCrCrCrCrUrUrCrCrCrCrArCrUrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6337
MG3-6-B2M-sgRNA-A5
mC*mC*mA*rGrGrCrCrArCrCrCrCrGrCrCrGrCrUrUrCrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6338
MG3-6-B2M-sgRNA-B5
mG*mC*mC*rGrCrUrUrCrCrCrCrGrArGrArUrCrCrArGrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6339
MG3-6-B2M-sgRNA-C5
mC*mC*mA*rGrCrCrCrUrGrGrArCrUrArGrCrCrCrCrArCrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6340
MG3-6-B2M-sgRNA-D5
mU*mC*mA*rCrGrGrArGrCrGrArGrArGrArGrCrArCrArGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6341
MG3-6-B2M-sgRNA-E5
mA*mG*mA*rGrGrGrUrGrCrArGrArGrCrGrGrGrArGrArGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6342
MG3-6-B2M-sgRNA-F5
mA*mG*mG*rArCrCrArGrArGrCrGrGrGrArGrGrGrUrArGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6343
MG3-6-B2M-sgRNA-G5
mC*mG*mA*rGrArUrUrGrArArGrUrCrArArGrCrCrUrArArCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6344
MG3-6-B2M-sgRNA-H5
mA*mG*mA*rArArArArCrGrCrCrUrGrCrCrUrUrCrUrGrCrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6345
MG3-6-B2M-sgRNA-A6
mU*mC*mU*rCrCrArGrArGrCrArArArCrUrGrGrGrCrGrGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6346
MG3-6-B2M-sgRNA-B6
mG*mG*mC*rCrCrUrGrUrGrGrUrCrUrUrUrUrCrGrUrArCrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6347
MG3-6-B2M-sgRNA-C6
mA*mC*mU*rUrUrCrGrGrUrUrUrUrGrArArArArCrArUrGrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6348
MG3-6-B2M-sgRNA-D6
mA*mA*mA*rGrArGrGrArArGrCrCrCrUrCrUrGrUrArCrGrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6349
MG3-6-B2M-sgRNA-E6
mA*mG*mC*rCrCrUrCrUrGrUrArCrGrArArArArGrArCrCrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6350
MG3-6-B2M-sgRNA-F6
mU*mG*mC*rGrCrUrCrCrCrGrCrArArArArGrCrCrCrUrGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6351
MG3-6-B2M-sgRNA-G6
mA*mA*mA*rArGrArArArArGrArArArGrArArArGrArArGrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6352
MG3-6-B2M-sgRNA-H6
mA*mA*mA*rGrArUrArArUrCrCrArArGrArUrGrGrUrUrArCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6353
MG3-6-B2M-sgRNA-A7
mU*mA*mC*rCrArArGrArCrUrGrUrUrGrArGrGrArCrGrCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6354
MG3-6-B2M-sgRNA-B7
mU*mC*mC*rArArArGrUrArArUrArCrArUrGrCrCrArUrGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUmU*mU*mU

6355
MG3-6-B2M-sgRNA-C7
mA*mU*mU*rArCrUrUrUrGrGrArArArUrUrUrUrCrArArArAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6356
MG3-6-B2M-sgRNA-D7
mA*mA*mA*rUrArArGrArUrUrUrUrUrUrUrUrUrArArArUrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6357
MG3-6-B2M-sgRNA-E7
mU*mG*mC*rCrArGrGrUrArCrUrUrArGrArArArGrUrGrCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6358
MG3-6-B2M-sgRNA-F7
mC*mU*mC*rArArCrArGrUrCrUrUrGrGrUrArArCrCrArUrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6359
MG3-6-B2M-sgRNA-G7
mU*mG*mA*rUrArCrUrUrGrUrCrCrUrCrUrUrCrUrUrArGrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6360
MG3-6-B2M-sgRNA-H7
mG*mC*mU*rUrUrUrArArUrGrUrUrArUrGrArArArArArArAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6361
MG3-6-B2M-sgRNA-A8
mU*mA*mU*rGrArArArArArArArUrCrArGrGrUrCrUrUrCrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6362
MG3-6-B2M-sgRNA-B8
mG*mA*mU*rUrCrCrCrCrArArUrCrCrArCrCrUrCrUrUrGrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6363
MG3-6-B2M-sgRNA-C8
mG*mG*mC*rArGrCrUrArCrUrCrCrUrCrCrUrUrGrUrCrUrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

6364
MG3-6-B2M-sgRNA-D8
mG*mC*mU*rGrUrGrGrGrGrArGrArArGrGrArGrGrArGrUrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6365
MG3-6-B2M-sgRNA-E8
mU*mA*mG*rArArArCrArCrCrCrUrArUrCrArUrUrArArGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

6366
MG3-6-B2M-sgRNA-F8
mA*mG*mG*rCrUrArCrUrArGrCrCrCrCrArUrCrArArGrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6367
MG3-6-B2M-sgRNA-G8
mG*mA*mG*rGrUrGrGrArUrUrGrGrGrGrArArUrCrUrArArUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6368
MG3-6-B2M-sgRNA-H8
mA*mU*mA*rArGrArArCrArUrArUrUrArArArUrGrCrCrUrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6369
MG3-6-B2M-sgRNA-A9
mU*mA*mA*rArUrGrCrCrUrCrArGrGrGrArUrCrArGrArGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

6370
MG3-6-B2M-sgRNA-B9
mC*mU*mC*rUrCrUrGrUrUrUrGrArGrGrGrArArGrGrCrGrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

6371
MG3-6-B2M-sgRNA-C9
mC*mU*mA*rArGrArArGrArGrGrArCrArArGrUrArUrCrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6372
MG3-6-B2M-sgRNA-D9
mC*mA*mC*rCrUrArUrCrCrCrUrGrUrUrGrUrArUrUrUrUrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6373
MG3-6-B2M-sgRNA-E9
mA*mU*mU*rUrGrCrCrArGrCrUrCrUrUrGrUrArUrGrCrArUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6374
MG3-6-B2M-sgRNA-F9
mG*mA*mA*rArUrUrArGrGrUrArCrArArArGrUrCrArGrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6375
MG3-6-B2M-sgRNA-G9
mU*mA*mU*rArArArArCrCrUrCrArGrCrArGrArArArUrArAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6376
MG3-6-B2M-sgRNA-H9
mU*mG*mU*rUrGrUrUrUrGrGrUrArArGrArArCrArUrArCrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6377
MG3-6-B2M-sgRNA-A10
mA*mA*mC*rArArArArCrCrUrCrUrUrUrArUrUrUrCrUrGrCr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6378
MG3-6-B2M-sgRNA-B10
mA*mU*mU*rUrCrUrGrCrUrGrArGrGrUrUrUrUrArUrArUrGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6379
MG3-6-B2M-sgRNA-C10
mG*mC*mA*rArArUrArCrCrUrUrArArArUrGrGrUrUrGrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6380
MG3-6-B2M-sgRNA-D10
mA*mU*mA*rArArArUrArCrArArCrArGrGrGrArUrArGrGrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6381
MG3-6-B2M-sgRNA-E10
mA*mA*mU*rGrGrArGrUrArArUrGrCrArUrGrUrGrArCrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6382
MG3-6-B2M-sgRNA-F10
mA*mC*mA*rGrGrUrGrArUrUrGrCrUrGrUrArArArCrUrArGr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6383
MG3-6-B2M-sgRNA-G10
mC*mU*mU*rUrCrCrArArArArUrGrArGrArGrGrCrArUrGrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6384
MG3-6-B2M-sgRNA-H10
mA*mA*mU*rArUrUrGrCrCrArGrGrGrUrArUrUrUrCrArCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6385
MG3-6-B2M-sgRNA-A11
mU*mG*mC*rCrUrUrUrUrUrUrGrUrUrUrUrUrUrUrUrCrUrAr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

6386
MG3-6-B2M-sgRNA-B11
mU*mC*mU*rArGrCrArGrUrArUrCrUrUrCrUrGrUrCrArCrUr

GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

Notations for chemical modifications: m = 2′O-methyl ribonucleotide (e.g mC = cytosine ribonucleotide with 2′-O Methyl in place of 2′ hydroxyl); f = 2′-fluoro ribonucleotide (e.g fC = cytosine ribonucleotide with 2′ fluorine in place of 2′ hydroxyl); * = phosphorothioate bond; r: native RNA linkage comprising the sugar ribose (for example the ribose or RNA form of the A base is written rA), d: deoxyribose sugar (DNA) linkage (for example a deoxyribose form of the A base is written dA)

TABLE 1B

Sites targeted in Example 7

SEQ

ID

NO:
Entity Name
Sequence

6387
MG3-6-B2M-target site-A1
CGCTACTCTCT

CTTTCTGGCCT

6388
MG3-6-B2M-target site-B1
AGAGACTCACG

CTGGATAGCCT

6389
MG3-6-B2M-target site-C1
GAGAGAGTAGC

GCGAGCACAGC

6390
MG3-6-B2M-target site-D1
CCCGATATTCC

TCAGGTACTCC

6391
MG3-6-B2M-target site-E1
ATTCCTCAGGT

ACTCCAAAGAT

6392
MG3-6-B2M-target site-F1
AATTTCCTGAA

TTGCTATGTGT

6393
MG3-6-B2M-target site-G1
GAGAATTGAAA

AAGTGGAGCAT

6394
MG3-6-B2M-target site-H1
GCATTCAGACT

TGTCTTTCAGC

6395
MG3-6-B2M-target site-A2
AGACTTACCCC

ACTTAACTATC

6396
MG3-6-B2M-target site-B2
TTCAGTGTAGT

ACAAGAGATAG

6397
MG3-6-B2M-target site-C2
AGTTCTCCTTG

GTGGCCCGCCG

6398
MG3-6-B2M-target site-D2
GTGGCCCGCCG

TGGGGCTAGTC

6399
MG3-6-B2M-target site-E2
CCGCCGTGGGG

CTAGTCCAGGG

6400
MG3-6-B2M-target site-F2
GCCCCTTTCGG

CGGGGAGCAGG

6401
MG3-6-B2M-target site-G2
GACCTTTGGCC

TACGGCGACGG

6402
MG3-6-B2M-target site-H2
GCGTCGATAAG

CGTCAGAGCGC

6403
MG3-6-B2M-target site-A3
CGTCAGAGCGC

CGAGGTTGGGG

6404
MG3-6-B2M-target site-B3
GGGTTTCTCTT

CCGCTCTTTCG

6405
MG3-6-B2M-target site-C3
GCGCAGCTGGA

GTGGGGGACGG

6406
MG3-6-B2M-target site-D3
GCTCGTCCCAA

AGGCGCGGCGC

6407
MG3-6-B2M-target site-E3
TGTGAACGCGT

GGAGGGGCGCT

6408
MG3-6-B2M-target site-F3
GTCTGCTGCGG

CTCTGCTTCCC

6409
MG3-6-B2M-target site-G3
GCTTCCCTTAG

ACTGGAGAGCT

6410
MG3-6-B2M-target site-H3
AAGTTCGCATG

TCCTAGCACCT

6411
MG3-6-B2M-target site-A4
TCCTAGCACCT

CTGGGTCTATG

6412
MG3-6-B2M-target site-B4
CCTCCCCACGG

TGTGGCCCCAC

6413
MG3-6-B2M-target site-C4
AAGGGAAGCAG

AGCCGCAGCAG

6414
MG3-6-B2M-target site-D4
GCTTACCCGGG

CGACGCCTCCC

6415
MG3-6-B2M-target site-E4
CTCCAGCTGCG

CTGGGGGAGCC

6416
MG3-6-B2M-target site-F4
TTGTCCCGACC

CTCCCGTCGCC

6417
MG3-6-B2M-target site-G4
GACCCTCCCGT

CGCCGTAGGCC

6418
MG3-6-B2M-target site-H4
GTGCGCACCCC

CTTCCCCACTC

6419
MG3-6-B2M-target site-A5
CCAGGCCACCC

CGCCGCTTCCC

6420
MG3-6-B2M-target site-B5
GCCGCTTCCCC

GAGATCCAGCC

6421
MG3-6-B2M-target site-C5
CCAGCCCTGGA

CTAGCCCCACG

6422
MG3-6-B2M-target site-D5
TCACGGAGCGA

GAGAGCACAGC

6423
MG3-6-B2M-target site-E5
AGAGGGTGCAG

AGCGGGAGAGG

6424
MG3-6-B2M-target site-F5
AGGACCAGAGC

GGGAGGGTAGG

6425
MG3-6-B2M-target site-G5
CGAGATTGAAG

TCAAGCCTAAC

6426
MG3-6-B2M-target site-H5
AGAAAAACGCC

TGCCTTCTGCG

6427
MG3-6-B2M-target site-A6
TCTCCAGAGCA

AACTGGGCGGC

6428
MG3-6-B2M-target site-B6
GGCCCTGTGGT

CTTTTCGTACA

6429
MG3-6-B2M-target site-C6
ACTTTCGGTTT

TGAAAACATGA

6430
MG3-6-B2M-target site-D6
AAAGAGGAAGC

CCTCTGTACGA

6431
MG3-6-B2M-target site-E6
AGCCCTCTGTA

CGAAAAGACCA

6432
MG3-6-B2M-target site-F6
TGCGCTCCCGC

AAAAGCCCTGG

6433
MG3-6-B2M-target site-G6
AAAAGAAAAGA

AAGAAAGAAGT

6434
MG3-6-B2M-target site-H6
AAAGATAATCC

AAGATGGTTAC

6435
MG3-6-B2M-target site-A7
TACCAAGACTG

TTGAGGACGCC

6436
MG3-6-B2M-target site-B7
TCCAAAGTAAT

ACATGCCATGC

6437
MG3-6-B2M-target site-C7
ATTACTTTGGA

AATTTTCAAAA

6438
MG3-6-B2M-target site-D7
AAATAAGATTT

TTTTTTAAATA

6439
MG3-6-B2M-target site-E7
TGCCAGGTACT

TAGAAAGTGCT

6440
MG3-6-B2M-target site-F7
CTCAACAGTCT

TGGTAACCATC

6441
MG3-6-B2M-target site-G7
TGATACTTGTC

CTCTTCTTAGA

6442
MG3-6-B2M-target site-H7
GCTTTTAATGT

TATGAAAAAAA

6443
MG3-6-B2M-target site-A8
TATGAAAAAAA

TCAGGTCTTCA

6444
MG3-6-B2M-target site-B8
GATTCCCCAAT

CCACCTCTTGA

6445
MG3-6-B2M-target site-C8
GGCAGCTACTC

CTCCTTGTCTG

6446
MG3-6-B2M-target site-D8
GCTGTGGGGAG

AAGGAGGAGTA

6447
MG3-6-B2M-target site-E8
TAGAAACACCC

TATCATTAAGG

6448
MG3-6-B2M-target site-F8
AGGCTACTAGC

CCCATCAAGAG

6449
MG3-6-B2M-target site-G8
GAGGTGGATTG

GGGAATCTAAT

6450
MG3-6-B2M-target site-H8
ATAAGAACATA

TTAAATGCCTC

6451
MG3-6-B2M-target site-A9
TAAATGCCTCA

GGGATCAGAGC

6452
MG3-6-B2M-target site-B9
CTCTCTGTTTG

AGGGAAGGCGG

6453
MG3-6-B2M-target site-C9
CTAAGAAGAGG

ACAAGTATCAG

6454
MG3-6-B2M-target site-D9
CACCTATCCCT

GTTGTATTTTA

6455
MG3-6-B2M-target site-E9
ATTTGCCAGCT

CTTGTATGCAT

6456
MG3-6-B2M-target site-F9
GAAATTAGGTA

CAAAGTCAGAG

6457
MG3-6-B2M-target site-G9
TATAAAACCTC

AGCAGAAATAA

6458
MG3-6-B2M-target site-H9
TGTTGTTTGGT

AAGAACATACC

6459
MG3-6-B2M-target site-A10
AACAAAACCTC

TTTATTTCTGC

6460
MG3-6-B2M-target site-B10
ATTTCTGCTGA

GGTTTTATATG

6461
MG3-6-B2M-target site-C10
GCAAATACCTT

AAATGGTTGAG

6462
MG3-6-B2M-target site-D10
ATAAAATACAA

CAGGGATAGGT

6463
MG3-6-B2M-target site-E10
AATGGAGTAAT

GCATGTGACAG

6464
MG3-6-B2M-target site-F10
ACAGGTGATTG

CTGTAAACTAG

6465
MG3-6-B2M-target site-G10
CTTTCCAAAAT

GAGAGGCATGA

6466
MG3-6-B2M-target site-H10
AATATTGCCAG

GGTATTTCACT

6467
MG3-6-B2M-target site-A11
TGCCTTTTTTG

TTTTTTTTCTA

6468
MG3-6-B2M-target site-B11
TCTAGCAGTAT

CTTCTGTCACT

Example 8—Gene Editing Outcomes at the DNA Level for Mouse TRAC

Primary T cells were purified from C57BL/6 mouse spleens. Nucleofection of MG3-6 RNPs (126 pmol protein/160 pmol guide) (SEQ ID NOs: 6469-6508) was performed into T cells (200,000) using the Lonza 4D electroporator and 100 pmol transfection enhancer (IDT). Cells were harvested and genomic DNA prepared five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 6509-6548). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 2). For analysis by flow cytometry, 3 days post-nucleofection, 100,000 mouse T cells were stained with anti-mouse CD3 antibody (Clone 17A2, Invitrogen 11-0032-82) for 30 minutes at 4° C. and analyzed on an Attune Nxt flow cytometer.

TABLE 2A

Guide sequences used in Example 8

SEQ

ID

NO:
Entity Name
Sequence

6469
MG3-6-mTRAC-sgRNA-
mA*mG*mA*rArCrCrUrGrCrUrGrUrGrUrArCrCrArGrUrUrArGr

A1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6470
MG3-6-mTRAC-sgRNA-B1
mA*mA*mC*rUrGrUrGrCrUrGrGrArCrArUrGrArArArGrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6471
MG3-6-m TRAC-sgRNA-
mA*mA*mG*rCrUrArUrGrGrArUrUrCrCrArArGrArGrCrArArGr

C1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6472
MG3-6-m TRAC-sgRNA-
mUmC*mA*rCrCrUrGrCrCrArArGrArUrArUrCrUrUrCrArArGrU

D1
rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6473
MG3-6-mTRAC-sgRNA-E1
mA*mG*mU*rUrUrUrGrUrCrArGrUrGrArUrGrArArCrGrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6474
MG3-6-mTRAC-sgRNA-F1
mG*mA*mA*rCrArGrGrCrArGrArGrGrGrUrGrCrUrGrUrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6475
MG3-6-mTRAC-sgRNA-
mC*mA*mG*rArGrGrGrUrGrCrUrGrUrCrCrUrGrArGrArCrCrGr

G1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6476
MG3-6-mTRAC-sgRNA-
mA*mG*mG*rArUrCrUrUrUrUrArArCrUrGrGrUrArCrArCrArGr

H1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6477
MG3-6-mTRAC-sgRNA-
mUmU*mU*rArArCrUrGrGrUrArCrArCrArGrCrArGrGrUrUrGr

A2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6478
MG3-6-mTRAC-sgRNA-B2
mA*mG*mG*rUrUrCrUrGrGrGrUrUrCrUrGrGrArUrGrUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6479
MG3-6-mTRAC-sgRNA-
mA*mA*mC*rUrUrUrCrArArArArCrCrUrGrUrCrArGrUrUrArGrU

C2
rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6480
MG3-6-mTRAC-sgRNA-
mC*mG*mA*rArUrCrCrUrCrCrUrGrCrUrGrArArArGrUrArGrGr

D2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6481
MG3-6-mTRAC-sgRNA-E2
mG*mG*mA*rUrUrUrArArCrCrUrGrCrUrCrArUrGrArCrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6482
MG3-6-mTRAC-sgRNA-F2
mC*mU*mU*rUrCrArUrGrCrCrUrUrCrUrUrArCrCrUrCrArArGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6483
MG3-6-mTRAC-sgRNA-
mG*mA*mC*rCrArCrArGrCrCrUrCrArGrCrGrUrCrArUrGrArGr

G2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6484
MG3-6-m TRAC-sgRNA-
mU*mA*mA*rArUrCrCrGrGrCrUrArCrUrUrUrCrArGrCrArGrGr

H2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6485
MG3-6-mTRAC-sgRNA-
mA*mG*mG*rArUrUrCrGrGrArGrUrCrCrCrArUrArArCrUrGrGr

A3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6486
MG3-6-mTRAC-sgRNA-B3
mA*mU*mA*rArCrUrGrArCrArGrGrUrUrUrUrGrArArArGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6487
MG3-6-m TRAC-sgRNA-
mG*mU*mA*rCrUrUrCrCrUrCrArCrUrCrCrArGrGrUrCrUrGrGr

C3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6488
MG3-6-mTRAC-sgRNA-
mC*mC*mA*rCrCrUrCrGrUrCrArArGrArCrGrGrCrUrGrUrCrGr

D3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6489
MG3-6-mTRAC-sgRNA-E3
mU*mG*mG*rCrCrCrUrGrArUrUrCrArCrArArUrCrCrCrArCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6490
MG3-6-mTRAC-sgRNA-F3
mU*mU*mC*rArCrArArUrCrCrCrArCrCrUrGrGrArUrCrUrCrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6491
MG3-6-mTRAC-sgRNA-
mC*mU*mG*rGrArUrCrUrCrCrCrArGrArUrUrUrGrUrGrArGrGr

G3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUmU*mU*mU

6492
MG3-6-mTRAC-sgRNA-
mC*mA*mU*rUrCrArCrArArArArArArCrGrGrCrArGrGrGrGrGr

H3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6493
MG3-6-m TRAC-sgRNA-
mA*mA*mC*rGrGrCrArGrGrGrGrCrGrGrGrGrCrUrUrCrUrCrGr

A4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6494
MG3-6-mTRAC-sgRNA-B4
mG*mG*mG*rCrGrGrGrGrCrUrUrCrUrCrCrUrGrGrArUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6495
MG3-6-mTRAC-sgRNA-
mA*mU*mC*rUrGrArArGrArCrCrCrCrUrCrCrCrCrCrArUrGrGr

C4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6496
MG3-6-mTRAC-sgRNA-
mG*mU*mU*rUrUrUrUrGrUrUrUrUrUrUrUrUrUrUrUrUrUrUrGrU

D4
rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6497
MG3-6-mTRAC-sgRNA-E4
mG*mG*mU*rGrUrArGrArArArUrUrArUrCrUrCrArUrUrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6498
MG3-6-mTRAC-sgRNA-F4
mG*mG*mC*rUrCrArArUrArCrArCrArCrArGrUrArGrCrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6499
MG3-6-mTRAC-sgRNA-
mA*mU*mU*rUrUrUrUrUrUrArCrArArCrArUrUrCrUrCrCrArGrU

G4
rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6500
MG3-6-m TRAC-sgRNA-
mA*mC*mA*rGrGrGrGrArGrUrCrUrGrCrCrArUrGrGrGrGrGrGr

H4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6501
MG3-6-m TRAC-sgRNA-
mG*mU*mC*rUrGrCrCrArUrGrGrGrGrGrArGrGrGrGrUrCrUrGr

A5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6502
MG3-6-mTRAC-sgRNA-B5
mA*mG*mC*rArArCrCrUrUrCrCrUrCrArCrArArArUrCrUrGrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6503
MG3-6-mTRAC-sgRNA-
mU*mC*mA*rCrArArArUrCrUrGrGrGrArGrArUrCrCrArGrGrGr

C5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6504
MG3-6-mTRAC-sgRNA-
mA*mG*mA*rUrCrCrArGrGrUrGrGrGrArUrUrGrUrGrArArUrGr

D5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6505
MG3-6-mTRAC-sgRNA-E5
mU*mG*mG*rGrArUrUrGrUrGrArArUrCrArGrGrGrCrCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6506
MG3-6-mTRAC-sgRNA-F5
mG*mA*mC*rArGrCrCrGrUrCrUrUrGrArCrGrArGrGrUrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6507
MG3-6-mTRAC-sgRNA-
mU*mG*mA*rGrGrArGrGrArUrGrGrArGrCrUrUrGrGrGrArGrGr

G5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6508
MG3-6-mTRAC-sgRNA-
mG*mG*mA*rGrUrCrArGrGrCrUrCrUrGrUrCrArGrUrCrUrUrGr

H5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Notations for chemical modifications: m = 2′O-methyl ribonucleotide (e.g mC = cytosine ribonucleotide with 2′-O Methyl in place of 2′ hydroxyl); f = 2′-fluoro ribonucleotide (e.g fC = cytosine ribonucleotide with 2′ fluorine in place of 2′ hydroxyl); * = phosphorothioate bond; r: native RNA linkage comprising the sugar ribose (for example the ribose or RNA form of the A base is written rA), d: deoxyribose sugar (DNA) linkage (for example a deoxyribose form of the A base is written dA)

TABLE 2B

List of sites targeted in Example 8

SEQ

ID

NO:
Entity Name
Sequence

6509
MG3-6-mTRAC-target site-
AGAACCTGCTGTGTACCAGTTA

A1

6510
MG3-6-mTRAC-target site-
AACTGTGCTGGACATGAAAGCT

B1

6511
MG3-6-mTRAC-target site-
AAGCTATGGATTCCAAGAGCAA

C1

6512
MG3-6-mTRAC-target site-
TCACCTGCCAAGATATCTTCAA

D1

6513
MG3-6-mTRAC-target site-
AGTTTTGTCAGTGATGAACGTT

E1

6514
MG3-6-mTRAC-target site-
GAACAGGCAGAGGGTGCTGTCC

F1

6515
MG3-6-mTRAC-target site-
CAGAGGGTGCTGTCCTGAGACC

G1

6516
MG3-6-mTRAC-target site-
AGGATCTTTTAACTGGTACACA

H1

6517
MG3-6-mTRAC-target site-
TTTAACTGGTACACAGCAGGTT

A2

6518
MG3-6-mTRAC-target site-
AGGTTCTGGGTTCTGGATGTCT

B2

6519
MG3-6-mTRAC-target site-
AACTTTCAAAACCTGTCAGTTA

C2

6520
MG3-6-mTRAC-target site-
CGAATCCTCCTGCTGAAAGTAG

D2

6521
MG3-6-mTRAC-target site-
GGATTTAACCTGCTCATGACGC

E2

6522
MG3-6-mTRAC-target site-
CTTTCATGCCTTCTTACCTCAA

F2

6523
MG3-6-mTRAC-target site-
GACCACAGCCTCAGCGTCATGA

G2

6524
MG3-6-mTRAC-target site-
TAAATCCGGCTACTTTCAGCAG

H2

6525
MG3-6-mTRAC-target site-
AGGATTCGGAGTCCCATAACTG

A3

6526
MG3-6-mTRAC-target site-
ATAACTGACAGGTTTTGAAAGT

B3

6527
MG3-6-mTRAC-target site-
GTACTTCCTCACTCCAGGTCTG

C3

6528
MG3-6-mTRAC-target site-
CCACCTCGTCAAGACGGCTGTC

D3

6529
MG3-6-mTRAC-target site-
TGGCCCTGATTCACAATCCCAC

E3

6530
MG3-6-mTRAC-target site-
TTCACAATCCCACCTGGATCTC

F3

6531
MG3-6-mTRAC-target site-
CTGGATCTCCCAGATTTGTGAG

G3

6532
MG3-6-mTRAC-target site-
CATTCACAAAAAACGGCAGGGG

H3

6533
MG3-6-mTRAC-target site-
AACGGCAGGGGCGGGGCTTCTC

A4

6534
MG3-6-mTRAC-target site-
GGGCGGGGCTTCTCCTGGATCT

B4

6535
MG3-6-mTRAC-target site-
ATCTGAAGACCCCTCCCCCATG

C4

6536
MG3-6-mTRAC-target site-
GTTTTTTGTTTTTTTTTTTTTT

D4

6537
MG3-6-mTRAC-target site-
GGTGTAGAAATTATCTCATTGT

E4

6538
MG3-6-mTRAC-target site-
GGCTCAATACACACAGTAGCAG

F4

6539
MG3-6-mTRAC-target site-
ATTTTTTTTACAACATTCTCCA

G4

6540
MG3-6-mTRAC-target site-
ACAGGGGAGTCTGCCATGGGGG

H4

6541
MG3-6-mTRAC-target site-
GTCTGCCATGGGGGAGGGGTCT

A5

6542
MG3-6-mTRAC-target site-
AGCAACCTTCCTCACAAATCTG

B5

6543
MG3-6-mTRAC-target site-
TCACAAATCTGGGAGATCCAGG

C5

6544
MG3-6-mTRAC-target site-
AGATCCAGGTGGGATTGTGAAT

D5

6545
MG3-6-mTRAC-target site-
TGGGATTGTGAATCAGGGCCAA

E5

6546
MG3-6-mTRAC-target site-
GACAGCCGTCTTGACGAGGTGG

F5

6547
MG3-6-mTRAC-target site-
TGAGGAGGATGGAGCTTGGGAG

G5

6548
MG3-6-mTRAC-target site-
GGAGTCAGGCTCTGTCAGTCTT

H5

Example 9—Gene Editing Outcomes at the DNA Level for HPRT

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (126 pmol protein/160 pmol guide) (SEQ ID NOs: 6549-6615) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 6616-6682). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 3).

TABLE 3A

Guide sequences used in Example 9

SEQ

ID

NO:
Entity Name
Sequence

6549
MG3-6-HPRT-sgRNA-A1
mU*mU*mC*rCrUrCrUrGrCrArUrCrArGrUrUrUrUrArArUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6550
MG3-6-HPRT-sgRNA-B1
mG*mU*mG*rGrGrCrUrUrGrUrGrUrUrCrUrArArArGrGrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6551
MG3-6-HPRT-sgRNA-C1
mA*mG*mG*rArGrUrGrArGrArUrUrGrGrUrUrUrUrUrUrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6552
MG3-6-HPRT-sgRNA-D1
mU*mA*mA*rArArArArUrArArUrArUrUrUrArUrArArUrUrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6553
MG3-6-HPRT-sgRNA-E1
mG*mA*mG*rUrArUrUrUrUrUrArUrUrGrArArArArGrCrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6554
MG3-6-HPRT-sgRNA-F1
mA*mA*mA*rArArUrArUrUrUrUrCrCrCrUrArArCrArArArGrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6555
MG3-6-HPRT-sgRNA-G1
mA*mU*mC*rUrCrArGrCrUrArUrUrUrArGrUrCrArArArArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6556
MG3-6-HPRT-sgRNA-H1
mG*mUmC*rCrUrArCrUrUrUrUrGrArCrUrArArArUrArGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6557
MG3-6-HPRT-sgRNA-A2
mA*mA*mC*rUrCrUrCrCrArArUrArUrArGrGrUrGrGrCrUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6558
MG3-6-HPRT-sgRNA-B2
mA*mU*mU*rUrUrUrCrCrCrArUrArArArUrUrCrArArGrArUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6559
MG3-6-HPRT-sgRNA-C2
mC*mC*mA*rGrGrArCrUrGrGrArUrUrUrUrGrUrArGrGrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6560
MG3-6-HPRT-sgRNA-D2
mU*mG*mC*rArCrCrUrArCrArArArArUrCrCrArGrUrCrCrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6561
MG3-6-HPRT-sgRNA-E2
mG*mU*mA*rArGrArArUrGrCrCrArGrCrCrCrCrCrArGrGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6562
MG3-6-HPRT-sgRNA-F2
mA*mA*mG*rCrArGrUrArArGrArArUrGrCrCrArGrCrCrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6563
MG3-6-HPRT-sgRNA-G2
mG*mC*mU*rGrGrCrArUrUrCrUrUrArCrUrGrCrUrUrGrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6564
MG3-6-HPRT-sgRNA-H2
mU*mG*mC*rUrUrGrCrUrGrArGrGrGrCrCrArGrArUrGrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6565
MG3-6-HPRT-sgRNA-A3
mA*mU*mA*rGrArUrUrCrCrArGrArArUrArUrCrUrCrCrArUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6566
MG3-6-HPRT-sgRNA-B3
mU*mG*mA*rCrArGrUrArUrUrGrCrArGrUrUrArUrArCrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6567
MG3-6-HPRT-sgRNA-C3
mC*mG*mA*rArArArGrUrArArUrGrUrArArUrCrUrCrArUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6568
MG3-6-HPRT-sgRNA-D3
mG*mG*mA*rUrUrArUrArUrCrUrUrArArGrUrCrUrUrArUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6569
MG3-6-HPRT-sgRNA-E3
mA*mA*mC*rArCrArUrGrArCrArArArArUrUrArUrUrUrArArGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6570
MG3-6-HPRT-sgRNA-F3
mG*mU*mU*rUrGrUrCrCrUrGrArArUrArGrCrArUrGrGrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6571
MG3-6-HPRT-sgRNA-G3
mC*mUmG*rArArUrArGrCrArUrGrGrCrArGrArGrGrArUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6572
MG3-6-HPRT-sgRNA-H3
mA*mU*mC*rCrUrUrArUrUrCrUrUrArArUrUrUrUrGrCrArArGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6573
MG3-6-HPRT-sgRNA-A4
mG*mC*mC*rCrCrCrUrUrGrCrArArArArUrUrArArGrArArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6574
MG3-6-HPRT-sgRNA-B4
mG*mG*mU*rGrArGrGrArArGrUrGrArUrArGrGrArArGrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6575
MG3-6-HPRT-sgRNA-C4
mG*mU*mG*rArUrArGrGrArArGrGrGrGrUrGrGrGrCrCrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6576
MG3-6-HPRT-sgRNA-D4
mG*mG*mA*rArGrGrGrGrUrGrGrGrCrCrCrUrGrArArGrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6577
MG3-6-HPRT-sgRNA-E4
mA*mA*mU*rUrCrCrArGrGrArGrGrUrCrCrArGrArUrCrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6578
MG3-6-HPRT-sgRNA-F4
mU*mC*mA*rUrCrArCrUrCrArArUrUrCrCrArGrGrArGrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6579
MG3-6-HPRT-sgRNA-G4
mC*mA*mG*rCrArUrUrCrArUrCrArCrUrCrArArUrUrCrCrArGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6580
MG3-6-HPRT-sgRNA-H4
mC*mA*mG*rCrArUrArGrGrUrArArGrGrUrGrArGrGrArGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6581
MG3-6-HPRT-sgRNA-A5
mA*mC*mA*rUrArArArArArCrUrGrCrArGrArCrUrGrArUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6582
MG3-6-HPRT-sgRNA-B5
mA*mC*mC*rUrGrArCrCrCrCrUrArCrArUrArArArArArCrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6583
MG3-6-HPRT-sgRNA-C5
mG*mA*mU*rCrArGrUrCrUrGrCrArGrUrUrUrUrUrArUrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mUmU

6584
MG3-6-HPRT-sgRNA-D5
mU*mC*mU*rGrCrUrUrUrUrUrCrCrUrArArGrUrGrArUrUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6585
MG3-6-HPRT-sgRNA-E5
mA*mC*mA*rGrArUrArCrCrGrUrGrArUrUrUrUrUrUrCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6586
MG3-6-HPRT-sgRNA-F5
mA*mC*mU*rGrCrUrGrArCrArUrArUrGrArCrUrCrArCrUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6587
MG3-6-HPRT-sgRNA-G5
mC*mA*mU*rArUrGrUrCrArGrCrArGrUrUrUrGrArCrUrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6588
MG3-6-HPRT-sgRNA-H5
mU*mA*mU*rCrArGrUrGrArGrUrUrUrUrUrCrUrUrUrUrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6589
MG3-6-HPRT-sgRNA-A6
mG*mC*mU*rUrArUrUrUrUrUrCrUrArCrArUrGrCrUrCrUrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6590
MG3-6-HPRT-sgRNA-B6
mU*mU*mA*rArArUrGrUrCrArArCrCrUrArCrUrGrUrGrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mUxmU*mU

6591
MG3-6-HPRT-sgRNA-C6
mG*mA*mG*rGrArUrUrArArArGrUrCrUrArUrGrCrCrArCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6592
MG3-6-HPRT-sgRNA-D6
mA*mA*mG*rArArCrArArCrArArArArGrArArUrArCrCrCrArGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6593
MG3-6-HPRT-sgRNA-E6
mU*mG*mG*rUrArUrArUrGrCrUrGrUrGrGrArArUrUrGrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6594
MG3-6-HPRT-sgRNA-F6
mG*mA*mG*rArUrArGrArCrUrGrGrUrUrCrGrUrGrArGrCrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6595
MG3-6-HPRT-sgRNA-G6
mG*mU*mA*rGrGrArCrArUrGrCrUrCrArArArCrArArUrArCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6596
MG3-6-HPRT-sgRNA-H6
mA*mU*mU*rArArGrCrArGrCrUrGrCrUrCrArCrUrArCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6597
MG3-6-HPRT-sgRNA-A7
mG*mA*mG*rArUrGrGrArGrCrUrUrUrArUrUrArArArCrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6598
MG3-6-HPRT-sgRNA-B7
mG*mA*mA*rCrUrCrArGrCrArCrUrUrCrArUrArUrGrCrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6599
MG3-6-HPRT-sgRNA-C7
mU*mG*mA*rGrUrUrCrUrCrUrUrGrArArCrUrCrCrUrArArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6600
MG3-6-HPRT-sgRNA-D7
mA*mU*mU*rCrCrUrGrArGrUrUrCrArGrGrUrArGrGrGrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6601
MG3-6-HPRT-sgRNA-E7
mU*mA*mU*rArUrArUrGrUrUrUrArArArGrArGrCrUrGrGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6602
MG3-6-HPRT-sgRNA-F7
mG*mG*mU*rArUrGrArArArGrCrArUrArArGrUrUrUrUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6603
MG3-6-HPRT-sgRNA-G7
mU*mG*mA*rGrArCrUrGrCrCrUrUrUrArArCrArUrCrUrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6604
MG3-6-HPRT-sgRNA-H7
mA*mA*mU*rArUrUrUrUrUrCrArArCrArGrGrCrArGrCrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6605
MG3-6-HPRT-sgRNA-A8
mC*mU*mC*rCrCrArCrArCrCrCrUrUrUrUrArUrArGrUrUrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6606
MG3-6-HPRT-sgRNA-B8
mU*mA*mU*rArGrUrUrUrArGrGrGrArUrUrGrUrArUrUrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6607
MG3-6-HPRT-sgRNA-C8
mA*mG*mG*rGrArUrUrGrUrArUrUrUrCrCrArArGrGrUrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6608
MG3-6-HPRT-sgRNA-D8
mA*mG*mU*rGrUrCrArArUrGrArGrCrArArArGrArUrGrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6609
MG3-6-HPRT-sgRNA-E8
mC*mC*mA*rUrUrGrArArGrGrGrGrArGrCrUrArArUrArArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6610
MG3-6-HPRT-sgRNA-F8
mU*mG*mG*rArCrArCrArUrGrGrGrUrArGrUrCrArGrGrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6611
MG3-6-HPRT-sgRNA-G8
mC*mC*mU*rGrGrArArCrCrUrGrArArGrGrArCrArGrUrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6612
MG3-6-HPRT-sgRNA-H8
mG*mU*mG*rCrArGrGrUrCrUrCrArGrArArCrUrGrUrCrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6613
MG3-6-HPRT-sgRNA-A9
mA*mU*mG*rArArArUrGrGrArGrArGrCrUrArArArUrUrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6614
MG3-6-HPRT-sgRNA-B9
mG*mU*mC*rArCrUrUrUrUrArArCrArCrArCrCrCrArArGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6615
MG3-6-HPRT-sgRNA-C9
mU*mA*mG*rArGrArGrGrCrArCrArUrUrUrGrCrCrArGrUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Notations for chemical modifications: m = 2′O-methyl ribonucleotide (e.g mC = cytosine ribonucleotide with 2′-O Methyl in place of 2′ hydroxyl); f = 2′-fluoro ribonucleotide (e.g fC = cytosine ribonucleotide with 2′ fluorine in place of 2′ hydroxyl); * = phosphorothioate bond; r: native RNA linkage comprising the sugar ribose (for example the ribose or RNA form of the A base is written rA), d: deoxyribose sugar (DNA) linkage (for example a deoxyribose form of the A base is written dA)

TABLE 3B

Sites targeted in Example 9

SEQ

ID

NO:
Entity Name
Sequence

6616
MG3-6-HPRT-target site-
TTCCTCTGCAT

A1
CAGTTTTAATG

6617
MG3-6-HPRT-target site-
GTGGGCTTGTG

B1
TTCTAAAGGAG

6618
MG3-6-HPRT-target site-
AGGAGTGAGAT

C1
TGGTTTTTTGT

6619
MG3-6-HPRT-target site-
TAAAAAATAAT

D1
ATTTATAATTT

6620
MG3-6-HPRT-target site-
GAGTATTTTTA

E1
TTGAAAAGCAT

6621
MG3-6-HPRT-target site-
AAAAATATTTT

F1
CCCTAACAAAG

6622
MG3-6-HPRT-target site-
ATCTCAGCTAT

G1
TTAGTCAAAAG

6623
MG3-6-HPRT-target site-
GTCCTACTTTT

H1
GACTAAATAGC

6624
MG3-6-HPRT-target site-
AACTCTCCAAT

A2
ATAGGTGGCTA

6625
MG3-6-HPRT-target site-
ATTTTTCCCAT

B2
AAATTCAAGAT

6626
MG3-6-HPRT-target site-
CCAGGACTGGA

C2
TTTTGTAGGTG

6627
MG3-6-HPRT-target site-
TGCACCTACAA

D2
AATCCAGTCCT

6628
MG3-6-HPRT-target site-
GTAAGAATGCC

E2
AGCCCCCAGGA

6629
MG3-6-HPRT-target site-
AAGCAGTAAGA

F2
ATGCCAGCCCC

6630
MG3-6-HPRT-target site-
GCTGGCATTCT

G2
TACTGCTTGCT

6631
MG3-6-HPRT-target site-
TGCTTGCTGAG

H2
GGCCAGATGAT

6632
MG3-6-HPRT-target site-
ATAGATTCCAG

A3
AATATCTCCAT

6633
MG3-6-HPRT-target site-
TGACAGTATTG

B3
CAGTTATACAT

6634
MG3-6-HPRT-target site-
CGAAAAGTAAT

C3
GTAATCTCATA

6635
MG3-6-HPRT-target site-
GGATTATATCT

D3
TAAGTCTTATA

6636
MG3-6-HPRT-target site-
AACACATGACA

E3
AAATTATTTAA

6637
MG3-6-HPRT-target site-
GTTTGTCCTGA

F3
ATAGCATGGCA

6638
MG3-6-HPRT-target site-
CTGAATAGCAT

G3
GGCAGAGGATT

6639
MG3-6-HPRT-target site-
ATCCTTATTCT

H3
TAATTTTGCAA

6640
MG3-6-HPRT-target site-
GCCCCCTTGCA

A4
AAATTAAGAAT

6641
MG3-6-HPRT-target site-
GGTGAGGAAGT

B4
GATAGGAAGGG

6642
MG3-6-HPRT-target site-
GTGATAGGAAG

C4
GGGTGGGCCCT

6643
MG3-6-HPRT-target site-
GGAAGGGGTGG

D4
GCCCTGAAGAT

6644
MG3-6-HPRT-target site-
AATTCCAGGAG

E4
GTCCAGATCTT

6645
MG3-6-HPRT-target site-
TCATCACTCAA

F4
TTCCAGGAGGT

6646
MG3-6-HPRT-target site-
CAGCATTCATC

G4
ACTCAATTCCA

6647
MG3-6-HPRT-target site-
CAGCATAGGTA

H4
AGGTGAGGAGG

6648
MG3-6-HPRT-target site-
ACATAAAAACT

A5
GCAGACTGATC

6649
MG3-6-HPRT-target site-
ACCTGACCCCT

B5
ACATAAAAACT

6650
MG3-6-HPRT-target site-
GATCAGTCTGC

C5
AGTTTTTATGT

6651
MG3-6-HPRT-target site-
TCTGCTTTTTC

D5
CTAAGTGATTA

6652
MG3-6-HPRT-target site-
ACAGATACCGT

E5
GATTTTTTCAA

6653
MG3-6-HPRT-target site-
ACTGCTGACAT

F5
ATGACTCACTA

6654
MG3-6-HPRT-target site-
CATATGTCAGC

G5
AGTTTGACTGT

6655
MG3-6-HPRT-target site-
TATCAGTGAGT

H5
TTTTCTTTTAA

6656
MG3-6-HPRT-target site-
GCTTATTTTTC

A6
TACATGCTCTT

6657
MG3-6-HPRT-target site-
TTAAATGTCAA

B6
CCTACTGTGGC

6658
MG3-6-HPRT-target site-
GAGGATTAAAG

C6
TCTATGCCACA

6659
MG3-6-HPRT-target site-
AAGAACAACAA

D6
AAGAATACCCA

6660
MG3-6-HPRT-target site-
TGGTATATGCT

E6
GTGGAATTGAG

6661
MG3-6-HPRT-target site-
GAGATAGACTG

F6
GTTCGTGAGCG

6662
MG3-6-HPRT-target site-
GTAGGACATGC

G6
TCAAACAATAC

6663
MG3-6-HPRT-target site-
ATTAAGCAGCT

H6
GCTCACTACAA

6664
MG3-6-HPRT-target site-
GAGATGGAGCT

A7
TTATTAAACAT

6665
MG3-6-HPRT-target site-
GAACTCAGCAC

B7
TTCATATGCCT

6666
MG3-6-HPRT-target site-
TGAGTTCTCTT

C7
GAACTCCTAAT

6667
MG3-6-HPRT-target site-
ATTCCTGAGTT

D7
CAGGTAGGGAG

6668
MG3-6-HPRT-target site-
TATATATGTTT

E7
AAAGAGCTGGA

6669
MG3-6-HPRT-target site-
GGTATGAAAGC

F7
ATAAGTTTTCT

6670
MG3-6-HPRT-target site-
TGAGACTGCCT

G7
TTAACATCTGT

6671
MG3-6-HPRT-target site-
AATATTTTTCA

H7
ACAGGCAGCAT

6672
MG3-6-HPRT-target site-
CTCCCACACCC

A8
TTTTATAGTTT

6673
MG3-6-HPRT-target site-
TATAGTTTAGG

B8
GATTGTATTTC

6674
MG3-6-HPRT-target site-
AGGGATTGTAT

C8
TTCCAAGGTTT

6675
MG3-6-HPRT-target site-
AGTGTCAATGA

D8
GCAAAGATGAA

6676
MG3-6-HPRT-target site-
CCATTGAAGGG

E8
GAGCTAATAAG

6677
MG3-6-HPRT-target site-
TGGACACATGG

F8
GTAGTCAGGGT

6678
MG3-6-HPRT-target site-
CCTGGAACCTG

G8
AAGGACAGTTC

6679
MG3-6-HPRT-target site-
GTGCAGGTCTC

H8
AGAACTGTCCT

6680
MG3-6-HPRT-target site-
ATGAAATGGAG

A9
AGCTAAATTAT

6681
MG3-6-HPRT-target site-
GTCACTTTTAA

B9
CACACCCAAGG

6682
MG3-6-HPRT-target site-
TAGAGAGGCAC

C9
ATTTGCCAGTA

Example 10—Gene Editing Outcomes at the DNA Level for Human TRBC1/2

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 or MG3-8 RNPs (106 pmol protein/160 pmol guide) (MG3-6: SEQ ID NOs: 6683-6721; MG3-8: SEQ ID NOs: 6761-6781) was performed into T cells (200,000) using the Lonza 4D electroporator. For analysis by flow cytometry, 3 days post-nucleofection, 100,000 T cells were stained with anti-CD3 antibody for 30 minutes at 4° C. and analyzed on an Attune Nxt flow cytometer (FIG. 4).

TABLE 4A

Guide sequences used in Example 10

SEQ

ID

NO:
Entity Name
Sequence

6683
MG3-6-TRBC1/2-sgRNA-
mA*mG*mG*rUrCrCrUrCrUrGrGrArArArGrGrGrArArGrGrUrUr

A6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6684
MG3-6-TRBC1/2-sgRNA-
mC*mA*mG*rGrUrCrCrUrCrUrGrGrArArArGrGrGrArArGrUrUr

B6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6685
MG3-6-TRBC1/2-sgRNA-
mC*mC*mA*rCrArCrUrGrGrUrGrUrGrCrCrUrGrGrCrCrGrUrUr

C6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6686
MG3-6-TRBC1/2-sgRNA-
mG*mA*mA*rUrGrGrGrArArGrGrArGrGrUrGrCrArCrArGrUrUr

D6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6687
MG3-6-TRBC1/2-sgRNA-
mU*mG*mA*rGrGrGrCrGrGrGrCrUrGrCrUrCrCrUrUrGrGrUrUr

E6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6688
MG3-6-TRBC1/2-sgRNA-
mA*mG*mU*rArUrCrUrGrGrArGrUrCrArUrUrGrArGrGrGrUrUr

F6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6689
MG3-6-TRBC1/2-sgRNA-
mA*mU*mA*rCrUrGrCrCrUrGrArGrCrArGrCrCrGrCrCrGrUrUr

G6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6690
MG3-6-TRBC1/2-sgRNA-
mU*mU*mG*rArCrArGrCrGrGrArArGrUrGrGrUrUrGrCrGrUrUr

H6
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6691
MG3-6-TRBC1/2-sgRNA-
mC*mU*mU*rGrArCrArGrCrGrGrArArGrUrGrGrUrUrGrGrUrUr

A7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6692
MG3-6-TRBC1/2-sgRNA-
mC*mC*mG*rCrUrGrUrCrArArGrUrCrCrArGrUrUrCrUrGrUrUr

B7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6693
MG3-6-TRBC1/2-sgRNA-
mU*mC*mG*rGrArGrArArUrGrArCrGrArGrUrGrGrArCrGrUrUr

C7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6694
MG3-6-TRBC1/2-sgRNA-
mC*mA*mG*rArUrCrGrUrCrArGrCrGrCrCrGrArGrGrCrGrUrUr

D7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6695
MG3-6-TRBC1/2-sgRNA-
mC*mG*mG*rCrGrCrUrGrArCrGrArUrCrUrGrGrGrUrGrGrUrUr

E7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6696
MG3-6-TRBC1/2-sgRNA-
mG*mC*mC*rArArCrArGrUrGrUrCrCrUrArCrCrArGrCrGrUrUr

F7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6697
MG3-6-TRBC1/2-sgRNA-
mC*mU*mU*rCrCrCrUrArGrCrArGrGrArUrCrUrCrArUrGrUrUr

G7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6698
MG3-6-TRBC1/2-sgRNA-
mA*mU*mA*rCrArGrGrGrUrGrGrCrCrUrUrCrCrCrUrArGrUrUr

H7
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6699
MG3-6-TRBC1/2-sgRNA-
mG*mG*mC*rGrCrUrGrArCrCrArGrCrArCrArGrCrArUrGrUrUr

A8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6700
MG3-6-TRBC1/2-sgRNA-
mU*mC*mU*rCrUrUrCrUrGrCrArGrGrUrCrArArGrArGrGrUrUr

B8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6701
MG3-6-TRBC1/2-sgRNA-
mC*mC*mU*rGrCrArGrArArGrArGrArArArGrUrUrUrUrGrUrUr

C8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6702
MG3-6-TRBC1/2-sgRNA-
mA*mC*mC*rUrGrCrArGrArArGrArGrArArArGrUrUrUrGrUrUr

D8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6703
MG3-6-TRBC1/2-sgRNA-
mC*mC*mA*rCrArCrUrGrGrUrGrUrGrCrCrUrGrGrCrCrGrUrUr

E8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6704
MG3-6-TRBC1/2-sgRNA-
mA*mC*mC*rArGrCrUrCrArGrCrUrCrCrArCrGrUrGrGrGrUrUr

F8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6705
MG3-6-TRBC1/2-sgRNA-
mG*mA*mA*rUrGrGrGrArArGrGrArGrGrUrGrCrArCrArGrUrUr

G8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6706
MG3-6-TRBC1/2-sgRNA-
mU*mG*mA*rGrGrGrCrGrGrGrCrUrGrCrUrCrCrUrUrGrGrUrUr

H8
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6707
MG3-6-TRBC1/2-sgRNA-
mA*mG*mU*rArUrCrUrGrGrArGrUrCrArUrUrGrArGrGrGrUrUr

A9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6708
MG3-6-TRBC1/2-sgRNA-
mA*mU*mA*rCrUrGrCrCrUrGrArGrCrArGrCrCrGrCrCrGrUrUr

B9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6709
MG3-6-TRBC1/2-sgRNA-
mU*mU*mG*rArCrArGrCrGrGrArArGrUrGrGrUrUrGrCrGrUrUr

C9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6710
MG3-6-TRBC1/2-sgRNA-
mC*mU*mU*rGrArCrArGrCrGrGrArArGrUrGrGrUrUrGrGrUrUr

D9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6711
MG3-6-TRBC1/2-sgRNA-
mC*mC*mG*rCrUrGrUrCrArArGrUrCrCrArGrUrUrCrUrGrUrUr

E9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6712
MG3-6-TRBC1/2-sgRNA-
mU*mC*mG*rGrArGrArArUrGrArCrGrArGrUrGrGrArCrGrUrUr

F9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6713
MG3-6-TRBC1/2-sgRNA-
mC*mA*mG*rArUrCrGrUrCrArGrCrGrCrCrGrArGrGrCrGrUrUr

G9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6714
MG3-6-TRBC1/2-sgRNA-
mC*mG*mG*rCrGrCrUrGrArCrGrArUrCrUrGrGrGrUrGrGrUrUr

H9
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6715
MG3-6-TRBC1/2-sgRNA-
mG*mU*mC*rArArCrArGrArGrUrCrUrUrArCrCrArGrCrGrUrUr

A10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6716
MG3-6-TRBC1/2-sgRNA-
mC*mU*mU*rCrCrCrUrArGrCrArArGrArUrCrUrCrArUrGrUrUr

B10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6717
MG3-6-TRBC1/2-sgRNA-
mG*mC*mU*rGrArUrGrGrCrCrArUrGrGrUrArArGrGrArGrUrUr

C10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6718
MG3-6-TRBC1/2-sgRNA-
mU*mG*mU*rGrGrArArGrArGrArGrArArCrArUrUrUrUrGrUrUr

D10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6719
MG3-6-TRBC1/2-sgRNA-
mC*mU*mG*rUrGrGrArArGrArGrArGrArArCrArUrUrUrGrUrUr

E10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6720
MG3-6-TRBC1/2-sgRNA-
mU*mC*mU*rCrUrUrCrCrArCrArGrGrUrCrArArGrArGrGrUrUr

F10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6721
MG3-6-TRBC1/2-sgRNA-
mA*mG*mG*rUrCrArArGrArGrArArArGrGrArUrUrCrCrGrUrUr

G10
GrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrGrCr

ArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrCrGr

UrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGrGrUr

ArUrGrU*mU*mU*mU

6761
MG3-8-TRBC1/2-sgRNA-
mA*mG*mG*rUrCrCrUrCrUrGrGrArArArGrGrGrArArGrGrUrUr

D3
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6762
MG3-8-TRBC1/2-sgRNA-
mC*mU*mG*rArArCrArArGrGrUrGrUrUrCrCrCrArCrCrGrUrUr

E3
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6763
MG3-8-TRBC1/2-sgRNA-
mC*mU*mC*rGrGrGrUrGrGrGrArArCrArCrCrUrUrGrUrGrUrUr

F3
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6764
MG3-8-TRBC1/2-sgRNA-
mA*mA*mU*rGrGrGrArArGrGrArGrGrUrGrCrArCrArGrGrUrUr

G3
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6765
MG3-8-TRBC1/2-sgRNA-
mG*mG*mG*rCrUrGrCrUrCrCrUrUrGrArGrGrGrGrCrUrGrUrUr

H3
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6766
MG3-8-TRBC1/2-sgRNA-
mU*mA*mC*rUrGrCrCrUrGrArGrCrArGrCrCrGrCrCrUrGrUrUr

A4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6767
MG3-8-TRBC1/2-sgRNA-
mU*mU*mG*rArCrArGrCrGrGrArArGrUrGrGrUrUrGrCrGrUrUr

B4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrUxmU*mU*mU

6768
MG3-8-TRBC1/2-sgRNA-
mG*mU*mG*rArCrGrGrGrUrUrUrGrGrCrCrCrUrArUrCrGrUrUr

C4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6769
MG3-8-TRBC1/2-sgRNA-
mC*mG*mG*rCrGrCrUrGrArCrGrArUrCrUrGrGrGrUrGrGrUrUr

D4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6770
MG3-8-TRBC1/2-sgRNA-
mC*mC*mA*rArCrArGrUrGrUrCrCrUrArCrCrArGrCrArGrUrUr

E4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6771
MG3-8-TRBC1/2-sgRNA-
mC*mC*mU*rGrCrArGrArArGrArGrArArArGrUrUrUrUrGrUrUr

F4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6772
MG3-8-TRBC1/2-sgRNA-
mC*mU*mG*rArArArArArCrGrUrGrUrUrCrCrCrArCrCrGrUrUr

G4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6773
MG3-8-TRBC1/2-sgRNA-
mC*mU*mU*rGrGrGrUrGrGrGrArArCrArCrGrUrUrUrUrGrUrUr

H4
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6774
MG3-8-TRBC1/2-sgRNA-
mA*mA*mU*rGrGrGrArArGrGrArGrGrUrGrCrArCrArGrGrUrUr

A5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6775
MG3-8-TRBC1/2-sgRNA-
mG*mG*mG*rCrUrGrCrUrCrCrUrUrGrArGrGrGrGrCrUrGrUrUr

B5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrUxmU*mU*mU

6776
MG3-8-TRBC1/2-sgRNA-
mU*mA*mC*rUrGrCrCrUrGrArGrCrArGrCrCrGrCrCrUrGrUrUr

C5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6777
MG3-8-TRBC1/2-sgRNA-
mU*mU*mG*rArCrArGrCrGrGrArArGrUrGrGrUrUrGrCrGrUrUr

D5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6778
MG3-8-TRBC1/2-sgRNA-
mG*mU*mG*rArCrArGrGrUrUrUrGrGrCrCrCrUrArUrCrGrUrUr

E5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6779
MG3-8-TRBC1/2-sgRNA-
mC*mG*mG*rCrGrCrUrGrArCrGrArUrCrUrGrGrGrUrGrGrUrUr

F5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6780
MG3-8-TRBC1/2-sgRNA-
mU*mC*mA*rArCrArGrArGrUrCrUrUrArCrCrArGrCrArGrUrUr

G5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrU*mU*mU*mU

6781
MG3-8-TRBC1/2-sgRNA-
mU*mG*mU*rGrGrArArGrArGrArGrArArCrArUrUrUrUrGrUrUr

H5
GrArGrArArUrCrUrUrUrCrGrArArArGrArArArGrArUrUrCrUrUr

ArArUrArArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUr

UrCrUrCrArCrCrGrUrCrCrGrGrCrUrCrCrUrCrUrUrArGrGrArAr

CrGrGrGrCrGrGrUrArUrGrUxmU*mU*mU

Notations for chemical modifications: m = 2′O-methyl ribonucleotide (e.g mC = cytosine ribonucleotide with 2′-O Methyl in place of 2′ hydroxyl); f = 2′-fluoro ribonucleotide (e.g fC = cytosine ribonucleotide with 2′ fluorine in place of 2′ hydroxyl); * = phosphorothioate bond; r: native RNA linkage comprising the sugar ribose (for example the ribose or RNA form of the A base is written rA), d: deoxyribose sugar (DNA) linkage (for example a deoxyribose form of the A base is written dA)

TABLE 4B

Sites targeted in Example 10

SEQ

ID

NO:
Entity Name
Sequence

6722
MG3-6-TRBC1/2-target
AGGTCCTCTGGAAAGGGAAG

site-A6

6723
MG3-6-TRBC1/2-target
CAGGTCCTCTGGAAAGGGAA

site-B6

6724
MG3-6-TRBC1/2-target
CCACACTGGTGTGCCTGGCC

site-C6

6725
MG3-6-TRBC1/2-target
GAATGGGAAGGAGGTGCACA

site-D6

6726
MG3-6-TRBC1/2-target
TGAGGGCGGGCTGCTCCTTG

site-E6

6727
MG3-6-TRBC1/2-target
AGTATCTGGAGTCATTGAGG

site-F6

6728
MG3-6-TRBC1/2-target
ATACTGCCTGAGCAGCCGCC

site-G6

6729
MG3-6-TRBC1/2-target
TTGACAGCGGAAGTGGTTGC

site-H6

6730
MG3-6-TRBC1/2-target
CTTGACAGCGGAAGTGGTTG

site-A7

6731
MG3-6-TRBC1/2-target
CCGCTGTCAAGTCCAGTTCT

site-B7

6732
MG3-6-TRBC1/2-target
TCGGAGAATGACGAGTGGAC

site-C7

6733
MG3-6-TRBC1/2-target
CAGATCGTCAGCGCCGAGGC

site-D7

6734
MG3-6-TRBC1/2-target
CGGCGCTGACGATCTGGGTG

site-E7

5735
MG3-6-TRBC1/2-target
GCCAACAGTGTCCTACCAGC

site-F7

6736
MG3-6-TRBC1/2-target
CTTCCCTAGCAGGATCTCAT

site-G7

6737
MG3-6-TRBC1/2-target
ATACAGGGTGGCCTTCCCTA

site-H7

6738
MG3-6-TRBC1/2-target
GGCGCTGACCAGCACAGCAT

site-A8

6739
MG3-6-TRBC1/2-target
TCTCTTCTGCAGGTCAAGAG

site-B8

6740
MG3-6-TRBC1/2-target
CCTGCAGAAGAGAAAGTTTT

site-C8

6741
MG3-6-TRBC1/2-target
ACCTGCAGAAGAGAAAGTTT

site-D8

6742
MG3-6-TRBC1/2-target
CCACACTGGTGTGCCTGGCC

site-E8

6743
MG3-6-TRBC1/2-target
ACCAGCTCAGCTCCACGTGG

site-F8

6744
MG3-6-TRBC1/2-target
GAATGGGAAGGAGGTGCACA

site-G8

6745
MG3-6-TRBC1/2-target
TGAGGGCGGGCTGCTCCTTG

site-H8

6746
MG3-6-TRBC1/2-target
AGTATCTGGAGTCATTGAGG

site-A9

6747
MG3-6-TRBC1/2-target
ATACTGCCTGAGCAGCCGCC

site-B9

6748
MG3-6-TRBC1/2-target
TTGACAGCGGAAGTGGTTGC

site-C9

6749
MG3-6-TRBC1/2-target
CTTGACAGCGGAAGTGGTTG

site-D9

6750
MG3-6-TRBC1/2-target
CCGCTGTCAAGTCCAGTTCT

site-E9

6751
MG3-6-TRBC1/2-target
TCGGAGAATGACGAGTGGAC

site-F9

6752
MG3-6-TRBC1/2-target
CAGATCGTCAGCGCCGAGGC

site-G9

6753
MG3-6-TRBC1/2-target
CGGCGCTGACGATCTGGGTG

site-H9

6754
MG3-6-TRBC1/2-target
GTCAACAGAGTCTTACCAGC

site-A10

6755
MG3-6-TRBC1/2-target
CTTCCCTAGCAAGATCTCAT

site-B10

6756
MG3-6-TRBC1/2-target
GCTGATGGCCATGGTAAGGA

site-C10

6757
MG3-6-TRBC1/2-target
TGTGGAAGAGAGAACATTTT

site-D10

6758
MG3-6-TRBC1/2-target
CTGTGGAAGAGAGAACATTT

site-E10

6759
MG3-6-TRBC1/2-target
TCTCTTCCACAGGTCAAGAG

site-F10

6760
MG3-6-TRBC1/2-target
AGGTCAAGAGAAAGGATTCC

site-G10

6782
MG3-8-TRBC1/2-target
AGGTCCTCTGGAAAGGGAAG

site-D3

6783
MG3-8-TRBC1/2-target
CTGAACAAGGTGTTCCCACC

site-E3

6784
MG3-8-TRBC1/2-target
CTCGGGTGGGAACACCTTGT

site-F3

6785
MG3-8-TRBC1/2-target
AATGGGAAGGAGGTGCACAG

site-G3

6786
MG3-8-TRBC1/2-target
GGGCTGCTCCTTGAGGGGCT

site-H3

6787
MG3-8-TRBC1/2-target
TACTGCCTGAGCAGCCGCCT

site-A4

6788
MG3-8-TRBC1/2-target
TTGACAGCGGAAGTGGTTGC

site-B4

6789
MG3-8-TRBC1/2-target
GTGACGGGTTTGGCCCTATC

site-C4

6790
MG3-8-TRBC1/2-target
CGGCGCTGACGATCTGGGTG

site-D4

6791
MG3-8-TRBC1/2-target
CCAACAGTGTCCTACCAGCA

site-E4

6792
MG3-8-TRBC1/2-target
CCTGCAGAAGAGAAAGTTTT

site-F4

6793
MG3-8-TRBC1/2-target
CTGAAAAACGTGTTCCCACC

site-G4

6794
MG3-8-TRBC1/2-target
CTTGGGTGGGAACACGTTTT

site-H4

6795
MG3-8-TRBC1/2-target
AATGGGAAGGAGGTGCACAG

site-A5

6796
MG3-8-TRBC1/2-target
GGGCTGCTCCTTGAGGGGCT

site-B5

6797
MG3-8-TRBC1/2-target
TACTGCCTGAGCAGCCGCCT

site-C5

6798
MG3-8-TRBC1/2-target
TTGACAGCGGAAGTGGTTGC

site-D5

6799
MG3-8-TRBC1/2-target
GTGACAGGTTTGGCCCTATC

site-E5

6800
MG3-8-TRBC1/2-target
CGGCGCTGACGATCTGGGTG

site-F5

6801
MG3-8-TRBC1/2-target
TCAACAGAGTCTTACCAGCA

site-G5

6802
MG3-8-TRBC1/2-target
TGTGGAAGAGAGAACATTTT

site-H5

Example 11—MG3-6 Guide Screen for Mouse HAO-1 Gene Using mRNA Transfection

Guides for MG3-6 were identified in exons 1, 2, 3, and 4 of the human HAO1 gene using a guide-finding algorithm that searches for the appropriate PAM sequence. A total of 19 guides were selected for evaluation in mammalian cells. 300 ng mRNA and 120 ng single guide RNA were transfected into Hepa1-6 cells as follows. One day prior to transfection, Hepa1-6 cells that had been cultured for less than 10 days in DMEM, 10% FBS, 1×NEAA media, without Pen/Step, were seeded into a TC-treated 24 well plate. Cells were counted, and the equivalent volume to 60,000 viable cells were added to each well. Additional pre-equilibrated media was added to each well to bring the total volume to 500 μL. On the day of transfection, 25 μL of OptiMEM media and 1.25 μL of Lipofectamine Messenger Max Solution (Thermo Fisher) were mixed in a mastermix solution, vortexed, and allowed to sit for at least 5 minutes at room temperature. In separate tubes, 300 ng of the MG3-6 mRNA and 120 ng of the sgRNA were mixed together with 25 μL of OptiMEM media and vortexed briefly. The appropriate volume of MessengerMax solution was added to each RNA solution, mixed by flicking the tube, and briefly spun down at a low speed. The complete editing reagent solutions were allowed to incubate for 10 minutes at room temperature, then added directly to the Hepa1-6 cells. Two days post transfection, the media was aspirated off of each well of Hepa1-6 cells and genomic DNA was purified by automated magnetic bead purification, via the KingFisher Flex with the MagMAX™ DNA Multi-Sample Ultra 2.0 Kit. The activity of the guides is summarized in Table 5A and FIG. 5, while the primers used are summarized in Table 5B.

TABLE 5A

Average Activity of MG3-6 guides at mouse HAO1 delivered by mRNA

Transfection

SEQ

Editing Activity

Guide

ID

(Average %

Name
PAM
NO.
Spacer Sequence
INDELs)

mH36-1
GCAGACC
11802
CATGCTGTTCATAATCACTGAT
0

mH36-2
ACAGGTC
11803
CAGAAGTCAGTGTATGACTATT
12.5

mH36-3
CCAGACC
11804
TAACGTCTCCTGATCATTTGCC
0

mH36-4
ACAGATC
11805
CTCTGTCCTAAAACAGAAGTTG
25

mH36-5
TGGGGCT
11806
GAGTCAGCATGCCAATATGTGT
33.5

mH36-6
TCAGACC
11807
TTCTCCATTTCATTACAGCCTG
0

mH36-7
ACAGGCT
11808
TCATGCCAGTTCCCATGGTCTG
0

mH36-8
TTGGGCT
11809
GAACTGGCATGATGCTGAGTTC
5

mH36-9
CTGGGCC
11810
AGTTGCATCCAGCGAAGTGCCT
28

mH36-10
AAAGACC
11811
CTGGATGCAACTGTACATCTAC
0

mH36-11
TGAGATC
11812
AACTGTACATCTACAAAGACCG
0

mH36-12
CAGGGTT
11813
GATAGTGAAGCGAGCTGAGAAG
45.5

mH36-13
CAAGGCC
11814
AGCGAGCTGAGAAGCAGGGTTA
27.5

mH36-14
ACAGGTT
11815
AACCGCATTGATGACGTGCGGA
0

mH36-15
TCAGGTC
11816
AGGTTCAAGCTGCCACCACAAC
41.5

mH36-16
GTGGACT
11817
AAGGGAAATTTTGGAGACAACA
0

mH36-17
ATAGACC
11818
TGCTGAATATGTGGCACAAGCT
0

mH36-18
ATGGGTC
11819
GTAATATCATCCCAGCTGAGAG
35

mH36-19
AGAGGTT
11820
TATTGTTGTAAAGGGCATTTTG
21

TABLE 5B

Primers designed for the mouse HAO1 gene, used for PCR at each of the first

four exons, and for sanger sequencing

Target

SEQ

Exon
Use
Primer Name
ID NO.
Primer Sequence

Mouse
Fwd PCR
PCR mHE1_F_+233
11821
GTGACCAACCCTACCCGTTT

HAO1
Rev PCR
PCR mHE1_R_−553
11822
GCAAGCACCTACTGTCTCGT

Exon 1
Sequencing
Seq_mHE1_F_+139
11823
GTCTAGGCATACAATGTTTGCTCA

Mouse
Fwd PCR
HAO1_E2_F5721
11824
CAACGAAGGTTCCCTCCAGG

HAO1
Rev PCR
HAO1_E2_R6271
11825
GGAAGGGTGTTCGAGAAGGA

Exon 2
Sequencing
5938F_Seq_HAO1_E2
11826
CTATGCAAGGAAAAGATTTGGCC

Mouse
Fwd PCR
HAO1_E3_F23198
11827
TGCCCTAGACAAGCTGACAC

HAO1
Rev PCR
HAO1_E3_R23879
11828
CAGATTCTGGAAGTGGCCCA

Exon 3
Sequencing
HAO1_E3_F23198
11827
Same as Fwd PCR Primer

Mouse
Fwd PCR
PCR_mHE4_F_+300
11829
GGCTGGCTGAAAATAGCATCC

HAO1
Rev PCR
HAO1_E4_R31650
11830
AGGTTTGGTTCCCCTCACCT

Exon 4
Sequencing
PCR_mHE4_R_−149
11831
TCTGCCATGAAGGCATATGGAC

Example 12—Guide Chemistry Optimization for the MG3-6 Type II Nuclease (Prophetic)

Various chemically modified guides are designed and tested for activity. The most active guide in a guide screen in mouse hepatocytes (Hepa1-6 cells)—targeting albumin intron 1 is chosen as the spacer sequence model to insert various chemical modifications. The gRNA comprises the spacer located in the 5′ followed by the CRISPR repeat and the trans-activating CRISPR RNA (tracr). The CRISPR repeat and the tracr are identical to MG3-6. The CRISPR repeat and tracr form a structured RNA comprising 3 stem loops. Different areas of the stem loops are modified by replacing the 2′ hydroxyl in the ribose by 2′-O-methyl groups or replacing the phosphodiester backbone by a phosphorothioate (PS) bond. Moreover, the spacer in the 5′ of the guide is modified by adding 2′-O-methyls, PS bonds, and 2′-fluoros. The editing activity of guides with the exact same base sequence but different chemical modifications is evaluated in Hepa1-6 cells by co-transfection of mRNA encoding MG3-6 and the guide. A guide with the same base sequence and a commercially available chemical modification called AltR1/AltR2 is used as a control. The spacer sequence in these guides targets a 22 nucleotide region in albumin intron1 of the mouse genome.

In order to test the stability of the chemically modified guides compared to the guide with no chemical modification (native RNA), a stability assay using crude cell extracts is used. Crude cell extracts from mammalian cells are selected because they contain the mixture of nucleases that a guide RNA will be exposed to when delivered to mammalian cells in vitro or in vivo. Hepa 1-6 cells are collected by adding 3 ml of cold PBS per 15 cm dish of confluent cells and releasing the cells from the surface of the dish using a cell scraper. The cells are pelleted at 200 g for 10 min and frozen at −80° C. for future use. For the stability assays, cells are resuspended in 4 volumes of cold PBS (e.g., for a 100 mg pellet cells are resuspended in 400 μL of cold PBS). Triton X-100 is added to a concentration of 0.2% (v/v), cells are vortexed for 10 seconds, put on ice for 10 minutes, and vortexed again for 10 seconds. Triton X-100 is a mild non-ionic detergent that disrupts cell membranes but does not inactivate or denature proteins at the concentration used. Stability reactions are set up on ice and comprise 20 μL of cell crude extract with 2 pmoles of each guide (1 μL of a 2 μM stock). Six reactions are set up per guide comprising: input, 0.5 hour, 1 hour, 4 hours, 9 hours, and in some cases 21 hours (The time in hours referring to the length of time each sample is incubated). Samples are incubated at 37° C. from 0.5 hours up to 21 hours while the input control is left on ice for 5 minutes. After each incubation period, the reaction is stopped by adding 300 μL of a mixture of phenol and guanidine thiocyanate (Tri reagent, Zymo Research) which immediately denatures all proteins and efficiently inhibits ribonucleases and facilitates the subsequent recovery of RNA. After adding Tri Reagent, the samples are vortexed for 15 seconds and stored at −20° C. RNA is extracted from the samples using Direct-zol RNA miniprep kit (Zymo Research) and eluted in 100 μL of nuclease-free water. Detection of the modified guide is performed using Tagman RT—qPCR using the Taqman miRNA Assay technology (Thermo Fisher). Data is plotted as a function of percentage of sgRNA remaining in relation to the input sample.

Example 13—Efficiency of mRNA Electroporation in T Cells

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of mRNA was performed as follow: 200,000 cells were co-transfected with 500 ng of mRNA and the indicated amount of guide RNA using a Lonza 4D electroporator (DS-120). Cells were harvested and genomic DNA prepared three days post initial transfection. For conditions labeled “+gRNA”: 15 h post initial transfection, cells were nucleofected with indicated amount of additional guide. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA. The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 6).

Example 14—ELISA Assay to Assess Pre-Existing Antibody Response

MG3-6 and MG3-8 were expressed in and purified from human HEK293 cells using the Expi293™ Expression System Kit (ThermoFisher Scientific). Briefly, 293 cells were lipofected with plasmids encoding the nucleases driven by a strong viral promoter. Cells were grown in suspension culture with agitation and harvested two days post-transfection. The nuclease proteins were fused to a Six-His affinity tag and purified by metal-affinity chromatography to between 50-60% purity. Parallel lysates were made from mock-transfected cells and were subjected to an identical metal-affinity chromatography process. Cas9 was purchased from IDT and was >95% pure.

MaxiSorp® ELISA plates (Thermo Scientific) were coated with 0.5 μg of nucleases or control proteins diluted in 1× phosphate buffered saline (PBS) and incubated overnight at room temperature. Plates were then washed and incubated with a 1% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich)/1×PBS solution (1% BSA-PBS) for an hour at room temperature. After another washing step, wells were incubated for 1 h at room temperature with more than 50 separate serum samples taken from randomly selected donors (1:50 dilution in 1% BSA-PBS). Plates were then washed and incubated for an hour at room temperature with a peroxidase-labeled goat anti-human (Fcγ fragment-specific) secondary antibody (Jackson Immuno Research), diluted 1:50,000 in 1% BSA-PBS. The assay was developed using a 3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System kit (Sigma-Aldrich), according to the manufacturer's specifications. Antibody titers are reported as absorbance values measured at 450 nm (FIG. 7). Tetanus toxoid was used as the positive control due to wide-spread vaccination against this antigen and was purchased from Sigma Aldrich.

Example 15—Gene Editing Outcomes at the DNA and Cell-Surface Protein Level for TRAC in Human Peripheral Blood B Cells

Human Peripheral Blood B cells were purchased from STEMCELL Technologies and expanded using ImmunoCult™ Human B Cell Expansion Kit for 2 days prior to nucleofection. Nucleofection of MG3-6 RNPs (106 pmol protein/160 pmol guide) was performed into B cells (200,000) using the Lonza 4D electroporator. Post-nucleofection cells were immediately recovered into media containing AAV-6 sourced from Virovek. Cells were harvested and genomic DNA prepared five days post-transfection. For NGS analysis, PCR primers appropriate for use in NGS-based DNA sequencing were used to amplify the target sequence for the TRAC 6 guide RNA (SEQ ID NO: 6804). The amplicon was sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing. For analysis by flow cytometry, 100,000 cells were stained for viability, expression of B cell surface marker CD19 (CD19 Monoclonal Antibody (HIB19), APC, eBioscience™) and for transgene (SEQ ID NO: 6810) insertion as measured by expression of tLNGFR (CD271 (LNGFR) Antibody, anti-human, REAfinity™). Cells were stained for 30 min at 4° C. and data was acquired on an Attune Nxt flow cytometer. Cells expressing tLNGFR were gated on single, live, CD19+ cells (FIG. 8).

TABLE 6

Guide sequences used in Example 15

SEQ

ID

NO:
Entity Name
Sequence

6804
MG3-6-TRAC-
mC*mG*mA*rArUrCrCrUrCrCrUrCrCrUrGrArArArGrUrGrGrGr

sgRNA-6
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Example 16—Gene Editing Outcomes at the DNA Level for TRAC and AAVS1 in Hematopoietic Stem Cells (HSCs)

Mobilized peripheral blood CD34+ cells were acquired from AllCells and cultured in STEMCELL StemSpan™ SFEM II media supplemented with StemSpan™ CC110 cytokine cocktail for 48 hours prior to nucleofection. Nucleofection of MG3-6 RNPs (106 pmol protein/120 pmol guide for standard dose, 52 pmol protein/60 pmol guide for half dose) was performed into HSCs (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in Sanger and NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 6804, 6806, and 6808). The NGS amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing. The ICE amplicons were sent to Elim Biopharmaceuticals Inc. for Sanger sequencing and analyzed with a proprietary Python script to measure gene editing (FIG. 9).

TABLE 7

Guide sequences used in Example 16

SEQ

ID

NO:
Entity Name
Sequence

6804
MG3-6-TRAC-
mC*mG*mA*rArUrCrCrUrCrCrUrCrCrUrGrArArArGrUrGrGrGr

sgRNA-6
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6806
MG3-6-AAVS1-
mA*mG*mG*rArArUrCrUrGrCrCrUrArArCrArGrGrArGrGrUrGr

sgRNA-B2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6808
MG3-6-AAVS1-
mU*mA*mG*rGrArArGrGrArGrGrArGrGrCrCrUrArArGrGrArGr

sgRNA-D2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Example 17—Gene Editing Outcomes at the DNA and Cell-Surface Protein Level for TRAC in Induced Pluripotent Stem Cells (iPSCs) for MG3-6 Delivered as Ribonucleoprotein

ATCC-BXS0116 Human [Non-Hispanic Caucasian Female] Induced Pluripotent Stem (IPS) Cells are cultured on Corning Matrigel-coated plasticware in mTESR Plus media (STEMCELL Technologies) containing 10 μM ROCK inhibitor Y-27632 for 24 hr prior to nucleofection. Nucleofection of MG3-6 RNPs (106 pmol protein/120 pmol guide) was performed into iPSCs (200,000) using the Lonza 4D electroporator. Cells were harvested with Accutase for flow cytometry and genomic DNA extraction five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were used to amplify the individual target sequences for the TRAC 6 gRNA (SEQ ID NO: 6804). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing. For analysis by flow cytometry, 5 days post-nucleofection 100,000 iPSCs per sample were stained with LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit and CD271 (LNGFR) Antibody, anti-human, REAfinity™ to measure viability and transgene (SEQ ID NO: 6810) insertion, respectively. Cells were fixed and permeabilized (Inside Stain Kit, Miltenyi) and further stained for pluripotency transcription factors Oct4 and Sox2 (Anti-Oct3/4 Isoform A-APC, human and mouse REA338 1: Anti-Sox2-FITC, human and mouse REA320. Cells were acquired on an Attune NxT flow cytometer, and analyzed for tLNGFR expression based on gating on single, live Oct4+Sox2+ cells (FIG. 10)

TABLE 8

Guide sequences used in Example 17

SEQ

ID

NO:
Entity Name
Sequence

6804
MG3-6-TRAC-
mC*mG*mA*rArUrCrCrUrCrCrUrCrCrUrGrArArArGrUrGrGrGr

sgRNA-6
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Example 18—Gene Editing Outcomes at the DNA Protein Level for TRAC in Induced Pluripotent Stem Cells (iPSCs) for MG3-6 Delivered as mRNA

ATCC-BXS0116 Human [Non-Hispanic Caucasian Female] Induced Pluripotent Stem (IPS) Cells are cultured on Corning Matrigel-coated plasticware in mTESR Plus (STEMCELL Technologies) containing 10 μM ROCK inhibitor Y-27632 for 24 hr prior to nucleofection. Nucleofection of MG3-6 RNPs (106 pmol protein/120 pmol guide) or mRNA (250 or 500 ng mRNA/12 pmol guide) was performed into iPSCs (200,000) using the Lonza 4D electroporator. Cells were harvested with Accutase for genomic DNA extraction five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were used to amplify the individual target sequences for the TRAC 6 gRNA (SEQ ID NO: 6804). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 11).

TABLE 9

Guide sequences used in Example 18

SEQ

ID

NO:
Entity Name
Sequence

6804
MG3-6-TRAC-
mC*mG*mA*rArUrCrCrUrCrCrUrCrCrUrGrArArArGrUrGrGrGr

sgRNA-6
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Example 19—Gene Editing Outcomes at the DNA Level for CD2

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (106 pmol protein/160 pmol guide) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA. The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 12).

TABLE 10A

Guide sequences used in Example 19

SEQ

ID

NO:
Entity Name
Sequence

6811
MG3-6-CD2-sgRNA-A1
mA*mU*mU*rUrArCrArUrGrGrArArArGrCrUrCrArUrCrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6812
MG3-6-CD2-sgRNA-B1
mU*mU*mU*rUrUrArUrArGrGrUrGrCrArGrUrCrUrCrCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6813
MG3-6-CD2-sgRNA-C1
mU*mG*mC*rCrUrUrGrGrArArArCrCrUrGrGrGrGrUrGrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6814
MG3-6-CD2-sgRNA-D1
mG*mG*mG*rArArArArArArCrUrUrCrArGrArCrArArGrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6815
MG3-6-CD2-sgRNA-E1
mU*mU*mG*rCrArCrArArUrUrCrArGrArArArArGrArGrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6816
MG3-6-CD2-sgRNA-F1
mG*mA*mA*rCrUrCrUrGrArArArArUrUrArArGrCrArUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6817
MG3-6-CD2-sgRNA-G1
mU*mG*mU*rUrGrGrArArArArArArUrArUrUrUrGrArUrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6818
MG3-6-CD2-sgRNA-H1
mU*mG*mA*rUrGrUrCrCrUrGrArCrCrCrArArGrGrCrArCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6819
MG3-6-CD2-sgRNA-A2
mC*mC*mA*rArGrGrCrArUrUrCrGrUrArArUrCrUrCrUrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6820
MG3-6-CD2-sgRNA-B2
mU*mU*mU*rUrArGrArGrArGrGrGrUrCrUrCrArArArArCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6821
MG3-6-CD2-sgRNA-C2
mG*mG*mG*rUrCrUrCrArArArArCrCrArArArGrArUrCrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6822
MG3-6-CD2-sgRNA-D2
mG*mG*mA*rArArCrArUrCrUrArArArArCrUrUrUrCrUrCrArGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6823
MG3-6-CD2-sgRNA-E2
mC*mU*mC*rArGrArGrGrGrUrCrArUrCrArCrArCrArCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6824
MG3-6-CD2-sgRNA-F2
mC*mC*mG*rCrCrArCrGrCrArCrCrUrGrGrArCrArGrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6825
MG3-6-CD2-sgRNA-G2
mU*mG*mG*rArCrArGrCrUrGrArCrArGrGrCrUrCrGrArCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6826
MG3-6-CD2-sgRNA-H2
mG*mC*mU*rGrUrGrCrArCrUrUrGrArArUrUrUrUrGrCrArCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6827
MG3-6-CD2-sgRNA-A3
mU*mU*mU*rArGrArUrGrUrUrUrCrCrCrArUrCrUrUrGrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6828
MG3-6-CD2-sgRNA-B3
mC*mC*mA*rUrCrUrUrGrArUrArCrArGrGrUrUrUrArArUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6829
MG3-6-CD2-sgRNA-C3
mG*mG*mU*rCrArGrUrUrCrCrArUrUrCrArUrUrArCrCrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6830
MG3-6-CD2-sgRNA-D3
mU*mU*mC*rCrArUrUrCrArUrUrArCrCrUrCrArCrArGrGrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6831
MG3-6-CD2-sgRNA-E3
mG*mG*mG*rUrUrGrUrGrUrUrGrArUrArCrArArGrUrCrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6832
MG3-6-CD2-sgRNA-F3
mA*mA*mG*rUrCrCrArGrGrArGrArUrCrUrUrUrGrGrUrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6833
MG3-6-CD2-sgRNA-G3
mG*mG*mC*rArGrCrArUrCrCrUrUrGrGrCrCrArGrArGrUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6834
MG3-6-CD2-sgRNA-H3
mG*mC*mC*rArGrArGrUrArArUrGrGrGrCrUrCrUrCrUrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6835
MG3-6-CD2-sgRNA-A4
mC*mA*mC*rUrUrCrUrCrUrUrCrCrUrUrUrUrGrCrArGrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6836
MG3-6-CD2-sgRNA-B4
mU*mA*mU*rArGrArArArArCrGrArGrCrArGrUrGrCrCrArCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6837
MG3-6-CD2-sgRNA-C4
mA*mG*mC*rArGrUrGrCrCrArCrArArArGrArCrCrArUrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6838
MG3-6-CD2-sgRNA-D4
mA*mU*mG*rCrCrArArUrGrArUrGrArGrArUrArGrArUrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUmU*mU*mU

6839
MG3-6-CD2-sgRNA-E4
mG*mA*mA*rGrArGrArArGrUrGrGrGrArUrGrGrCrUrGrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6840
MG3-6-CD2-sgRNA-F4
mC*mC*mA*rCrArGrArGrUrArGrCrUrArCrUrGrArArGrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6841
MG3-6-CD2-sgRNA-G4
mC*mG*mU*rGrUrUrCrArGrCrArCrCrArGrCrCrUrCrArGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6842
MG3-6-CD2-sgRNA-H4
mG*mG*mG*rCrArCrArCrArArGrUrUrCrArCrCrArGrCrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6843
MG3-6-CD2-sgRNA-A5
mC*mA*mG*rCrArGrArArArGrGrCrCrCrGrCrCrCrCrUrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6844
MG3-6-CD2-sgRNA-B5
mU*mG*mA*rGrUrUrUrUrCrUrGrCrUrGrCrCrCrCrArUrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6845
MG3-6-CD2-sgRNA-C5
mA*mU*mG*rGrGrGrArGrGrUrUrUrUrGrGrCrUrGrArArCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6846
MG3-6-CD2-sgRNA-D5
mU*mG*mA*rArCrUrCrGrArGrGrUrCrUrGrGrGrGrArGrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6847
MG3-6-CD2-sgRNA-E5
mA*mA*mC*rUrUrGrUrGrUrGrCrCrCrGrArCrGrGrArGrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mUxmU*mU

6848
MG3-6-CD2-sgRNA-F5
mC*mG*mA*rCrGrGrArGrCrArGrGrArGrGrCrCrUrCrUrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6849
MG3-6-CD2-sgRNA-G5
mG*mG*mA*rGrGrArGrGrArUrGrUrUrGrGrGrArArGrUrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6850
MG3-6-CD2-sgRNA-H5
mG*mU*mU*rGrGrGrArArGrUrUrGrCrUrGrGrArUrUrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6851
MG3-6-CD2-sgRNA-A6
mA*mG*mG*rGrGrUrUrGrArArGrCrUrGrGrArArUrUrUrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6852
MG3-6-CD2-sgRNA-B6
mC*mC*mC*rUrUrUrCrUrUrCrArGrUrArGrCrUrArCrUrCrUrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Notations for chemical modifications: m = 2′O-methyl ribonucleotide (e.g mC = cytosine ribonucleotide with 2′-O Methyl in place of 2′ hydroxyl); f = 2′-fluoro ribonucleotide (e.g fC = cytosine ribonucleotide with 2′ fluorine in place of 2′ hydroxyl); * = phosphorothioate bond; r: native RNA linkage comprising the sugar ribose (for example the ribose or RNA form of the A base is written rA), d: deoxyribose sugar (DNA) linkage (for example a deoxyribose form of the A base is written dA)

TABLE 10B

Sites Targeted in Example 19

SEQ

ID

NO:
Entity Name
Sequence

6853
MG3-6-CD2-target site-A1
ATTTACATGGAAAGCTCATCTT

6854
MG3-6-CD2-target site-B1
TTTTTATAGGTGCAGTCTCCAA

6855
MG3-6-CD2-target site-C1
TGCCTTGGAAACCTGGGGTGCC

6856
MG3-6-CD2-target site-D1
GGGAAAAAACTTCAGACAAGAA

6857
MG3-6-CD2-target site-E1
TTGCACAATTCAGAAAAGAGAA

6858
MG3-6-CD2-target site-F1
GAACTCTGAAAATTAAGCATCT

6859
MG3-6-CD2-target site-G1
TGTTGGAAAAAATATTTGATTT

6860
MG3-6-CD2-target site-H1
TGATGTCCTGACCCAAGGCACC

6861
MG3-6-CD2-target site-A2
CCAAGGCATTCGTAATCTCTTT

6862
MG3-6-CD2-target site-B2
TTTTAGAGAGGGTCTCAAAACC

6863
MG3-6-CD2-target site-C2
GGGTCTCAAAACCAAAGATCTC

6864
MG3-6-CD2-target site-D2
GGAAACATCTAAAACTTTCTCA

6865
MG3-6-CD2-target site-E2
CTCAGAGGGTCATCACACACAA

6866
MG3-6-CD2-target site-F2
CCGCCACGCACCTGGACAGCTG

6867
MG3-6-CD2-target site-G2
TGGACAGCTGACAGGCTCGACA

6868
MG3-6-CD2-target site-H2
GCTGTGCACTTGAATTTTGCAC

6869
MG3-6-CD2-target site-A3
TTTAGATGTTTCCCATCTTGAT

6870
MG3-6-CD2-target site-B3
CCATCTTGATACAGGTTTAATT

6871
MG3-6-CD2-target site-C3
GGTCAGTTCCATTCATTACCTC

6872
MG3-6-CD2-target site-D3
TTCCATTCATTACCTCACAGGT

6873
MG3-6-CD2-target site-E3
GGGTTGTGTTGATACAAGTCCA

6874
MG3-6-CD2-target site-F3
AAGTCCAGGAGATCTTTGGTTT

6875
MG3-6-CD2-target site-G3
GGCAGCATCCTTGGCCAGAGTA

6876
MG3-6-CD2-target site-H3
GCCAGAGTAATGGGCTCTCTGC

6877
MG3-6-CD2-target site-A4
CACTTCTCTTCCTTTTGCAGAG

6878
MG3-6-CD2-target site-B4
TATAGAAAACGAGCAGTGCCAC

6879
MG3-6-CD2-target site-C4
AGCAGTGCCACAAAGACCATCA

6880
MG3-6-CD2-target site-D4
ATGCCAATGATGAGATAGATGT

6881
MG3-6-CD2-target site-E4
GAAGAGAAGTGGGATGGCTGGG

6882
MG3-6-CD2-target site-F4
CCACAGAGTAGCTACTGAAGAA

6883
MG3-6-CD2-target site-G4
CGTGTTCAGCACCAGCCTCAGA

6884
MG3-6-CD2-target site-H4
GGGCACACAAGTTCACCAGCAG

6885
MG3-6-CD2-target site-A5
CAGCAGAAAGGCCCGCCCCTCC

6886
MG3-6-CD2-target site-B5
TGAGTTTTCTGCTGCCCCATGG

6887
MG3-6-CD2-target site-C5
ATGGGGAGGTTTTGGCTGAACT

6888
MG3-6-CD2-target site-D5
TGAACTCGAGGTCTGGGGAGGG

6889
MG3-6-CD2-target site-E5
AACTTGTGTGCCCGACGGAGCA

6890
MG3-6-CD2-target site-F5
CGACGGAGCAGGAGGCCTCTTC

6891
MG3-6-CD2-target site-G5
GGAGGAGGATGTTGGGAAGTTG

6892
MG3-6-CD2-target site-H5
GTTGGGAAGTTGCTGGATTCTG

6893
MG3-6-CD2-target site-A6
AGGGGTTGAAGCTGGAATTTGG

6894
MG3-6-CD2-target site-B6
CCCTTTCTTCAGTAGCTACTCT

Example 20—Gene Editing Outcomes at the DNA Level for CD5

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (106 pmol protein/160 pmol guide) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA. The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 13).

TABLE 11A

Guide sequences used in Example 20

SEQ

ID

NO:
Entity Name
Sequence

6895
MG3-6-CD5-sgRNA-A1
mA*mG*mA*rArGrGrCrCrArGrArArArCrCrArUrGrCrCrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6896
MG3-6-CD5-sgRNA-B1
mG*mU*mA*rCrArArGrGrUrGrGrCrCrArGrCrGrGrUrUrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6897
MG3-6-CD5-sgRNA-C1
mU*mU*mC*rUrGrArCrCrCrCrCrArGrArUrUrUrCrCrArGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6898
MG3-6-CD5-sgRNA-D1
mC*mA*mC*rCrCrGrUrUrCrCrArArCrUrCrGrArArGrUrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6899
MG3-6-CD5-sgRNA-E1
mA*mC*mU*rCrGrArArGrUrGrCrCrArGrGrGrCrCrArGrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6900
MG3-6-CD5-sgRNA-F1
mG*mC*mA*rCrArUrGrGrUrUrUrGrCrArGrCrCrArGrArGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6901
MG3-6-CD5-sgRNA-G1
mG*mG*mG*rCrCrGrGrArGrCrUrCrCrArArGrCrArGrUrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6902
MG3-6-CD5-sgRNA-H1
mC*mU*mC*rArArUrCrArUrCrUrGrCrUrArCrGrGrArCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6903
MG3-6-CD5-sgRNA-A2
mC*mA*mG*rArArArUrGrArCrArUrGrUrGrUrCrArCrUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6904
MG3-6-CD5-sgRNA-B2
mG*mG*mC*rUrGrGrCrUrArGrUrUrArCrCrCrArCrCrUrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6905
MG3-6-CD5-sgRNA-C2
mG*mC*mU*rArGrUrUrArCrCrCrArCrCrUrArArGrCrArGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6906
MG3-6-CD5-sgRNA-D2
mU*mG*mA*rGrGrUrGrUrGrUrArGrGrUrGrArCrArArGrGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6907
MG3-6-CD5-sgRNA-E2
mG*mU*mG*rUrArGrGrUrGrArCrArArGrGrArArGrGrGrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6908
MG3-6-CD5-sgRNA-F2
mG*mC*mA*rCrCrCrCrArCrArGrUrUrCrArGrCrCrGrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6909
MG3-6-CD5-sgRNA-G2
mU*mG*mG*rCrArGrArCrUrUrUrUrGrArCrGrCrUrUrGrArCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6910
MG3-6-CD5-sgRNA-H2
mC*mC*mA*rUrGrUrGrCrCrArUrCrCrGrUrCrCrUrUrGrArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6911
MG3-6-CD5-sgRNA-A3
mG*mG*mU*rGrArGrCrCrUrUrGrCrCrUrGrGrArArArUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6912
MG3-6-CD5-sgRNA-B3
mC*mA*mG*rArArGrArCrArArCrArCrCrUrCrCrArArCrGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6913
MG3-6-CD5-sgRNA-C3
mC*mA*mA*rCrUrCrCrArGrArGrCrCrCrArCrArGrGrUrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6914
MG3-6-CD5-sgRNA-D3
mG*mG*mG*rCrUrCrUrGrGrArGrUrUrGrUrGrGrUrGrGrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6915
MG3-6-CD5-sgRNA-E3
mU*mG*mU*rCrGrUrUrGrGrArGrGrUrGrUrUrGrUrCrUrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6916
MG3-6-CD5-sgRNA-F3
mC*mU*mC*rUrCrUrCrCrUrCrUrCrCrUrArGrCrUrCrCrUrCrGrU

rUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGrG

rCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCrC

rGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6917
MG3-6-CD5-sgRNA-G3
mG*mC*mC*rUrGrGrGrGrGrGrUrArCrCrArUrCrArGrCrUrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6918
MG3-6-CD5-sgRNA-H3
mC*mC*mA*rUrCrArGrCrUrArUrGrArGrGrCrCrCrArGrGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6919
MG3-6-CD5-sgRNA-A4
mC*mU*mA*rUrGrArGrGrCrCrCrArGrGrArCrArArGrArCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6920
MG3-6-CD5-sgRNA-B4
mG*mC*mU*rCrCrUrUrCrUrUrGrArArGrCrArUrCrUrGrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6921
MG3-6-CD5-sgRNA-C4
mA*mG*mA*rGrArCrUrGrArGrGrCrArGrGrCrArGrArGrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6922
MG3-6-CD5-sgRNA-D4
mA*mC*mC*rArGrCrCrCrUrUrGrCrCrArArUrCrCrArArUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6923
MG3-6-CD5-sgRNA-E4
mU*mG*mC*rCrCrUrCrCrUrUrUrGrCrUrCrArGrGrUrArArGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6924
MG3-6-CD5-sgRNA-F4
mG*mG*mC*rArArGrArArCrUrCrGrGrCrCrArCrUrUrUrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6925
MG3-6-CD5-sgRNA-G4
mC*mC*mA*rGrGrGrArGrGrUrArCrArGrCrUrUrGrArGrUrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6926
MG3-6-CD5-sgRNA-H4
mA*mG*mC*rUrUrGrArGrUrUrCrUrGrGrArUrCrUrUrCrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6927
MG3-6-CD5-sgRNA-A5
mC*mU*mG*rGrArUrCrUrUrCrCrArUrUrGrGrArUrUrGrGrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6928
MG3-6-CD5-sgRNA-B5
mG*mG*mC*rUrGrGrUrGrUrUrCrCrCrGrUrGrGrCrUrCrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6929
MG3-6-CD5-sgRNA-C5
mG*mU*mU*rCrCrCrGrUrGrGrCrUrCrCrCrCrUrGrGrGrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6930
MG3-6-CD5-sgRNA-D5
mU*mG*mC*rUrUrCrArArGrArArGrGrArGrCrCrArCrArCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6931
MG3-6-CD5-sgRNA-E5
mA*mG*mG*rUrUrGrUrUrGrCrArGrArGrGrArArGrUrUrCrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6932
MG3-6-CD5-sgRNA-F5
mU*mG*mC*rArGrArGrGrArArGrUrUrCrUrCrCrArGrGrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUxmU*mU*mU

6933
MG3-6-CD5-sgRNA-G5
mU*mC*mU*rCrCrArGrGrUrCrCrUrGrGrGrUrCrUrUrGrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6934
MG3-6-CD5-sgRNA-H5
mG*mC*mC*rUrCrArUrArGrCrUrGrArUrGrGrUrArCrCrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6935
MG3-6-CD5-sgRNA-A6
mC*mA*mC*rGrCrCrGrGrCrArCrArGrUrGrCrUrGrGrCrCrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6936
MG3-6-CD5-sgRNA-B6
mA*mA*mG*rGrCrArCrCrGrUrGrGrArGrGrUrGrCrGrCrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6937
MG3-6-CD5-sgRNA-C6
mG*mA*mC*rGrCrUrGrGrUrGrArCrCrCrArArCrArUrCrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6938
MG3-6-CD5-sgRNA-D6
mG*mG*mA*rCrArGrArArGrArGrCrCrCrCrCrGrGrGrArUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6939
MG3-6-CD5-sgRNA-E6
mU*mC*mC*rUrGrGrCrUrGrArArGrArGrCrUrGrUrCrArCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6940
MG3-6-CD5-sgRNA-F6
mC*mC*mC*rCrArCrCrArGrArCrGrGrCrUrCrUrGrCrArCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6941
MG3-6-CD5-sgRNA-G6
mC*mC*mC*rArGrGrCrCrArGrGrArUrCrCrArArArCrCrCrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6942
MG3-6-CD5-sgRNA-H6
mU*mU*mC*rArCrUrArGrCrUrUrCrUrUrGrUrArGrGrCrArArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6943
MG3-6-CD5-sgRNA-A7
mC*mC*mA*rGrCrArGrCrArCrCrArCrCrArGrGrArGrCrArCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6944
MG3-6-CD5-sgRNA-B7
mA*mU*mG*rCrUrUrGrCrCrArCrCrGrUrGrCrCrUrGrCrGrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6945
MG3-6-CD5-sgRNA-C7
mA*mC*mC*rGrUrGrCrCrUrGrCrGrGrCrCrArGrGrCrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6946
MG3-6-CD5-sgRNA-D7
mC*mC*mU*rGrCrGrGrCrCrArGrGrCrCrUrGrCrGrGrGrGrUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6947
MG3-6-CD5-sgRNA-E7
mU*mC*mC*rGrCrCrArGrArArGrArArGrCrArGrCrGrCrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUmU*mU*mU

6948
MG3-6-CD5-sgRNA-F7
mU*mU*mA*rCrUrGrUrUrUrUrGrGrUrUrCrArUrUrCrCrCrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6949
MG3-6-CD5-sgRNA-G7
mU*mC*mC*rArCrUrGrGrCrGrCrUrGrCrUrUrCrUrUrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6950
MG3-6-CD5-sgRNA-H7
mA*mG*mC*rUrGrArCrArGrGrUrGrGrGrArGrUrUrCrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6951
MG3-6-CD5-sgRNA-A8
mG*mG*mC*rUrGrUrArUrUrCrGrUrUrArUrCrCrArCrGrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6952
MG3-6-CD5-sgRNA-B8
mUmC*mG*rUrUrArUrCrCrArCrGrUrGrGrGrArGrGrCrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6953
MG3-6-CD5-sgRNA-C8
mG*mG*mA*rGrGrCrUrGrUrGrGrGrGrUrUrCrUrCrArGrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6954
MG3-6-CD5-sgRNA-D8
mC*mC*mU*rUrUrCrUrUrUrCrCrCrCrArGrCrUrCrUrGrGrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6955
MG3-6-CD5-sgRNA-E8
mC*mC*mG*rArCrArGrUrGrArCrUrArUrGrArUrCrUrGrCrArGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrUmUxmU*mU

6956
MG3-6-CD5-sgRNA-F8
mG*mA*mC*rUrArUrGrArUrCrUrGrCrArUrGrGrGrGrCrUrCrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6957
MG3-6-CD5-sgRNA-G8
mC*mU*mU*rUrArCrArGrCrCrUrCrUrGrArGrCrCrCrCrArUrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

6958
MG3-6-CD5-sgRNA-H8
mA*mU*mA*rGrUrCrArCrUrGrUrCrGrGrArGrGrArGrUrUrGrGr

UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArGr

GrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrArCr

CrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGrCrGr

GrUrArUrGrU*mU*mU*mU

Notations for chemical modifications: m = 2′O-methyl ribonucleotide (e.g mC = cytosine ribonucleotide with 2′-O Methyl in place of 2′ hydroxyl); f = 2′-fluoro ribonucleotide (e.g fC = cytosine ribonucleotide with 2′ fluorine in place of 2′ hydroxyl); * = phosphorothioate bond; r: native RNA linkage comprising the sugar ribose (for example the ribose or RNA form of the A base is written rA), d: deoxyribose sugar (DNA) linkage (for example a deoxyribose form of the A base is written dA)

TABLE 11B

Sites Targeted in Example 20

SEQ

ID

NO:
Entity Name
Sequence

6959
MG3-6-CD5-target site-A1
AGAAGGCCAGAAACCATGCCCA

6960
MG3-6-CD5-target site-B1
GTACAAGGTGGCCAGCGGTTGC

6961
MG3-6-CD5-target site-C1
TTCTGACCCCCAGATTTCCAGG

6962
MG3-6-CD5-target site-D1
CACCCGTTCCAACTCGAAGTGC

6963
MG3-6-CD5-target site-E1
ACTCGAAGTGCCAGGGCCAGCT

6964
MG3-6-CD5-target site-F1
GCACATGGTTTGCAGCCAGAGC

6965
MG3-6-CD5-target site-G1
GGGCCGGAGCTCCAAGCAGTGG

6966
MG3-6-CD5-target site-H1
CTCAATCATCTGCTACGGACAA

6967
MG3-6-CD5-target site-A2
CAGAAATGACATGTGTCACTCT

6968
MG3-6-CD5-target site-B2
GGCTGGCTAGTTACCCACCTAA

6969
MG3-6-CD5-target site-C2
GCTAGTTACCCACCTAAGCAGG

6970
MG3-6-CD5-target site-D2
TGAGGTGTGTAGGTGACAAGGA

6971
MG3-6-CD5-target site-E2
GTGTAGGTGACAAGGAAGGGGC

6972
MG3-6-CD5-target site-F2
GCACCCCACAGTTCAGCCGCTG

6973
MG3-6-CD5-target site-G2
TGGCAGACTTTTGACGCTTGAC

6974
MG3-6-CD5-target site-H2
CCATGTGCCATCCGTCCTTGAG

6975
MG3-6-CD5-target site-A3
GGTGAGCCTTGCCTGGAAATCT

6976
MG3-6-CD5-target site-B3
CAGAAGACAACACCTCCAACGA

6977
MG3-6-CD5-target site-C3
CAACTCCAGAGCCCACAGGTAA

6978
MG3-6-CD5-target site-D3
GGGCTCTGGAGTTGTGGTGGGC

6979
MG3-6-CD5-target site-E3
TGTCGTTGGAGGTGTTGTCTTC

6980
MG3-6-CD5-target site-F3
CTCTCTCCTCTCCTAGCTCCTC

6981
MG3-6-CD5-target site-G3
GCCTGGGGGGTACCATCAGCTA

6982
MG3-6-CD5-target site-H3
CCATCAGCTATGAGGCCCAGGA

6983
MG3-6-CD5-target site-A4
CTATGAGGCCCAGGACAAGACC

6984
MG3-6-CD5-target site-B4
GCTCCTTCTTGAAGCATCTGCC

6985
MG3-6-CD5-target site-C4
AGAGACTGAGGCAGGCAGAGCC

6986
MG3-6-CD5-target site-D4
ACCAGCCCTTGCCAATCCAATG

6987
MG3-6-CD5-target site-E4
TGCCCTCCTTTGCTCAGGTAAG

6988
MG3-6-CD5-target site-F4
GGCAAGAACTCGGCCACTTTTC

6989
MG3-6-CD5-target site-G4
CCAGGGAGGTACAGCTTGAGTT

6990
MG3-6-CD5-target site-H4
AGCTTGAGTTCTGGATCTTCCA

6991
MG3-6-CD5-target site-A5
CTGGATCTTCCATTGGATTGGC

6992
MG3-6-CD5-target site-B5
GGCTGGTGTTCCCGTGGCTCCC

6993
MG3-6-CD5-target site-C5
GTTCCCGTGGCTCCCCTGGGTC

6994
MG3-6-CD5-target site-D5
TGCTTCAAGAAGGAGCCACACT

6995
MG3-6-CD5-target site-E5
AGGTTGTTGCAGAGGAAGTTCT

6996
MG3-6-CD5-target site-F5
TGCAGAGGAAGTTCTCCAGGTC

6997
MG3-6-CD5-target site-G5
TCTCCAGGTCCTGGGTCTTGTC

6998
MG3-6-CD5-target site-H5
GCCTCATAGCTGATGGTACCCC

6999
MG3-6-CD5-target site-A6
CACGCCGGCACAGTGCTGGCCG

7000
MG3-6-CD5-target site-B6
AAGGCACCGTGGAGGTGCGCCA

7001
MG3-6-CD5-target site-C6
GACGCTGGTGACCCAACATCCC

7002
MG3-6-CD5-target site-D6
GGACAGAAGAGCCCCCGGGATG

7003
MG3-6-CD5-target site-E6
TCCTGGCTGAAGAGCTGTCACA

7004
MG3-6-CD5-target site-F6
CCCCACCAGACGGCTCTGCACC

7005
MG3-6-CD5-target site-G6
CCCAGGCCAGGATCCAAACCCC

7006
MG3-6-CD5-target site-H6
TTCACTAGCTTCTTGTAGGCAA

7007
MG3-6-CD5-target site-A7
CCAGCAGCACCACCAGGAGCAC

7008
MG3-6-CD5-target site-B7
ATGCTTGCCACCGTGCCTGCGG

7009
MG3-6-CD5-target site-C7
ACCGTGCCTGCGGCCAGGCCTG

7010
MG3-6-CD5-target site-D7
CCTGCGGCCAGGCCTGCGGGGT

7011
MG3-6-CD5-target site-E7
TCCGCCAGAAGAAGCAGCGCCA

7012
MG3-6-CD5-target site-F7
TTACTGTTTTGGTTCATTCCCG

7013
MG3-6-CD5-target site-G7
TCCACTGGCGCTGCTTCTTCTG

7014
MG3-6-CD5-target site-H7
AGCTGACAGGTGGGAGTTCCTG

7015
MG3-6-CD5-target site-A8
GGCTGTATTCGTTATCCACGTG

7016
MG3-6-CD5-target site-B8
TCGTTATCCACGTGGGAGGCTG

7017
MG3-6-CD5-target site-C8
GGAGGCTGTGGGGTTCTCAGCA

7018
MG3-6-CD5-target site-D8
CCTTTCTTTCCCCAGCTCTGGA

7019
MG3-6-CD5-target site-E8
CCGACAGTGACTATGATCTGCA

7020
MG3-6-CD5-target site-F8
GACTATGATCTGCATGGGGCTC

7021
MG3-6-CD5-target site-G8
CTTTACAGCCTCTGAGCCCCAT

7022
MG3-6-CD5-target site-H8
ATAGTCACTGTCGGAGGAGTTG

Example 21—Targeted RNA Cleavage by MG3-6 and MG3-8

A 101 ft RNA containing the spacer (GGUCAGGGCGCGUCAGCGGGUGUUGGCGGGUGUCGGGGCUGGCUUAAAUUUUG GACCAGUCGAGGCUUGCGACGUGGUGGCUUUUCCAGUCGGGAAACCUG) with 5′ adjacent sequence UUGGACCA were prepared via transcription of a T7 promoter-containing PCR product using the T7 Megascript kit (NEB) according to manufacturer instructions. The resulting RNA was purified using a Monarch RNA prep spin column (NEB) and then labeled with the 5′ EndTag kit (Vector labs) using a FAM-maleimide dye per recommended instructions. The resulting RNA has one 5′ label and an expected band size of 60 nt if cleaved at a single position in the spacer. For testing RNA cleavage, 2 pmol of protein and sgRNA were pre-incubated for 15 minutes before adding ssRNA target. The RNP complex was added to the labeled RNA at a 10:1 ratio (200 nM RNA: 2 μM RNP) in cleavage buffer (10 mM Tris, 100 mM NaCl, and 10 mM MgCl₂) and incubated at 37° C. for 1 hr. Reactions were quenched with proteinase K and resolved on a 1500 TBE Urea-PAGE gel (Bio-rad). The gel shows site-directed RNA cleavage by MG3-6 and MG3-8 as well as commercial positive control SauCas9 (NEB) (FIG. 14). The results indicated that MG3-6 and MG3-8 are capable of targeted RNA cleavage and are comparable in terms of RNA cleavage to SauCas9.

Example 22—Gene Editing Outcomes at the DNA Level for FAS

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (104 pmol protein/120 pmol guide) (SEQ ID NOs: 7023-7056) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 7057-7090). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 15).

TABLE 12

Guide RNAs and Sequences Targeted for Example 22

SEQ

ID

NO:
NAME
SEQUENCE

7023
MG3-6-FAS-sgRNA-
mC*mU*mG*rArUrGrArGrUrGrGrUrUrUrCrCrCrUrGrArGrCrG

A1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmU*mU*mU

7024
MG3-6-FAS-sgRNA-
mU*mU*mA*rGrArUrGrCrUrCrArGrArGrUrGrUrGrUrGrCrArG

B1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7025
MG3-6-FAS-sgRNA-
mG*mU*mG*rUrGrCrArCrArArGrGrCrUrGrGrCrArCrGrCrCrG

C1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7026
MG3-6-FAS-sgRNA-
mG*mA*mG*rArCrArArGrCrCrUrArUrCrArArCrArCrCrUrArGr

D1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7027
MG3-6-FAS-sgRNA-
mA*mC*mC*rArCrCrArGrUrCrUrUrGrUrArGrGrUrGrUrUrGrG

E1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7028
MG3-6-FAS-sgRNA-
mC*mU*mU*rGrUrCrUrCrUrGrUrUrCrCrArCrCrUrUrUrCrArGr

F1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7029
MG3-6-FAS-sgRNA-
mA*mG*mU*rArGrArCrUrGrUrUrArGrUrGrCrCrArUrGrArGrG

G1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mUxmU*mU

7030
MG3-6-FAS-sgRNA-
mU*mU*mA*rCrArGrGrUrUrCrUrUrArCrGrUrCrUrGrUrUrGrGr

H1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7031
MG3-6-FAS-sgRNA-
mC*mA*mA*rGrUrGrArCrUrGrArCrArUrCrArArCrUrCrCrArGr

A2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmU*mU*mU

7032
MG3-6-FAS-sgRNA-
mA*mC*mU*rCrCrArArGrGrGrArUrUrGrGrArArUrUrGrArGrG

B2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7033
MG3-6-FAS-sgRNA-
mU*mG*mA*rGrGrArArGrArCrUrGrUrUrArCrUrArCrArGrUrG

C2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7034
MG3-6-FAS-sgRNA-
mU*mA*mC*rArGrUrUrGrArGrArCrUrCrArGrArArCrUrUrGrGr

D2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUmU*mU*mU

7035
MG3-6-FAS-sgRNA-
mU*mU*mU*rGrUrGrUrArArCrArUrArCrCrUrGrGrArGrGrArG

E2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7036
MG3-6-FAS-sgRNA-
mU*mG*mG*rCrArGrArArUrUrGrGrCrCrArUrCrArUrGrArUrG

F2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7037
MG3-6-FAS-sgRNA-
mU*mU*mG*rGrGrCrArGrGrUrGrArArArGrGrArArArGrCrUrG

G2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7038
MG3-6-FAS-sgRNA-
mC*mU*mG*rCrArCrArGrUrCrArArUrGrGrGrGrArUrGrArArG

H2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7039
MG3-6-FAS-sgRNA-
mU*mU*mU*rUrCrUrUrCrCrArArArUrGrCrArGrArArGrArUrGr

A3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7040
MG3-6-FAS-sgRNA-
mA*mU*mC*rUrUrCrUrGrCrArUrUrUrGrGrArArGrArArArArGr

B3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7041
MG3-6-FAS-sgRNA-
mU*mA*mG*rArArGrUrGrGrArArArUrArArArCrUrGrCrArCrGr

C3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7042
MG3-6-FAS-sgRNA-
mA*mA*mG*rArCrUrArArArArCrUrUrArCrUrUrGrGrUrGrCrGr

D3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmU*mU*mU

7043
MG3-6-FAS-sgRNA-
mG*mU*mU*rUrArCrArUrCrUrGrCrArCrUrUrGrGrUrArUrUrGr

E3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7044
MG3-6-FAS-sgRNA-
mA*mA*mG*rArArGrArCrArArArGrCrCrArCrCrCrCrArArGrGr

F3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7045
MG3-6-FAS-sgRNA-
mA*mC*mA*rArArGrCrCrArCrCrCrCrArArGrUrUrArGrArUrGr

G3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7046
MG3-6-FAS-sgRNA-
mC*mC*mC*rCrArArGrUrUrArGrArUrCrUrGrGrArUrCrCrUrGr

H3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7047
MG3-6-FAS-sgRNA-
mC*mA*mG*rArArArGrCrArCrArGrArArArGrGrArArArArCrGr

A4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7048
MG3-6-FAS-sgRNA-
mA*mA*mU*rArCrCrUrArCrArGrGrArUrUrUrArArArGrUrUrGr

B4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7049
MG3-6-FAS-sgRNA-
mC*mA*mG*rUrGrGrCrArArUrArArArUrUrUrArUrCrUrGrGrGr

C4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7050
MG3-6-FAS-sgRNA-
mA*mG*mU*rCrArUrGrArCrArCrUrArArGrUrCrArArGrUrUrGr

D4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUmUmU*mU

7051
MG3-6-FAS-sgRNA-
mG*mU*mG*rUrCrArArUrGrArArGrCrCrArArArArUrArGrArGr

E4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7052
MG3-6-FAS-sgRNA-
mA*mG*mA*rArGrCrGrUrArUrGrArCrArCrArUrUrGrArUrUrGr

F4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mUxmU*mU

7053
MG3-6-FAS-sgRNA-
mU*mU*mU*rGrUrArCrUrCrUrUrGrCrArGrArGrArArArArUrGr

G4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7054
MG3-6-FAS-sgRNA-
mG*mU*mU*rUrUrUrCrArCrUrCrUrArGrArCrCrArArGrCrUrGr

H4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7055
MG3-6-FAS-sgRNA-
mU*mG*mA*rArUrUrUrUrCrUrCrUrGrCrArArGrArGrUrArCrGr

A5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7056
MG3-6-FAS-sgRNA-
mA*mG*mA*rGrUrArCrArArArGrArUrUrGrGrCrUrUrUrUrUrGr

B5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmU*mU*mU

7057
MG3-6-FAS-target
CTGATGAGTGGTTTCCCTGAGC

site-A1

7058
MG3-6-FAS-target
TTAGATGCTCAGAGTGTGTGCA

site-B1

7059
MG3-6-FAS-target
GTGTGCACAAGGCTGGCACGCC

site-C1

7060
MG3-6-FAS-target
GAGACAAGCCTATCAACACCTA

site-D1

7061
MG3-6-FAS-target
ACCACCAGTCTTGTAGGTGTTG

site-E1

7062
MG3-6-FAS-target
CTTGTCTCTGTTCCACCTTTCA

site-F1

7063
MG3-6-FAS-target
AGTAGACTGTTAGTGCCATGAG

site-G1

7064
MG3-6-FAS-target
TTACAGGTTCTTACGTCTGTTG

site-H1

7065
MG3-6-FAS-target
CAAGTGACTGACATCAACTCCA

site-A2

7066
MG3-6-FAS-target
ACTCCAAGGGATTGGAATTGAG

site-B2

7067
MG3-6-FAS-target
TGAGGAAGACTGTTACTACAGT

site-C2

7068
MG3-6-FAS-target
TACAGTTGAGACTCAGAACTTG

site-D2

7069
MG3-6-FAS-target
TTTGTGTAACATACCTGGAGGA

site-E2

7070
MG3-6-FAS-target
TGGCAGAATTGGCCATCATGAT

site-F2

7071
MG3-6-FAS-target
TTGGGCAGGTGAAAGGAAAGCT

site-G2

7072
MG3-6-FAS-target
CTGCACAGTCAATGGGGATGAA

site-H2

7073
MG3-6-FAS-target
TTTTCTTCCAAATGCAGAAGAT

site-A3

7074
MG3-6-FAS-target
ATCTTCTGCATTTGGAAGAAAA

site-B3

7075
MG3-6-FAS-target
TAGAAGTGGAAATAAACTGCAC

site-C3

7076
MG3-6-FAS-target
AAGACTAAAACTTACTTGGTGC

site-D3

7077
MG3-6-FAS-target
GTTTACATCTGCACTTGGTATT

site-E3

7078
MG3-6-FAS-target
AAGAAGACAAAGCCACCCCAAG

site-F3

7079
MG3-6-FAS-target
ACAAAGCCACCCCAAGTTAGAT

site-G3

7080
MG3-6-FAS-target
CCCCAAGTTAGATCTGGATCCT

site-H3

7081
MG3-6-FAS-target
CAGAAAGCACAGAAAGGAAAAC

site-A4

7082
MG3-6-FAS-target
AATACCTACAGGATTTAAAGTT

site-B4

7083
MG3-6-FAS-target
CAGTGGCAATAAATTTATCTGG

site-C4

7084
MG3-6-FAS-target
AGTCATGACACTAAGTCAAGTT

site-D4

7085
MG3-6-FAS-target
GTGTCAATGAAGCCAAAATAGA

site-E4

7086
MG3-6-FAS-target
AGAAGCGTATGACACATTGATT

site-F4

7087
MG3-6-FAS-target
TTTGTACTCTTGCAGAGAAAAT

site-G4

7088
MG3-6-FAS-target
GTTTTTCACTCTAGACCAAGCT

site-H4

7089
MG3-6-FAS-target
TGAATTTTCTCTGCAAGAGTAC

site-A5

7090
MG3-6-FAS-target
AGAGTACAAAGATTGGCTTTTT

site-B5

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 23—Gene Editing Outcomes at the DNA Level for PD-1

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (104 pmol protein/120 pmol guide) (SEQ ID NOs: 7091-7128) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 7129-7166). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 16).

TABLE 13

Guide RNAs and Sequences Targeted for Example 23

SEQ

ID

NO:
NAME
SEQUENCE

7091
MG3-6-PD-1-sgRNA-
mG*mG*mU*rGrGrCrCrArArGrGrArArGrCrCrGrGrUrCrArGrG

A1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7092
MG3-6-PD-1-sgRNA-
mG*mG*mG*rCrCrArArGrArGrCrArGrUrGrUrCrCrArUrCrCrG

B1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmU*mU*mU

7093
MG3-6-PD-1-sgRNA-
mG*mG*mC*rCrCrUrCrGrGrArGrUrGrCrCrCrArGrCrCrArCrG

C1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7094
MG3-6-PD-1-sgRNA-
mG*mG*mC*rCrUrCrArGrUrGrGrCrUrGrGrGrCrArCrUrCrCrG

D1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7095
MG3-6-PD-1-sgRNA-
mG*mG*mG*rCrArCrCrUrCrArUrCrCrCrCrCrGrCrCrCrGrCrGr

E1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7096
MG3-6-PD-1-sgRNA-
mC*mU*mG*rCrUrCrArGrGrGrArCrArCrArGrGrGrCrArCrGrG

F1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7097
MG3-6-PD-1-sgRNA-
mG*mG*mA*rCrArCrArGrGrGrCrArCrGrGrGrGrGrGrCrUrCrG

G1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7098
MG3-6-PD-1-sgRNA-
mA*mG*mC*rUrGrGrArUrUrUrCrCrArGrUrGrGrCrGrArGrArG

H1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7099
MG3-6-PD-1-sgRNA-
mG*mU*mU*rCrUrCrUrGrUrGrGrArCrUrArUrGrGrGrGrArGrG

A2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7100
MG3-6-PD-1-sgRNA-
mC*mU*mC*rArGrCrCrGrUrGrCrCrUrGrUrGrUrUrCrUrCrUrGr

B2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7101
MG3-6-PD-1-sgRNA-
mA*mC*mA*rGrArGrArArCrArCrArGrGrCrArCrGrGrCrUrGrG

C2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7102
MG3-6-PD-1-sgRNA-
mG*mG*mG*rUrCrCrUrGrGrCrCrGrUrCrArUrCrUrGrCrUrCrG

D2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7103
MG3-6-PD-1-sgRNA-
mC*mG*mG*rCrCrCrGrGrGrArGrCrArGrArUrGrArCrGrGrCrG

E2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mUxmU

7104
MG3-6-PD-1-sgRNA-
mG*mG*mG*rArGrCrArGrArUrGrArCrGrGrCrCrArGrGrArCrG

F2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7105
MG3-6-PD-1-sgRNA-
mU*mG*mG*rGrCrArGrCrCrUrGrGrUrGrCrUrGrCrUrArGrUrG

G2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7106
MG3-6-PD-1-sgRNA-
mG*mC*mC*rArGrGrArCrCrCrArGrArCrUrArGrCrArGrCrArG

H2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7107
MG3-6-PD-1-sgRNA-
mA*mC*mU*rArGrCrArGrCrArCrCrArGrGrCrUrGrCrCrCrArGr

A3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7108
MG3-6-PD-1-sgRNA-
mG*mG*mC*rCrGrCrCrCrArCrGrArCrArCrCrArArCrCrArCrGr

B3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7109
MG3-6-PD-1-sgRNA-
mA*mA*mC*rUrGrGrCrCrGrGrCrUrGrGrCrCrUrGrGrGrUrGrG

C3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7110
MG3-6-PD-1-sgRNA-
mA*mC*mA*rGrCrCrCrArCrCrCrCrArGrCrCrCrCrUrCrArCrGr

D3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7111
MG3-6-PD-1-sgRNA-
mC*mU*mG*rGrCrCrUrGrGrGrUrGrArGrGrGrGrCrUrGrGrGrG

E3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7112
MG3-6-PD-1-sgRNA-
mC*mC*mU*rGrUrCrArCrCrCrUrGrArGrCrUrCrUrGrCrCrCrGr

F3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7113
MG3-6-PD-1-sgRNA-
mG*mG*mC*rUrCrUrCrUrUrUrGrArUrCrUrGrCrGrCrCrUrUrGr

G3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7114
MG3-6-PD-1-sgRNA-
mC*mC*mA*rUrCrUrCrCrCrUrGrGrCrCrCrCrCrArArGrGrCrGr

H3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7115
MG3-6-PD-1-sgRNA-
mA*mU*mG*rArCrArGrCrGrGrCrArCrCrUrArCrCrUrCrUrGrGr

A4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mUxmU*mU

7116
MG3-6-PD-1-sgRNA-
mG*mG*mU*rArGrGrUrGrCrCrGrCrUrGrUrCrArUrUrGrCrGrG

B4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7117
MG3-6-PD-1-sgRNA-
mG*mU*mG*rArCrUrUrCrCrArCrArUrGrArGrCrGrUrGrGrUrG

C4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7118
MG3-6-PD-1-sgRNA-
mG*mA*mC*rArCrGrGrArArGrCrGrGrCrArGrUrCrCrUrGrGrG

D4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUmU*mU*mU

7119
MG3-6-PD-1-sgRNA-
mC*mG*mA*rGrGrArCrCrGrCrArGrCrCrArGrCrCrCrGrGrCrG

E4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7120
MG3-6-PD-1-sgRNA-
mG*mG*mA*rCrArArGrCrUrGrGrCrCrGrCrCrUrUrCrCrCrCrG

F4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7121
MG3-6-PD-1-sgRNA-
mG*mC*mC*rArGrCrUrUrGrUrCrCrGrUrCrUrGrGrUrUrGrCrG

G4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7122
MG3-6-PD-1-sgRNA-
mU*mG*mU*rCrCrCrCrUrUrCrGrGrUrCrArCrCrArCrGrArGrGr

H4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7123
MG3-6-PD-1-sgRNA-
mA*mG*mC*rArGrGrGrCrUrGrGrGrGrArGrArArGrGrUrGrGrG

A5
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7124
MG3-6-PD-1-sgRNA-
mU*mG*mG*rGrGrArGrArArGrGrUrGrGrGrGrGrGrGrUrUrCr

B5
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArA

rGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

7125
MG3-6-PD-1-sgRNA-
mC*mU*mC*rCrArUrCrUrCrUrCrArGrArCrUrCrCrCrCrArGrGr

C5
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7126
MG3-6-PD-1-sgRNA-
mG*mC*mC*rArGrGrArUrGrGrUrUrCrUrUrArGrGrUrArGrGrG

D5
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7127
MG3-6-PD-1-sgRNA-
mA*mG*mU*rCrGrUrCrUrGrGrGrCrGrGrUrGrCrUrArCrArArG

E5
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7128
MG3-6-PD-1-sgRNA-
mA*mG*mA*rCrGrArCrUrGrGrCrCrArGrGrGrCrGrCrCrUrGrG

F5
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7129
MG3-6-PD-1-target
GGTGGCCAAGGAAGCCGGTCAG

site-A1

7130
MG3-6-PD-1-target
GGGCCAAGAGCAGTGTCCATCC

site-B1

7131
MG3-6-PD-1-target
GGCCCTCGGAGTGCCCAGCCAC

site-C1

7132
MG3-6-PD-1-target
GGCCTCAGTGGCTGGGCACTCC

site-D1

7133
MG3-6-PD-1-target
GGGCACCTCATCCCCCGCCCGC

site-E1

7134
MG3-6-PD-1-target
GGACACAGGGCACGGGGGGCTC

site-F1

7135
MG3-6-PD-1-target
GGACACAGGGCACGGGGGGCTC

site-G1

7136
MG3-6-PD-1-target
AGCTGGATTTCCAGTGGCGAGA

site-H1

7137
MG3-6-PD-1-target
GTTCTCTGTGGACTATGGGGAG

site-A2

7138
MG3-6-PD-1-target
CTCAGCCGTGCCTGTGTTCTCT

site-B2

7139
MG3-6-PD-1-target
ACAGAGAACACAGGCACGGCTG

site-C2

7140
MG3-6-PD-1-target
GGGTCCTGGCCGTCATCTGCTC

site-D2

7141
MG3-6-PD-1-target
CGGCCCGGGAGCAGATGACGGC

site-E2

7142
MG3-6-PD-1-target
GGGAGCAGATGACGGCCAGGAC

site-F2

7143
MG3-6-PD-1-target
TGGGCAGCCTGGTGCTGCTAGT

site-G2

7144
MG3-6-PD-1-target
GCCAGGACCCAGACTAGCAGCA

site-H2

7145
MG3-6-PD-1-target
ACTAGCAGCACCAGGCTGCCCA

site-A3

7146
MG3-6-PD-1-target
GGCCGCCCACGACACCAACCAC

site-B3

7147
MG3-6-PD-1-target
AACTGGCCGGCTGGCCTGGGTG

site-C3

7148
MG3-6-PD-1-target
ACAGCCCACCCCAGCCCCTCAC

site-D3

7149
MG3-6-PD-1-target
CTGGCCTGGGTGAGGGGCTGGG

site-E3

7150
MG3-6-PD-1-target
CCTGTCACCCTGAGCTCTGCCC

site-F3

7151
MG3-6-PD-1-target
GGCTCTCTTTGATCTGCGCCTT

site-G3

7152
MG3-6-PD-1-target
CCATCTCCCTGGCCCCCAAGGC

site-H3

7153
MG3-6-PD-1-target
ATGACAGCGGCACCTACCTCTG

site-A4

7154
MG3-6-PD-1-target
GGTAGGTGCCGCTGTCATTGCG

site-B4

7155
MG3-6-PD-1-target
GTGACTTCCACATGAGCGTGGT

site-C4

7156
MG3-6-PD-1-target
GACACGGAAGCGGCAGTCCTGG

site-D4

7157
MG3-6-PD-1-target
CGAGGACCGCAGCCAGCCCGGC

site-E4

7158
MG3-6-PD-1-target
GGACAAGCTGGCCGCCTTCCCC

site-F4

7159
MG3-6-PD-1-target
GCCAGCTTGTCCGTCTGGTTGC

site-G4

7160
MG3-6-PD-1-target
TGTCCCCTTCGGTCACCACGAG

site-H4

7161
MG3-6-PD-1-target
AGCAGGGCTGGGGAGAAGGTGG

site-A5

7162
MG3-6-PD-1-target
TGGGGAGAAGGTGGGGGGGTTC

site-B5

7163
MG3-6-PD-1-target
CTCCATCTCTCAGACTCCCCAG

site-C5

7164
MG3-6-PD-1-target
GCCAGGATGGTTCTTAGGTAGG

site-D5

7165
MG3-6-PD-1-target
AGTCGTCTGGGCGGTGCTACAA

site-E5

7166
MG3-6-PD-1-target
AGACGACTGGCCAGGGCGCCTG

site-F5

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 24—Gene Editing Outcomes at the DNA Level for hRosa26

Primary T cells were purified from PBMCs using a negative selection kit (Miltenyi) according to the manufacturer's recommendations. Nucleofection of MG3-6 RNPs (104 pmol protein/120 pmol guide) (SEQ ID NOs: 7167-7198) was performed into T cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 7199-7230). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 17).

TABLE 14

Guide RNAs and Sequences Targeted for Example 24

SEQ

ID

NO:
NAME
SEQUENCE

7167
MG3-6-hRosa26-
mA*mU*mC*rUrGrUrCrUrGrGrUrUrUrCrGrCrGrArGrArCrArG

sgRNA-A1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7168
MG3-6-hRosa26-
mU*mU*mU*rCrGrCrGrArGrArCrArCrCrArGrGrCrUrArCrCrGr

sgRNA-B1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7169
MG3-6-hRosa26-
mA*mG*mC*rArArGrUrArCrArArCrArArArUrGrGrArArArArGr

sgRNA-C1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7170
MG3-6-hRosa26-
mG*mC*mA*rArArArGrCrUrArArArArUrUrUrUrUrCrUrArUrGr

sgRNA-D1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7171
MG3-6-hRosa26-
mU*mG*mC*rUrArCrArCrUrUrUrGrGrUrGrGrUrGrCrArGrCrG

sgRNA-E1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7172
MG3-6-hRosa26-
mA*mC*mU*rCrCrCrCrUrGrCrArGrGrGrCrArArCrGrCrCrCrGr

sgRNA-F1
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7173
MG3-6-hRosa26-
mC*mG*mA*rCrUrCrGrArCrArUrGrGrArGrGrCrGrArUrGrArG

sgRNA-G1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7174
MG3-6-hRosa26-
mA*mU*mC*rArCrGrCrGrArGrGrArGrGrArArArGrGrArGrGrG

sgRNA-H1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7175
MG3-6-hRosa26-
mA*mG*mG*rArArArGrGrArGrGrGrArGrGrGrCrUrUrCrUrUrG

sgRNA-A2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7176
MG3-6-hRosa26-
mA*mC*mC*rUrCrCrUrCrCrArCrCrGrCrArGrCrUrCrCrCrUrGr

sgRNA-B2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUmUmU*mU

7177
MG3-6-hRosa26-
mG*mC*mG*rCrCrUrCrCrCrArCrCrCrArCrArArArCrCrArGrGr

sgRNA-C2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmU*mU*mU

7178
MG3-6-hRosa26-
mC*mC*mC*rArCrCrCrCrCrArCrGrArGrUrGrCrCrUrGrUrArGr

sgRNA-D2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7179
MG3-6-hRosa26-
mC*mU*mC*rGrUrGrGrGrGrGrUrGrGrGrGrGrArGrGrArGrCr

sgRNA-E2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArA

rGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

7180
MG3-6-hRosa26-
mG*mC*mU*rGrCrGrGrUrGrGrArGrGrArGrGrUrGrGrArGrArG

sgRNA-F2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7181
MG3-6-hRosa26-
mU*mC*mU*rCrUrGrCrUrGrCrCrUrCrCrCrGrUrCrUrUrGrUrGr

sgRNA-G2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7182
MG3-6-hRosa26-
mC*mU*mC*rCrCrGrUrCrUrUrGrUrArArGrGrArCrCrGrCrCrGr

sgRNA-H2
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7183
MG3-6-hRosa26-
mC*mG*mA*rGrUrCrGrCrUrUrCrUrCrGrArUrUrArUrGrGrGrG

sgRNA-A3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7184
MG3-6-hRosa26-
mA*mU*mU*rArUrGrGrGrCrGrGrGrArUrUrCrUrUrUrUrGrCrG

sgRNA-B3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mUxmU*mU

7185
MG3-6-hRosa26-
mG*mG*mG*rArUrUrCrUrUrUrUrGrCrCrUrArGrGrCrUrUrArG

sgRNA-C3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrUxmUxmU*mU

7186
MG3-6-hRosa26-
mC*mC*mU*rGrCrArGrGrGrGrArGrUrGrArGrCrArGrCrUrGrG

sgRNA-D3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7187
MG3-6-hRosa26-
mA*mC*mU*rCrCrGrArUrUrArGrUrUrUrArUrCrUrUrCrCrCrGr

sgRNA-E3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7188
MG3-6-hRosa26-
mU*mC*mC*rCrArCrGrGrArCrUrArGrArGrUrUrGrGrUrGrUrG

sgRNA-F3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7189
MG3-6-hRosa26-
mA*mA*mA*rUrGrGrArGrCrUrUrArGrUrCrArUrUrCrArCrCrGr

sgRNA-G3
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7190
MG3-6-hRosa26-
mA*mC*mC*rUrGrGrGrGrCrUrGrArUrUrUrUrArUrGrCrArArG

sgRNA-H3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7191
MG3-6-hRosa26-
mG*mC*mU*rGrArUrUrUrUrArUrGrCrArArCrGrArGrArCrUrGr

sgRNA-A4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7192
MG3-6-hRosa26-
mA*mU*mC*rArCrCrUrGrArGrUrUrUrUrArUrArCrCrArUrUrGr

sgRNA-B4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7193
MG3-6-hRosa26-
mG*mC*mU*rGrCrArCrCrArCrCrArArArGrUrGrUrArGrCrArGr

sgRNA-C4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7194
MG3-6-hRosa26-
mU*mU*mC*rCrCrUrCrCrCrUrCrArCrCrCrUrCrUrCrUrCrCrGr

sgRNA-D4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7195
MG3-6-hRosa26-
mG*mC*mC*rUrGrGrUrGrUrCrUrCrGrCrGrArArArCrCrArGrG

sgRNA-E4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrA

rCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7196
MG3-6-hRosa26-
mA*mC*mA*rGrArUrUrGrGrUrUrCrCrArCrCrArCrArArArUrGr

sgRNA-F4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7197
MG3-6-hRosa26-
mC*mA*mC*rCrArCrArArArUrUrArArGrGrCrUrUrGrArGrCrGr

sgRNA-G4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7198
MG3-6-hRosa26-
mC*mA*mU*rUrUrUrArUrCrCrUrUrUrUrUrCrCrUrUrArGrCrGr

sgRNA-H4
UrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArArG

rGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCrAr

CrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGrGr

CrGrGrUrArUrGrU*mU*mU*mU

7199
MG3-6-hRosa26-
ATCTGTCTGGTTTCGCGAGACA

target site-A1

7200
MG3-6-hRosa26-
TTTCGCGAGACACCAGGCTACC

target site-B1

7201
MG3-6-hRosa26-
AGCAAGTACAACAAATGGAAAA

target site-C1

7202
MG3-6-hRosa26-
GCAAAAGCTAAAATTTTTCTAT

target site-D1

7203
MG3-6-hRosa26-
TGCTACACTTTGGTGGTGCAGC

target site-E1

7204
MG3-6-hRosa26-
ACTCCCCTGCAGGGCAACGCCC

target site-F1

7205
MG3-6-hRosa26-
CGACTCGACATGGAGGCGATGA

target site-G1

7206
MG3-6-hRosa26-
ATCACGCGAGGAGGAAAGGAGG

target site-H1

7207
MG3-6-hRosa26-
AGGAAAGGAGGGAGGGCTTCTT

target site-A2

7208
MG3-6-hRosa26-
ACCTCCTCCACCGCAGCTCCCT

target site-B2

7209
MG3-6-hRosa26-
GCGCCTCCCACCCACAAACCAG

target site-C2

7210
MG3-6-hRosa26-
CCCACCCCCACGAGTGCCTGTA

target site-D2

7211
MG3-6-hRosa26-
CTCGTGGGGGTGGGGGAGGAGC

target site-E2

7212
MG3-6-hRosa26-
GCTGCGGTGGAGGAGGTGGAGA

target site-F2

7213
MG3-6-hRosa26-
TCTCTGCTGCCTCCCGTCTTGT

target site-G2

7214
MG3-6-hRosa26-
CTCCCGTCTTGTAAGGACCGCC

target site-H2

7215
MG3-6-hRosa26-
CGAGTCGCTTCTCGATTATGGG

target site-A3

7216
MG3-6-hRosa26-
ATTATGGGGGGATTCTTTTGC

target site-B3

7217
MG3-6-hRosa26-
GGGATTCTTTTGCCTAGGCTTA

target site-C3

7218
MG3-6-hRosa26-
CCTGCAGGGGAGTGAGCAGCTG

target site-D3

7219
MG3-6-hRosa26-
ACTCCGATTAGTTTATCTTCCC

target site-E3

7220
MG3-6-hRosa26-
TCCCACGGACTAGAGTTGGTGT

target site-F3

7221
MG3-6-hRosa26-
AAATGGAGCTTAGTCATTCACC

target site-G3

7222
MG3-6-hRosa26-
ACCTGGGGCTGATTTTATGCAA

target site-H3

7223
MG3-6-hRosa26-
GCTGATTTTATGCAACGAGACT

target site-A4

7224
MG3-6-hRosa26-
ATCACCTGAGTTTTATACCATT

target site-B4

7225
MG3-6-hRosa26-
GCTGCACCACCAAAGTGTAGCA

target site-C4

7226
MG3-6-hRosa26-
TTCCCTCCCTCACCCTCTCTCC

target site-D4

7227
MG3-6-hRosa26-
GCCTGGTGTCTCGCGAAACCAG

target site-E4

7228
MG3-6-hRosa26-
ACAGATTGGTTCCACCACAAAT

target site-F4

7229
MG3-6-hRosa26-
CACCACAAATTAAGGCTTGAGC

target site-G4

7230
MG3-6-hRosa26-
CATTTTATCCTTTTTCCTTAGC

target site-H4

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 25—Gene Editing Outcomes at the DNA Level for TRAC and AAVS1 in K562 Cells

Nucleofection of MG21-1, MG23-1, MG73-1, MG89-2, and MG71-2 mRNA along with the matching guide RNA (500 ng mRNA/150 pmol guide) was performed into K562 cells (200,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA. The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 18).

TABLE 15

Guide RNAs and Sequences Targeted for Example 25 When Targeting TRAC

SEQ

ID

NO:
NAME
SEQUENCE

7231
MG21-1-TRAC-
mC*mA*mC*rCrUrUrCrUrUrCrCrCrCrArGrCrCrCrArGrGrUrGr

sgRNA-H9
UrUrGrUrArGrUrUrCrCrCrCrUrUrUrUrGrArArArArArArArGrU

rGrUrGrUrUrArCrUrGrCrArArUrArArGrGrUrArArArArCrArCr

CrArCrGrArArGrCrUrCrUrGrCrCrCrUrArArCrUrGrCrCrUrUrA

rGrCrArGrUrUrArGrGrGrCrArUrC*mU*mU*mU

7232
MG21-1-TRAC-
mC*mA*mA*rGrArGrCrArArCrArGrUrGrCrUrGrUrGrGrCrCrG

sgRNA-B7
rUrUrGrUrArGrUrUrCrCrCrCrUrUrUrUrGrArArArArArArArGr

UrGrUrGrUrUrArCrUrGrCrArArUrArArGrGrUrArArArArCrArC

rCrArCrGrArArGrCrUrCrUrGrCrCrCrUrArArCrUrGrCrCrUrUr

ArGrCrArGrUrUrArGrGrGrCrArUrC*mU*mU*mU

7233
MG21-1-TRAC-
mA*mG*mA*rCrArUrGrArGrGrUrCrUrArUrGrGrArCrUrUrCrG

sgRNA-D6
rUrUrGrUrArGrUrUrCrCrCrCrUrUrUrUrGrArArArArArArArGr

UrGrUrGrUrUrArCrUrGrCrArArUrArArGrGrUrArArArArCrArC

rCrArCrGrArArGrCrUrCrUrGrCrCrCrUrArArCrUrGrCrCrUrUr

ArGrCrArGrUrUrArGrGrGrCrArUrC*mU*mU*mU

7234
MG21-1-TRAC-
mC*mC*mA*rArArGrCrUrGrCrCrCrUrUrArCrCrUrGrGrGrCrGr

sgRNA-C10
UrUrGrUrArGrUrUrCrCrCrCrUrUrUrUrGrArArArArArArArGrU

rGrUrGrUrUrArCrUrGrCrArArUrArArGrGrUrArArArArCrArCr

CrArCrGrArArGrCrUrCrUrGrCrCrCrUrArArCrUrGrCrCrUrUrA

rGrCrArGrUrUrArGrGrGrCrArUrC*mU*mU*mU

7235
MG21-1-TRAC-target
CACCTTCTTCCCCAGCCCAGGT

site-H9

7236
MG21-1-TRAC-target
CAAGAGCAACAGTGCTGTGGCC

site-B7

7237
MG21-1-TRAC-target
AGACATGAGGTCTATGGACTTC

site-D6

7238
MG21-1-TRAC-target
CCAAAGCTGCCCTTACCTGGGC

site-C10

7239
MG23-1-TRAC-
mC*mC*mG*rUrGrUrArCrCrArGrCrUrGrArGrArGrArCrUrCrG

sgRNA-E1
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7240
MG23-1-TRAC-
mU*mU*mG*rGrGrUrUrCrCrGrArArUrCrCrUrCrCrUrCrCrUrGr

sgRNA-H8
UrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7241
MG23-1-TRAC-
mA*mC*mA*rGrUrGrCrUrGrUrGrGrCrCrUrGrGrArGrCrArArG

sgRNA-A3
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7242
MG23-1-TRAC-
mU*mG*mA*rArArGrUrUrUrArGrGrUrUrCrGrUrArUrCrUrGrG

sgRNA-C10
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7243
MG23-1-TRAC-
mG*mC*mU*rUrGrArCrArUrCrArCrArGrGrArArCrUrUrUrCrGr

sgRNA-H7
UrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7244
MG23-1-TRAC-
mA*mA*mC*rCrCrArArUrCrArCrUrGrArCrArGrGrUrUrUrUrGr

sgRNA-B10
UrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7245
MG23-1-TRAC-
mC*mC*mU*rGrUrGrArUrGrUrCrArArGrCrUrGrGrUrCrGrArG

sgRNA-H6
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrUxmU*mU*mU

7246
MG23-1-TRAC-
mU*mA*mG*rArCrCrCrCrUrGrUrCrUrUrArCrCrUrGrUrUrUrGr

sgRNA-E7
UrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7247
MG23-1-TRAC-
mA*mG*mC*rCrGrCrArGrCrGrUrCrArUrGrArGrCrArGrArUrG

sgRNA-C9
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7248
MG23-1-TRAC-target
CCGTGTACCAGCTGAGAGACTC

site-E1

7249
MG23-1-TRAC-target
TTGGGTTCCGAATCCTCCTCCT

site-H8

7250
MG23-1-TRAC-target
ACAGTGCTGTGGCCTGGAGCAA

site-A3

7251
MG23-1-TRAC-target
TGAAAGTTTAGGTTCGTATCTG

site-C10

7252
MG23-1-TRAC-target
GCTTGACATCACAGGAACTTTC

site-H7

7253
MG23-1-TRAC-target
AACCCAATCACTGACAGGTTTT

site-B10

7254
MG23-1-TRAC-target
CCTGTGATGTCAAGCTGGTCGA

site-H6

7255
MG23-1-TRAC-target
TAGACCCCTGTCTTACCTGTTT

site-E7

7256
MG23-1-TRAC-target
AGCCGCAGCGTCATGAGCAGAT

site-C9

7269
MG73-1-TRAC-
mU*mC*mU*rUrGrGrUrUrUrUrArCrArGrArUrArCrGrArArCrCr

sgRNA-G3
UrGrUrUrArUrArGrUrGrGrGrArArArUrCrArCrUrArUrArArUrA

rArGrUrGrArArArUrCrGrCrArArGrGrCrUrCrUrGrUrUrCrUrUr

GrArArCrArUrCrCrUrUrUrArUrUrArUrArArArArCrUrCrCrUrG

rCrCrArArUrCrGrGrUrUrGrGrGrArGrU*mU*mU*mU

7270
MG73-1-TRAC-target
TCTTGGTTTTACAGATACGAACCT

site-G3

7271
MG89-2-TRAC-
mA*mU*mA*rUrCrCrArGrArArCrCrCrUrGrArCrCrCrUrGrCrCr

sgRNA-F1
GrGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCrA

rArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArAr

ArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrArG

rGrUrGrArGrGrGrCrU*mU*mU*mU

7272
MG89-2-TRAC-
mG*mG*mC*rCrArCrUrUrUrCrArGrGrArGrGrArGrGrArUrUrC

sgRNA-G5
rGrGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCr

ArArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArA

rArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrAr

GrGrUrGrArGrGrGrCrU*mU*mU*mU

7273
MG89-2-TRAC-
mC*mG*mC*rArGrCrGrUrCrArUrGrArGrCrArGrArUrUrArArAr

sgRNA-E5
CrGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCrA

rArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArAr

ArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrArG

rGrUrGrArGrGrGrCrU*mU*mU*mU

7274
MG89-2-TRAC-
mC*mG*mG*rCrCrArCrUrUrUrCrArGrGrArGrGrArGrGrArUrU

sgRNA-F5
rCrGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCr

ArArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArA

rArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrAr

GrGrUrGrArGrGrGrCrU*mU*mU*mU

7275
MG89-2-TRAC-
mG*mC*mC*rGrUrGrUrArCrCrArGrCrUrGrArGrArGrArCrUrC

sgRNA-G1
rUrGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCr

ArArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArA

rArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrAr

GrGrUrGrArGrGrGrCrU*mU*mU*mU

7276
MG89-2-TRAC-
mC*mC*mC*rArCrArGrArUrArUrCrCrArGrArArCrCrCrUrGrAr

sgRNA-E1
CrGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCrA

rArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArAr

ArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrArG

rGrUrGrArGrGrGrCrU*mU*mU*mU

7277
MG89-2-TRAC-
mA*mU*mC*rCrUrCrUrUrGrUrCrCrCrArCrArGrArUrArUrCrCr

sgRNA-B1
ArGrUrUrGrUrArGrCrUrUrCrCrUrUrGrArArGrArArArUrUrCrA

rArCrGrUrUrGrUrUrArCrArArUrArArGrGrUrUrUrUrCrGrArAr

ArGrArUrUrArCrCrGrArArCrCrCrGrCrCrCrUrCrArCrUrUrArG

rGrUrGrArGrGrGrCrUxmU*mU*mU

7278
MG89-2-TRAC-target
ATATCCAGAACCCTGACCCTGCCG

site-F1

7279
MG89-2-TRAC-target
GGCCACTTTCAGGAGGAGGATTCG

site-G5

7280
MG89-2-TRAC-target
CGCAGCGTCATGAGCAGATTAAAC

site-E5

7281
MG89-2-TRAC-target
CGGCCACTTTCAGGAGGAGGATTC

site-F5

7282
MG89-2-TRAC-target
GCCGTGTACCAGCTGAGAGACTCT

site-G1

7283
MG89-2-TRAC-target
CCCACAGATATCCAGAACCCTGAC

site-E1

7284
MG89-2-TRAC-target
ATCCTCTTGTCCCACAGATATCCA

site-B1

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

TABLE 16

Guide RNAs and Sequences Targeted for Example 25 When Targeting AAVS1

SEQ

ID

NO:
NAME
SEQUENCE

7257
MG23-1-AAVS1-
mG*mC*mU*rArCrUrGrGrCrCrUrUrArUrCrUrCrArCrArGrGrGr

sgRNA-B1
UrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7258
MG23-1-AAVS1-
mC*mU*mA*rCrUrGrGrCrCrUrUrArUrCrUrCrArCrArGrGrUrGr

sgRNA-C1
UrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7259
MG23-1-AAVS1-
mA*mC*mU*rGrArCrGrCrArCrGrGrArGrGrArArCrArArUrArG

sgRNA-G1
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7260
MG23-1-AAVS1-
mG*mG*mA*rArCrArArUrArUrArArArUrUrGrGrGrGrArCrUrG

sgRNA-B2
rUrUrUrGrArGrArArCrCrUrGrArArArArGrGrUrGrArGrUrGrCr

ArArArUrArArGrGrUrUrUrArArCrCrGrArArArUrUrGrUrUrUrA

rCrCrUrGrCrArUrUrGrUrGrCrArGrUrArUrArArGrArArArGrAr

CrCrGrCrGrArGrGrUrCrU*mU*mU*mU

7261
MG23-1-AAVS1-target
GCTACTGGCCTTATCTCACAGG

site-B1

7262
MG23-1-AAVS1-target
CTACTGGCCTTATCTCACAGGT

site-C1

7263
MG23-1-AAVS1-target
ACTGACGCACGGAGGAACAATA

site-G1

7264
MG23-1-AAVS1-target
GGAACAATATAAATTGGGGACT

site-B2

7265
MG71-2-AAVS1-
mG*mG*mA*rGrArGrGrGrUrArGrCrGrCrArGrGrGrUrGrGrUrU

sgRNA-C3
rUrGrArGrArGrUrGrArGrArArArUrCrArCrGrArGrUrUrCrArAr

ArArArArCrArUrGrArUrUrUrArUrUrCrArArArCrCrGrUrCrUrU

rCrUrUrCrGrGrArArGrGrCrCrCrCrArCrArGrUrGrUrGrUrGrGr

ArCrArGrUrArArArGrCrUrUrGrCrUrUrCrGrGrCrArArGrCrU*

mU*mU*mU

7266
MG71-2-AAVS1-
mG*mC*mC*rCrUrGrCrCrArGrGrArCrGrGrGrGrCrUrGrGrUrU

sgRNA-E2
rUrGrArGrArGrUrGrArGrArArArUrCrArCrGrArGrUrUrCrArAr

ArArArArCrArUrGrArUrUrUrArUrUrCrArArArCrCrGrUrCrUrU

rCrUrUrCrGrGrArArGrGrCrCrCrCrArCrArGrUrGrUrGrUrGrGr

ArCrArGrUrArArArGrCrUrUrGrCrUrUrCrGrGrCrArArGrCrU*

mU*mU*mU

7267
MG71-2-AAVS1-target
GGAGAGGGTAGCGCAGGGTG

site-C3

7268
MG71-2-AAVS1-target
GCCCTGCCAGGACGGGGCTG

site-E2

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 26—MG3-6 Nuclease Guide Screen for Human HAO-1 Gene Using mRNA Transfection of Hep3B Cells

Guide RNAs for the MG3-6 nuclease targeting exons 1 to 4 of the human HAO-1 gene (encodes glycolate oxidase) were identified in silico by searching for the PAM sequence 5′ NNRGRYY 3′. A total of 21 guides with the fewest predicted off-target sites in the human genome were chemically synthesized as single guide RNAs with AltR1/AltR2 end-modifications (IDT). The full sequences of the sgRNA are SEQ ID NOs: 11352-11372.

TABLE 17

Guide sequences used in Example 26

SEQ

ID

NO:
Entity Name
Sequence

11352
hH36-1
AAUUAGCCGGGGGAGCAUUUUCGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11353
hH36-2
CCCAGACCUGUAAUAGUCAUAUGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11354
hH36-3
CCAAAGUCUAUAUAUGACUAUUGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11355
hH36-4
CAAAGUUUCUUCAUCAUUUGCCGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11356
hH36-5
GAUGCUCCGGAAUGUUGCUGAAGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11357
hH36-6
CUCUGUCCUAAAACAGAAGUCGGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11358
hH36-7
UGUCGACUUCUGUUUUAGGACAGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11359
hH36-8
GGGUCAGCAUGCCAAUAUGUGUGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11360
hH36-9
UCAUGCCCGUUCCCAGGGACUGGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11361
hH36-10
ACUCAACAUCAUGCCCGUUCCCGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11362
hH36-11
GAACGGGCAUGAUGUUGAGUUCGUUGAGAAUCGAAAGAUUCUUAAUAAG

GCAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGG

CGGUAUGUUUU

11363
hH36-12
AGUUGCAGCCAACGAAGUGCCUGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11364
hH36-13
UUGGCUGCAACUGUAUAUCUACGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11365
hH36-14
GCUAGUGCGGCAGGCAGAGAAGGUUGAGAAUCGAAAGAUUCUUAAUAAG

GCAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGG

CGGUAUGUUUU

11366
hH36-15
GGCAGGCAGAGAAGAUGGGCUAGUUGAGAAUCGAAAGAUUCUUAAUAAG

GCAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGG

CGGUAUGUUUU

11367
hH36-16
AACCGUCUGGAUGAUGUGCGUAGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11368
hH36-17
GAGGAAAAUUUUGGAGACGACAGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11369
hH36-18
UGCUGCAUAUGUGGCUAAAGCAGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11370
hH36-19
UUGAUAUCUUCCCAGCUGAUAGGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11371
hH36-20
UGGGAAGAUAUCAAAUGGCUGAGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

11372
hH36-21
AAUUGUUGCAAAGGGCAUUUUGGUUGAGAAUCGAAAGAUUCUUAAUAAGG

CAUCCUUCCGAUGCUGACUUCUCACCGUCCGUUUUCCAAUAGGAGCGGGC

GGUAUGUUUU

Hep3B Transfection Protocol

The mRNA encoding MG3-6 was generated by T7 polymerase in vitro transcription of a plasmid in which the coding sequence of MG3-6 had been cloned. The MG3-6 coding sequence was codon optimized using human codon usage tables and flanked by nuclear localization signals derived from SV40 (at the N-terminus) and from Nucleoplasmin (at the C-terminus). In addition, a 5′ untranslated region (5′ UTR) was included at the 5′ end of the coding sequence to improve translation. A 3′ UTR followed by an approximately 90 to 110 nucleotide poly A tract was included in the mRNA (encoded in the plasmid) at the 3′ end of the coding sequence to improve mRNA stability in vivo. The DNA sequence that encodes the MG3-6 mRNA without the polyA tail is shown in SEQ ID 22. The in vitro transcription reaction included the Clean Cap® capping reagent (Trilink BioTechnologies) and the resulting RNA was purified using the MEGAClear™ Transcription Clean-Up kit (Invitrogen) and purity was evaluated using the TapeStation (Agilent) and found to be composed of >90% full length RNA.

300 ng of MG3-6 mRNA and 120 ng of each single guide RNA were transfected into Hep3B cells as follows. One day prior to transfection, Hep3B cells that had been cultured for less than 10 days in EMEM-10% FBS-2 mM glutamine-1% NEAA media, without Pen/Step, were seeded into a TC-treated 24 well plate. Cells were counted, and the equivalent volume to 60,000 viable cells were added to each well. Additional pre-equilibrated media was added to each well to bring the total volume to 500 μL. On the day of transfection, 25 μL of OptiMEM media and 1.25 μL of Lipofectamine Messenger Max Solution (Thermo Fisher) were mixed in a master mix solution, vortexed, and allowed to sit for at least 5 minutes at room temperature. In separate tubes, 300 ng of the MG3-6/3-4 mRNA and 120 ng of the sgRNA were mixed with 25 μL of OptiMEM media and vortexed briefly. The appropriate volume of MessengerMax solution was added to each RNA solution, mixed by flicking the tube, and briefly spun down at a low speed. The complete editing reagent solutions were allowed to incubate for 10 minutes at room temperature, then added directly to the Hep3B cells. Two days post transfection, the media was aspirated from each well of Hep3B cells and genomic DNA was purified by automated magnetic bead purification on the KingFisher Flex robot with the MagMAX™ DNA Multi-Sample Ultra 2.0 Kit.

PCR Amplification and Editing Analysis by Sanger Sequencing

HAO-1 gene sequences targeted by the different sgRNA were amplified by PCR from purified genomic DNA using the exon-specific primers of Table 18 and Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher).

TABLE 18

Primers designed for the human HAO1 gene, used for PCR at each of the first

four exons, and for Sanger sequencing.

Target

Exon
Use
Primer Name
Primer Sequence

Human
Fwd PCR
PCR_hHe1_F_+490
TTTCATGGATGCCCCGTTCA

HAO1
Rev PCR
PCR_hHe1_R_−412
ACGAAAAGCCAGCAGGAAGA

Exon 1
Sequencing
Seq_hHe1_R_−121
AGCCCCAAGAACTTTTCCCT

Human
Fwd PCR
PCR_hHe2_F_+391
TGCATCAGTGGTTGTCAGGG

HAO1
Rev PCR
PCR_hHe2_R_−387
CCTAGCTGTGACTTTGGGCA

Exon 2
Sequencing
Seq_hHe2_R_−152
TGGAAAGAAGAGGAGCAGGAC

Human
Fwd PCR
PCR_hHe3_F_+238
AGGCTGGATGTTCAGGTTCTT

HAO1
Rev PCR
PCR_hHe3_R_−212
TCCCAAAGCCAAAGCCCTTA

Exon 3
Sequencing
Seq_hHe3_F_+186
AGCAGAAATAACTCCAGTAGCCA

Human
Fwd PCR
PCR_hHe4_F_+324
GCTGGCTGAAAATCGTGTCAA

HAO1
Rev PCR
PCR_hHe4_R_−348
TCCTTGGGGCTTCTCTTTGG

Exon 4
Sequencing
Seq_hHe4_F_+174
ACTGATTAAGACCACTAGAGTATCACA

PCR products were purified and concentrated using DNA clean & concentrator 5 (Zymo Research) and 40 ng of PCR product subjected to Sanger sequencing (ELIM Biosciences).

The Sanger sequencing chromatograms were analyzed for insertions and deletions (INDELS) at the predicted target site for each sgRNA by an algorithm called Tracking of Indels by DEcomposition (TIDE) as described by Brinkman et al. (Nucleic Acids Res. 2014 Dec. 16; 42(22): e168. Published online 2014 Oct. 9. doi: 10.1093/nar/gku936). From this screen guides hH364-1, 14, and 15 were identified as having the highest editing activity in Hep3B cells (FIG. 19 and Table 19).

TABLE 19

Editing activity of MG3-6 guides at human HAO1 gene delivered by mRNA

transfection

Editing

Activity in

Guide

Hep3B (Average
Spacer Sequence

Name
PAM
Spacer Sequence
% indels)
SEQ ID NO:

hH36-1
ACAGG
AATTAGCCGGGGGAGCA
34.0
11773

TT
TTTTC

hH36-2
ATAGA
CCCAGACCTGTAATAGT
0.0
11774

CT
CATAT

hH36-3
ACAGG
CCAAAGTCTATATATGA
4.0
11775

TC
CTATT

hH36-4
CCAGA
CAAAGTTTCTTCATCATT
0.0
11776

CC
TGCC

hH36-5
ACAGA
GATGCTCCGGAATGTTG
0.0
11777

TC
CTGAA

hH36-6
ACAGA
CTCTGTCCTAAAACAGA
0.0
11778

TC
AGTCG

hH36-7
GAGGG
TGTCGACTTCTGTTTTAG
1.0
11779

TC
GACA

hH36-8
GGGGG
GGGTCAGCATGCCAATA
10.5
11780

CT
TGTGT

hH36-9
ACAGG
TCATGCCCGTTCCCAGG
0.0
11781

CT
GACTG

hH36-10
AGGGA
ACTCAACATCATGCCCG
0.0
11782

CT
TTCCC

hH36-11
CTGGG
GAACGGGCATGATGTTG
0.0
11783

CC
AGTTC

hH36-12
CAGGA
AGTTGCAGCCAACGAAG
0.0
11784

CC
TGCCT

hH36-13
AAGGA
TTGGCTGCAACTGTATAT
0.0
11785

CC
CTAC

hH36-14
ATGGG
GCTAGTGCGGCAGGCAG
19.5
11786

CT
AGAAG

hH36-15
CAAGG
GGCAGGCAGAGAAGATG
14.5
11787

CC
GGCTA

hH36-16
ACAGA
AACCGTCTGGATGATGT
0.0
11788

TT
GCGTA

hH36-17
GTGGA
GAGGAAAATTTTGGAGA
0.0
11789

CT
CGACA

hH36-18
ATAGA
TGCTGCATATGTGGCTA
0.0
11790

CC
AAGCA

hH36-19
ATGGG
TTGATATCTTCCCAGCTG
8.5
11791

TC
ATAG

hH36-20
GAAGA
TGGGAAGATATCAAATG
0.0
11792

CT
GCTGA

hH36-21
AGAGG
AATTGTTGCAAAGGGCA
5.0
11793

TT
TTTTG

Example 27—Gene Editing Outcomes at the DNA Level for Human GPR146

Nucleofection of MG3-6 RNPs (104 pmol protein/120 pmol guide) (SEQ ID NOs: 11374-11405) was performed into Hep3B cells (100,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 11406-11437). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 20).

TABLE 20

Guide RNAs and Sequences Targeted for Example 25 When Targeting GPR146

SEQ

ID NO:
NAME
SEQUENCE

11374
MG3-6-human
mA*mG*mC*rUrGrCrArGrCrUrGrGrUrUrCrArArCrGrGrCrAr

GPR146-A1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11375
MG3-6-human
mG*mG*mU*rGrGrArGrGrArGrCrUrGrCrCrUrGrCrCrUrGrCr

GPR146-B1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

11376
MG3-6-human
mC*mC*mU*rGrCrCrUrGrCrCrArGrGrArCrCrUrGrCrArGrCrG

GPR146-C1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11377
MG3-6-human
mG*mG*mG*rGrCrUrGrUrCrArCrUrGrUrUrGrUrCrGrCrUrGr

GPR146-D1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11378
MG3-6-human
mG*mG*mG*rCrCrUrGrGrUrGrGrUrGrGrGrCrGrUrGrCrCrAr

GPR146-E1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11379
MG3-6-human
mU*mG*mG*rUrGrCrUrGrGrCrCrArArCrCrUrArCrArCrArGrG

GPR146-F1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11380
MG3-6-human
mG*mU*mA*rCrUrUrUrGrUrCrArArCrArUrGrGrCrArGrUrGrG

GPR146-G1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11381
MG3-6-human
mG*mC*mG*rGrCrGrArArGrUrCrCrArCrGrUrGrGrCrArCrUr

GPR146-H1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11382
MG3-6-human
mA*mC*mU*rArCrArUrCrGrArGrCrGrUrGrCrArCrUrGrCrCrG

GPR146-A2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11383
MG3-6-human
mC*mG*mU*rCrCrGrCrArGrGrGrArGrGrArCrArCrGrCrCrCr

GPR146-B2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11384
MG3-6-human
mG*mG*mA*rCrArCrGrCrCrCrCrUrGrGrArCrCrGrGrGrArCr

GPR146-C2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11385
MG3-6-human
mG*mG*mC*rCrGrGrCrUrGrGrArGrCrCrCrUrCrGrGrCrArCr

GPR146-D2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11386
MG3-6-human
mG*mU*mG*rGrCrCrArCrCrGrUrGrUrGrCrArCrGrCrArGrUr

GPR146-E2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11387
MG3-6-human
mA*mA*mG*rCrCrCrGrUrGrGrArCrGrCrArCrArCrUrArCrCrG

GPR146-F2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11388
MG3-6-human
mC*mC*mU*rGrGrGrGrCrUrArCrUrGrCrArCrUrUrUrGrUrGr

GPR146-G2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11389
MG3-6-human
mG*mC*mU*rGrArUrGrArArArArArGrCrUrGrCrCrCrUrGrCrG

GPR146-H2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11390
MG3-6-human
mC*mU*mG*rCrGrGrGrGrArCrCrGrGrCrArCrUrGrCrUrCrCr

GPR146-A3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11391
MG3-6-human
mG*mU*mG*rGrUrGrUrCrArCrArArArGrCrUrGrCrUrGrGrAr

GPR146-B3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11392
MG3-6-human
mU*mA*mG*rCrCrCrCrArGrGrUrArGrUrGrUrGrCrGrUrCrCr

GPR146-C3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11393
MG3-6-human
mA*mG*mA*rUrGrArUrGrArCrCrGrUrGrUrGrCrCrCrCrArGr

GPR146-D3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11394
MG3-6-human
mG*mG*mC*rCrArCrCrArGrCrArGrCrCrUrGrUrGrUrGrCrCr

GPR146-E3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11395
MG3-6-human
mG*mC*mG*rUrGrUrUrGrUrArCrArCrGrCrUrGrGrCrCrArUr

GPR146-F3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11396
MG3-6-human
mA*mG*mU*rGrCrArCrGrCrUrCrGrArUrGrUrArGrUrGrGrUr

GPR146-G3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11397
MG3-6-human
mC*mC*mA*rCrCrArGrUrGrArGrGrArCrArCrArUrUrGrArArG

GPR146-H3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11398
MG3-6-human
mU*mG*mA*rArGrGrGrGrArUrCrUrGrCrArGrUrGrCrCrArCr

GPR146-A4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11399
MG3-6-human
mC*mA*mC*rArGrCrGrCrCrCrArCrCrGrGrGrArGrCrUrCrGr

GPR146-B4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11400
MG3-6-human
mU*mC*mG*rGrGrGrGrGrCrCrGrArGrCrArGrGrUrGrCrArCr

GPR146-C4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11401
MG3-6-human
mA*mC*mA*rGrGrGrGrCrCrArGrGrGrCrGrCrUrGrArGrCrAr

GPR146-D4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUmU*mU*mU

11402
MG3-6-human
mA*mU*mG*rGrUrCrArUrGrCrUrGrGrCrCrUrUrGrCrUrGrUr

GPR146-E4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11403
MG3-6-human
mA*mG*mC*rArCrCrArGrCrArGrGrGrCrGrUrUrGrUrArGrCr

GPR146-F4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11404
MG3-6-human
mA*mG*mG*rCrCrCrArCrUrGrGrCrArCrGrCrCrCrArCrCrArG

GPR146-G4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11405
MG3-6-human
mG*mA*mC*rArArCrArGrUrGrArCrArGrCrCrCrCrArGrCrUrG

GPR146-H4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11406
MG3-6-human
AGCTGCAGCTGGTTCAACGGCA

GPR146-A1

11407
MG3-6-human
GGTGGAGGAGCTGCCTGCCTGC

GPR146-B1

11408
MG3-6-human
CCTGCCTGCCAGGACCTGCAGC

GPR146-C1

11409
MG3-6-human
GGGGCTGTCACTGTTGTCGCTG

GPR146-D1

11410
MG3-6-human
GGGCCTGGTGGTGGGCGTGCCA

GPR146-E1

11411
MG3-6-human
TGGTGCTGGCCAACCTACACAG

GPR146-F1

11412
MG3-6-human
GTACTTTGTCAACATGGCAGTG

GPR146-G1

11413
MG3-6-human
GCGGCGAAGTCCACGTGGCACT

GPR146-H1

11414
MG3-6-human
ACTACATCGAGCGTGCACTGCC

GPR146-A2

11415
MG3-6-human
CGTCCGCAGGGAGGACACGCCC

GPR146-B2

11416
MG3-6-human
GGACACGCCCCTGGACCGGGAC

GPR146-C2

11417
MG3-6-human
GGCCGGCTGGAGCCCTCGGCAC

GPR146-D2

11418
MG3-6-human
GTGGCCACCGTGTGCACGCAGT

GPR146-E2

11419
MG3-6-human
AAGCCCGTGGACGCACACTACC

GPR146-F2

11420
MG3-6-human
CCTGGGGCTACTGCACTTTGTG

GPR146-G2

11421
MG3-6-human
GCTGATGAAAAAGCTGCCCTGC

GPR146-H2

11422
MG3-6-human
CTGCGGGGACCGGCACTGCTCC

GPR146-A3

11423
MG3-6-human
GTGGTGTCACAAAGCTGCTGGA

GPR146-B3

11424
MG3-6-human
TAGCCCCAGGTAGTGTGCGTCC

GPR146-C3

11425
MG3-6-human
AGATGATGACCGTGTGCCCCAG

GPR146-D3

11426
MG3-6-human
GGCCACCAGCAGCCTGTGTGCC

GPR146-E3

11427
MG3-6-human
GCGTGTTGTACACGCTGGCCAT

GPR146-F3

11428
MG3-6-human
AGTGCACGCTCGATGTAGTGGT

GPR146-G3

11429
MG3-6-human
CCACCAGTGAGGACACATTGAA

GPR146-H3

11430
MG3-6-human
TGAAGGGGATCTGCAGTGCCAC

GPR146-A4

11431
MG3-6-human
CACAGCGCCCACCGGGAGCTCG

GPR146-B4

11432
MG3-6-human
TCGGGGGGCCGAGCAGGTGCAC

GPR146-C4

11433
MG3-6-human
ACAGGGGCCAGGGCGCTGAGCA

GPR146-D4

11434
MG3-6-human
ATGGTCATGCTGGCCTTGCTGT

GPR146-E4

11435
MG3-6-human
AGCACCAGCAGGGCGTTGTAGC

GPR146-F4

11436
MG3-6-human
AGGCCCACTGGCACGCCCACCA

GPR146-G4

11437
MG3-6-human
GACAACAGTGACAGCCCCAGCT

GPR146-H4

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 28—Gene Editing Outcomes at the DNA Level for Mouse GPR146 in Hepa1-6 Cells

Nucleofection of MG3-6 RNPs (104 pmol protein/120 pmol guide) (SEQ ID NOs: 11438-11472) was performed into Hepa1-6 cells (100,000) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared five days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA (SEQ ID NOs: 11473-11507). The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 21).

TABLE 21

Guide RNAs and Sequences Targeted for Example 25 When Targeting GPR146

SEQ

ID NO:
NAME
SEQUENCE

11438
MG3-6-mouse
mG*mU*mG*rGrCrCrCrArCrUrCrArArCrArGrCrArCrArGrCrG

GPR146-A1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11439
MG3-6-mouse
mC*mC*mG*rCrUrGrUrGrCrCrGrGrArArCrCrUrGrCrGrCrCr

GPR146-B1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11440
MG3-6-mouse
mG*mC*mC*rGrGrArArCrCrUrGrCrGrCrCrUrGrGrGrGrCrUr

GPR146-C1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11441
MG3-6-mouse
mU*mC*mU*rCrGrCrUrGrCrUrCrUrArCrCrUrGrGrGrGrGrCr

GPR146-D1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11442
MG3-6-mouse
mG*mG*mG*rGrGrCrArGrGrGrGrUrCrCrCrUrGrUrGrArGrCr

GPR146-E1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11443
MG3-6-mouse
mU*mA*mC*rUrUrCrGrUrGrArArCrArUrGrGrCrCrGrUrGrGr

GPR146-F1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11444
MG3-6-mouse
mG*mG*mC*rArCrUrGrGrCrArCrCrUrGrCrGrUrArCrCrUrGr

GPR146-G1
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11445
MG3-6-mouse
mU*mG*mU*rUrGrGrGrCrCrCrUrGrCrCrCrArCrUrCrCrArGrG

GPR146-H1
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11446
MG3-6-mouse
mG*mG*mG*rCrCrCrUrGrUrGrGrArGrCrCrUrCrArGrCrArGr

GPR146-A2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11447
MG3-6-mouse
mU*mG*mU*rGrCrUrCrArUrCrGrGrCrUrArCrGrUrGrGrUrGr

GPR146-B2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11448
MG3-6-mouse
mA*mA*mU*rCrGrGrGrArArGrGrArArGrArCrArCrArCrCrCrG

GPR146-C2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11449
MG3-6-mouse
mA*mC*mA*rCrCrCrCrUrGrGrArCrCrArGrGrArCrArCrCrArG

GPR146-D2
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11450
MG3-6-mouse
mC*mC*mU*rGrGrArCrCrArGrGrArCrArCrCrArGrCrArGrGr

GPR146-E2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11451
MG3-6-mouse
mA*mG*mC*rArGrGrCrUrGrGrArCrCrCrCrUrCrGrGrUrGrCr

GPR146-F2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11452
MG3-6-mouse
mA*mC*mA*rCrArGrUrGrCrUrGrArCrGrUrCrArCrGrGrGrGr

GPR146-G2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11453
MG3-6-mouse
mA*mG*mG*rGrGrCrArUrUrArUrCrUrGrGrGrCrArUrCrCrUr

GPR146-H2
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11454
MG3-6-mouse
mU*mC*mU*rGrGrGrCrArUrCrCrUrArCrArGrGrUrUrGrCrUrG

GPR146-A3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11455
MG3-6-mouse
mG*mC*mC*rArUrCrArCrCrUrGrCrUrGrUrArUrCrCrCrCrGrG

GPR146-B3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11456
MG3-6-mouse
mU*mC*mA*rGrCrCrGrCrCrGrGrArGrCrUrUrGrCrCrGrGrGr

GPR146-C3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11457
MG3-6-mouse
mG*mU*mG*rGrUrGrUrCrArCrArGrArArCrUrGrCrUrUrGrAr

GPR146-D3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11458
MG3-6-mouse
mC*mU*mU*rGrArGrArArGrGrCrCrArGrGrArArCrUrUrGrGr

GPR146-E3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11459
MG3-6-mouse
mC*mG*mU*rGrArCrGrUrCrArGrCrArCrUrGrUrGrUrGrCrCr

GPR146-F3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11460
MG3-6-mouse
mA*mG*mG*rCrUrCrArArGrUrArGrUrArArGrGrUrGrUrCrCr

GPR146-G3
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUmU*mU*mU

11461
MG3-6-mouse
mG*mC*mC*rArCrCrArGrCrArGrCrCrUrGrUrGrCrArCrCrGrG

GPR146-H3
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11462
MG3-6-mouse
mA*mG*mU*rGrCrCrArGrGrGrCrArUrArCrArArCrArCrArGrG

GPR146-A4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11463
MG3-6-mouse
mA*mG*mG*rGrCrArCrGrCrUrCrGrArUrGrUrArGrUrArGrUr

GPR146-B4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrUxmU*mU*mU

11464
MG3-6-mouse
mU*mG*mA*rArCrArGrGrArUrGrArGrCrArGrUrGrUrCrArCr

GPR146-C4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11465
MG3-6-mouse
mA*mG*mU*rGrUrCrArCrArUrGrGrGrCrCrUrCrArCrUrGrCrG

GPR146-D4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11466
MG3-6-mouse
mG*mG*mG*rCrCrUrCrArCrUrGrCrUrGrArGrGrCrUrCrCrAr

GPR146-E4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11467
MG3-6-mouse
mC*mA*mC*rArGrGrGrCrCrCrArCrCrUrGrGrArGrUrGrGrGr

GPR146-F4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11468
MG3-6-mouse
mA*mU*mG*rGrUrCrArUrGrGrUrGrUrUrCrUrUrGrCrUrGrGr

GPR146-G4
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11469
MG3-6-mouse
mG*mA*mG*rCrArUrUrArUrArGrCrCrUrArArGrCrUrCrArCrG

GPR146-H4
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11470
MG3-6-mouse
mC*mU*mG*rCrCrCrCrCrArGrGrUrArGrArGrCrArGrCrGrAr

GPR146-A5
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11471
MG3-6-mouse
mG*mA*mG*rArGrGrArCrCrCrArCrArGrCrCrCrCrArGrGrCr

GPR146-B5
GrUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrAr

ArGrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUr

CrArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGr

GrGrCrGrGrUrArUrGrU*mU*mU*mU

11472
MG3-6-mouse
mU*mC*mA*rGrCrCrCrArCrGrCrUrGrUrGrCrUrGrUrUrGrArG

GPR146-C5
rUrUrGrArGrArArUrCrGrArArArGrArUrUrCrUrUrArArUrArAr

GrGrCrArUrCrCrUrUrCrCrGrArUrGrCrUrGrArCrUrUrCrUrCr

ArCrCrGrUrCrCrGrUrUrUrUrCrCrArArUrArGrGrArGrCrGrGr

GrCrGrGrUrArUrGrU*mU*mU*mU

11473
MG3-6-mouse
GTGGCCCACTCAACAGCACAGC

GPR146-A1

11474
MG3-6-mouse
CCGCTGTGCCGGAACCTGCGCC

GPR146-B1

11475
MG3-6-mouse
GCCGGAACCTGCGCCTGGGGCT

GPR146-C1

11476
MG3-6-mouse
TCTCGCTGCTCTACCTGGGGGC

GPR146-D1

11477
MG3-6-mouse
GGGGGCAGGGGTCCCTGTGAGC

GPR146-E1

11478
MG3-6-mouse
TACTTCGTGAACATGGCCGTGG

GPR146-F1

11479
MG3-6-mouse
GGCACTGGCACCTGCGTACCTG

GPR146-G1

11480
MG3-6-mouse
TGTTGGGCCCTGCCCACTCCAG

GPR146-H1

11481
MG3-6-mouse
GGGCCCTGTGGAGCCTCAGCAG

GPR146-A2

11482
MG3-6-mouse
TGTGCTCATCGGCTACGTGGTG

GPR146-B2

11483
MG3-6-mouse
AATCGGGAAGGAAGACACACCC

GPR146-C2

11484
MG3-6-mouse
ACACCCCTGGACCAGGACACCA

GPR146-D2

11485
MG3-6-mouse
CCTGGACCAGGACACCAGCAGG

GPR146-E2

11486
MG3-6-mouse
AGCAGGCTGGACCCCTCGGTGC

GPR146-F2

11487
MG3-6-mouse
ACACAGTGCTGACGTCACGGGG

GPR146-G2

11488
MG3-6-mouse
AGGGGCATTATCTGGGCATCCT

GPR146-H2

11489
MG3-6-mouse
TCTGGGCATCCTACAGGTTGCT

GPR146-A3

11490
MG3-6-mouse
GCCATCACCTGCTGTATCCCCG

GPR146-B3

11491
MG3-6-mouse
TCAGCCGCCGGAGCTTGCCGGG

GPR146-C3

11492
MG3-6-mouse
GTGGTGTCACAGAACTGCTTGA

GPR146-D3

11493
MG3-6-mouse
CTTGAGAAGGCCAGGAACTTGG

GPR146-E3

11494
MG3-6-mouse
CGTGACGTCAGCACTGTGTGCC

GPR146-F3

11495
MG3-6-mouse
AGGCTCAAGTAGTAAGGTGTCC

GPR146-G3

11496
MG3-6-mouse
GCCACCAGCAGCCTGTGCACCG

GPR146-H3

11497
MG3-6-mouse
AGTGCCAGGGCATACAACACAG

GPR146-A4

11498
MG3-6-mouse
AGGGCACGCTCGATGTAGTAGT

GPR146-B4

11499
MG3-6-mouse
TGAACAGGATGAGCAGTGTCAC

GPR146-C4

11500
MG3-6-mouse
AGTGTCACATGGGCCTCACTGC

GPR146-D4

11501
MG3-6-mouse
GGGCCTCACTGCTGAGGCTCCA

GPR146-E4

11502
MG3-6-mouse
CACAGGGCCCACCTGGAGTGGG

GPR146-F4

11503
MG3-6-mouse
ATGGTCATGGTGTTCTTGCTGG

GPR146-G4

11504
MG3-6-mouse
GAGCATTATAGCCTAAGCTCAC

GPR146-H4

11505
MG3-6-mouse
CTGCCCCCAGGTAGAGCAGCGA

GPR146-A5

11506
MG3-6-mouse
GAGAGGACCCACAGCCCCAGGC

GPR146-B5

11507
MG3-6-mouse
TCAGCCCACGCTGTGCTGTTGA

GPR146-C5

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 29—Gene Editing Outcomes at the DNA Level for Mouse GPR146 in Primary Mouse Hepatocytes

Lipofection with MessengerMax of MG3-6 mRNA and guide (0.42 ug mRNA, 1:20 nuclease:guide molar ratio) was performed in primary mouse hepatocytes (1E5 viable cells/guide) using the guide RNAs described in Example 29 above. Cells were harvested and genomic DYNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were used to amplify the individual target sequences for each guide RNA. The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing (FIG. 22). The results indicated that the GPR146-H2 sgRNA was highly effective for editing in mouse hepatocytes.

Example 30—Gene Editing Outcomes at the DNA Level for TRAC and AAVS1 in K562 Cells

Nucleofection of MG14-241 and MG99-1 mRNA along with the matching guide RNA (500 ng mRNA/150 pmol guide) was performed into 200,000 human lymphoblasts (K562 cells) using the Lonza 4D electroporator. Cells were harvested and genomic DNA prepared three days post-transfection. PCR primers appropriate for use in NGS-based DNA sequencing were generated, optimized, and used to amplify the individual target sequences for each guide RNA. The amplicons were sequenced on an Illumina MiSeq machine and analyzed with a proprietary Python script to measure gene editing. (FIG. 23).

TABLE 22

Guide RNAs and Sequences Targeted for Example 30

SEQ

ID

NO:
NAME
SEQUENCE

11508
MG14-241-AAVS1-E2
mU*mG*mG*rCrArCrArGrGrCrCrCrCrArGrArArGrGrArGrUr

CrUrUrGrCrCrGrGrArArArCrGrGrCrUrArGrArCrArArGrGrG

rArArUrCrGrCrUrUrUrUrArCrGrCrGrArUrUrArCrCrCrGrCrA

rArGrGrUrArArGrCrCrCrGrUrCrArGrCrArCrCrCrUrUrGrGr

UrGrUrCrGrGrCrGrGrGrCrGrArUrCrCrUxmU*mU*mU

11509
MG14-241-AAVS1-F2
mC*mC*mA*rCrUrArGrGrGrArCrArGrGrArUrUrGrGrUrGrUr

CrUrUrGrCrCrGrGrArArArCrGrGrCrUrArGrArCrArArGrGrG

rArArUrCrGrCrUrUrUrUrArCrGrCrGrArUrUrArCrCrCrGrCrA

rArGrGrUrArArGrCrCrCrGrUrCrArGrCrArCrCrCrUrUrGrGr

UrGrUrCrGrGrCrGrGrGrCrGrArUrCrCrUxmU*mU*mU

11510
MG14-241-AAVS1-B2
mA*mG*mG*rArGrArArCrGrGrGrGrUrGrUrCrCrArGrGrGrUr

CrUrUrGrCrCrGrGrArArArCrGrGrCrUrArGrArCrArArGrGrG

rArArUrCrGrCrUrUrUrUrArCrGrCrGrArUrUrArCrCrCrGrCrA

rArGrGrUrArArGrCrCrCrGrUrCrArGrCrArCrCrCrUrUrGrGr

UrGrUrCrGrGrCrGrGrGrCrGrArUrCrCrUxmU*mU*mU

11511
MG14-241-AAVS1-E2
TGGCACAGGCCCCAGAAGGA

11512
MG14-241-AAVS1-F2
CCACTAGGGACAGGATTGGT

11513
MG14-241-AAVS1-B2
AGGAGAACGGGGTGTCCAGG

11514
MG99-1-TRAC-G1
mG*mA*mC*rArCrCrUrUrCrUrUrCrCrCrCrArGrCrCrCrArGr

GrUrGrUrUrUrUrArGrUrUrCrUrCrUrGrArUrGrArArArArUrCr

ArGrUrArArGrUrUrCrUrArArArArUrArArGrGrCrArUrUrArUr

GrCrCrGrUrGrGrGrGrUrArUrGrGrUrGrGrUrArUrCrCrUrCrG

rUrUrCrArArArUrArUrCrCrArCrCrGrUrUrUrCrUrArArArArA

rArArUrCrGrCrGrCrGrCrCrGrCrCrGrGrCrGrUrGrCrU*mU*m

U*mU

11515
MG99-1-TRAC-H6
mC*mC*mC*rGrGrCrCrArCrUrUrUrCrArGrGrArGrGrArGrGr

ArUrGrUrUrUrUrArGrUrUrCrUrCrUrGrArUrGrArArArArUrCr

ArGrUrArArGrUrUrCrUrArArArArUrArArGrGrCrArUrUrArUr

GrCrCrGrUrGrGrGrGrUrArUrGrGrUrGrGrUrArUrCrCrUrCrG

rUrUrCrArArArUrArUrCrCrArCrCrGrUrUrUrCrUrArArArArA

rArArUrCrGrCrGrCrGrCrCrGrCrCrGrGrCrGrUrGrCrUxmU*m

U*mU

11516
MG99-1-TRAC-G1
GACACCTTCTTCCCCAGCCCAGGT

11517
MG99-1-TRAC-H6
CCCGGCCACTTTCAGGAGGAGGAT

r = native ribose base, m = 2′-O methyl modified base, F = 2′ Fluro modified base, * = phosphorothioate bond

Example 31—Novel Type II CRISPR Effectors are Active Nucleases with Diverse PAM Requirements

Novel nucleases of the MG3, MG15, MG150, MG123, MG124, and MG125 families were identified from phylogenetic analysis. The MG150 family of nucleases is more closely related to the MG3 family than to any other family identified (FIG. 24), and a new group of divergent effectors expanded the MG15 family of nucleases (FIG. 25). In vitro cleavage activity assays show that nucleases reported here generally have preference for cleavage at positions three or four from the PAM (Table 23). In addition, PAM sequence determination for Type II nucleases indicates diverse PAM requirements, as shown by the SeqLogo images from NGS data. (FIGS. 26-35)

TABLE 23

Cut sites of MG Family Variants

Cut Site from

Cut Site from

Candidate
NGS
Candidate
NGS

MG1-2 (SEQ ID
3
MG71-2
2 or 3

NO: 6)

MG1-4 (SEQ ID
4
MG72-1
3

NO: 1)

MG1-5 (SEQ ID
4
MG73-1 (SEQ
3

NO: 2)

ID NO: 11720)

MG1-6 (SEQ ID
4
MG73-2 (SEQ
3

NO: 3)

ID NO: 11721)

MG1-7 (SEQ ID
4
MG74-1 (SEQ
3

NO: 4)

ID NO: 11722)

MG14-1 (SEQ ID
1 or 3
MG86-1 (SEQ
3

NO: 678)

ID NO: 11723)

MG14-241 (SEQ ID
3
MG86-2 (SEQ
3

NO: 914)

ID NO: 11724)

MG14-244 (SEQ ID
3
MG87-1 (SEQ
3

NO:917)

ID NO: 11725)

MG14-246 (SEQ ID
3
MG87-2 (SEQ
3

NO: 919)

ID NO: 11726)

MG14-248 (SEQ ID
3
MG87-3 (SEQ
3

NO: 921)

ID NO: 11727)

MG14-5 (SEQ ID
3
MG88-1 (SEQ
3

NO: 681)

ID NO: 11728)

MG15-1 (SEQ ID
1 or 3
MG88-2 (SEQ
3

NO: 930)

ID NO: 11729)

MG15-115 (SEQ ID
3
MG88-3 (SEQ
3

NO: 1042)

ID NO: 11730)

MG15-135 (SEQ ID
3
MG89-2 (SEQ
3

NO: 1062)

ID NO: 11731)

MG15-54 (SEQ ID
3
MG89-3 (SEQ
3

NO: 981)

ID NO: 11732)

MG15-66 (SEQ ID
3
MG94-1 (SEQ
3

NO: 993)

ID NO: 11733)

MG15-94 (SEQ ID
3
MG94-2 (SEQ
3

NO: 1021)

ID NO: 8748)

MG16-1 (SEQ ID
1 or 3
MG95-1 (SEQ
3

NO: 11718)

ID NO: 8782)

MG16-2 (SEQ ID
3
MG95-2 (SEQ
3

NO: 1093)

ID NO: 8783)

MG16-3 (SEQ ID
3
MG96-1 (SEQ
3

NO: 11734)

ID NO: 8786)

MG17-2 (SEQ ID
3
MG98-1 (SEQ
3

NO: 7700)

ID NO: 8819)

MG18-1 (SEQ ID
1 or 3
MG98-2 (SEQ
3

NO: 1354)

ID NO: 8820)

MG2-4 (SEQ ID
1 or 3
MG99-1 (SEQ
3

NO: 11735)

ID NO: 11748)

MG2-5 (SEQ ID
3
MG100-1 (SEQ
3

NO: 323)

ID NO: 8960)

MG2-55 (SEQ ID
3
MG100-2 (SEQ
3

NO: 371)

ID NO: 8961)

MG2-7 (SEQ ID
3
MG111-1 (SEQ
3

NO: 321)

ID NO: 9037)

MG21-1 (SEQ ID
1 or 3
MG111-2 (SEQ
3

NO: 1512)

ID NO: 9038)

MG21-2 (SEQ ID
3
MG112-3 (SEQ
3

NO: 11736)

ID NO: 11749)

MG21-3 (SEQ ID
3
MG116-1 (SEQ
3

NO: 1513(

ID NO: 9150)

MG21-97 (SEQ ID
3
MG123-1 (SEQ
3

NO: 1607)

ID NO: 11750)

MG22-1 (SEQ ID
1 or 3
MG124-2 (SEQ
3

NO: 1656)

ID NO: 11751)

MG22-2 (SEQ ID
3
MG125-1 (SEQ
3

NO: 11737)

ID NO: 11752)

MG22-3 (SEQ ID
3
MG125-2 (SEQ
3

NO: 1657)

ID NO: 11753)

MG23-1 (SEQ ID
3
MG125-3 (SEQ
3

NO: 1756)

ID NO: 11754)

MG23-2 (SEQ ID
3
MG125-4 (SEQ
3

NO: 11738)

ID NO: 11755)

MG23-3 (SEQ ID
3
MG125-5 (SEQ
3

NO: 1757)

ID NO: 11756)

MG3-1_long (SEQ
3
MG150-5 (SEQ
3

ID NO: 424)

ID NO: 7363)

MG3-3 (SEQ ID
3
MG150-6 (SEQ
3

NO: 11739)

ID NO: 7364)

MG3-4 (SEQ ID
3
MG150-7 (SEQ
3

NO: 11740)

ID NO: 7365)

MG3-42 (SEQ ID
3 or 4
MG150-8 (SEQ
3

NO: 429)

ID NO: 7366)

MG3-6 (SEQ ID
3
MG150-9 (SEQ
3

NO: 426)

ID NO: 7367)

MG3-7 (SEQ ID
3
MG3-18 (SEQ
3

NO: 422)

ID NO: 11757)

MG3-8 (SEQ ID
3
MG3-89 (SEQ
3

NO: 428)

ID NO: 11758)

MG4-2 (SEQ ID
2 or 3
MG3-90 (SEQ
3

NO: 11741)

ID NO: 11759)

MG4-5 (SEQ ID
1 or 3
MG3-91 (SEQ
3

NO: 432)

ID NO: 11760)

MG40-1 (SEQ ID
3
MG3-92 (SEQ
3

NO: 5718)

ID NO: 11761)

MG40-2 (SEQ ID
3
MG3-93 (SEQ
3

NO: 5719)

ID NO: 11762)

MG40-3 (SEQ ID
3
MG3-95 (SEQ
3

NO: 5720)

ID NO: 11763)

MG40-4 (SEQ ID
3
MG3-96 (SEQ
3

NO: 5721)

ID NO: 11764)

MG40-5(SEQ ID
3
MG3-103 (SEQ
3

NO: 5722)

ID NO: 11765)

MG40-6 (SEQ ID
3
MG15-130 (SEQ
3

NO: 5723)

ID NO: 1057)

MG43-3 (SEQ ID
3
MG15-146 (SEQ
3

NO: 8359)

ID NO: 1073)

MG44-1 (SEQ ID
3
MG15-164 (SEQ
3

NO: 11742)

ID NO: 1091)

MG46-1 (SEQ ID
3
MG15-166 (SEQ
3

NO: 11743)

ID NO: 11766)

MG47-1 (SEQ ID
3
MG15-171 (SEQ
3

NO: 5751)

ID NO: 7605)

MG47-2 (SEQ ID
3
MG15-172 (SEQ
3

NO: 5752)

ID NO: 7606)

MG48-1 (SEQ ID
3
MG15-174 (SEQ
3

NO: 5769)

ID NO: 7608)

MG48-3 (SEQ ID
3
MG15-184 (SEQ
3

NO: 5771)

ID NO: 7618)

MG49-1 (SEQ ID
3
MG15-187 (SEQ
3

NO: 5805)

ID NO: 7621)

MG49-2 (SEQ ID
3
MG15-191 (SEQ
2

NO: 5806)

ID NO: 11767)

MG50-1 (SEQ ID
3
MG15-193 (SEQ
3

NO: 5824)

ID NO: 11768)

MG51-1 (SEQ ID
3
MG15-195 (SEQ
3

NO: 5827)

ID NO: 11769)

MG52-1 (SEQ ID
2
MG15-217 (SEQ
3

NO: 5831)

ID NO: 11770)

MG6-3 (SEQ ID
1
MG15-218 (SEQ
4

NO: 11744)

ID NO: 11771)

MG6-5 (SEQ ID
3
MG15-219 (SEQ
4

NO: 11745)

ID NO: 11772)

MG7-1 (SEQ ID
3
MG15-177 (SEQ
3

NO: 11746)

ID NO: 7611)

MG71-1 (SEQ ID
3

NO: 11747)

Embodiments

The following embodiments are illustrative in nature and are not intended to be limiting in any way:

- 1. A method of editing a B2M locus in a cell, comprising contacting to said cell
  - (a) an RNA-guided endonuclease; and
  - (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said B2M locus,
    - wherein said region of said B2M locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6387-6468.
- 2. The method of embodiment 1, wherein said RNA-guided endonuclease is a class 2, type II Cas endonuclease.
- 3. The method of embodiment 1, wherein said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244.
- 4. The method of embodiment 3, wherein said RNA-guided endonuclease further comprises an HNH domain.
- 5. The method of embodiment 1, wherein said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6305-6386.
- 6. The method of embodiment 1, wherein said region of said B2M locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6388, 6399, 6401, 6403, 6410, 6413, 6421, 6446, and 6448.
- 7. A method of editing a TRAC locus in a cell, comprising contacting to said cell
  - (a) an RNA-guided endonuclease; and
  - (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said TRAC locus,
    - wherein said region of said TRAC locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6509-6548.
- 8. The method of embodiment 7, wherein said RNA-guided endonuclease is a class 2, type II Cas endonuclease.
- 9. The method of embodiment 7, wherein said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244.
- 10. The method of embodiment 9, wherein said RNA-guided endonuclease further comprises an HNH domain.
- 11. The method of embodiment 7, wherein said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6469-6508.
- 12. The method of embodiment 7, wherein said region of said TRAC locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6517, 6520, and 6523.
- 13. A method of editing a HPRT locus in a cell, comprising contacting to said cell
  - (a) an RNA-guided endonuclease; and
  - (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said HPRT locus,
    - wherein said region of said HPRT locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6616-6682.
- 14. The method of embodiment 13, wherein said RNA-guided endonuclease is a class 2, type II Cas endonuclease.
- 15. The method of embodiment 13, wherein said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244.
- 16. The method of embodiment 15, wherein said RNA-guided endonuclease further comprises an HNH domain.
- 17. The method of embodiment 13, wherein said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6549-6615.
- 18. The method of embodiment 13, wherein said region of said HPRT locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6619, 6634, 6673, 6675, and 6679.
- 19. A method of editing a TRBC1/2 locus in a cell, comprising contacting to said cell
  - (a) an RNA-guided endonuclease; and
  - (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said TRBC1/2 locus,
    - wherein said region of said TRBC1/2 locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 6722-6760 or 6782-6802.
- 20. The method of embodiment 19, wherein said RNA-guided endonuclease is a class 2, type II Cas endonuclease.
- 21. The method of embodiment 19, wherein said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242 or SEQ ID NO: 2244.
- 22. The method of embodiment 21, wherein said RNA-guided endonuclease further comprises an HNH domain.
- 23. The method of embodiment 19, wherein said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6683-6721 and 6761-6781.
- 24. The method of embodiment 19, wherein said region of said TRBC1/2 locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 6734, 6753, 6790, and 6800.
- 25. A method of editing a HAO1 locus in a cell, comprising contacting to said cell
  - (a) an RNA-guided endonuclease; and
  - (b) an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a region of said HAO1 locus,
    - wherein said region of said HAO1 locus comprises a targeting sequence having at least 85% identity to at least 18 consecutive nucleotides of any one of SEQ ID NOs: 11802-11820.
- 26. The method of embodiment 25, wherein said RNA-guided endonuclease is a class 2, type II Cas endonuclease.
- 27. The method of embodiment 25, wherein said RNA-guided endonuclease comprises a RuvCIII domain comprising a sequence having at least 75% sequence identity to SEQ ID NO: 2242.
- 28. The method of embodiment 27, wherein said RNA-guided endonuclease further comprises an HNH domain.
- 29. The method of embodiment 25, wherein said region of said HAO1 locus comprises a sequence at least 75%, 80%, or 90% identical to at least 19 of the non-degenerate nucleotides of any one of SEQ ID NOs: 11806, 11813, 11816, and 11819.
- 30. The method of embodiment 1 wherein said RNA-guided endonuclease is a Cas endonuclease.
- 31. The method of embodiment 2, wherein said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431.
- 32. The method of any one of embodiments 1-4, 30-31, wherein said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421.
- 33. The method of any one of embodiments 1-4, 30-32, wherein said engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 6305-6386.
- 34. The method of any one of embodiments 1-4, 30-32, wherein said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6306, 6317, 6319, 6321, 6328, 6331, 6339, 6364, and 6366.
- 35. The method of embodiment 7, wherein said RNA-guided endonuclease is a Cas endonuclease.
- 36. The method of embodiment 8, wherein said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431.
- 37. The method of any one of embodiments 7-10, 35-36, wherein said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421.
- 38. The method of any one of embodiments 7-10, 35-37, wherein said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6477, 6480, and 6483.
- 39. The method of embodiment 13, wherein said RNA-guided endonuclease is a Cas endonuclease.
- 40. The method of embodiment 14, wherein said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431.
- 41. The method of any one of embodiments 13-16, 39-40, wherein said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421 or SEQ ID NO: 423.
- 42. The method of any one of embodiments 13-16, 39-40, wherein said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6552, 6567, 6606, 6608, and 6612.
- 43. The method of embodiment 19, wherein said RNA-guided endonuclease is a Cas endonuclease.
- 44. The method of embodiment 20, wherein said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431.
- 45. The method of any one of embodiments 19-22, 43-44, wherein said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421 or SEQ ID NO: 423.
- 46. The method of any one of embodiments 19-22, 43-45, wherein said engineered guide RNA comprises a sequence at 80%, or at least 90% identical to any one of SEQ ID NOs: 6695, 6714, 6769, and 6779.
- 47. The method of embodiment 25, wherein said RNA-guided endonuclease is a Cas endonuclease.
- 48. The method of embodiment 26, wherein said class 2, type II Cas endonuclease comprises an endonuclease having at least 75% sequence identity to any one of SEQ ID NOs: 421-431.
- 49. The method of any one of embodiments 25-28, 47-48, wherein said RNA-guided endonuclease comprises a sequence at least 75%, 80%, or 90% identical to SEQ ID NO: 421.
- 50. The method of any one of embodiments 1-24, 30-46, wherein said cell is a peripheral blood mononuclear cell (PBMC).
- 51. The method of any one of embodiments 1-24, 30-46, wherein said cell is a T-cell or a precursor thereof or a hematopoietic stem cell (HSC).

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

TABLE 24

Listing of additional protein and nucleic acid sequences referred to herein not included in the sequence listing

SEQ

Category
ID:
Description
Type
Organism
Sequence

MG123 active
11518
MG123-1 3′ PAM
Nucleotide
artificial
nnnnCAAa

effectors PAM

sequence

MG124 active
11519
MG124-2 3′ PAM
Nucleotide
artificial
nnnnATAA

effectors PAM

sequence

MG125 active
11520
MG125-1 3′ PAM
Nucleotide
artificial
nnnnATAA

effectors PAM

sequence

MG125 active
11521
MG125-2 3′ PAM
Nucleotide
artificial
nnGTACAA

effectors PAM

sequence

MG125 active
11522
MG125-3 3′ PAM
Nucleotide
artificial
nnnnRCAC

effectors PAM

sequence

MG125 active
11523
MG125-4 3′ PAM
Nucleotide
artificial
nnnnGnnA

effectors PAM

sequence

MG125 active
11524
MG125-5 3′ PAM
Nucleotide
artificial
nnnnCnnn

effectors PAM

sequence

MG150 active
11525
MG150-5 3′ PAM
Nucleotide
artificial
nnnMCMnn

effectors PAM

sequence

MG150 active
11526
MG150-6 3′ PAM
Nucleotide
artificial
nnRMYTnn

effectors PAM

sequence

MG150 active
11527
MG150-7 3′ PAM
Nucleotide
artificial
nnwMCrnn

effectors PAM

sequence

MG150 active
11528
MG150-8 3′ PAM
Nucleotide
artificial
nnwMCCnn

effectors PAM

sequence

MG150 active
11529
MG150-9 3′ PAM
Nucleotide
artificial
nnnMCMnn

effectors PAM

sequence

MG3 active
11530
MG3-18 3′ PAM
Nucleotide
artificial
nnRGGTY

effectors PAM

sequence

MG3 active
11531
MG3-89 3′ PAM
Nucleotide
artificial
nnRwwYYn

effectors PAM

sequence

MG3 active
11532
MG3-90 3′ PAM
Nucleotide
artificial
nnRmwYnn

effectors PAM

sequence

MG3 active
11533
MG3-91 3′ PAM
Nucleotide
artificial
nnRwYCCn

effectors PAM

sequence

MG3 active
11534
MG3-92 3′ PAM
Nucleotide
artificial
nnRGnCAn

effectors PAM

sequence

MG3 active
11535
MG3-93 3′ PAM
Nucleotide
artificial
nnCACnn

effectors PAM

sequence

MG3 active
11536
MG3-95 3′ PAM
Nucleotide
artificial
nnnMYAY

effectors PAM

sequence

MG3 active
11537
MG3-96 3′ PAM
Nucleotide
artificial
nRwYAYn

effectors PAM

sequence

MG3 active
11538
MG3-103 3′ PAM
Nucleotide
artificial
nnRGCCCn

effectors PAM

sequence

MG15 active
11539
MG15-130 3′ PAM
Nucleotide
artificial
nnnnCwAC

effectors PAM

sequence

MG15 active
11540
MG15-146 3′ PAM
Nucleotide
artificial
nnnnGTRY

effectors PAM

sequence

MG15 active
11541
MG15-164 3′ PAM
Nucleotide
artificial
nnRnRYAW

effectors PAM

sequence

MG15 active
11542
MG15-166 3′ PAM
Nucleotide
artificial
nnnnGYTA

effectors PAM

sequence

MG15 active
11543
MG15-171 3′ PAM
Nucleotide
artificial
nnnnCWAW

effectors PAM

sequence

MG15 active
11544
MG15-172 3′ PAM
Nucleotide
artificial
nnCCRCAT

effectors PAM

sequence

MG15 active
11545
MG15-174 3′ PAM
Nucleotide
artificial
nnRGAYA

effectors PAM

sequence

MG15 active
11546
MG15-184 3′ PAM
Nucleotide
artificial
nnRnRYAA

effectors PAM

sequence

MG15 active
11547
MG15-187 3′ PAM
Nucleotide
artificial
nnnnCAAn

effectors PAM

sequence

MG15 active
11548
MG15-191 3′ PAM
Nucleotide
artificial
GnnnnCMA

effectors PAM

sequence

MG15 active
11549
MG15-193 3′ PAM
Nucleotide
artificial
nnRnRYAY

effectors PAM

sequence

MG15 active
11550
MG15-195 3′ PAM
Nucleotide
artificial
nnnnGAAA

effectors PAM

sequence

MG15 active
11551
MG15-217 3′ PAM
Nucleotide
artificial
nnRnRTGA

effectors PAM

sequence

MG15 active
11552
MG15-218 3′ PAM
Nucleotide
artificial
nnnCnAT

effectors PAM

sequence

MG15 active
11553
MG15-219 3′ PAM
Nucleotide
artificial
nnnRTATW

effectors PAM

sequence

MG15 active
11554
MG15-177 3′ PAM
Nucleotide
artificial
nnnSRYTA

effectors PAM

sequence

MG71 effectors
11711
MG71-2 effector
protein
unknown
MFDNLDASKVNDFNAVFSEVENYVRDEMGIEDWSCQNIDELAKVLCD

VNLGRTTKQKAMQSLLPAQTKQQKAIIQLFSGGKAKLAELFVDEELD

ECEKKSVSFQDDDLNEFEPVLTAALGERYEGLLRFKAIYDWSLLAKIL

HLDTSKKDEDEQHLLSECKMQVYEDHKRDLAVLKSMLKGKPLYNKIF

RQDGDISYEKYAKGIKGRNQIDFCKDLKKQLEGIAEYKKIMQEITSIDD

AKTEEERLLFRITNGFAFPKQTTKDNGHIPIQVHLAELKCILDNAEGYLP

FLGETDNNGLSVREKIEQIVKFRIPYYVGPLAGTRMSREQGRCWVVRK

NEKIYPWNFTEIVNLEESAEKFITNMTAKCTYLVGEDVLPKESLLYSEF

MVRNAINNITVDGERLPVDVLEKIFKQLFLAKTSKVTKKTLERFFRQE

NISFQNIGGIDDKINASMKSYNDFRRIFGEDYIQLHRDEIENIIRWITLFC

DEKKCWSLK

MG73 effectors
11712
MG73-1 effector
protein
unknown
MTKILGLDLGIASVGYAVVNLDEQKFDGGEILTAGVRIFEAAENPKDG

ASLSAPRREARALRRILRRKTIRLQQIRNLFIKYQILTTEELNHLYASPL

PSVWEIRTLSLYEKQPLQHIARALLHIAKRRGFRSMRKSAEEKNYETG

QLLQGISLLQNLLKQSGRQTIGEFLYHLPQSEPKRNKAGSYNHSIARSM

LEEEVRLILEKQRTYGNTALSSEFEQEFRAIAFDQQPLKPSSPGKCTFLP

DEDRAPKQAYTAELFAALSKINHIRIVSQGTSRALSADERQIALDLCLE

KENNNFAQLRKLLELQENEFFNISYIIPRAKQNTDYQPEKKTAVYKMT

GYHALRKALKDHKPLWTTYMDNPNGGLDQIAVVLATFKSDKEIINAL

EKLQFPSELIEAVKSLSFSGFMHLSLKAMRNINPFLLEGHTYDKACELA

GYNFQAAKRNAGLTKLPPLTEEENFSITSPVVKRSIAQTRKVVNALNRK

YGPFDAVHIELAREMGRNWAQRKELTQQQKENQEERDLIKAQGIEGL

FPKNSLDIKKIRLWKEQGGYCIYSNQYIKPEQILEEGYCQVDHIIPYSRS

FDNTLSNQVLCLTKENQDKRNDIPFDYFQRIQRDWDSFVTLVNASPTM

RPNKKQKLLRTELSEEDLAGFKDRNLNDTRFISSFVRKYLLQNLQLTN

KYKQGVFCRNGKITADLRNMWGLSKIREQDDKHHALDAIVLACCSNA

MMQQISTQYTHNKETAALKIKPLFPWPWKEFRTDVENALLSIFVSRPP

RKKITGAFHKETYYSAKHLARGFKTLKTDINTLTAEKLAKQRDLEIKY

YGVERNKKLYDAIEQALLARTDAKQPLKVYLGPAQTPVKKIKLIMEG

NKGVPVLKGTAVAENGAMPRVDVFYKNGTYFLVPVYTIDFTKEKLPLI

SIPDNQPMDVRDFRFSLYKDDYVQIKNKTGETFEGYFKQYNAQTGQIY

LETHDRSDSYTVSGKPASEKKFSKSTFVDFTKYQIDILGNQHRVEKEKY

TGITRKNKGFGG

MG89 effectors
11713
MG89-2 effectors
protein
unknown
MSYVLGLDLGIASVGWSIVEPGNRIIDLGVRVFKKAETDKEGDPLNLIR

RESRLSRRRLYRRAHRLSRLLNFLISSGLIHSKDEVLKNVYNENPWALR

TLGLNSVLTNNQLARVIYHICKHRGFYWASSADDGQADNGKIKKSLSS

NQLVMKEKGYKTVGQMIFTEYPNCQRNKSGEYSKSLPRTDLDKELRA

IFKAQQSFSNPIVTKDFINAIVGCGDRKTGFLWEQRPALQGEDLLKMV

GHCRFEKDELRAPAANFYSEQLVWLTKINNLRVYDEDSQERPLTREER

DLILNMPLEMKSDIKYSSLTSAFEKANLWKSGQFKYKSVDYEQKTQKK

KNTAKSVDITKSSKKNPEDKVFYKSSHLHEIRKALGSSLSEEWEKIRTE

VLSGKYDRYNRIAYVLTVYKEDSDVIEQLSPYESRTLIEALLPVRFSGFV

ALSEKSLKKIIPHMVLGKRYDEACSEANYKHYKQNQAEFKKLKYLPPL

FSGREPNGTLIFNEEIGDIPRNPVVLRVINQTRKVVNAIVKKYGSPKSVH

IELARDLAKSRAERNEIEKRNEEAASRHIKERDEFEKLFGSKCLNGTNL

LKYRLYKEQDCKSMYSSKEIDHKRLFEKGYVQIDHILPYSRSYDDSQSN

KVLVLTNENQDKGNRIPFEYFEAKQHGFSWYEFEQWVKSCKNLNQKK

KRNLLRCSLSKDAKKDFLERNLNDTRYACRFVKNYIDSFLCLSENSDNS

GCVVVAGQLTAYLRNCWGLNKVREENDRHHALDATVIACCTRKIVQ

KVGAWSKSREMNSYNSSYVDPDSPVDEDEKLLQKLYVNTRKPDFPKP

WECFRSEVESRVFESALEKLKEKLKLQCSYTESELKNVRTLFVSRACE

KIGKGALHGDTVYRQTSEMRKENVAVKKVSLKKLKYARIEAIVDADT

RNKNLCDALKKRYEEYARKIGKKIEDFVDKDIAKIFADDNPLHMPNSD

GQEDPCNPIVKSVRVKEAFSGVPIRNGVAGNSTIIRVDLFKKDGKYYCI

PVYAWNKTLPNRAYVSGKKETDWALVDDSFEWCFSIRQNELLKIKLK

GETIFGYYNGFDRDRGSFNILLHDRQDGKDHKQGLIRKGIKTAISITKY

DVDVLGNYYLSKPEKRLELA

MG73-1 sgRNA
11714
MG73-1 sgRNA
Nucleotide
unknown
(N24)GUUAUAGUGGGAAAUCACUAUAAUAAGUGAAAUCGCAAGGCU

(RNA)

CUGUUCUUGAACAUCCUUUAUUAUAAAACUCCUGCCAAUCGGUUG

GGAGUUUU

MG89-2 sgRNA
11715
MG89-2 sgRNA
Nucleotide
unknown
(N24)GUUGUAGCUUCCUUGAAGAAAUUCAACGUUGUUACAAUAAGG

(RNA)

UUUUCGAAAGAUUACCGAACCCGCCCUCACUUAGGUGAGGGCUUU

U

MG99 effectors
11716
MG99-1 effector
protein
unknown
MRDLSYRIGLDIGIGSIGWAVVSSETEDHPARIENFGTRIFDSGEDPKTR

ESLCQARRADRGVRRLERRRAFRKEMLKNHFQNIGLLNNTENDDYES

CRDDDVYLLKVKGLDGKLEAAELFKCLAHTCNHRGYKDFYEPEDDDE

NEESGVNEKAANLFEKEFAASGKRTVSEYLVEKYFNNGFVKFRNRSGS

DAPYMLIRRSLLKDEAEKIIKKQSEYYPCLGGINAERTVSIIFSQRDFED

GPGDPNDPHRRYHGFLETLGRCPYYKDEKRGFRGTVISDVFAVTNTLS

QYVFFEKETGECRLDPKIANELVSYLLTNAGLTMTEVKKILKSHGYEL

KKSEKSDDKAISKAVKFLSIAKKCVEEAGKSWEALISEDQFDAANLSTL

HRIGELISKFQTPSRRVQEMKKAGIDGDLIKAFSGKKISGTSSVSYKYM

TDSINAFLSGDIYGNFQANFIKENAAVKEEERSYKLEPRHIDDPEVRDN

RVVFKAINETRKVVNAIIDIYGSPEDIVIEVASELGKSVEARIEETKRQR

ANEKENDRIKSEIAKLLSIDVQSVKTTMIERYKLYNIQEGKCAYSLEPL

GDLKDVVENVNKVYEIDHIVPFSLILDNTLNNKALVFTRENQTKGQRT

PLMYLSEEKAKEFLAFSNHLFSKKTGGISKTKLEYLKLETIYGEAAAEK

LNAWKSRNINDTRYITKYIAGLFDKQLIFAGDKKQHVFTVKGSVTQKF

RREWFRGTEWGKDEKDRTTYLNHALDALVAANLTKAYIEIGSDAIKLS

QIYRAHRYQITEEYESYLDKCVKKMSKYYGFSEGYTKKLLSKPERIPSF

VPRLKEEVAVRENDSDSEAFDKGVSKLYSAEAPFIDPPHIPITSHKQNKK

FKGCIADSNPIRVEEIDGEAHKIRRIDIKTLSAKKLKDLYTGDVSLREEL

AAMLDGKPESYTVGDSLKESGKEFFLSKSGAVIRKVSVDDGIVSNYYR

KEIKDGQYSTLGMLKYYCIEVYKDAKGKTRIYGIRFVDVVKKNKKLY

QKAESYPEDYASHVMYLFTGDFVRITDKKGKLKFEGFYQAVKNINSSI

LYFSPVNLANTVIKGISLTDNIEKYYVDILGRIGGKIRCSEPLQSTAEKK

SL

MG14 sgRNA
11717
MG14-241 sgRNA
Nucleotide
unknown
N(20)GUCUUGCCGGAAACGGCUAGACAAGGGAAUCGCUUUUACGCG

(RNA)

AUUACCCGCAAGGUAAGCCCGUCAGCACCCUUGGUGUCGGCGGGC

GAUCCUUUU

MG16 effectors
11718
MG16-1 effector
protein
unknown
MIKNILGLDLGVGSIGWALIQTEDDQPKQIIGMGSRIVPLTKDDSDQFT

KGQAISKNAERTARRTTRKGYDRYQLRRALLTQVLRQNGMLPECMD

ENMIDLWKLRSDAATEGKQLTLQQIGRVLYHINQKRGYKHAKSDDNG

DSKQTKYVEAVNLRYKEIQEKNVTVGQHFYAELLNSKVESGNGPYYTF

RIKDKVFPRAAYIAEFDQIMGVQKEYYPNVLTDELIETLRNRIIFYQRPL

KSCKHLVGLCEFEMRPYKKDGKIVYGGPKCAPRTSPLAQLCAMWET

VNNITLTNRNNERLEISNEQRRQLVQFLCTHETLKLTDLYKILGITKKD

GWYGGKAIGKGIKGNVTLNQLRKALDGKYSQWLEMPIERIDVVDRNT

AEAFWAVSPKVEETPLFQLWHAVYSLQNVEELTKTLQNRFSITDPQVI

DALCKIDFVKPGYANKSHKFIRRLLPYLMEGMMYSEACACIQINHSNS

MTKAEREARPLAERIELLQKNALRQPVIEKILNQMINLVNRLQQEYGPI

DEARVELARELKQSREERKDAFDRNNKNEKRNKEISALISEQGIRPSRS

RIQKYKMWEESEHRCMYCGKVVNLSEFLNGADVEIEHIIPRSILFDDSF

SNKVCACRDCNREKDNMTAMDYMASKPEGEFEAYKQRVDEAFNAHR

ISKTKRDHLLWRRADIPQDFIDRQLRLSQYIATKAVEILQQGIRQVWTS

GGGVTDFLRHQWGYDEILHTLNLPRYRQVEDLTEMVHYEHAGQEHD

EERIKNWSKRIDHRHHAIDALTVALTRQSYIQRLNTLEASHEHMEKLV

KEANTPYKEKKSLLEKWVALQPHFSVEEVTTQVDGILVSFRAGKRVTT

PARRAVYHGGKRTIVQRGIQVPRGALTEDTIYGKLGDKFVVKYALDH

PSMKPENIVDPTIRLLVENRITALGKKDAFKTPLYSAEGMEIKSVRCYT

SLSEKGVVPIKYNEKGNAIGFAKKGNNHHVAIYKDQSGQYQEMVVSF

WDAVERKLYGVPTVITNPKTVWDELLEKELPQDFLEKLPKDNWQYVL

SMQENEMFVLGMEEDEFNDAIDTQDYNTLNKHLYRVQKLSHADYTFR

FHTETKVDDKYDGVENGRNTSMSLKALVRIRSFNGLFTQFPHKVKIDI

MGRITKA

MG16-1 sgRNA
11719
MG16-1 sgRNA
Nucleotide
unknown
N(22)GUUGUGUAUGGAAACAUACACAAUAAGGAUUAUUCCGUUGUG

(RNA)

AAAACAUUCAGGGUGGGACGCAAGUCUCGCCCUUUU

MG73 effectors
11720
MG73-1 effector
protein
unknown
MTKILGLDLGIASVGYAVVNLDEQKFDGGEILTAGVRIFEAAENPKDG

ASLSAPRREARALRRILRRKTIRLQQIRNLFIKYQILTTEELNHLYASPL

PSVWEIRTLSLYEKQPLQHIARALLHIAKRRGFRSMRKSAEEKNYETG

QLLQGISLLQNLLKQSGRQTIGEFLYHLPQSEPKRNKAGSYNHSIARSM

LEEEVRLILEKQRTYGNTALSSEFEQEFRAIAFDQQPLKPSSPGKCTFLP

DEDRAPKQAYTAELFAALSKINHIRIVSQGTSRALSADERQIALDLCLE

KENNNFAQLRKLLELQENEFFNISYIIPRAKQNTDYQPEKKTAVYKMT

GYHALRKALKDHKPLWTTYMDNPNGGLDQIAVVLATFKSDKEIINAL

EKLQFPSELIEAVKSLSFSGFMHLSLKAMRNINPFLLEGHTYDKACELA

GYNFQAAKRNAGLTKLPPLTEEENFSITSPVVKRSIAQTRKVVNALNRK

YGPFDAVHIELAREMGRNWAQRKELTQQQKENQEERDLIKAQGIEGL

FPKNSLDIKKIRLWKEQGGYCIYSNQYIKPEQILEEGYCQVDHIIPYSRS

FDNTLSNQVLCLTKENQDKRNDIPFDYFQRIQRDWDSFVTLVNASPTM

RPNKKQKLLRTELSEEDLAGFKDRNLNDTRFISSFVRKYLLQNLQLTN

KYKQGVFCRNGKITADLRNMWGLSKIREQDDKHHALDAIVLACCSNA

MMQQISTQYTHNKETAALKIKPLFPWPWKEFRTDVENALLSIFVSRPP

RKKITGAFHKETYYSAKHLARGFKTLKTDINTLTAEKLAKQRDLEIKY

YGVERNKKLYDAIEQALLARTDAKQPLKVYLGPAQTPVKKIKLIMEG

NKGVPVLKGTAVAENGAMPRVDVFYKNGTYFLVPVYTIDFTKEKLPLI

SIPDNQPMDVRDFRFSLYKDDYVQIKNKTGETFEGYFKQYNAQTGQIY

LETHDRSDSYTVSGKPASEKKFSKSTFVDFTKYQIDILGNQHRVEKEKY

TGITRKNKGFGG

MG73 effectors
11721
MG73-2 effector
protein
unknown
MNKILGIDMGIASLGYAVVNIDDENFVNGDILASGVRIFDVAESPDGSSL

AAPRRAARSVRRILRRKVMRIKAIKQLFLDENLLSPQELDLLSKQDFKT

LYQATPEGQPIPSVWEIRARALDNPCSLVDICRALLHIAKRRGFRSMRK

SEKLTGEAGKLLKGVEEMQKKLQESNFRTIGELLFHLPATEPKRNKD

GSYSHSVARSLLEEEVHLILQVQRAKGANALSQEFETQFCKIAFLQNPL

QPSDPGFCTLEPTEPRAPKNAYTAELFAALCKINHIYLEEDGQSHALSA

AQRALALEKCFSTQKTNYKQLRELFNLPNDIKFNISYTAPAKKKSKKK

EEAQSPEQAVQAPQEYDAEKNTTLYNMAGFHALKKALKSSPLWAEYQ

TNPNGILDKIAEVLSRYKSDGEIRQHLTALGLPAEAVEKLQNVNFSGFM

NLSLVAMNKIIPFLKEGFRYDVACKKAGYNFQAPQQNKGLSKLPPLTE

EDNHTITSPVAKRSLAQARKVINALNKKYGPFDAVHIEVAREIGKSFEK

RKEIEAEQKAHAEERARLKEVGIDGIIPQTETDLKKLRLWKEQDGRC

MYSLQYIEPRKILEEGYCQVDHIIPYSLSFDNSLNNQVLCLTSENQHKK

NQIPYEYFHSGKAQITWEDFEGYVNSLQNIRMAKKHRLLKQELTEDDL

QGFKERNLSDTKLISRFMKNYLLANLRLTGKYKQGVFCVNGKHTSTL

RGFWRLQKIREDGDKHHALDAIVIACCTNRLMQYISTKYRQNRELEL

QRKEVAVPWPFPHFKHAVENSLLSIFVSRPPRKKVTGALHKNTFFSAK

HIKKGIKTLRTDIQKLTLDSLKKQRELEVKYFGVERNKPLYDLIETALN

NRPNDKTPIQVQMPTKNGGFVPVRHIKLISESTSGIPVLGGTALAENDS

MPRVDVFLEDGQYYVVPVYTMDFAKGVLPLVAQPSGRLMKKENFVFS

LYKDDYVNLVNKQGETWEGYFKQLNAQTGQIYLESHDRSAQYTVSGK

PSNQKKIASSTLKLIEKYQIDIFGGKHLVKKEKYIGIIRKNKGFGG

MG74 effectors
11722
MG74-1 effector
protein
unknown
MQVHDDVILGLDIGVGSLGWALLEEDLQTGEQRLLQRQTPQGETTYA

LGVRLFHVPENAKTKELLNVKRRTARMQRRTTARRAQRMRRVRALL

DSLGVPGVRDADAFHLGKGRGAQCDPWQLRREGLERRLEAREWAVV

LLHIAKHRGFRSNSKTDRSGSDKEMGQVLQAVSNLQQEVEASGLTVG

ALLASRERRRNRADHTGAPRYDLCMLRSLQENEVDILFTRQRELGNPL

AGEEVRCRYAELAFAQRPLAPVSHMVGPCAFLEGERRAPRFAPTAELF

RYVQALCNMRLRQETGEETPLSEEQRQAACAVFGSVQSVTYKKLRQV

LRLPAGCRFAGLSYGVTEKGNVQDPEKADVVMRTGKCCQGTACLRGI

LGDAYEALHEQRLDEADAARLAATGALSAPAAALLARGMAGLRLTDA

VARIVSELNDLDQIRAVLALLPLAAPRIAALSQAAGEGKLGIFQGTARL

SLRAMEAILPHMLACGEYAAACELAGFDPRAAQKTDVTDIRNPVVLRV

FREVRRQFSAICREFGFLPGRVHVELLREVGKSGEERNRISRGLERRTK

EKEAARKAVAQLLGKSPETVSAGEVQRYELWRQQDGKCAYYMLWR

HAGGERAYGDAMPQGSIPPDWLADGVNAVQVDHILPRSRTFDNSFHN

LCLCCHAANQAKGGRTPWEWLGAAQPQAWHDFEQWVQSLPLKGLK

KRNYLLRDLNAEVQGRFHARNLTDSGYVARLTLRWLEEEYARHDVP

MQDADGRTRRRFFARPGQVTDFLRRHWGVQALKKIDGQRSGDRHHA

LDALLVAACSEGMLQRMVRAFQREENGPERLHIPCPWQDFSATVGRA

LGSVFVSRVERGRTKGPLHEETLRAIREERQPDGETRRVLYERKAVAR

LTAADLDKIKDAARCPDVVAALRRWLDAGKPGDALPRSAHGDIIRHVR

VCAGEFSSGVVLQRGSGQAQASNGGMVRTDIYSRDGKFYMVPVYAKD

VADKRLPLRACVAAKAEKDWREMTADYRFLFSLTPDCYVLTENRKGE

VKEGYFAGANRNTSAISLSLAHDKQNVIQGIGITTLKRFEKYRVDRFGR

LSLVRREADPRGRS

MG86 effectors
11723
MG86-1 effector
protein
unknown
MKKILSFDLGITSIGYSVLTEDEAQKYSLLDYGVSMFDKPTDKDGNSK

KLLHAQALSTKKLYKLRKERKKNLALLFEKYALAKASKLLEQEKKNL

YMYKWQLRAKKVFEERLSIGEIFTILYHIAKHRGYKSLDSGDLLEELC

VELGIKIDVKKEKKDDEKGKIKQALSTIESLRKEYPKKTVAQIIYEVEL

QKERPVFRNHDNYNYMIRREHINDEIATIIRKQKEFGNFENIDSEVFIVD

IIAAIDDQKESTNDMSLFGKCEYYPKEHVAHQYSLLSDIFKMYQAVANI

TFNKEKIKITKEQIRLLTEDFLNKIKKGKSVKELKYKDVRKILKLDESV

KIFNKEDSYQRAGKKVEHTITKFHFVDNLSKIDKSFIEDIFNADESYVL

MREIFDVIHKEKSPKRIYEQLKSKVSSEAVIIDLIRYKKGSSLNISSYAMA

KFLPYFEEGMTLDAIKEKLDLGRKEDYSVYKKGIKYLHISTYEKDDDL

EINNHPVKYVVSAVLRVVKHLHAKHGTFDEIKVESTRELSLNDKVKKE

IDKANKAREKEIEKIISNDEYQKIAKEYGKNIHKYARKILMWEAQERFD

VYSGKSIGIDDIFSNRVDVDHIVPQSLGGLYVQHNLVLVHRDENLQKSN

QLPMNYITDKEAYINRVEHLFSEHKINWKKRKNLLASNLDEIYKDTFES

KDLRATSYIEALTANILKRYYPFIDEKKSVDGSAVRHIQGRATANIRKV

LGVKTKSRESNIHHGVDALLIGVTNPSWLQKLSNIFRENFGKIDDEARK

NIKKALPYIDGVEVKDIVKEIEQKYNSYGEDSIFYKDIWGKAKTVNFW

VSKKPMISKVHKDTIYADKGNGIFTVRESIIAKFINLKITPTTFPEDFMK

KFHKEILEKMYLYKTNSNDVICKIVQQRAEEIKELLWSFEFLDVKNKE

EMQEAKANLESLVHRELFDNNGNVVRKVKFYQTNLTGFKVRGGLAT

KEKTFIGFRAFKKDKKLEYKRIDVSNFEKIKKSNDGSFKVYKNDIVFFV

FDEEKYKGGKIVSFLEDKKMAAFSNPKYPANIQAQPESFLTIFKGKANS

HKQVSVGKAKGIIKLKVDILGNIESYQVLGNAKSKLLDEIKSIVSH

MG86 effectors
11724
MG86-2 effector
protein
unknown
MKKILSLDLGITSIGYSVIEEFGNDRYSLIDYGVSMFDKATDKDGNSKK

LLHSASTSTSKLYDLRKKRKKDLAQLFHNFGLGDKNSLLSQEKQNIYK

NKWYLRCHKAFKEKLNINELFTIFYTLAKHRGYKSLDSSDLLEELCEK

LNIPLETKTKKDDERGKIKKALKTIEELKQNSTKTVAQIIYEIELKKENP

TFRNHDNYNYMIRREYIDQEIEKIIKTQKDFGLFDDKFDIDNFIEKLKDI

ITYQNPSTNDMRLFGNCEYYEDEKAAHQYSVISDIFKMYESVSNITFNT

KPSIKITKEQINKIADDFFTKIKKGKNIADIKYKDIRKILALSDDTKIFNK

DDSYISKGKKVEHTIIKFHFVNNLSKFDNSFIVENLNSLENLKEIFEVLQ

FEKDPTAIYEKLKDKIEDKQTIINLIKHKSGNSLNISAKAMVEFIPYFKD

GLTTDKIKEKLELNRCEDYSKFYKGIKYLNIRQFEQDDNLDINNHPVK

YVVSATLRVIKYLHIVCGTFDEIRVESTRELSQNEETKKAIEKANKELE

KQINDIVQNKEYQNIAQHYGKNLQKYARKILLYEAQNRRDIYTGEGIE

FEDIFTKKVDIDHIVPQSVGGLSVKHNLVLVFRDTNIQKSNQLPMNFVK

DKQDFINRVEHLFSEHKINWKKRKNLLATNLDEIYKDTFESKSLRATSY

IEALTAQILKRYYPFKDKEKQENGKAVSYIQGRATSNIRKILKVKTKTR

DTNIHHAIDAILIGLTNQSWLQKLSNTFRENFGKIDEEARANIKKDMPIF

EIIIDDEVKYLEPKELVELIEKNYNYDGENSIFYKDIWGKIKSVNFWVSK

KPMVSKIHKDTIYSKKDDGIYTVRENIINHFINLKITPKTSSKKFEEEFN

KKILNKMYLFKTNPKDAVCKAIIKRANDIKTLLDSFIDIDTKDKEAMNN

AKTKLDELIHKDIPDNNGKPIRKIKFYQTNLTGFDVRGGLATKEKTFIG

FKAQIINGKLNYTRIDVANIDKIKKENDNSFKVYKNDLVFFIYTDGTNK

GGKIVSFLEDKRIAAFSNPRFPSSIGFQPHFFVTIFNGKANSHKQHSLNK

AIGIIKLNLDILGNIKSYQKIGSCESELLEFIKKVIKD

MG87 effectors
11725
MG87-1 effector
protein
unknown
MEKYIIGLDLGINNVGWSVVDAQTNKIKYLGVKQFEASDSAKDRRTQR

NTRRRLKRRETRKTDILKILSNINFPNNLTIDTMLIETRCKGINEQISKQ

DITNILCYMATHRGYIPFGDEEVSFVDLDGKYPCEYYYEMFKSSTNNK

YRALRNTVKNEENINEVKKMLETQRKYYPEITNETIENIVTTLQRKRK

FWEGPGSINALTDYGRFKTPEDVVEYLDKKKENPEYEKYIFEDLIGKCS

VIPNEKCVSQINFYAEKFNLLNDFINISFKSIEELNNKDDFYETQVKTYK

LRESGLNKVFDYCMSKDTLTIKGLFKDLFATTIDNISGYRQDGHDPNK

PEMSTMNTFRSIRKTFKECNANMDIFKPENTDLYNEIINYMMLVPGQV

ELINMLSTIMPLSENDKEALKKVFKSKKTNLKYHSLCEKILIRACNDML

SLQKNYMQVYKLKDYGKESRKEFVKRYEESNKGEKLMNPTFIDDIISS

PQVKKTLRQSVKVINEIIKNEKSLPDVIVVESTKDTLNSEKMRKVYIDIN

KKQKALHDKAIKTLSSIGYSEKDISKKKIEKLMLYEEFDGLCPYCNNQI

TLKYLINGSDEIEHILPRSNSFDDSFDNRTVSCANCNKNKNNQTPLEFLK

GNEKESFIERIKSNKNISEFKKENFLFAGDISKYRTRFFNRNLRDTAYAT

KEMINQINIFNLYLESKNKDERIKTLSTPGQITHSIRKRYDLEKDRDTDI

PYHHAIDASILALLPTTKIGSKVVMFQNDNKFFLNENNKDKMTEIGLEL

KYYDTSEGKIEYDDYIADFKNINDTSNIFMYSPEVKKEPNKGLFNANMY

KVIKIDDKYYKIDQINDIYNLSDSDKKLLPKLFDDAKNETLLCKLQHKE

FYEKLKNIYIKYSDSKNSPFEDYQREINNLSKEDKFDYLKHGLKMSENA

PSVKRLRYYTPISEPYLIDKKSINKKDGTYLAFDSLAQAGIEVYYNETK

NCFAFVPIPSVCYNLKTRKVNRKHKLYKRYKELNLKDYKVKYIVTLYN

GNTIEVLKKDNTIIKGVVSSYHKTNDKIVLKNGSYFTKSDLEFSIIDYNPI

GKSQKRLTKRIK

MG87 effectors
11726
MG87-2 effector
protein
unknown
MKKYTIGLDLGINNVGWAKYDLETKKVIDKGVVRFKESSTAQDRRIIR

GSRRLRKRKQHRVERLAIQLSNINFCTSRSYEPELLNKRIKGLNESLSE

QEITNIIYWFAIHRGYIPFDEEKPEREVHKFAEDEYPCQYIFDYYKEYG

VYRGQCDLISLKDNLKELKQILLTQQKYHSKLTDEVIDNILYIIQSKREF

WEGPGASKENQLSPYGRYRTLEDLEKYKADPTYHQYLYEMLIGKCEL

SIDKDGFMDQVAPKCNFYAEEFNFYNDFINMSVKEPSQIDEEYRNKITL

KGKFTEDTIEEIKKEIISTKKVSLDKLVKKILGLELKDIQGYRIDKKYKP

EISQFEFYKYLLKSFKDEKLNPSWLENDDKTIYNQIVYILTVAPSTYAIE

DMLKDRVKEVEFKKEEIDVLIDIKKKKNPDLKYHSLSERILKKALDDIK

RHNCEYNFMQIMKRLEYEKEMKEYFQNNYSTKTQSPYTIEDQYIDHLI

ANPQVKKTLRKAIKIINAIIKEEKNYPETIVIESATSLNSKERKKQIEEEQ

KTFNQLNKEVKKELEDNGYEATDKNMQLLINWKETNESCIYCGESISL

KEVLITEIEHILPKSKSMDNSHNNTTCSCLKCNKEKNNRTPYQYLTSKN

MYEGFKNRVMNQYDKMSQDKKSNLLFEGDIDKYSIKFINRNLRDTSYA

SVALVQELKKYNEYLGAKEGYKINIITSPGQLTSKIRQYLKIKDKDRTY

LYHHVVDAMILASIPDTEIGKVLIEAQNDSQYWFKDKNKENKYKEEVY

NMLNNVWLSNRDQIQKFNQDCDNMPDNNKEGLIKRSYEVLKNPVRQF

SQYTEYAKYIKQNDVYYKISQIDNIYNLLIRKKDGSADKDKKLLDELFD

LSNKKNKTLLCEKKDPKLYQKLKNIYEKNSFSINPFVDESKYMYGLED

GDKFDCLKQGIRKTDNSNSPLVIKLRYLEKVTNPYIKNNITTRRKNLYN

EFTINKPKKDTLIGLDGLKQVSTRIFYSYEDKKFIFLPICAISFVNGKLN

KKEKNYQTTYNRLIGNKNVKEMGNIYVGEWVGVYKKNGEYFEGRYK

GYHKTSNVLEYYINGLDTLSCATIGSSDLRIIIYTTDILGNRHIRLDTQKE

I

MG87 effectors
11727
MG87-3 effector
protein
unknown
MTKNYSIGIDMGVNNIGWSILNNDTKKLENYGVRLFPTSNDAKERREV

RNTRRRLKRKETRLDDTLYLLKKYGFNEDNTIEENLIEKRVKGLNEKL

EKQDIVNILCYMIKHRGYIPFGDEEVTLVDLNGKYPCEFYYEMYKNGG

KYRNRKMTVRITDNEKEIKKILETQSKYYKNINQDFINKYLNILTRKRK

YWEGPGSINDLTPFGRFKTQEDVENYLEEKRKNPSYEKYIYEDLIKKC

DYELEERCCCKLNIYYELFNMYQDFINVSFKNIEELENKDCFYETKNGL

YKLNKKGLLMVKDYCMNNFKLKYTDILKKLFNTDKDNISGYRIDKDH

KPEFSTLNSYRKIMLEFTEKGFDTTWVSDYNCYNEIMEKMTLTPGGVE

FIKEIENNKLVPYKFNEEEKSLFKELKEYFNKKTLLSYGSLSQKILQKAI

NDMLDLEKNFMQVSRIKDYGKEARENFIKQYKKTSNKLEINASFVDDII

ASPQVKKSLRQAIKIINAIIEKEGCLPVSIAIESTKELNSDKKKKEIEKEQ

KIQENLRKQASNYLSTVFGDSSVTETNILKVMLYNETNGHCAYCNKPL

SINDIFADNIQVDHILPISKSENDSENNKIISCKKCNDDKKNNTPYQFLKN

KNYFEEFEKRVLENKNISDYKKDNLLYKDDLDKYKTRFFNRNLRDTAY

ATTELINQIEIFNNYLEILDKKRINTLSVPGQITSSIRNRYVKNEDKTSLE

KNRDAGVFHHAVDASIVVSVSDTHIGQIMLKAQNDKEYWIKNKSNYDD

IYKYLINLRIDDTINQIEKINNENIKVSKQVSKNPQGKLANSNIYKMIKK

DNEQYIINQIDNIYTFDFKKDENKKLFEKLLNEENNEFTLLCYDNDKNT

FNYIKKIYNEYKNEKGNPFVNYLIDKGEIPDGNSFDYDITGIRMVTKKG

NGPIIKRLRYYSKKNDLYILNKKNINKKDSNYLALDSLKQFCVKVYVD

NDNKKFVFLPIYTISLDPKTKKVNENDEFYKLFYNKYIGNKNVTFFADI

YNGNKLEITKKDGTIVSGYYSTFNKANNKLILNNGDTFTLSDKKISIIHT

DILGNEKKG

MG88 effectors
11728
MG88-1 effector
protein
unknown
MKYKIGLDLGSTSLGWAVVELNEADQITSLVDMGVRIFPDGRDAKSH

KPINVIRREHRQMRRRGDRVLLRKKRVLQLIHKYGLDFDISADIKLED

PYVLRARAVSDKLSSAELGRVLFHLALRRGFKSNRKETRGDSGGKLK

KATLALHDAIGDKTLGEFQVDSKRYRFADQFDGNKIKDGALYPTRDM

YLDEFNRICSVQNMSDDMRQQFEYAIFHQRPLVPPEIGTCMFELDQPR

AYKFEPVFQRFRVLQQINQLRIINNGEIKELTAEQREKLQDALLATFCG

VKRDKSGRPKITFAEVKKLLGLSRNTKFNLESEKRKDMDVDATAFAFA

ECELADFWRACTDNVKSQVLAHLNDDELSDSDLVDYLAHEYGISQDK

AEKLIQQPFEDGVANLSVCAMQKMLPFLEQGHLYHIAAKEAGYDHAD

RGIVHLDTLPYYGDVMALRPSLVQDKMGRYRTMNATVHIALNQLRAV

VNDLIARFDGEPYAINIEMGRDVSAGADERAEIEKQQAANKRENDRIAT

ELVAMGVRVCRENIQKYKLWENLGKSPLDRRCVYTGEIISKEKLFSPE

FEIEHILPFSRTLDDSMANKTISAAVANRFKGNRSPDEAFSDPKSPWKY

EDVVARAQNLPDATKWRFNRGAMDVFLQGKECIARAMNDTRFMTRM

AVTYLQHVCADKNRVNGMPGRLTASLRDEWHLNWWKNKAEESKYR

GNHIHHAIDAFVIACTDENILRKLADAKSDMHTPFPGFDYFDFKMRCE

NTIISYRQSQKNPKDAHSTVGCLHEDTAYNLECFEDGGCGVNAVMSHR

EELPTTDKDKKAFAKDFKNVNPKTLQMFLNDAGVANEEPDIAIKFLD

WCAMRNIRKVRMYKTGVDVTTYVPVFRTKKQRDVYRAAYLNWYVN

TGVASGIVDKKLRAVQQEKEKHLLQEFQDAAKQAYKWYVGGNNFCA

EIFEIRDDDTRYPKLRGRWQVEILSNYNAQLNAGAPLWRHKYATAKRI

MSLRINDMVMAEFSKDDPKLPKGLVETVAHQCAIEKTDKVNVVFRVK

KLNSSGTVYLRPHFIAKEDADTKSWIASATSLQEHKARKVCVSPSGKIL

GLK

MG88 effectors
11729
MG88-2 effector
protein
unknown
MNYRLGLDMGATSIGWSIYDVETEKLLDTGVRIFDDGREDKSKASLCV

KRRNARGARKLNNRRHIKTQELLKILTTLGLFPQEQNKREDLKNDNP

YKLRKEALDRQLSTYELGRTLMQLAKRKGFKSNRKDNREEGGKLKK

GFAELKDIMQKENARTYGEFLYNCMQRNPDKPIRLKNTFDESGKYKG

GLFPFREIYVNEFEQIWHKQKEYYPQILTDENKEKLKNIIFFQRPLKEA

EEGECQFEKGEKRIPRAHPLFQEFRIWQNVLNLTFSAENEPDYKPLEK

VQELIKLLMNPQEVKPNKQGIIIYANLKKALGLDKNGVFNFERQNNRD

TDLEKGLLVNTTQNAINESEFLAPYWNNFSDAQKGELINVIMRPHNYIP

FPKTRISIEEEDDLIINYVRKRFNLPQEAAEELLFDIDLEDDFGSLSEKAI

SKILPFMKQGTPYHDACQSAGYHHSYKEYEHIDKLPYYGEILGQSCLG

KKNNPKCVEEEFGKINNATVHVALNQIRHLINEHIMRYGKPYDIAVEYA

RDLNASTQERLAMTDTRDKNELENQRIIKELQSKLGNHPYSKNDIQKY

KIWKKLPFYDKNPLIRECPFSGEQIPLSELLNGQKFQIEHLIPFSRSLDD

SLNNKVIATVEANRYKGNRTPFEAFGQSKDGYNWKDIQHRAKKLSVE

QQWRFAPDAMQRFEKQEGPIVRSLIDTRYMTRLLQDYLQPIVKEDGK

QRVQAVVGQLTSLVRKAWGLNVYKEKADKDKYREFHNHHAIDAIVIS

AINRAQIKDVVGILAHVRDDIREEYKDELFQLSDNNVPEDKKREIKKEI

RDVTAKREIAIAKKYFPLPKSFNIPDILQQVAAINISHKPNLKNIKQKDS

TIGQLHQDTAYGLQKFVDDKSLKAIFKTKKAGDEASDDKTTPKDITQY

IPMFRNKEDKKAYYDAFREWFKFNGKAASMDAKTKEDKKLKAEIAQ

KEQAAIQTLRQTALKAFKWFVGGNNFCAEIYEINPNNKIEGVASKDRG

EWKTEIVSNYNATVRNSRGEDIAYWRYKYPNAKRIMSLRGNDMVMAT

FSREQAFDEKFPKGIQEYVREKFQQKSDCQELDILFRVKKMGSNGICF

TPHNIAKENADTKSWIASAGAMQKYRVRKIHISYMGRIQNA

MG88 effectors
11730
MG88-3 effector
protein
unknown
MKYKFAFDLGSTSCGWAVVNTDEDGNVVGLADMGVRIFPDGRNAKT

KEPLQVARRNARGARVRNDRILQRRHKIIDLLKENGMIYDCSDERENP

YKLRSDAVDKEITLKQLGRIMYNLSLRRGFKSNRKPTQKENDSDLKKA

TEKLKQELKGQTLGQYLWGKMKKNLDKEKENKGKDVKNKIGKVRF

SNLFDGNKIKDGSVYPSREMYEDEFNRIWSKQAEFHDILTDELKGKFY

NAIFFQRPLKPQQRGFCMFEDGELRIYKAHPLFQRFRALQTINQMEID

DKPLTEEQREALKKELFEEFKTKNTKAGTVSFSDIRTILGLKKGVKINL

EKNDDDENDGDNTRADKTPEDKDNKKDDDKEYDNIYADKTAYLLSRP

ECFGEKWFEIPFDEQCSIVDILTDCVYNNIEEKKKYDEQQEQNGKHILE

DDEIKQFLQEHYNLDDEQCNAIMNAPLEEGTGSLSQKAIEKILPYLEEG

QLYNDACKSAGYHHSLFDGDVEMLGELPYYGDVLKKSCVQDKDGNY

RITNISVHVALNQLRLVVNELIKKYGNPDFVAVEIARDLKMGTEELKN

LNNKQNSNKKENDKITKAIKEANGNPNNAKDREKFKLWELCQKRCVY

TGKQISATELFSDRVHVDHILPFSRTFNNGFFNKVVCFGDANEDKGNST

PYEAFKNGYQGQSYEEILDRVKKIVEAMKEKKMFKKKTVKDKDGKK

KKVDIDEFSWRFKEDAMEKFKEQEGLIARQLNDTKYMSRLAVQYLKH

ICKVEYYTDEEGKEHRKNNCYGLPGTMTDFCRKGWGVNWLKDKSNK

EGYRSSHAHHAVDAFVVACMTRGQLQKIASMANWIEEHGGQCQDDK

LYLSILFKKCKKPFDTFDRERIYELCDKMPISFKPKLKDPKQENSTVGA

LCEDTAYSLLEFDKGLNGVFVKREDVGSLVLKDLPNIIDTQADKLIKEY

VETEEAFNKFKEYCEKNGIKKIRCKSFADVSTYIPIFKTKEERDEYHKA

YEDWFIFEGRSPANETEEQKQERKEKEQELLKIVQQKALKAYKWFVG

GNNFCADVYQISPRDKVYTDKKEQGSWKVEVLSNYMATLNKGQALW

RKKHPTARLVMRLKIDDMVMGENFTKEEAEQKLQQEIEKWEKSKEM

KKYKDKLTEWEKTHEGKEPKKPEKPKSINEIIIEKCNKEKTSSTSFLFR

VKKISSDGSVYIRPDFITKEESDKKSVKLSASSYQKYKIRKVFVSPAGKL

VDNGFSDKWNDTKCN

MG89 effectors
11731
MG89-2 effector
protein
unknown
MSYVLGLDLGIASVGWSIVEPGNRIIDLGVRVFKKAETDKEGDPLNLIR

RESRLSRRRLYRRAHRLSRLLNFLISSGLIHSKDEVLKNVYNENPWALR

TLGLNSVLTNNQLARVIYHICKHRGFYWASSADDGQADNGKIKKSLSS

NQLVMKEKGYKTVGQMIFTEYPNCQRNKSGEYSKSLPRTDLDKELRA

IFKAQQSFSNPIVTKDFINAIVGCGDRKTGFLWEQRPALQGEDLLKMV

GHCRFEKDELRAPAANFYSEQLVWLTKINNLRVYDEDSQERPLTREER

DLILNMPLEMKSDIKYSSLTSAFEKANLWKSGQFKYKSVDYEQKTQKK

KNTAKSVDITKSSKKNPEDKVFYKSSHLHEIRKALGSSLSEEWEKIRTE

VLSGKYDRYNRIAYVLTVYKEDSDVIEQLSPYESRTLIEALLPVRFSGFV

ALSEKSLKKIIPHMVLGKRYDEACSEANYKHYKQNQAEFKKLKYLPPL

FSGREPNGTLIFNEEIGDIPRNPVVLRVINQTRKVVNAIVKKYGSPKSVH

IELARDLAKSRAERNEIEKRNEEAASRHIKERDEFEKLFGSKCLNGTNL

LKYRLYKEQDCKSMYSSKEIDHKRLFEKGYVQIDHILPYSRSYDDSQSN

KVLVLTNENQDKGNRIPFEYFEAKQHGFSWYEFEQWVKSCKNLNQKK

KRNLLRCSLSKDAKKDFLERNLNDTRYACRFVKNYIDSFLCLSENSDNS

GCVVVAGQLTAYLRNCWGLNKVREENDRHHALDATVIACCTRKIVQ

KVGAWSKSREMNSYNSSYVDPDSPVDEDEKLLQKLYVNTRKPDFPKP

WECFRSEVESRVFESALEKLKEKLKLQCSYTESELKNVRTLFVSRACE

KIGKGALHGDTVYRQTSEMRKENVAVKKVSLKKLKYARIEAIVDADT

RNKNLCDALKKRYEEYARKIGKKIEDFVDKDIAKIFADDNPLHMPNSD

GQEDPCNPIVKSVRVKEAFSGVPIRNGVAGNSTIIRVDLFKKDGKYYCI

PVYAWNKTLPNRAYVSGKKETDWALVDDSFEWCFSIRQNELLKIKLK

GETIFGYYNGFDRDRGSFNILLHDRQDGKDHKQGLIRKGIKTAISITKY

DVDVLGNYYLSKPEKRLELA

MG89 effectors
11732
MG89-3 effector
protein
unknown
MDLIFGLDLGIASVGWSVVDDENKRIVDLGVRAFKAAETEDKGKSLNL

VRRTSRLSRRRIYRRANRLNSLLNYLIKSGLISSKDEILNNEHHENPWNL

RVKGLDGVLSNNQLARIIYHICKHRGFYWSSSAEETEDTEKGKIKKCL

AQNSLALTNEHFRTIGETILNKYPDAQRNKADEYTKSISRVLLNEELKQ

ILTVQKEVFHNPLLTDDFFKAILGTGDKKSGFLWKQKPPLQGEQLLK

MVGHCRFEKDELRSPKANYFAERHVWLTKLLNLRIYSEDCEDRALTV

EEISIVINKIYEQKSDIRYSSLTTAFVKSGIWPKNHQYKYKGLNYDQLTS

SKKKKVEDTASTSEDSTDTKKTAKKTNPESKIFYKSSCYQNIKDAYMSN

SLEQEWNILSTQISQGNYDRYNRIAYILSIYKDDEEVKKHLLDCGEKSE

VAEALLKIRFNGFSALSEKALKKIVPIMEQGKRFDVACSEAGYAHYKQ

SQDSKEKRKYLPPLFSGREPNGTLIINSELDDLPRNPVVMRVINQTRKV

VNALVKKYGSPKSVHIELARDLSKTFEERIDIQKRQEEIKERRQKEQEE

FDRIFGVGIRSGKNLEKYSLYKQQDCKSIYSGETIDLGRLFEQGYVEVD

HVLPYSRSFNDSQDNKVLVLTKENQNKGNMLPYEYFMSHNLDWNQFE

ARVLSNKKLRKNKRCNLLKKSLNRNSKKEFLDRNLNDTRYACRFVKN

FIDKYLRLSDKADKSGCVVVSGQLTAYLRKHWGLNKNRSENDRHHAV

DATVVACCSRRMVQLIGYWSKHKERQYLKDSQSDPDLESDEELLLKK

SIGSQKLYFPYPWVKFRKELNLRVFSSDIEELKNELSLFESYTEEDISKV

KTLFVSRAIQKIGRGALHADTVRSQTEEMNKEKVAVSRVKLSELSYDR

ISKIVDSDTRNKNLCNALKRRFEAYCKSNNINEISKLKAKDSAKIFTTNN

PMHMPNSNGEEDPLNPVVRTVRVKETFSGVPIRHGIAGNGDIFRVDIFF

KEGKYYLVPIYAIAKELPNRACVAKKHESEWTVIDDTYQWCFSVTQYD

LIKIELKKETYFGYFNGFDRATGAVNIILHDRSTEKYKKGLIRSIGLKTA

KSVTKYRVDVLGNYYLAGAEKRLELA

MG94 effectors
11733
MG94-1 effector
protein
unknown
MRKKIRYVIGLDIGIASVGWAALLLDENDNVCGIVRAGVHTFDEAVVG

QSKITGAAYRRGYRSGRRSIRRKVNRIQRVKNLLQRLNIISKKDLEEYF

SGAVENIYYLRCAAIQNEPAYILNNKELAQLLIYYAKHRGYKSNTSYEQ

KTDDSKKVLSALSENKKYMLEKGYQTAGEMLYRDEKFRRKRYGSSEE

CELLLVRNSGDDYSHSISRELLVEEVHVIFARQRELGNKLTTKELEDQF

VEIMQSQRNYDEGSGEGSPYGGNLIEKMVGECTFEKGEKRACKASYTS

ERFVLLEKLNHLRIQSKNGDVRALTEEERDAIIKLAYKNKDVKYKALR

TILKLNPDERFGGLTYSRGDIENSTEGKSVFVSLEYWYEIKKVLGLFYD

DLDNEETQQLLDSIGTILTCYKSDDLRRRKFEQLHLEQEKIEHLLALNY

TKFQNLSFKAMKNIMPELEKGLSYTEACSNAGYGDKETIEGKNKYISK

ELLNNTLDSIMNPTVKRAVRRTIRILNELIKQYGSPVEVHVEMARDLTH

SQTVTNKMKKRQDENKAEKEEAKRFICENFGKTEAQVSGKDILRYRL

WKSQNQIDIYSNTMIPVSDILDYEKYEVDHIIPYSCSFNDSFNNKMLVRK

KDNQDKKNRTPYEYIGSDEKKWEAFATCANTYVMNYGKRKNMLTKV

PASNTGEWMSRNLNDTRYTTKVVTDLIRKHLKFEAYVDQKRKKHIYPI

NGGITAKLRYEWGLEKDREKSDKHHAQDAVVIACCTDGMIQRLSRQY

MLQEIGIVTWKNHKLVDRRTGEIVEETNLPWECFREEVEMFMADSPE

DYIEKAKKNGYKGEAPKPIFVSRLPQKKTTGKINEDTLRSVRIDSKGKA

RFVNKTKLQDLKLVEVDGKKQIKDYYRPEDDKLLYDKLLERLVKNDD

AKVVFAEPFYKPKKDGSDGPIVRSVKTYGKTVKNQVLVGDGVAERGG

IYRCDVFKRKDEYYAVVVYYRDLYIGNLPNNAAHFDIEMKKGEFEFSL

YKDDLIRFVKDGKEQYAYYKYINANNSQITYTEHDTSKETKCTTIRTLD

KFQKMNVDLLGNIYSSDKEEREWN*

MG16 effectors
11734
MG16-3 effector
protein
unknown
MATKKILGLDLGTNSIGWALIETEDSNPKSILAMGSRIVPLSTDDSTQFA

KGQAITKNADRTQKRTARKGLNRYQMRRAMLTEELRRHGMLPERTD

ENIMDLWRLRSDAATDGKQLSLPQIGRVLYHINQKRGYKHSKADNSA

NTKQTKYVEAVNQRYRDIQACHQTIGQYFYEQLLSSAVQTPSGSYYTY

RIKDKVLPREAYIAEFDQIMKVQRVFYPDVLTDELVDTLRNHIIFYQRP

LKSCKHLVSLCEFEKRPFKREDGQIVYSGPKCAPRTSPLAQFCTVWEA

VNNITLTNRQNETFEITQEQRVAMADFLNQHDKMGVKDLQKILGISPK

DGWWAGKAIGKGLKGNTTFTQLREALGNLPNAEHLLKMKLSMVDAA

VDTTTGELIRQVSPQVEEEPLFRLWHLVYSLQNEDELRKALRKQFGID

DEEVLDKLCKIDFVKPGYANKSHKFIRKLLPYLMEGYQYHEACAHIGV

NHSDSLTAEQNAARPLLDKIPLLEKNELRQPVIEKILNQMINVVNALKA

EYGDIDDVRIELARELKSSKDEREAAFKRNNENERQNKIYENRIREYGI

QPSRSRIQKYKMWEESNHLCFYCGKPVNVTDFLAGAEVEIEHIIPQSVL

FDDSYSNKVCACRACNQAKGNLTAREFMEKHSKEEYDSYLRRVDDAF

NAHRISKTKRDHLLWRKEDIPQDFIDRQLLQSQYIAKKAAEILRQGYR

NVYATSGSVTDFLRHQWGYDEILHRLNLPRYQQVEGLTEDVTYDHCG

QEHQQERIKGWTKRLDHRHHAIDALTIALTQQSVIQRLNTLNNSREQ

MFDELGKRTDTPEYTEKRSLLEKWVDAQPHFSVQEVTDKVDGILVSFR

AGKRAATPAKRAVYQNGKRHIVQTGLQVPRGALSEETVYGKLGNKY

VVKYPLGHQSMKMDDIVDPTIREIVRTRLNAFGGKAKDAFAEPLYSDA

AHQMQIKTVRCYTGLQDKAVVPVRFNAQGEPVGFVKMGNNHHIAIYR

DAKGQYQESVVSFWQAVERKRYGIPVVIEQPHEVWDKLINSDNIPQDF

LETLPHDDWQFVVSLQQNEMFILGMDDADFEAAMEQKDYRTLNKYL

YRVQKISSKEYCFRYHTETSVDDKYDGVINKSISMELQKLKRLTSISAFF

SQHPHKVRVNLLGEVSAL

MG2 effectors
11735
MG2-4 effector
protein
unknown
MNSTRSTPLVLSFDIGYASIGWSVAEVVDPANNLQAGVVTFPSDDVLNS

ERAGHRRARRNIAARRNRVQRLKLASVGAGFVTAEEIETLDRMERKS

APEWRHCPWFLAARVLGESPESTLTGLQLFHVLRWYAHNRGYAPPSW

GLFDEADGEQEEDFEKVRNAEKAMHEFGADTMAQTWCALLDADPTA

GRWPEPRHWAKGENMAFPRERVQAEVTRLLVAHVGKLPGVTSDFVR

CLIDDWEHHPKIRSWLQGADPRTGKLRDYALPKRYEGGLLFGQHIPR

FDNKIIPWCPFTLKEDTNSGKISGRNVPKKHSRAFLDFKVAMRLNDLA

LSELGESGGRLSAGQRMTLFKRIEGYGDVTVRQFADLVAEVCAIPKPD

LTTRIPEREGSDRPFELRPERKALIAILTGGRSLPSWPLIHSIWDCFEDA

EAVLRPVFHGKPTSWADLIEQAKAPDVLLERLEELFRLGKGKPSRSKK

AQPPPDFEVLLRCKITITKAHGRARYCSDKLRAATDEALGGLDPRRAP

TTETSDDAGCLYLNERQRDLQDRLPLSKLINNHLVRHRLLIFRRLLQD

LVNTYANGDRERIDAIVVEVARDLNEYSGKNTKQRVALFQEKQRPFND

AAEAFAQALIDDAQYTPEQAQALATYANVRRFRLMREQNFECPFTGR

HLSAEDIAKDRVDFEHIIPRSLKPTDSLDAMVITYRAVNQAKRNRTAMR

FIKDMAGERLDADDAGWSYHTPQQFETAVNRMRPKGRLNTAAKRSQ

ANRCDALLVEDYEPREADFLQRDLTQTGYLMKYAVGEARKFFRSAPR

QPRFIHLEGRVTTFFKKAWRLTETLAPISPLFLREYADPRTGRWQSTV

RPKAELRRFTQLHHALDALTLGLATALVPGIERKELRRALSLRQAKGD

DATLLRSDPKLGEALRWRTEDRFEAAPLSGKLESAVRRALAEGRVVQ

HVPAKRQGMKVDSNFFGFVEFDETGRLRVRQKMRSPTTRRREIKTTV

KNGKNLHTLSHLSLDPKSWLGAPDHPLRRKQLEHGLRTENDLANPKL

GNIRGMLPIRENWGIALITKDGSPRLDVIPYINVHQWLEVLALENGGGS

PVVLRKGHLVGFDAEKCPEEYCGAWMLLGVKDGRSGTTLELIRPWM

VAPRKGGTKESSAKQAIKPASGYSEKEGKASGVFLQRSADVFLKLGLR

PLDHDLTGIAAF

MG21 effectors
11736
MG21-2 effector
protein
unknown
HNTSGVYDLTVARTFIEEEAHKLFAAQRQFGNAFATENIENEYCEILLS

QRHFSDGPGGERTFKFDLRGNCTFEKDELRAFKACYTFEFFKLLQDIN

HLRIIPEYRKGSNKQTRPLTPEERQKIIDLCLKSSSIDFSKLRKELKLAD

DEIFNRVGYDVKKKKSKKKDAEEQPEEQLTPEQQRTKCEEATKFTQM

QSYHEMRKALDKVAKGTISKFSHDKLDEIGEILSLYKADDKRRERLEQ

IGLSNEEIEALLPLTFTKAGNLSLGAMRKLIPYLEQGLTYDKACEIVYG

DHRAQYKGERMPLLSFGKLKEEGALDSVNNPVVLRAIAQTFKVVNAII

RRYGSPQAIHIELARDMKRNFADRQDIKSKQKDNWSENNRRREKVEEI

KGSVATGQDIVKMKLYEDQNGVCLYSGKQLELHRLFEVGYAEVDHIV

PYSKCFDDSYNNKVLVFSSENQRKGNRLPLEYMLAEGDEDKLDDYVTL

VEANIKNTRKKQRLLKPCLTEQDITDWKARNLTDTQYITKAVADILRN

YLAFEEDSPFIKKPVRSINGAVTDQVRKRLGLQKHREEGDLHHAMDA

AVIAVTTDGYINRISRYTQRREFGKRIGCYKDKQTGEKVEIERQKGQA

PLYIDPETGEKLTEQVFDHKYAPTFPAPWKEFTKELKARMAPNADEAI

RQLYLPSYGSEEIKPIFVSQMPDRKISGQAHAETIRSARIDVDESGKERII

AVAKTPLTSLKLDKDGEIDGYYMPSSDRLLYEELKNRLIKTKTSGKTY

GNAEQAFKEPVYKPKKDGSQGPRVYKVKTWKPTTSNVKVAGGIAKK

GDIVRVDIFHITGGKDQGYYFVPIYVADTIKNTLPKHAVVTNFKSSKVE

WKEMDDSNFIFSLYKGDLIHIELCADCRDKDSNNKIRKAKDMYVYYDG

MG22 effectors
11737
MG22-2 effector
protein
unknown
MKNILGLDLGTNSIGWAWIQSKVPQQTDDCPSSSEYLMPDCATIRMAG

SRVLPMDGKMLSGFESGLAVSKTKERTTYRMARRVNERFQLRRERLN

RVLRILGFLPAHYEACLDRYGKIDEEKNVTIPWVPTADGKRKFLFYAS

FLEMKERFHEHHPNLEKIPLDWTLYYLRTKALQQAITKEELAWVLHS

FNQKRGYNQSRDEVKDEDASQKEEYVKVKVVSVVDSGEKKKGKTSYI

VTTESNLQFTTENAAAPSWLDKEREFIVTTKLNPTGLPKMNQEGRIDC

TVRIPKEEDWELKKKRTEALIADSHMTVGEYIFHSLLDNPDAKIKGAK

VGTIDRHFYKEELIAILKKQAAFHPELKDAERYAECVSALYASNEMHR

NILSAWDMPRLIVNDIIFYQRPLKSKKSDIAECPFESRYFMDKEKKLQK

QGIKCIPTSHPHFQEYRIWQFLSNLRVLRREVRENGRYMTDVDVSAHY

LTDKVKVELYEWLAGKANVKQKELLSKLRMSEKEFRWNYVEDNIYP

CGETRSLLSTRLKKAKLPLSLLDSPSSDGSHTFEFELWHILYSVSDLAEL

RKALRRFARKHDFTAEQQEAFVETFVKCPPFKKDYGAYSDKALVKLL

SLMRIGKYWNADRIDTNTRRRIACLLDGEACDSISLRTREKVAERGLQ

QSIEQFQGLPQSLACYVVYDRHAEASEVVRWESPADLQQFTRQFKQYS

LRNPIVEQVVLETLRVVHDLWEEIQKDGGTIDEIHLEMGRDLKNTAEQ

RARIMRRNRENEMTNFRIKLLLQELHDCQPDIEGIRPYSPSQQELLRLY

EETVWESESGKLGGKEASKDIPDDIKKIRDLLSKPSDKPIPQSAIQRYRL

WLDQKYLSPYTGRPIPLARLFTADYEIEHIIPRSIFFDDSYANKVICESAV

NKLKNNRLGMQFIREMDGRVETVKLGEGRETSILSVDGYVDLVNDLF

RNNPRKRNNLLAEEITEDFCHRQLSDTRYIARYIKGILSNIVRQRAADG

TLEQEATSKNLIVCTGQITDRVKQDWGLNDVWNHIITPRFERLNRMTG

SNDYGEWCCKEGKRYFQTRVPLHLQIGFNKKRIDHRHHAMDAIAIAC

VNRNVVNYLNNAAAHATDRMDLRMRICRPSGNGQTKKEIRSPWKNFA

HDAECALQAITVSFKQNVRIITKATNTYEGYDASGKKVRRCQTSSDHY

SIRKPLHKDTVYGEVVLPVVNQVPLKKALLRVNRIVNGKLRKKIQEM

QSSGLTDKQIVDFFMKTCADSPEWNSINFKKIEVRAYSNEEGQTRMAAI

RTAIDESFSEKVIGSITDVSIQRILLNHLRECNGDSEEAFSPEGIETMNRN

IVRLNGGKPHLPIYKVRLGEAMGKKFAVGQRGNKGKKFVITAKNTNL

FFAVYANDEGKRSFETIDLHCALEMQKQGSSVAPPINENGDKLLFVLSP

NDLVYVPSESELQHDIDSEDLKLDHVFKVVSFSENRCCFVPHSMSSPIAA

GFEFNSPNKIEVVSRLGLFEQDKETVSIKNICLPIKMDRLGHLHLVKI

MG23 effectors
11738
MG23-2 effector
protein
unknown
MSEKIPYYIGLDMGTNSVGWAVTDENYKILRGKGKDMWGVRLFDEA

QTAAERRTNRVSRRRRQREVARIGLVKEYFADALNAVDPGFMVRLEE

SKYWLEDRSEENQQKFALFNDKDFTDKEYYTVYPTIFHLRKELIESTE

QHDVRLVYLAILNLFKRRGHFLNKSLESDGETMSMAEAYAALVDEAA

ALEITLPMPIDAKKLEEVLSQKGVSRKFVEQDTNEFFGFSKKASEAREL

VKLMCGLTGKMRNIYGEELIDDDNKKLALSFRSNDYEEKMNEVAELV

GDENMRLLEAVKEVHDIALLANILSGEQYLSVARVKQYNKHKEDLQQ

LKRVLRTYDKAAYKKMFRVMGKDNYSAYVGSVNYKEHKERRNAGA

GKDGESFRKAVEKVIDALPEEAQLDQDVIEIREKIKNEAFLPKQLTSAN

GIIPNQVHLRELKRILENASGYLPFLNEIDESGLTVKERIAQLYEFQIPY

YVGPLSKQNSKNAWANRRPGEEKGRILPWNFEQKIDVNQAAEDFIKR

MVRHCSYLDAEFTLPKQSLMYEKYMVLNELNNLRINGEKPTVLQKQQ

IYNELFGKGKRITQKALINYLKDEGIVEKDSEPIISGIDGDFKASLSTFG

KLRTVLKEEARKDSSQEMMDQIVFWATVYGDDKRFIRARIEEHYSEIL

DDHAIKQLLGMKFNGWGNLSKAFLEMEGASKEDGVYRSVIQALWET

NDNLMELLGQRYTYKEELEKRVQTKEKPLAEWTIDDLDGMYLSPSVK

RMVWQTLKIIREITEVRGSAPSKIFVEMARDDAQTKAKNKGKRTKSRK

DELLECYKDDKAWKDELTSVDDGELRAKKLYLYYLQMGRCMYSGEA

IDLASLMSGNTMYDIDHIHPRHFVKDDSLENNLVLVKKDKNAHKSDNY

PLESEIRNKQFGFWKSLLDKGLITKTKFTRLIRSEDFSPEELAGFINRQL

VETRQGTKAITKILQQAFPDDDMEVVFTKAGVAAKLRHDFDLVKVRC

VNDTHHAHDAYLNIVAGNVYNAKFTSNPLRFIKNEVKKGNASYHMDKI

FFRDVKRGNKLVWQAPNNEEKTPGTIAIVREQLARRTVLQTRRSYMA

HGILSDATIYSKDTAKTESYRPVKSSDERLSDVKKYGGMTSIKNTAYAL

VEYTVKGKTIRSLEGVPIYLGNCSKDDKKLLQYLQEILQRENKNKQVE

NVSVRMYPIRQRSYLKVDGYYYYLGGATGSSVYLLDAMSVYLSKEDM

GYVKKVEKAVAQQRYDECTKEGEFVLTREKNMDLYNKLVDKFSHGV

FIKRKASILKTLEEGIDVFSELNIEKQCGIIMQIFAWITTSQQNVNLTDIG

GVAHAGTLLISKKLSTSREALLIEQSLTGLWSKTTDLLTV

MG3 effectors
11739
MG3-3 effector
protein
unknown
MSADSLNYRIGVDVGDRSVGLAAIELDDDGFPLKKLAMVTFRHDGGK

DPATGKTPKSRKETAGVARRTMRMRRRKKKRLKDLDKKLRDLGYFV

PRDEEPQTYEAWSSRARLAESRFEDPHERGEHLVRAVRHMARHRGW

RNPWWSFSQLEEASQEPSETFGRILERAQHEWGERVSDNATLGMLGA

LAANNNILLRPRRYEHNPKTGKNAEKLNVRGQEPILLDKVRQEDVLAE

LRRICKVQGIEDQYPELAHAVFTQVRPYVPTERVGKDPLQPMKIRASR

ASLEFQEFRIRDAVANLRIRVGGSERRPLTEEEYDRAVDYLMEYSDTTP

PTWGEVADELEIAENTLIAPVIDDVRLNVAPYDRSSAIVEAKLKRKTQA

RQWWDDDANLDLRSQLILLVSDATDDTARVAENSGLLEVFESWSDEE

KQTLQDLKFDSGRAAYSIDTLNKLNAYMHEHRVGLHEARQNVFGVSD

TWRPPRDRLDEPTGQPTVDRVLTIVRRFILDCERAWGRPQKIVVEHAR

TGLMGPSQRADVLKEIARNRNANERIRQELREGGIEAPNRADIRRNSII

QDQESQCLYCGKEIGVLTAELDHIVPRAGGGSSKRENLAAVCRACNAS

KGSRPFAVWAGPARLERTIQRLRELQAFKTKSKKRTLNAIIRRLKQRE

EDEPIDERSLASTSYAATSIRERLEQHENDDLPDGFAPVAVDVYGGSLT

RESRRAGGIDKSIMLRGQSDKNRFDVRHHAIDAAVMTLLNPSVAVTLE

QRRMLKQENDYSSPRGQHDNGWRDFIGRGEASQSKFLHWKKTAVVL

ADLISEAIEQDTIPVVNPLRLRPQNGSVHKDTVEAVLERTVGDSWTDK

QVSRIVDPNTYIAFLSLLGRKKELDADHQRLVSVSAGVKLLADERVQIF

PEEAASILTPRGVVKIGDSIHHARLYGWKNQRGDIQVGMLRVFGAEFP

WFMRESGVKDILRVPIPQGSQSYRDLAATTRKFIENGQATEFGWITQN

DEIEISAEEYLATDKGDILSDFLGILPEIRWKVTGIEDNRRIRLRPLLLSS

EAIPNMLNGRLLTQEEHDLIALVINKGVRVVVSTFLALPSTKIIRRNNL

GIPRWRGNGHLPTSLDIQRAATQALEGRD

MG3 effectors
11740
MG3-4 effector
protein
unknown
MSTDPKNYRIGVDVGDRSVGLAAIEFDDAGFPIQKLALVTFRHDGGLD

PTKNKTPVSRKKTRGDARRTMRMNRRRKQRLRDLDMMLTNLGYTVP

EGPEPETYEAWTSRALLASIKLANVDELNEHLVRAVRHMARHRGWAN

PWWSIDRLENASREPSETFEIILARARELFGEKVPADPTLGMLGALAAN

NEVLLRPRDGKKKKTGYVRGTPLLVAKVRQEDQLAELRRICEIQGIEG

QYDALRSAIFTHKMAYVPTERVGKDPLNPSKNRTIRASLEFQEFRILDS

VANLRVRTDSRSKRELTEAEYDVAVEFLMSYTANEQPSWADVAEVIGV

PGNRLIAPVLEDVQQKTAPFDRSSAAFEKAMGKKTEARQWWESTDDD

QLRSLFISFLVDATDDTEEAAAEAGLPELYMSWPAEEREVLSDIDFEKG

RVAYSQETLSKLSEYMHEYRVGLHEARKAVFGVDDTWRPPLDKLDEQ

TGQPTVDRVLTILRRFVLDCERQWGRPRAITVEHARTGLVGPAQRQEI

LNEQKKNRENNELIRGDLRKSGVENPSRAEVRRHLIVQEQESQCLYCG

AVIRTDTSELDHIVPRAGGGSSRRENMAAVCHYCNSKKKRTLFYDWA

GPVKLQETVDRVRQLEAFKDSKKAKMFKNQIRRLKQTEADVPIDERSL

ASTSYAAVAVRERLEQHFNEGLAPDDKSRVVLDVYAGAVTRESRRAG

GIDERILLRGERDKNRFDVRHHAIDAAVMTLLNRSVALTLEQRSQLRR

AFYELELDKLDRDQLKPGEDWRNFTGLYEASQNKFSEWKKAATVLGD

LLAEAIEDDAIAVVSPLRLRPQNGSVHDDTINAVKKLTLGSAWPADAV

KRIVDPEIYLAMKDVLGKLKELPEDSARSLELSDGRYIEADDEVLFFPK

KAASILTPRGAAEIGNSIHHARLYSWLTKKGELKFGMLRVYGAEFPWL

MRESGSRDVLHMPIHPGSQSFRGMQDGVRKAVESGEAVEFGWITQDD

ELEFDPEDYIAHGGDDELNRLLRVMPERRWRVDGFYNAGTLRIRPALL

SAEQLPSELQKKVADKTLSDVELILLRAVQRGLFVAISSFLPLESLKVIR

RNNLGFPRWRGNGNLPTSFEVRSSALRALGVEG

MG4 effectors
11741
MG4-2 effector
protein
unknown
MLREPGNSVKSKIMGQQAKRRSYVLGLDIGTHSVGWALLKFRDGRPC

GVERAGVRIFEPGVEEVAFERGRAEPPGQKRRQARALRRQTERRARR

KAKLLHILQRAGLLPKGEADEILPALDRDILARHSAAWPGARDALPYW

LRSGALDHRLEPHEFGRALYHLGQRRGFLSNRRAPMRKNEEDGKVKA

GISTLKEQMEKAGARTLGEFFAGLDPHQERIRQRYTSREMYEQEFEAV

WSAQAAHHPAILTDDLKARVHHAVFHQRPLHNQSYLAGSCTLEPDRK

RTPWACLIAQRFRMLQKLNDTRVLPASGPERPLSDEERQTVLTELDRK

KELKFDRVRKLLGLSADSSFNWESGGEDRLVGNTTNARLAKVFGKRW

WSLSPDDRDQVVEDVRSYEKAEALARRGREHWGLDEKAAGELSKLSL

EDGYCRLSRQAIERLLPGMEKGTAYMELVRKLYPDRWAAGKPVDLLP

ALAETDLDMRNPVVRRCLTELRKVVNAVVRHYGKPSAIRIELARDLRK

SAKQREQTWRRNRRNQQDREAAAEKLLQEARIANPSRADVEKVLLAE

ECGWHCPYTGHGFGMADLFGPHPHFDVEHIVPFSRSLDNSFLNKTICE

ARENRDRKRNHTPYEAYGADAERWDQIIARVQSFRGTASREKLRRFQ

QHEVEDLDGVAQRELNDTRYASLLAVQYVGMLYGGAVDAGHVRRVQ

AAKGGTTGYLRDMYGLGFVLGEGRKERSDHRHHAVDAVAIALTDPA

ALKSISQAASDERRGGRVSFGAVALPWVDFIGDVQAAIEAINVSHRPSR

KVNGALHEETFYGPRGMDGDGRPTGYVQRKPVERLSAKEIPNIPDPAV

REAVQAKLDEVGGTPAQAFKDPANHPVRKRGIPVHKVRLRLNINPVQ

VGSGATERHVLTGSNHHMEIIEVRDAKGGKKWTGRLVHRLEAKRRA

LGRETIVDRAVQAGRQFQFSLSPGDMIELTGEDGERKLHVVRSISEGRI

EYVDARDARKKADIRASGDWRKPAVGSLLRLHCRKVVVTPFGEIRYA

ND

MG44 effectors
11742
MG44-1 effector
protein
unknown
MEKFYLGADIGTNSVGIACTDENYELIRAKGKDCWAVRLFDESKTAET

RRNFRTSRRRLERRKQRISWLQALFAPYINDETFFIRLNNSQFLPEDKD

EILQADKNALFGDEGYTDKNYHVEFPTIYHLREKLIEGGKYDLKLYYL

TIHHIVKYRGHELFEGATMEEIRDIKRLFENLNAVWEATYAENVPHINL

AKSDEAKEILLDTKKGLRDKQIALEKLFGENTALMKESIKAMLGGKIS

PETLFGEEYKDEKSFSFKDMDEEAFDALQSTYGDNFECLNALRSIYNFV

AFEKLLCGHKNISSAMIAVYNKHAADLSLLKSFIRSERPNDYNKIFKSTT

EKANYVNYIGYTKKGGEKKKVAKCKSDDEFFAYMKKYLSSLDDIKDG

ATRDKILGEIENGSFLPKILHSDKGLFPRQVNEAELKAIASNMVKYYPE

TKEIADKIIPLFEYRIPYFVGPLAGVNSWAVRKSGEITPWNIGEKIDLAA

SNEEFMRKMTSKCSYIFGEDVLPKCSIIYQKFDVLNQLNKLRVNDRPLT

VDLKKGIFNELFLKYPKVSDKKIKDYLIRNGHFSPTDGEITLSGKDGEF

KASMSSYIQLKRILGDFVDKDLENGGEVCENIILWHTLNTDKKIVYDLI

EKRYKNIPEIADSVKALKGLSFKNFGRLSKKFLVDLYSADNETGELVNI

LDVLYETNENLNEILNDEKYAFGKLVDEANGVADSKITYEDIEKLYVSP

AVRRGIWQTVTMIDEYVEAIGRTPDKIFVEVTREDGVKGDAGRTQPRK

RQLQEKYKNVSKTYADVISELGDEKYSDMKLRQERLFLYFRQLGKCM

YSGQRIDLDRLDTDTYDVDHILPRTFIKDDSLDNKVLVLRSKNAEKADR

YPLPQGFSDQQDFWKMLLDKNLIAKTTYDRLTRTEPLGDNDYKDFINR

QKVITDQTVKAVAELMKRKYPTAKIVYSKAKNVNDFKNKFDIFKCRET

NDLHHARDAYLNVVVGNVYDTVFSNPLDMFRKDGDMWRTYNLKKLF

TRDVKGAWDCSRIARIKSICGSHTMAVTRYAYCNKGEFYNQTVYGKD

DAGVSSPRKSNGPLSDTKKYGGYKSQTTAYFAIVSSLDKKDNRVKTIEA

VPVLVAYRLKNNPKAVEEYFNSYLKSPEVLIPKIKNKQLVSYNGSLVYI

AGVTGDRISVHNATQLFTDNKMDEYVNGLLKLLDMDAKKMLVGDEP

RYVIKTNRNKEEKLVIDKEKNVELYGYLKNKLCDKIYSGLSAFATFAK

NIENGKEKFIDLTIVEQAKVLIQILMMFKRKDILSDLTLIGGSSHSGKIL

FNKKIDDVNFEIIHLSPAGLRVIKNKV

MG46 effectors
11743
MG46-1 effector
protein
unknown
MKENYYLGLDIGTNSVGYAVTDGGFNLLKYKGEPMWGSHVFEEGKQ

CSDRRMHRTARRRLDRRQQRVHLTQEIFAKAISEVDERFFVRLKESAL

FREDTSGRDTYIFFQDENYTDKEYHRDYPTIHHLIKELMEDTTPHDVRL

VYLAVAWLMAHRGHFLSEVNKDNITELLDFDSIYGNLMELFTTPPWIC

SDKEEFKNILLLHQTIKNKERKFWGLLYEGKKPKTDEEDYINKEGMIR

LLSGGTVEAGKLFNQKEFQEKISISLKKSEEDFQLLLDEMDEEDSEYLI

RLRALYDWALLVDSLHGCSSISEAKVQDYAQHEADLKMLKNFVRKYC

PNEYAAIFKNAEKENYASYVYNIPKGKRTKEYKKKITQEEFCDYLKKK

LKDIQIEEEDQEIYQDMMFRLETYTFMPKQVTGDNRVIPYQLYYDELK

KILENAENYLPFLKKVDEQGISNKTKLLSIFEFRIPYYVGPLCSASKYA

WLKRKAEGKIYPWNFEEKVDLDQSEKAFINRMTNNCSYLPGETVLPQ

NSLLYCKFTVLNEINNIKINGIPISVECKQEIYRLFEENKKVTVDKIKKY

LISNNYMEKEDVLGGIDITIKSSLKPQHDFKRLLHSKILNEKEVEQIIECI

TYSEEKSRVLRRLEREFPKLSDEDRRYLSKLKYSGFGRLSREFFTGIHG

ANKETGESFSIIQALWDTNDNLMQLLSDRYTFKDSIEEEQRQYYEEHP

MTVESLLEEMYVSNAVKRPIYRTLDVIKDIQSVCKAAPKKIYIEMARG

QEEGSNRKRSRKDQILELYKNMDKGEVRELSKQLEDCSDRELRSEVLF

LYFMQLGRSMYSGKPIDIEKLKTNAYDVDHIYPQCRVKDDSLSNKVLV

LSEENRAKGDKYPISAVIRQNMGEMWRVYHEKGLISDEKYRRLTRVS

AFSNAEKMEFINRQLVETRQSTKALTRIFRYIFPETEIVFVKAGLVSDFR

NEVLKCAKSRIVNDLHHAKDAYLNIVAGEVYHARFTSKFFKIDQDEYS

VKTKAIFGNKVWNGKELVWDGEKDIARVKKILTKNSVHYTRYAFERK

GGLFDQQPLRAASGLIERKAGLDTEKYGGYNKSTASYFLLVKYAEAG

KKPKQDVMFVPIDLMESEQIIKSESYAKYYVRNAIAHIIGKSREIVQEVS

FPLGMRKMKVNTLLTLDGFEAILASKSNGGKTLVFGSMMPLFVNNKK

EIYIKRLESFSKKKKQNNFLFVDEVYDKITKEENRELFLFLINKVEEEP

YCLIFGSQLQVLHDKENEFENLNLEQQVETLLNLLSIFKTGRTTGCDL

KLLGGAGQAGIFTESSKLSNWKKSYKDVRIVDISAAGLHRKTSQNLLE

LL

MG6 effectors
11744
MG6-3 effector
protein
unknown
MKKVLGIDLGVASIGWGIIETDEKNENGRILKSGVRIFQGNEQRADAA

PGESSNADRRNKRSVRRQRDRRTRRKINLYVTLKKNGLAPNKSEWDK

WVSINPYTIRAKALDEKVSLHEFGRALYHLNQRRGYKSNRKAGSDKE

GAVKEGISKVRNHMAKHNARTIGEYFHEIYDNHLQNDTEHDDFDWRI

RDKYTHRKMFKEEFDALWDAQSVFHKELTNDLGEVLKKIIFHQRKM

KSQSHLIGKCELETDKKRIAKAHLLFQEFRVLKNINNLSISDENGFPIKL

TEGDRKLFKEIFDKKDKVSWSQLKTALINSGTIGNKNAVFNLERGGRK

NIEGNRTNAALSHKKAFGEKWYELEDDFKKHVVDVLIHVDKPEIVKNL

ALNKWDRTEEQAEYITHKLTLEQRYGGFSEKAIKKLLPYLKKGMEES

SAIKKAGYSLFEQNPGKMNQLPMPDQTIKNPVVYHALIELRKVVNGIIR

EYGMPDVIRVELARDLKAGYERRQKMTKKMRELEKKNDKAYKALQ

KEPFNIQYPGYNDIIWFNLWEECDKTCPYTGKTIPAEAFNSGEFQIEHIL

PFSRSLDNSYANKTLCEADFNRKKGNRTPWECVEAGIMEEDTMLQRIR

NLPWNKRNKFTQKEIDEDKFLNRQLSDTRYISKEASSYLKHLSCERVE

VVKGQTTSLLRHLWGLNGVLNKEGPDMKNRDDHRHHAIDAIVVAFTN

RSTLKRLSDENKRIGTAEWMDADESGRATNDEIKRRLGGRIDLSEPWP

TFRNDVEVSINNITVSHRVNRKVSGALHEETYYGPTDEPAPKNKEMMV

LRKSVHQLSKKDLGLIRDETIRQIVNDEVQKRMDNGESQANAIASLEA

DPPFIISPKAKVPIRKVRLLMKKDPQIMHYFENKNGEEDRAALYGNNH

HIAIYETSDKNGVKKQIGIVIPMMEAARRVKDGDPIVMKDYRPDHTFL

YSLAKNDMIFNHEDEQIYRVQKINSDGTIMFRQNNVAMKGQSDPGVYF

KSGSRLGASKIKISPIGEIFPAND

MG6 effectors
11745
MG6-5 effector
protein
unknown
MDSYTLGLDIGSNSIGWSLIKEDKNPTIIDIGVRVFPEGIDRDTKGAEISK

NKTRRNARSSRRMHQRRSYRKSKLVKISREQGILPQEDKELDKLFLKD

PYELRAKGIDEKISLFEFGRALFHLNQRRGFLSNRKSGKSKEDGVVTKS

ASELQSTIKKTGCRTLGEYLNKLDSTEERRRSYYTFRSMYEEEFEKLW

EKQKEFYPKILNDDLKKVIKDETIFFQRPIRWDRDTIRDCDLEPGEKVC

PRSDWHARRFRILQDINNLEIYNTDGSSDKLSDERRKVLLEELLNKKD

MTFGALRKKYGLFESQTFNLEEGSADKKKAKLKGDEFAAQMRSAKIL

GKKGWEKLNESQRIEINDLIVDDDIEDNELVKILIDKYRFSQTQAEATL

DISLPSKYSSFSKVALQKLLIYMEKGKLVHEAIQAVYGKPQAITNKGEI

MDFLPMPEDLRNPIANRGLFEVRKLVNAIIREYGKPKKINIEMAREVK

GSKRERDEIHLKQYKNERINEEARKTLIDDFKIPNPSRDDIIKYKLWVE

CNKVCPYTGKSISQHQLFGPNPEFQIEHIIPYSRCLDDSYMNKTLCFVD

ENKEKGNETPYEYYSEKIPKQYEQILQRIRTLPYPKRRRFSQQEVKLDN

FIERQLNDTRYISREVVKYLKKLGVIVKGTRGQVTSELRHQWGLNNIL

DLAGEGLKNRDDNRHHSIDAAVTAVIGNEHLRELARTKFRKNNKEFK

QPWPDFREELEEKIKHINVSYRVQRKVSGALHEETSYGPTGRKDEKGQ

DIFVYRKKLEDLTISMVNKIVDLVVRDIVKKRLVERGIDPEKDKKIPKE

VWNEPLYMKTTKSDKKVQIRKVRIQDVFNNMIMLKDKKGKPCRAVA

PGNNHHIEIFEYKDKKGGKKRDGRVITMFDAVQRSQKRESVVKRDYG

DGKEFVCSLATNEMFIMDNVDGNTELYRIQKITQSGNNKTIILRPHTYA

GKLSDSDKPPLIQRKSPNTLKGHKVTVDMLGRFHMAND

MG7 effectors
11746
MG7-1 effector
protein
unknown
MSNKTILGLDLGVSSIGWAIIERNDENGRIVKSGVRVIPSSKSELSVFKD

FDKGKPASFSKERTEKRGIRRSYFRKKLRRAKLIEHLKENNMFDPELL

GPKYSIDVWEWREKATKEKITLAQLGRVLLHINQKRGYKSNRKAIVD

EESDSNWLNAINDNSKLLREKGITVGEYFYQEGKLHERKPKVKFALHF

RMKVRIFNRKDYLDEIEQIWKKQSEFYPELTDELKESIIDHTIFYQRPL

KSAKHLLSECRYEKMHKVIARSNPLFQLFRVLEKVNNLRAEDAFGNNR

EITDEEKLKIIEACTSAQSWKLLDKKKNLSKSKIKSILGLGKDYEINLDS

IEGSKTLHSIWEVLMKSWGEAGDWIDFDWSIQGNDFSKQKSYQLWHA

LYSIDEPQYLRKKLCEGFGFDLDTARLLMNIRLESDYGALSARAIKRIIP

ELLKFPKDATKAIENAGYKFTDSETKEERESRELKDRIEHLKKGALRN

PVVEKVLNQLVTLVNAIYAHPELPNPDEIRVELARELKSGAKERRRAE

LGMARAAKDNDRIRELLQTEFGIPYPGRRDILRYRFWEEQDMRCVYS

GDVIPRNKLFVGEEYELDHIIPRARLENDSNSNLVLVKSSENKDKSDMT

AADYMKSKGEKAFEEYLVRVKNLYDKGAKKKAGERGSGINKGKRNF

LIMKKEEIPQDFIERQLRESQYIVKEAVKLLKEVCRDVTTTTGKITDLL

KHQWGANDVFRNIQVPKYRKWGMTETIVDRKTGEVIERIIDWSKRKD

HRHHALDAIIVACTRQSYIQQLNRLNVLYENDYESLKSYRKFELPWPSF

HNDLISSLESLLVSFRNKRRVATMNKNRIKVGGKKKYIVQKTLTPRDA

FHLETTYGRRLVNNYKLVKLNKKFSMELAELVIDPDLKEKILNRLMEF

GNDPQKAFANLKKNPFKWKNENLEEVLIYDEVFTTRKKLDEKENNPSE

IIDPEVREIVTQRLKEFDNNPKKAFADIENKPVWYNKDKQIRIKTVNTR

AKASDLYPVRTKENGNPKDFVFTRNNHHITVYQKEDGKYYDKVTSFW

EAFELKKAKMPIYKENDDAAKAVLHLKINDMVLVDLNPEDLDQNDPE

FFNTLSEHLYRVQKLASGDVTFRHHLETELSNKNTEVRVTNAESLYNR

VVMYPLDVLGLPK

MG71 effectors
11747
MG71-1 effector
protein
unknown
MDNLILRREKMLVTKIKNTYPQISDDEIKAIKKLKYKDWGRLSATLLN

SSTIAYEDKAFGELVTIISALRHTNKNFMELLSSYCSYDFIGKIKEFNGS

RQSSNGKLTYKDVEELYVSPSAKRSIWQTLTILEEIKKIMGCEPKRIFIE

MARSKEESKRTDSRLKKLQDLYKKCREENIDFMPRKDEFNALKTQLSS

KKEEDLRSDKLYLYYTQMGRCMYTGERIELASLYDNNLYDIDHIYPRS

KTKDDSLSNRVLVKKQVNAAKTDIYPLDAAIRTKMHSFWKLLYDKGFI

DERKYERLTRSTQLRDEELAGFISRQLVETRQSTKAVAAILKTAYQNSE

VVYVKAGNVSDFRQQFKFVKCRDVNDLHHAKDAYLNIVVGNCYHVKF

TANPLNFITKNQDNRRYSLKPEIFYKFSIKRDGEIAWLGGEDGTMATV

ARTMHKNNILFTRQPLEGKGELFKQNPLKAKSGQLPLKAGLSVEKYG

GYDSLTTAYFALVKSEGKQGSVQLSIEGIPLVYAKQGEKAVQDYLTEV

VQLCKPEIKIPKIKKYSLFKINGFPMHISGRTGKQLVFYGAGQLCIADD

VADYLKKALKHETDIAEKEKTLADQNADDIQKQKAQKGLDFYEQKW

GISGAVNVQLYDMFIAKSANNLYKNRPASQTITLKEKREHFVKLTLSK

QIHIIKEILNLFKCASASADFKLIDKGTSCGTLKISNNITKLKECILINQSP

TGVFEQEVDLMKL

MG99 effectors
11748
MG99-1 effector
protein
unknown
Same as SEQ ID 11716 above

MG112 effectors
11749
MG112-3 effector
protein
unknown
MGYNKVVLGLDVGVGSIGWGLVQLDEEKYADEKQDGTVEEKYKITD

GKIIAAGVRRFQLPQDRQKKSLALIRGTARRSRRTIKRRARRLKRLIEL

GKEFNLLGNDFDRDKFLIPKKGDKKEKWDTWRFRKEALERKLTDEEF

FRVLYHIAKHRGAYFQTRAERLELEKDSKAAKDQGEKGEEKQDNEKK

KEREKMKKGLKRIQELLKRSQYKTVGAMFYEMFKNGRKRNAPDKYS

NSIRRELLHDEINEIFKAQRALGNEKADPDLEKQYLRAVLMQEKGPDD

EKMQKMIGRCEIIKELCSQAGKECTADCPDLNRCRCAPKESYTAERFV

LFNRLNSLKIIGGQAIDLAKHRDNIEKLAYTHDKIDFSQIRKELCLTDKP

HLRFNLCSYSEKNPEYEKTLKYEVSNGQLQFGPEHRVQMDNFDTGET

KVFDKEIRAIFQKRLATTPNYKKINVRYSDIRKELQGPQVDLAGFKFTA

LKKEYTKSSAQLESEFFTKPKNKGKNFNGDAAYIKQFEDDAIFVELKG

YHKIRKVLENRDGTWEKLKSDGTRIDTIAEALTYCKKDETRTAYLKER

GITDESVIDAALTLNMEKIATYSKEAMVKLLEHMEKGLLVNDAKARC

GYDKFEHKKQAYLAPYSGFFENNPVVARVIAQTRKVVNAIVRKYGEQ

YPIDQIHIEVATELANSEKTRKRIKDAQDKNKDEKSRARSICEEFGINSD

EGQNLTMVRLLDEQGHFCPYTGKAIVLRSTGAANEVHINDCEIDHIIP

MSRSENDGMNNKILCCAKANQDKRNRIPFEWFEETHGPNSQQWFEFT

RRVEKMYDVPYSKKKNLLRKSWTDEEMKKFMDRNLNDTRYATRHIA

DYLRKYFDFSNRRDDIKDVSRIKLRSGGVTAFLRYLCGLNKNRDENDL

HHATDALITACATDGHVFLVSNLSKQIEEKGKNWYKHFGMEKFKPLR

PWETVREDILEATQKIFVSRMPRHKVTSAAHEDEVWSFDEKKRTKKA

QKKKKSSIPKDTARVMKINNGYAKIGEIVRADVFEDGKHKNYVVPIYA

VDIFSKKPLPDKYLKKNNTPYDEWPSAAADNLTFKFSLFKDDLITINGT

PYYVDFVEGTQANIKVRNINGSKFESTNEKTRKFGYRNIELKKFSVDM

LGNYKEVKEEKRLGNEGVKWTKKRPKK*

MG123 effectors
11750
MG123-1 effector
protein
unknown
MRILGLDLGIASCGWALIDQAKDGEEGRILALGVRCFDAPEDSKDRTP

NNQARRQHRGLRRVLRRRRQRMQELRHLFLAHGLLASAGPDALALP

GIDPWAMRAEALDRALAPCELAVALGHIARHRGFRSNRNQRSNEAED

RTMLAAIAARQERTGHYRTIGEAFARDPEFARRKRNRDGDYGRSILRE

EHEREVRLIFARQRALGSQCATEALEQAFTDIAFFQRPLAASEDRVGPC

PFEPGERRSARFAPSFELFRFLARLTTLRIGTRREERALTAEEIARAEQG

FGTQQGMTFKRLRKLLNLAEAEGFIGISPEDEGRDVVNRSPGNGCMR

GSAALRQAIGEGAWLRLLSTPERLDAIAFVLSFAAAKEFPERLAALGIE

EDVIAAVLAGVEQGMFDHFAGAGHISAKACRKIIPGLRRGLVYSEACQ

EAGYDHARRPETSLSDVANPVARKAIGETLKQVRAIVAEYGLPERIHIE

LARDVGKSAEERAEIARGIEKRNRERDRLRRIFVETVGREPAGSEDML

RFELWLEQAGRCLYTDHCIPPDAIVAADNRVQVDHILPWSRFGDDSFA

NKTLCFATANQEKRGRTPFEWLGADQERWNRFVAVVEGCKGMKGR

KKRIYLLKDAVSSEEKFRTRNLNDTRYAARIVLEHLAHFYPEDGSRRVF

ARPGALTDRLRRGWGLQDLKKKLEPDGEKRHEDDRHHALDALIVAA

TSESALQRLTRAFQEAETRGSHRDFSALTSPWPGFVDQAQEAFKTILVS

RAERGRARGEAHEATIRQVRKDEDGPVVYERKSVEALTEKDLARVKD

PERNAALIESLRAWIAAGKPKASPPLSPKGDPIAKVRLRTDKKPAIEVR

GGVAERGEMVRVDVFRARNRHGRWEFYLVPIYPHQVADKVRWPTPP

DRAVQGNTPEEQWPVMDAGYEFLFSLHQRSFIEVEKRDRTVITGYFM

GLDRHTGSIAISTPHSTKALARGIGARTLMRFEKFRVDRLGRTFAVRQ

ETRTWHGVPCT*

MG124 effectors
11751
MG124-1 effector
protein
unknown
MTLTLGLDIGTNSIGHALVETDEQGNVISLKHIGVRIFSDSRTDKEKKP

LNEARRTARQARRQRERKKSRMKAVLRVLREHGLDPQDSLLESPYAA

RAAALTGPLSRSQVGRAIWHIAKHRGPRLVRKDDKEQGVIKEGIRSLE

TEMLAQKARTYGELLERIRLNGGSVRLRANSEGSYNRYPSRQVMEAEF

NHLWESQVPHHPEVMTEALRERLITAIFYQRPLKPVYPGRCTLEPDEY

RMPKAMPMAHEFRIRSEVANLTLKQGDEVRTLTANERQIVVDGLLNS

EKLTFTAIAKLLGFRAGVKFNLEGDDGDGGKARNYLIGDLTSSKIRSV

WPNFSKMPENMRLSLILALLDIDDELELKCKLRSDFGISPEVVDQLSSL

MLPAGYINLSQKAVRAVLPYLQQGMGYAQACAAAGYHHSDHRPEEL

TPILPFYNELPGMKRYLGQEQKGKPGRISNPTVHVALNQVRKVYNTLV

EVFGVPDCVNIEVTRELKQTAKQKIAANKQNAANKKVRDAFKEKFPE

RANSDQDLVRWRLWNELPEERKVCVYSGKEITLNDLFSPRVEIDHIIPH

SISFDNSPSNLVLCAQGANRLKTNKTPHEAFAPGLHKEFNWSAIEQRVF

ELAADKCGTWAKKKLRFKPDYLDVGGDFATRQLNDTAYLSKVVRIYL

GHSCPKVLAVRGAVTAICRKEWGLDRLLRDTVSDHADLFCLSSVKSTG

VFMAPHHVTGGSHDIREDCSVNKLLKFGAEVVRVDPIGRFQTPGEIRRI

EPRGPKVNFQNLRTTTRKPLTSLTANSISQIKDDGLRTKITAHIKEVNP

KLLTDTLNREAKVELSRLLGEFGQKHSVGRVRIVANKSGVIVRHGAAN

QHTKVLIADTNHHGDVVVRDGKVKMLLTTYAELNHPPEVEAGWTLK

MRLHKGDMIRVPGYVYNKYPKKPNYGKDRSDHRHHAVDAFVIACITP

SLLRKISRSIALSKYNQLHEFPEPYERFKQELKTHLRKLVVSNKLDHSIS

APIFTETNYGFTA*

MG125 effector
11752
MG125-1 effector
protein
unknown
MRPYGIGLDIGISSVGWAAIALDHQDSPCGILDMGARIFDAAENPKDGA

SLAAPRREKRSQRRRLRRHRHRNERIRRMLLKEGLLSEAELTGLFDGA

LEDIYALRTRALDEALTKQEFARVLLHLSQRRGFRSNRRATAAQEDGK

LLDAVSENAKRMADCGYRTVGEMLYRDAVFAKHKRNKGGEYLTTVS

RAMIEDEVKLVFASQRRLGSAFASEALEQGYLDILLSQRSFDEGPGGNS

PYGGAQIERMIGKCTFYPEEPRAARACYSFEYFSLLQKVNHIRLQKDG

ESTPLTSEQRLQLIELAHKTENLDYARIRRALQIPDAYRENTVSYRIESD

PAAAEKKEKFQYLRAYHTMRKAIDGASKGRFALLSQEQRDQIGTVLT

LYKSQERISEKLTEAGIEPCDIAALESVSGFSKTGHISLRACKELIPYLEQ

GMNYNEACAAAGIEFHGHSGTERTVVLHPTPDDLADITSPVVRRAVAQ

TVKVINAVIRRYGSPVFVNIELARELAKDFTERKKLEKDNKTNRAENE

RLMRRIREEYGKMNPTGLDLVKLRLYEEQAGVCPYSQKQMSLQRLFE

PNYAEVDHIIPYSISFDDSRRNKVLVLAEENRNKGNRLPLQYLTGERRD

NFIVWVNSSVRDYRKKQKLLKPTVTDEDKQQFKERNLQDTKTMSRFL

MNYINDHLQFGVSAKERKKRVTAVNGIVTSYLRKRWGITKIRGDGDL

HHAVDALVIACATDGMIRQITRYAQYRECRYMQTDTGSAAIDEATGEV

LRIFPYPWEHFRKELEARLSSDPARAVNALRLPFYLDSGEPLPKPLFVS

RMPRRKVSGAAHKDTVKSPKAMAEGKVIVRRALTDLKLKNGEIENYF

DPGSDRLLYDALKARLAAFGGDGAKAFREPFYKPRHDGTPGPLVKKV

KLCEPTTLNVAVHGGKGVADNDSMVRIDVFRVEGDGYYFVPIYIADTL

KPVLPNKACVAFKPYSEWRTMDDRDFIFSLYPNDLIRVTHKSALKLSR

VSKESTLPESIESKTALLYYVSAGISGAAVSCRNHDNSYEIKSMGIKTLE

KLEKYTVDVLGEYHKVEKERRMPFTGKRS*

MG125 effector
11753
MG125-2 effector
protein
unknown
MLSYAIGLDIGISSVGWATVALDGEDRPSGIIGMGSRIFDAAEQPKTGD

SLAAPRREARSARRRLRRRRHRKERIRALILREGLLNETQLAALFDGQ

LEDIYALRVRALDEAITAEALARIMLHLSQRRGFLSNRKTAASKEDGEL

LAAVSANRARMQAHGYHTVGEMLLKDESYREHRRNKGGAYISTVGR

DMIVEEVRQIFAAQRTFGNVAASEALEANYLEILLSQRSFDAGPGEPSP

YAGSQIENMVGKCTLEPDESRAARATYSFEYFALLEAVNHIRLTGAGV

SAPLTAEQRERLIALAHKTADLSYAKIRKELNIPAEQRFNAVSYGKSDS

PDEAEKKTKLKQLKAYHQMRGAFEKASKGSFVLLTKEQRNAIGQTLS

IYKTGDNIRRSLRDAGLSEEQIAIVEGLSFSGFGHLSVKACDKLIPCLEQ

GMNYNDACAAAGYAFRAHEGQEKKKLLPPLNAEAKDTITSPVVLRAV

SQTIKVVNAIIRERGGSPTFINIELAREMAKDFSERTQIKHEHDENRKQN

ERLMERIKNEYGKSAPTGLDLVKLKLYEEQAGVCAYSLRQMSLEHLF

DPNYAEIDHIIPYSISFDDGYKNKVLVLAKENRDKGNRLPLEYLNGKRR

EDFIVWVNSAVRDWKKKQRLLKEHITQEDEAKFKERNLQDTKTASRF

LLNYIADNLAFAPFQTERKKHVTAVNGSVTAYLRKRWGITKTRANGD

LHHAVDALVIACTTDGLIQKVSRYAQYQENRYSADGGLVVDLHTGEV

VAQFPEPWAHFRQELDARLSDDPARAVRGLGLAHYATGEIRPRPLFVS

RMPRRKITGAAHKETIKSPRALDEGLLITKTPLDALKLDKDSEIAGYYK

PESDRLLYEALKERLRQFGGDGKKAFAEPFRKPKHDGTPGPLVTKVK

LCEPTTLSVAVHGGLGAANNDSMVRIDVFHVEGDGYYFVPIYIADTLK

PELPNKACVAGKKPSEWKRMNPNDFVFSLFPNDLIYVSHRKGICLSLV

NKESTLPASREEKCTFLYLVKGKSSTASLECRNHDNTYHIKSLGIKTLE

KIEKYTVDVLGEVHKIEKEPRMPFTNMEG*

MG125 effector
11754
MG125-3 effector
protein
unknown
MYPYAIGFDIGITSVGWAVVALDGEDKPFGIINMGSRIFDAAEQSKTGA

SLAAPRREARSMRRRLRRHRHRLERIRHLLVAENVISQAELDALFEGK

LEDIYTLRVKALDTAVSHADFARILLHIAQRRGFKSNRKSSTSKEDGEL

LAAVSANRALMAEKGYRTVGEMLLKDPQYSGSKRNKGGKYLATVGR

DMVEEEVRAIFKAQREQGQAFAATELEEQYLEILLSQRSFDEGPGEGS

PYRGSQIEKMIGKCTLEAGEPRAAKASYSFEYFTLLQNINHLRLICGGE

SRPLSDAQREFLIALAHKTKDLNFSRIRKELDIPADTTFNAVSYKSADGY

EDAEKKAKFCYLKAYHQMKAAFNKLSKGHFDSLARQQKNELGRVLS

TYKTSANIRPRLAAAGLSEMEIDIAETMSFSKFGHISVKACDKLIPFLEK

GLKYNDACAAAGYDFKGYDSETRTRLLHPTEDDFADVTSPVVRRAISQ

TAKVLNAIIRERGNSPTFINIELAREMARDFTERSKMKKDMDENHARN

ERIMERIRTEYGKEHPTGQDLVKFKLWEEQHGECAYSQKHLSLKHLF

DPDYAEVDHIIPYSISFDDGYKNKVLVLAEENRNKGNRLPLLYLQGERR

ADFIVWVENSIHDYRKKQRLLKETITAEDEKGFKERNLQDTKTMSRFL

LNYISDHLEFSDFSTGRKKHVTAVNGAITSYLRKRWGIAKIRENGDLH

HAVDALVVVCTTDGMIQQLSRYSTLRECEYVQTEAGSIAVSMHTGEVL

KRFPYPWPEFRRELEARLGDDPRRAVISQRFPVYANGDIPVRKLFVSR

MPRRKVTGAAHKETIKSPKALNDGIVVVKRALTDLKLDPKTGEISNYY

MPQSDRLLYEALKEALKKHGGDAAKAFAAPFHKPKSDGTPGPVVNKV

KLCEPTTLNVAVLNGAGVADNDSMVRIDVFRVENDGYYFVPIYIADTL

KAELPNKACTRGKPYAEWREMDAEDFLFSLYPNDLIRVTSQKGLTLSK

AQKESTLPDTYETKQEMLYYTSASINTAAVACRTHDNSYEIKSMGIKTL

EKLEKFTVDVLGEYHKVEKEPRMAFCRK*

MG125 effector
11755
MG125-4 effector
protein
unknown
MRSYAIGLDIGITSVGWATLALDGNENPCGIIGMGARIFDAAEQPKTGE

SLAAPRRAARSSRRRLRRHRHRNERIKNLMVSKGVLSSDELETLFDGR

LEDIYALRVKALDGKVSRSEFARILLHLSQRRGFRSNRKNPSSKEDGAL

LKAVSENAERMEKHGYRTVGEMLLCDEAFKQHKRNKGGNYLTTVTR

DMVADEARAIFAAQRSFGSEYASEEFENEYLEILLSQRSFDEGPGGNSP

YGGSQIERMIGRCTFFPEERRAARATYSFEYFSLLQKVNHIRIVINGAA

ERLTAEQRNTVIELAHTTKDLSYAKIRKALKLSDGQLFNIRYSDKASAE

DTEKKEKLGVMKAYHQMRSAFEKQSKGRFDFVTTPQRNDIGTALSLY

KTSDKIREYLKDSGFDEIDMDAVESIGSFSKFGHISVKACDMLIPFLERG

MNYNEACAAAGLNFKAHDTGEKTRFLHPTEDDYEDITSPVVRRAISQT

VKVINAIIRKEGGSPTFINIELAREMAKDFTERNKLKKENDENRAKNEK

LLERIRTEYGKSDPSGLDLVKLRLYEEQGGVCMYSLRQMSLEKLFSPN

YAEVDHIVPYSKSFDDSRKNKVLVLTEENRNKGNRLPLQYLTGQRRDD

FIVWVNNNVRDYRKRRLLLKETLTDEDELGFKERNLQDTKTMSRFLL

NYISDNLEFAESTCGRKKKVTAVNGAVTAYMRKRWGITKIREDGDLH

HAVDAVVIACTTDGMIQRVSKYARLRECRYMPTEEGSLVIDDGTGEVL

HQFPYPWRDFRKELEARIGTDPARTINDLRLPFYMSSGMPLPEPIFVSR

MPKRKVTGAAHKDTVKSPKELDKGCVVVKRPLTDLKLKDGKIENYY

NPQSDRLLYDALKKALIEHGGDANKAFAGEFHKPKSDGTPGPIVSKVK

LLEPTTLNVPVHGGAGVADNDSMVRVDVFLTKGKYNLVPIYVADTLK

PELPNKAIAAHKPYSEWPEMSDDDFIFSLYPNDLVCVTHKKGIKLTVTN

KNSTLPPTVEGKSFMLYYISTNISGGSIKGITHDNTYEIGGLGAKTLEKL

EKYTVDVLGEYHKVGKEVRQPFNIKRR*

MG125 effector
11756
MG125-5 effector
protein
unknown
MRPYAIGLDIGITSVGWAALALDADENPCGIIDLGSRIFYAAEHPQTGE

SLAAPRREARGSRRRLRRHRHRNERIRSLMLEERLISQDELETLFDGRL

EDIYALRVKALDEIVSRTDFARILLHISQRRGFKSNRKNPTTKEDGILLA

AVNENKQRMSEHGYRTVGEMFLLDETFKDHKRNKGGNYITTVARDM

VADEVRAIFSAQRELGASFASEEFEERYLEILLSQRSFDEGPGGNSPYGG

SQIERMVGRCTFFPDEPRAAKATYSFEYFTLLQKVNHIRIVENGVSSKL

TDEQRRIIIELAHTTKDVSYTKIRKALKLSDKQLFNIRYTDNLPAEDSEK

KEKLGLMKAYHQMRSAIDRISKGRFAMMPRAQRNAIGTALSLYKTSD

KIRKYLTDAGLDEIDINSADSIGSFSRFGHISVKACDMLIPFLEQGMNYN

EACAAAGLNFKGHDAGEKSKLLHPKEEDYEDITSPVVRRAIAQTIKVIN

AIIRKEGSSPTFINIELAREMAKDFRERNRIKKENDDNRAKNERLLERIR

TEYGKNNPTGLDLVKLRLYEEQSGVCMYSLKQMSLEKLFEPNYAEVD

HIVPYSISFDDSRKNKVLVLTEENRNKGNRLPLQYLKGRRREDFIVWV

NNNVKDYRKRRLLLKEELTAEDESGFKERNLQDTKTMSRFLLNYIADN

LEFAESTRGRKKKVTAVNGAVTAYMRKRWGITKIREDGDCHHAVDA

VVIACTTDAMIRQVSRYARFRECEYMQTESGSVAVDTGTGEVLRTFPY

PWPDFRKELEARLANDPAKVINDLHLPFYMSAGRPLPEPVFVSRMPRR

KVTGAAHKDTIKSARELDNGYLIVKRPLTNLKLKNGEIENYYNPQSDK

CLYDALKNALIEHGGDAKKAFADEFRKPKSDGTPGPIVNKVKLLESAT

MCVPVHGGKGAAYNDSMVRVDVFLSGGKYYLVPIYVADTLKPELPNK

AVTRGKKYSEWLEMADENFIFSLYPNDLICATSKNGITLSVCRKDSTLP

PTVENKSFMLYYRGTDISTGSISCITHDNAYKLRGLGVKTLEKLEKYTV

DVLGEYHKVGKEVRQPFNIKRRKACPSEML*

MG3 effector
11757
MG3-18 effector
protein
unknown
MSTDMKNYRIGVDVGDRSVGLAAIEFDDDGLPIQKLALVTFRHDGGLD

PTKNKTPMSRKETRGIARRTMRMNRERKRRLRNLDNVLENLGYSVPE

GPEPETYEAWTSRALLASIKLASADELNEHLVRAVRHMARHRGWANP

WWSLDQLEKASQEPSETFEIILARARELFGEKVPANPTLGMLGALAAN

NEVLLRPRDEKKRKTGYVRGTPLMFAQVRQGDQLAELRRICEVQGIE

DQYEALRLGVFDHKHPYVPKERVGKDPLNPSTNRTIRASLEFQEFRILD

SVANLRVRIGSRAKRELTEAEYDAAVEFLMDYADKEQPSWADVAEKIG

VPGNRLVAPVLEDVQQKTAPYDRSSAAFEKAMGKKTEARQWWESTD

DDQLRSLLIAFLVDATNDTEEAAAEAGLSELYKSWPAEEREALSNIDFE

KGRVAYSQETLSKLSEYMHEYRVGLHEARKAVFGVDDTWRPPLDKLE

EPTGQPAVDRVLTILRRFVLDCERQWGRPRAITVEHTRTGLMGPTQR

QKILNEQKKNRADNERIRDELRESGVDNPSRAEVRRHLIVQEQECQCL

YCGTMITTTTSELDHIVPRAGGGSSRRENLAAVCRACNAKKKRELFYA

WAGPVKSQETIERVRQLKAFKDSKKAKMFKNQIRRLNQTEADEPIDER

SLASTSYAAVAVRERLEQHFNEGLALDDKSRVVLDVYAGAVTRESRRA

GGIDERILLRGERDKNRFDVRHHAVDAAVMTLLNRSVALTLEQRSQLR

RTFYEQGLDKLDRDQLHPGEDWRNFTGLYPASQKKFLEWKDAATAL

GNVLAEAIEDDSIAVVSPLRLRPQNGSVHDETIDPVKKQTLGSDWPADA

VKRIVDPEIYLAMKDALGKLKELPEDSARSLELPDGRFVEADDEVLFFP

ENAASILTPRGVAEIGGSIHHARLYGWLTKKGELKVGMLRVYGAEFP

WLMRESGSRNVLSMPIHRGSQSFRDMQDTTRKAVESGEAVEFAWITQ

NDELEFDPDDYIAHGGKDELRQFLGFMPECRWRVDGFKKNYQIRIRPA

MLSREQLPSDIQRRLESKTLTKNESLLLKALDTGLVVAIGGLLPLETLK

VIRRNNLGFPRWRGNGNLPTSFEVRSSALRALGVEG

MG3 effector
11758
MG3-89 effector
protein
unknown
MSAPLNYRLGFDVGERSVGFAAVEYDDQGYPLKFLAIGSYLHDGGMD

PTTNKNPKSRKETRGVARRTMRMRRQKIKRLKKTDKVLRELGYQVS

HYTDEPQTYEAWYSRRLLATQKLSSEELNDHMVRAVRHMARHRGWR

NPWWSLTQLESASAEPSETFVQMFEKAQERWADELILPIEETTLGMLG

ALSDDNKVLLRPRTYDSKKEKHKEKLNVKGEEPVFFAKVRQEDILREL

RIICVRQGVESQYEELRKALFDQIRPHVPQENVGRDPLDPSQYRALRAS

LEFQRYRILDALANLGVREGRGKPRSLTGEERTQAWKFLSTYRDQKN

APTWGDVAEAMGVEPALLVAPVIDEVRLNKAPYFSSLVAVEKKLKKK

HQIYKWWVEASVESRGLLIRVLADATNATLDEASEAGLLELIEGLPEE

EREVLDGLSFETGRAAYSADTLTKLADYMEEHLAEGIGVHEARKAVF

GVDDSWQPPKATLEEATGQPTVDRVLTIVRRVVLSAQRQWGDPAEIM

VEYARTGLMGPAQLAEVKREIAKNRKERDRIRQDLKDGGVSEPKKRH

IMAHRIVQDQNCQCMYCGAMITAASCELDHIVPRAAGGSSRRENLAG

VCRDCNASKGGRMFADWAADNPRGVSLKDTLGRLRSWEPFKKADKK

RLLKLIERRLKQSVMSPEQIDERSLAPTAYAATAIRERLRRHFEDDAKP

IPRKDVVKAYAGGLTRESRRAGLIDEKLLLRGSRDKSRLDVRHHAIDA

AVLTMLNVPVARTLEERRLMKRERDLSARDNDWRDYTGTAEDKPKF

VQWKQAAGEMADLLIDAVDQDSIAVINPLRLRPQNGAVHDDTIRPLEE

RALGAEWDPATIKRVVDPSIYLALVDALGKSKSLPADSQRELVLDDGT

LMSADDSIALFSTNAASILTPRGAAEIGGSVHHVRLYAWRDRKGEIEVG

MQRVFGAEFPWLMRESGVKDVFKVPVHRGSQSYRDLQDGVRKQIESG

AAVEIGWITQGDEIQLNLDEVRDSMRSKELLTFLEIFPETRWRVDGLPD

NRRLRMRPVLLASEGIEEFLKNAPEDIQTIVVNFFKNGALLSVSKVLAL

TETKIIRYNHLGFPRWRGVGRPVSLDIQRAAREALEGKK

MG3 effector
11759
MG3-90 effector
protein
unknown
MSQEATKYRIGIDVGDRSVGLAAFEFDDAGFPLRKLAMVTYRHDGGL

DPTQNKSPKSRKETAGVARRVRRLRKRRKERLKKLDLKLLELGYPLP

EGEEAQTYQAWKSRALLTSQKIEDKAEQAEHLVRALRHMARHRGWR

NPWWQFGQLDSAPVPSETMVENLNHARLLWPGYITDQTTVGELGALA

ASPDILLRPRTRDIKKKPNGLHHQEGVRAVLGSKVRQEDLLAEVKKIW

QVQELPVSHYEELARALFEQVRPYVPAQNVGRDPLPGRHHLPRAPRAS

LEFTEFRIRQAVANLRVREGREKVPLTSGQHIAAVNYLMNYADKQPPT

WGDVAEQIGVEPTRLVAPVIDDVRLNKAPYNHSTSVFTRALPKKSEAM

QWWNSADVSLRSLLIIFLSDPTEEATAAADESGLSAIFESWPEKEREKL

EGLDFESGRAAYSIQSLIDLNQYMEEHQSDLHTARKEVFGVDDSWQPP

RENLHEPTGQPAVDRVLTIVRRFVMACERKWGKPDRIVIEHARTALM

GPTQRHEVLREIQRNRDANERIREELRADGLTSPTRADVRRHRVVQNQ

DCKCLYCGTMITTATAELDHIVPRAGGGSSKIDNLVAVCRGCNADKGR

IPFAVWAEQTSREGVSLDDALNRLWSFDKVVYKGVAGRKLKAQIARR

LRQAEEDEPIDERSLESTAYSAVAIRHRLETYFNTSRGLNRGDDGFTFID

VYAGALTREARRAGGIDEQILLRGQRDKNRFDVRHHAVDAAVMTVLD

HSVARTLAQRNLIYREDRLKRRENQDDTRWREFTGLGGEAQEKFLVW

KQKSYVLADLLAEAIAEDSIPVINPLRLTPRNGSVHKDTLSSLDKMYLG

GSWSSKDIARVVDPDIYLALMELLGRATTLDEDPQRSLTVKGKVLQAD

QEIKLFPESAASILAGTGAVKIGDSLHHARLYAWPTKKGHEIGMLRVF

GAEFPWLFKTYGTKNALTVPIHPGSQSYRDMKDTLRKKIESGEAREIG

WITQGDEIEIKIESYLQENDELGRFINLIPENRWKIDGENDNGRLRLRPI

LLSYEEIPESYGEDVLGAKNHQLIRKVLERGAIITAGKILGAEGTKVLR

RNHLGAPVWQGQQEARSLDISRAITEKLEG

MG3 effector
11760
MG3-91 effector
protein
unknown
MSMISTNDDRVEGMHMARYGERKYRVGIDVGDRSVGLAFIEFDEQDM

PSELLRMFTVRHDGGIDPTTNKTPKSRKETAGVARRVRKMRKRRTKR

LQELDALLMASGFPIVDVSVGETYECWQARAAAVEGFITDEQTRLETV

SRAIRHMARHRGWRNPWLTWQGFRELEVPTANHRKNIESANSKLHLD

LEDTSTLGQIAASASASNWMLRPRNGQKRKEASNPVLVAQVQQADQL

AELYKILEVQRIDSTITEKIARAVFDQVRPYVPKGNIGLDELPGMGAYY

RASKASLAFQEFRVRAAVANLRVKNSPRGQERLRLDPQDAQAVAEYL

LTWREDQPPQWGDVANALSIDENLLVIPVFEDAFLKLAPYDRTSSDLE

QRLSSSANKKKLAGVREWWDSADTQMRELFIEFITSPNESVYEEADES

GFSDVFNGWSDEAKEVLLGMQFESGRSAYSVESLRRLNLRLRTGEVDL

HEARRLEFGVDDTWRPSLPSIDERTGQPAVDRVLTIVRRAIMGAVDKW

GVPEAVVVEHARSGFMGASARNDYLNEVSRRTATRAKLREIVKQQGV

ERPSDGDIHKWECINRQRCTCAYCGNEITFTTAEMDHIVPRAGGGSNV

RENLVAVCRRCNSEKRNIPFAIFAESDAHPYTSLNETLTRVRNWDWSR

DRSEQRLKNRMLQRLKRRESDPEIDERSLASTAYAAVEVRQRIAEYLG

RITGEDELNRVQVYTGGATREARRAGKIDARIRIRGKDEKDRFDVRHH

AIDAAVMATLNHSVAFTLRERAEMKRSATMNRYLDPNEEWKDYSGRT

SSAQKRFTVWRQQAHRLADLIVDAVEADSVPVAQQLRLSASRGSVHK

DTVSALVRKQLGAPWTAQEILQIVDPEIYVHLRDLAAQNKGVLELDPS

RRIQLLSGVWISGSELVEVFPKAAASMKVSSGSVEIGEQIHHARVYAW

RGTKGEFQYGILRVFTAELPWLQRQAQSKDLFTMNIDDRSMSYRDLL

QTVRKKIESDEARCIGWLTQNDELVLNVEVLRQGSDKIAHFLSTYPESR

WKLDGFPENRRFRIRPLYLSREGSDHLDPICAEILEKGAIVGTSNLLSNV

HQIIRRDSLGFERWRSQGGLPASWSVPDSTADTVETGLK

MG3 effector
11761
MG3-92 effector
protein
unknown
MAQRRYRVGIDVGDRSVGAALVAFDDDGIPERVLHAVSYRHDGGIDPT

TNKTPQSRKHTAGVARRVRRMRARRTKRLAALDRALIELGLPVRDVS

DGETYEPWRMRARCVEGFIEDDAERRDAVSRALRHIARHRGWRNPW

HSVRRERLESVPTATHQKNVAAAQAVFPGEIAADATVGQLGEVASRFN

HMIRPRTGKKNPKQKTAVLNERVMQADQMAEVVAIWTTQRMPEAEL

NAVLELVFGQERPVVKAENIGRDELPGMGHLPRAPKASFEFQEFRIRA

TAATIGVRARQGSSKAERLDADAVDAVSHWLLEWDADDDPTWADVA

VEALNLDPRFIKAPVFDDVRRMTAPVNRTARILRKALKKRHNAPVRT

WWESASAESRAALVAFLVDPTDENEDLLDRTGLSDVVAAWPEEVLDD

LTNLNYEVGRAAYSRESLSKMNTIMAEQRVGLHDARKIAFGVDDTWA

PALPQLSEPTGQPTVDRVLPIVRRIVMAAYERYGVPEAVYIEHARSALL

GPAARAEHQREVNANRREREKNRQILIEQGIDDPNRSDIRRWHQVQLQ

NCLCLYCGQTISAAAGGAELDHVVPRAGGGSNRRENLVAVCRQCNSE

KGKLPFAVFAARTQREGVSVEAALERVRGFQWRPADRAVKRGLVHR

LKQTAADDPIDERSLESTAYSAVEVRRRLERFYSDHASPEAPRPEIFVFG

GSITSEARKAGGIDAIIRLRGKDVKDRFDARHHAVDAAVMTLVDRSVA

RTLQQRSDMRYAHRLTGSEPAWREHAGDSAAAQSRFAEWKKKSYRL

AELLREAISADAIPVIFPLRLGVNRGSVHKDTVRAAVPKRLGDAWSAAE

LDAVVSPAAHMALSSVFDGAAELPHDDGRMLTVRKRRLHADDTISLLP

GHAAAIEVNGGVVEIGESIHHARLVAWRDRKGVIQFGMVRVFTAEIPF

MQRLAGKKDVFSIPVHPSTLSYRGVQLRVRKALDAGIAVELGWITQGD

EIEIGLDDVASMTPEFRQFIAEIPEQRWRVDGFKDGGRLRVRPALLSAE

GDAAVSDLVSKTLDKGSFVNAAGFIGAPSSVVIRRSALGVPRWRSAQG

HLPVSFSPYQRAENLL*

MG3 effector
11762
MG3-93 effector
protein
unknown
MNEGVIQYRIGIDVGQNGVGLAAIAFEAGNPSEVLAMVTHRHDAGLDP

AAAKQGYSRKKTSGVARRTRRLRRNRARRLKKLDEILTSLGLEVPAH

EVPQTWEAWEARAELQEFPIDNEQELHEKLVLAVRHMARHRGWKNP

WWSWNTLWEAPTPTSNMNEIRDNARKVFADLPPTATIGQIGFVAAAT

NRLLRPRKDTTKAKTKRPTPVLNAKVMQEDQLAELRSYWDKQNLPD

EWLEKIAKAVFYQTRPKVKPELVGHDDLPGMTKLPRASRSSLEFQEFR

IRAAIANLKVKVPGSRQENFLSVGDKNRIVDLLMGWDDDEAPTWADV

AEELNISVRDLKRPEFDDSPLRVAPYDRSSNAIRNKLVSLRKDGKEALE

WWDTADRDQRSLFATWLGDQSQHDDAFLETSGLSDIIASWSEGVMEK

IDSLSLEPGRAAYSIESLKILNRHLAEGDNLHEARKHGFNVDDSWTPSL

PRFEDRTGQPVVDRVIRIVHRFINGCVYKWGVPESIVIEHVRSGLLGPE

ALLDYKRETTRHRNEREQIARDLKDQGISERPSSGDITRMRIVQEQQG

VCLYCGTAINIHCELDHIVPRAGGGSNFRENLAAVCRECNRLKGKTPF

ARWARETSQEGVSLEGALDRVKNFSVNGSTADLRNLKRRVSQRLRQT

DEDQPIDERSMASTAYAALEVRDRVREFTSRFTDTDIPVEVYRGSITSAA

RKAGHIDKLILLRDKDIKDRGDFRHHAIDAAVMTVINRSNSQVFAIREA

MRSAHAMTGSEPNWKDFRGNSPRQEEKFIEFETRAAHLARIIRERIDA

DRIPVISPLRLKPETGKVHADTIVPFDYKALESEWTDKDIVRVVDNELY

LALVDALGGKKVLPTDKISVIDQDLAKDHRQVALYGTPSPQIPVRGGS

AAISDSLHHFRVYAWKDKKGAIQFGQQRVFGAEFRAMWGDPRQVDV

FTAPVPRWAFAHREMPPKVKAAIEAGNAKQIGWYTRNDEIELDLSEL

MAQSNVLGEFLRELPEKSWRIRGSHSLSRLSLSPLYLSSEGTDLSEQSRP

VQDAVSKGIPVSASSILDSESMIIRRGPLGIPKWNGGNATSYSFRQVAEE

VLGTD

MG3 effector
11763
MG3-95 effector
protein
unknown
MTNHSPAGSISSTDWVLGVDLGQRSVGLAAVALDPDGTPTEILASNVV

RIDGGLLPGSEESPVSRKAAAGMARRVRRLHRRRRARLKALDRRLMD

LGFPVDDGPETYESWLDRARLVEGRIANETERKRATSRAVRHIARHRG

WRNPWLSWSAFAELSTPSDNHRRNLAAAAERFDRETEGWTVGQLGA

AGTDPRITIRPRTAKDSRRIVHGEAALLEHRVLQEDQLAELRQIWTTQ

EWDPAELPELEKAVFTQAEPFVPPGNVGRDALPGMQTHPRAPRASLEF

QRFRIQSVVGNLRVPVTERSGDLRPLTPEERERVTGLLERWHEREGHV

PGERPTWRDVAEAVGVSLRNLRGRDTSDYATATPPTMETLDRLKAGI

AALKPAAVRRDVAAWFDEAEDDQISAFVSYLADSTDASNEALDEAGLT

DIITGWDEAALEKLGDLPLEPGRAAYSLESLNRLTGRMQADAVDLQEA

RKREFGVDDSWTPPTPSIETPTGMPAVDRNLVAVRRFVMSMVSQFGM

PQLVVIEHVRESFLGVTAVEELRRQQRLDRRRRETAAKEVAAASGKEP

RAADVRRYSLIQRQNGQCAYCGTAIGLRNSELDHIVPRAVGGASTRAN

LLAVCRACNNLKGKQPFAVWAAADTRTDEDGEKLVSVEAALARTRS

WMAPRPSIRERNELREIRQRLRQRESDEPIDERSMESTAYAATALVERV

QNYLESQTPEGVQTPPVRVYRGSITASARKSSGVDKVIRLRGKSMKHR

GDFRHHAIDAAVCALITPSVARTLAIRESLRTAHRFTGDEHDWKSFTG

DSPQARAEHTAWTARMQTLAKLLRDAVDADQVPVSIPLRLGRRVGRV

HEDKVRPFDSRPLGGTWSAKELERIVDRRLYTALHHVAASATSGVEVT

PELCTELGSSMGATVKLYGSPAAQIPVRGGSARLGAIHHARLYAWRGT

RGIEFGMMRVFAGELTAMWPSPATDVLTAPVPEWSMSYRRTAPAVM

QQLRSDTAVQVGWIAPGDEIVVLPPREGARASSLDSLVSSVGEDRWTV

TGFERATTINVAPRLLSAEGISEETPKAVTSVLNRPGRLAASSLLPRIRVI

RRDALGRERRRGGGRLPSSFVPFEVAEQRLQGD

MG3 effector
11764
MG3-96 effector
protein
unknown
MSTDMKNYRIGVDVGDRSVGLAAIEFDDAGFPIQKLALVTFRHDGGLD

PTDNPKSRKETRGEARRRMRMTRRRKQRLCDLDKVLENLGYTVPEGP

EPETYEAWTSRALLASIKLASADELNEHLVRAVRHMARHRGWANPW

WSLDQLERASQEPSETFEIILARARELFGEKVPANPTLGMLGALAANN

EVLLRPRAEKKKKTGYVRGTPLLAAQVRQIDQVAELRRICEVQDIEEQ

YETLRNAIFAHKVAYVPTERVGKDPLAPSKNRTIRASLEFQEFRILDSV

ANLRVRTDSRAKRELTEGEYDAAVEFLMGYTAKEQPSWADVAEEIGV

PGNRLIAPVLEDVQQKTAPFDRSSAAFEKAMSKKTEARQWWESNDDD

QLRSLFIMFLADATNDTEEAAAVAGLPELYMSWPAEEREALSNIDFEK

GRVAYSHETLSKLSEYMHEYRVGLHEARKAVFGVDDTWRPPLAKLEE

PTSQPTVDRVLTILRRFVLDCERQWGRPQAITVEHARIGLMGPVQRQK

ILNEQKKNRGENERIRNELRESGVENPNRAEVRRHLIVQEQECQCLYC

GTMITTTTSELDHIVPRAGGGSSRRENLAAVCRYCNGKKNRKLFYEW

AGPVKMQETIDRVRQLRAFKDSKKAKMFKNQIRRLKQTEADEPIDERS

LASTSYAAVAVRERLEQHFNEGLTLDDKSRVVLDVYAGAVTRESRRAG

GIDERILLRGERDKNRFDVRHHAVDAAVMTLLNRSVALTLEQRSQLRR

AFYEQGLDKLDRDQLKPEEDWRDFIGLYPASKEKFLEWKKTATVLGD

VLAEAIEEDSIAVVSPLRLRPQNGSVHKETIAAVKKQTLGSSWSADAVK

RIVDPEIYLAMKDALGKLKELPEDSARSLELSDGRYIEADDEVLFFPEN

AASILTPRGVAEIGGSIHHARLYSWLTKKGDLKVNVLRVYGAEFPWL

MRESGSSDVLRMPIHPGSQSFRDVQEETIEMIEGGFAKEIAWITQNDEL

EFDPVEYINLPGRSDKLTRFLIYMPETRWRVDGFPESRNLRIRPLMLSQ

EDLPSEIKKHKEEKQLSDEEKLLVEALEKGLIITSSKLLGLKSIKVIRRN

NLGFPRWRGNGNLPTSFEVRSSALRALGVEG

MG3 effector
11765
MG3-103 effector
protein
unknown
MSADSLNYRIGVDVGDRSVGLAAIEFDDDGFPIKKLAMVTFRHDGGM

DPATGKTPKSRKETAGVARRTMRMRRRKKKRLKDLDKKLRDLGYFV

PRDEEPQTYEAWSSRARLAESRFEDPHERGEHLVRAVRHMARHRGW

RNPWWSFSQLEEASQEPSETFGRILERAQHEWGERVSDNATLGMLGA

LAANNNILLRPRRYEHNPKTGKNAEKLNVRGQEPILLDKVRQEDVLAE

LRRICKVQGIEDQYPELAHAVFTQVRPYVPTERVGKDPLQPMKIRASR

ASLEFQEFRIRDAVANLRIRVGGSERRPLTEEEYDRAVDYLMEYSDTTP

PTWGEVADELEIAENTLIAPVIDDVRLNVAPYDRSSAIVEAKLKRKTQA

RQWWDDDANLDLRSQLILLVSDATDDTARVAENSGLLEVFESWSDEE

KQTLQDLKFDSGRAAYSIDTLNKLNAYMHEHRVGLHEARQNVFGVSD

TWRPPRDRLDEPTGQPTVDRVLTIVRRFILDCERAWGRPQKIVVEHAR

TGLMGPSQRADVLKEIARNRNANERIRQELREGGIEAPNRADIRRNSII

QDQESQCLYCGKEIGVLTAELDHIVPRAGGGSSKRENLAAVCRACNAS

KGSRPFAVWAGPARLERTIQRLRELQAFKTKSKKRTLNAIIRRLKQRE

EDEPIDERSLASTSYAATSIRERLEQHENDDLPDGFAPVSVDVYGGSLTR

ESRRAGGIDKSIMLRGQRDKNRFDVRHHAIDAAVMTLLNPSVAVTLEQ

RRMLKQENDYSSPRGQHDNGWRDFIGRGEASQSKFLHWKKTAVVLA

DLISEAVEQDTIPVVNPLRLRPQNGSVHKDTVEAVLERTVGDSWTDKQ

VSRIVDPNTYIAFLSLLGKKKELEADHQRLVSVSAGVKLLADERVQIFP

EEAASILTPRGVVKIGDSIHHARLYGWKNQRGDIQVGMLRVFGAEFP

WFMRESGVKDILRVPIPQGSQSYRDLAATTRKFIENGQATEFGWITQN

DEIEISAEEYLATDKGDILSDFLTVLPENRWKVVGIGDNRRFKIRPLLLS

NEIIPDTLNGRSIKSEERDLIVSVLDKGVRVVASTLLTLPSTKIIRRNNLG

IPRWRGNSHLPTSLDIQRAATQALEGRD

MG15 effector
11766
MG15-166 effector
protein
unknown
MKYIIGLDMGITSVGFASMMLDDNDEPCRIIHMGSRIFEAAENPKDGSS

LAAPRRENRSMRRRLRRKRHRKERIKNLIIQNNMMTADEIDAIYNSGK

ELPDIYKVRAEALDRKLDTEEFVRLLIHLSQRRGFKSNRKVDAKEKGS

EAGKLLSAVKSNKELMVERNYRTIGEMLYKDEKFAEFKRNKADDYSN

TFARSEYEEEIREIFRAQQEYGNPYATEELKDSYLEIYLSQRSFDEGPGG

DSPYAGNQIEKMVGSCTLEPDEKRAAKATFSFEYFNLLTKVNSIKVVSS

AGKRSLNEDERKRVIKLAFAKNAISYASIRKELNLGDGERFNISYSQSD

KSIEEIEKKTKFTYLTAYHTFKKAYGSVFNEWSAEKKNHLAYALTAYK

NDNKIKKYLTENGFDAVETDIALTLPSFSKWGNLSEKALNKIIPYLEQG

MLYHDACTAAGYNFKADDTDKRMYLPAHEKEAPELGDITNPVVRRAI

SQTIKVVNAIIREMGESPCFVNIELARELSKNKAERSKIEKGQKENQAR

NDRIMERLRNEFGLLSPTGQDLIKLKLWEEQDGICPYSLKPIKIENLFD

VGYTDIDHIIPYSLSFDDTYNNKVLVMSSENRQKGNRIPMQYLDGKRR

DDFWLWVGSSNLSRRKKQNLLKETLSDDDLSGFKKRNLQDTQYLSRF

MLNYLKKYLTVAPNATGRKNTIQAVNGAVTSYMRKRWGIQKVREDG

DTHHAVDAVIISCVTAGMTKRISEYAKYKETEYQNPETGEYFDVNKNT

GEVINRFPMPYAWFRNELLMRCSEDPSRILHEMPLPNYATDEAVAPIFV

SRMPKHKVRGSAHKETIRQSFEEDGKKFTVSKTPLTDLKLKNGEIENY

FNPESDVLLYNALKERLIAFGGDAKKAFEAPFHKPKSDGSEGPLVKKV

KLICKSTLTVPVLKNTAVADNGSMVRVDVFFVEGEGYYLVPIYVSDTV

KKELPNKAIVAHKPYEEWKEMREENYVESLYQNDLIGIKLKKEMKFS

LVQKNSTLPKNINVKDGLFYYKGTNISGANISVINNDNTYTVESLGVKR

IPVIEKYQVDVLGNVSKVGKEKRVRFQ*

MG15 effector
11767
MG15-191 effector
protein
unknown
MKYIIGLDMGISSVGFATMMLNEKDEPCRIMHMGSRIFEAAEHPKDGS

SLAAPRRENRSMRRRLRRKCHRKERIKNLIVSNNILTADEIDTIYNSGK

DLTDIYQIRAESLDRKLNTEEFVRLLIHLSQRRGFKSNRKVDAKEKGSE

AGKLLSAVNSNKELMTEKNYRTIGEMLYKDDKFAVFKRNKADDYTNT

FAREEYEEEIQKIFSAQQEYGNQYATDELKEGYLEIYLSQRSFDEGPGG

NSKYAGDQIEKMVGFCTLEPDEKRAAKATYSFEYFNLLTKVNSFKILS

AEGKRSLNENERQKIIKLAFNKNAISYASLRKELSVGYSERFNISYSQSD

KSIDEIEKKTKFTYLTAYHTFKKAYGSALIEWSTEKKNHLAYALTAYK

NDNKIKNCLTEHGFNETECEIALTLPSFSKWGNLSEKALNKIIPYLEQG

MLYHDACTAAGYNYKADDTDKRMYLPAHEKEAPELENISNPVVRRAV

SQTIKVINAIIREIGESPCFVNIELARELSKNKTERNKIEKGQKDNQARN

DRIMERLRNEFGLISPTGQDLIKLKLWEEQDGICPYSLQAISIERLFEAG

YTDIDHIIPYSISFDDTYNNKVLVMSSENRQKGNRIPMQYLQGKRRDEF

WLWVDSSNLSRRKKQNLLKETLSDDDLSGFKKRNLQDTQYLSRFMLN

YLKKYLKLAPNATGRKNTIQAVNGAVTSYMRKRWGIQKVRENGDTH

HAVDAAVISCVTAGMTKRISEYAKYKETEYQYPENGEYFDVDKRTGE

VINRFPMPYPWFRNELLMRCSENPSRILQEMPLPNYAADEAVDPIFVSR

MPKHKAKGSAHKETIRKAFEEDGKKYTVSKVPLEDLKLKNGEIENYF

NPKSDTLLYNALKSRLIEFCGDAKKAFEAPFYKPKSDGSKGPLVKKVKI

VNKATLTVPVLKNTAVADNGSMVRVDVFFVEGEGYYLVPIYVADTVK

KELPQKAIIANKTYENWKEMKEENFVFSLYPNDLIRIKSKKEMKFNLV

NKESTLAPHYQSKDAYVYYKGSDISTAAITAITHDNTYKLRGLGVKTLL

AIEKYQVDVLGNIIKIGREKRMRFR*

MG15 effector
11768
MG15-193 effector
protein
unknown
MNYRLGLDIGITSVGWAVLEHDSSEEPFRIADLGVRIFDRAEHPKDGSA

LALPRREARSSRRRIRRHRHRLERIKALLESQGIITIEKLQEVYHGSKEL

TDIYELRCLGLDNLLTQEEWARVLIHLAQRRGFKSNRKKEIKENKKEK

NEDGKLLAAVRDNQALMQEKNYRTIGEMFYRDDKFSLNKRNKSELYS

HTVGREQILDEIAQLFTAQRRLGNSYAGEKVEQLYTDIVSRQRSFDEGP

GTPSPYAGNLIERMRGKCTFEKEEPRAAKACYSFELFNLLQKINSLRID

DKNSASRPLNKEERQLLIQSAHEKADIKYTDLRKKLQLSPEQRENTLSY

GRDDVEEIEKKNKFNYLKAYHDIRIALDKVSKGRIKQLPVEHIDMIGEI

LTLYKNEDRITSKLRKTGLTEYDIEELLSLSYSGFGRLSLKAIKNILPYL

QEGHIYSEASTLAGYNFRGHDNVVKQMYLPANNEQLQDITNPVVRRA

VSQTIKVINAVIRKYGSPQLICIELSREMGKNFFDRKRIEKQIKENTDLN

DAVRNKIIEYGHLNPTGLDIVKMKLWQEQDGRCAYSGEPISIQDLFDA

GIADVDHIIPYSVSFDDSYANKVLVKSSENRQKGNLLPLEYMKNNPNKQ

EKFIVWVNTNVRNFRKQQRLLKKTITEEDRNKWKERQLNDTKYISRF

MLNYIRDYLEFAPAENIGKRKVISVNGNITAYMRKRWGLKKDRLAGD

LHHAQDAVVVACVTEGMIQKITRYSQYCEAKNNRSHFVDYETGEVIDT

LRNRFGADFVEPWDNFKIEMVSRLSDDPALRIDAYKLDNYLDLKDIKPI

FISRMPNRKNKGAAHQETIRSSRLTGEGLVVSKINITKLKLDADGEIAN

YYNPKSDMRLYNALKNRLQQFNGNGEAAFKEPVYKPAAPGKTISPVK

KVKVIDKSNLNVAVGKGVAANGDMLRIDVFKKGDGYYWVPIYVADTV

KETLPNKACVHSKPYELWKEMDDNDFIFSLYPNDLIRFIPNNGEEAFM

YYIKAGISTASITVESHDRSQSIPSLGVKTLKILEKWNVDVLGNRTLVKN

EKRQYYPGQTTR*

MG15 effector
11769
MG15-195 effector
protein
unknown
MKYGIGLDIGIASVGSAIVLLDGSDEPYKIYRLSSRVFPKAETDKGESLA

SDRRNNRGMRRRLRRRRHRKERIRNLIYDVFDVNEDYITEIYAESGLK

DIYQIRYEALDRKLDKDEFIRLLIHLSQRRGFKSNRKSDVGKKDDGKLL

DAVKKNTELRQKMYRTIGEMLYCDDRFADSKRNTEGNYKNTFSRSEY

GEEIKCIFENQRAFGNEYATEDFEEKFIGIIMSQRSFDEGPGPGKDSKYS

GNLIERLVGKCTFEREEMRAPKASYTFEYFNLLSKINAIKIVSANNTRC

LTEEQRAIIKNLAFSKNDLSYKSLRKALGLNEDELFNISYTDSDTNKKK

AKNKKGTADKFSERDAVEDKTKFSYLKAYHTFKKAYGDEYDRWSTD

KKNYLGYVLTVFKTDKNVELKLRERNFSDDEINIAQTIPSFSKLGNLSV

KAMNKMIPFLENGEIYNKAAEMAGYNFKADDKCAGMYLPANESKAPE

LGDIANPVVRRSVSQTIKVINAIVREMGESPVYVNIELARDLAKSHDER

EKIEKNNNANRQKNDKLMEELRKEFKLANPKGEDLIKLKLWNEQNGR

CMYSYEPIVRERLFEPGYAEIDHIIPYSISFDDTMSNKVLVKAKENRDK

GDRLPLQYMTGKKADDFRVRVSNSILSRKKKNNLLKEQLTEEDRKSF

KQRNLQDTQYISRFMMNFIKKYLKFAGEAKIVAVNGRATDYMRKRW

GIRKIRADGDTHHAVDACVVACATHGMVQRISEYSKYKETEYIDDDGR

IYDINKKTGELTDRFPMPYPMFRKELEMLTSNDPQRILSQSKFPNYSGD

EQLEPIFVSRMPQHKVTGAAHEDTLRKPVTENGQNYVVQKVKLTKLK

LNDNGEIENYYMPQSDKLLYNALKERLAEYGGDGEKAFKNLTEPFRK

PKSDGTPGPIVTKVKTIEKQTCGVPLADNTTIADNGPMVRVDVFYVAG

EGYYLVPIYVSDTVKKELPNRACVANKPYSEWKVMDDKNFLFSLYNN

DLVKITFKREKKFSLVNKDSTLDKEHRTKSELLYYKGTNIHTASITVIT

HDNTYIFEGMGVKTLISIEKYEVDVLGRVRKVNKEKRMGF*

MG15 effector
11770
MG15-217 effector
protein
unknown
MRYVLGLDIGIASVGWAVLELDSFDEPFKIIDLNSRIFTKAENPQDGSSL

AKPRREARGNRRRLRRRRHRLDRIKHLIYVVGLMSKEGYDKLYTSGF

DKDVYTLRAEGLDRSLSAAEWTRVLIHIAKHRGFKSNRKSTTVAGEDG

KVLQAVKENQEILSKYRTVGEMFHNDDKFKSRKRNTTDSYILCVSRH

MLKDEIKALFTAQRSFNNPFTDEKFEAKYIEIFESQRAFDEGPGSESPYG

GNQIEKMIGQCTFEDGEKRAPKASYSFMRFNLLQKVNHIRIKSSSATRA

LSEEERSIIIALAYKSPNFTYGSIRKAIKLPYDMTFSDVYYKYEKGLSEE

ELIDKNEKSNKIKSLEPYHTIRKALDKVYKNRIEELSEDNINDIAYAFSV

YKTNAKISQKLKECGIDNKDIEALINNLGTFAKFGHLSVKACKKINKYL

ETGMTYDKACEAAGYDFKGHCGEKTKFLSGAADEIKEIPNPVVKRALS

QTIKVINAVVRKYGSPVEVHVELAREMARSKKDRDKINSIMKDNQAAN

DRIRGILKNEFNINNPTGIDILKYRLYQEQQGICVYSQKVMDLERVMK

DGKYAEIDHILPYSRSFDDSYNNKVLVKTEENRLKRNRTPYEYMQDNE

VKYKGFCEIVKSIIHNPTKVSNLLRENYNPQLVKDWKARNINDTRYISK

FVYNFLNDHLLLADGMRKRRIIAVNGAVTGYIRKRLGINKIRANGDTH

HAVDAVVIACVTQGVISKVTKYSQWQEVFYKNNNTGKLVDYETGEIIT

KDNFDEFIDSKFPEPWPLFRKELEARAGTNPKYEIECLRLDTYSPEEVT

SLRPMFVSRMPNRKVTGQAHQETIRSSRMANDGMTVSKVPLTSLKLS

KDGQSIEGYFSPESDRLLYEALLNRLQGFGGKADKAFTEPFYKPKNDG

SKGPIVKAVKITAPSTLNVRINNGKGLADNGSMVRIDVFHITAGKGAGY

YLVPIYVADTKKDKLPSKAIVAHKKYDEWKLMDEKDFVFSLYPNDLIY

VEKKGNIELSLDKKIEKDSTLPKKISSPQGYFYYVKAGIGDGSVQIKSH

DGVYLLPSMGVKTLKLLRKCVVDELGNISFVGKEKRQHF

MG15 effector
11771
MG15-218 effector
protein
unknown
MNKSVKFGLGLDVGIASIGWATVALDEKGEPYKLLNLGSRIFDKAENP

KDGSSLAMQRRQFRSQRRLIRRRRHRLDRVIFLFQKIGLCTNDELNKL

FQTPAPKNVYELRVDALDRKLDKQEWIRVLYSVLKHRGFKSNRKNAK

SEDGLLLKAIQSNEEIIFNNGYRTVGEMLFKDPLFTNSKRNKGGSYKNC

VSRISIQKELDLLFEKQREYGNEFTSDYFKESFLNIFLAQRNFDEGPGAP

SCYGGNLIEKMIGYCALKKDKKRAPKASLSFALFSFWSKINNIRYYDSN

RCKEYSISTEQARKVLQKALIKSDLNYSDIRKIIGLDDGCYFKDITYTSK

KSKKTKKKQQAKNNNESYLSIDGLTLVEDVLTPEKDANEQSVDTILDIE

KKSKIKFFNSFISIKKAANGMLDHLNPFDPEDRKIFNRISYAFTVSKNDD

GIAGYLNEIDISAEIKESLINNLDGFSQFGHISEEACEKLLPFLENGCDYT

SACVEAGYVSSSDDVVGKDLLPARSSELDDIVNPVVRRSVSQLIKVVNSI

IRENGKPEYINVEFARDLARSFADRREITKEQEDRKAHNEKVRKIIEET

FGRARASSKDILIYKLWMEQESKCIYSGKHIDAHRLFEPGYVEVDHILP

FSKSFDDSMTNKVLVFKEENQNKANRTPLEYMRASKPMYVDSYLAMV

KFLYKSNFKKLQNLTTEFCGNDREEWSTSNLNDTRYIAKFIHKYIKDH

LYPAKTGIKRVRAVNGRITSLLRHFWGIKKIRENGDLHHAVDAAVISV

TTDMIIKKFSEASKRHEEYDEKIMVEKPWEMFVDEISARISENPADQVE

RLGLSTYSDEEKSSLKTPFVSRMPRHKVTGSVHDSTLRSPVLLKQGINA

YVSKREINDKLLKVFDDKKCEFFNMQLDAKFYASLKSYLEDKNENKG

EFHKIKKDGSLGPVVRKVKVVENCSSGVFLNNGKAFAKNGDMIRIDVF

QVKEGKDKGFYFVPIYVADKVKDKLPSRAVIQGKDPKDWKEMKDEDF

IYSLYPNDLIYFSSKKIVGFKNNNKSSEILGVDMSEGYLYYTGADISTASI

NVDFVDNSFSKHGLGVKTLKEFRKFTIDVLGNIHEVKKEKRLVFGRK

MG15 effector
11772
MG15-219 effector
protein
unknown
MNYILGLDIGIASVGWAAVALDANDEPCKILDLNARIFEAAEQPKTGAS

LAAPRREARGSRRRTRRRRHRMERLRHLFAREELISAENIAALFEAPA

DVYRLRAEGLSRRLDEGEWARVLYHIAKRRGFKSNRKGAASDADEGK

VLEAVKENEALLKNYKTVGEMMERDEKFQTAKRNKGGSYTFCVSRG

MLAEEIGELFAAQREQGNPHASETFETAYSKIFADQRSFDDGPDANSRS

PYAGNQIEKMIGTCSLETDPPEKRAAKASYSFMRFSLLQKINHLRLKD

AKGEERPLTDEERAAVEALAWKSPSLTYGAIRKALPLPDELRFTDLYY

RWDKKPEEIEKKKLPFAAPYHEIRKALDKREKGRIQSLTPDALDAVGY

AFTVFKNDAKIEAALSAAGIDGEDAVALMAAGLTFRGFGHISVKACRK

LIPHLEKGMTYDKACKEAGYDLQKTGGEKTKLLSGNLDEIREIPNPVV

RRAIAQTVKVVNAVIRRYGSPVAVNVELAREMGRTFQERRDMMKSME

DNNAENEKRKEELKGYGVVHPSGLDIVKLKLYKEQGGVCAYSLAAMP

IEKVLKDHDYAEVDHILPYSRSFDDSYANKVLVLSKENRDKGNRTPME

YMANMPGRRHDFITWVKSAVRNPRKRDNLLLEKFGEDKEAAWKERH

LTDTKYIGSFIANLLRDHLEFAPWLNGKKKQHVLAVNGAVTDYTRKR

LGIRKIREDGDLHHAVDAAVIATVTQGNIQKLTDYSKQIERAFVKNRD

GRYVNPDTGEVLKKDEWIVQRSRHFPEPWPGFRHELEARVSDHPKEM

IESLRLPTYTPEEIDGLKPPFVSRMPTRKVRGAAHLETVVSPRLKDEGM

IVKKVSLDALKLTKDKDAIENYYAPESDHLLYEALLHRLQAFGGDGEK

AFAESFHKPKADGTPGPVVKKVKIAEKSTLSVPVHHGRGLAANGGMV

RVDVFFIPEGKDRGYYLVPVYTSDVVRGELPMRAVVQGKSYAEWKLM

REEDFIFSLYPNDLVYIEHEKGVKVKIQKKLREISTLPREKTMTSGLFY

YRTMGIAVASIHIYAPDGVYVQESLGVKTLKEFKKWTIDILGGEPHPV

QKEKRQDFASVKRDPHAAKSTSSG

MG3 effectors
11794
MG3-42 effectors
protein
unknown
HGDVLTATIPASTFSFRNTPATLRKKLLAGEAVSVGWLTQNDEIEIEVD

PI domain

EFACGNTSFAKFLTEIPEKRWRVDGFYDNRRLRIRPAYLSAEGLTDNHS

KVVHETLEKGQFVNAGALLSASRTLLIRRTALGAPRWKLDSSGLPVSF

SPLKLAEEAL

MG3 effectors
11795
MG3-42 effector
Nucleotide
unknown
(N22)

sgRNA

sgRNA
(RNA)

GTTGGGAATCGTCACTGAAAAGTGACGATTCTCAACAAAAGACTTT

TGTCTTGATTTCTTTATCCCCCGGCATTTTGTGCCGGGGGATTCGTT

ATT

MG3 effectors
11796
MG3-42 effector
Nucleotide
unknown
GCATCGTTTGAAGAAGTGACGATTCTCAACAAAAGACTTTTGTCTT

tracr

tracr
(RNA)

GATTTCTTTATCCCCCGGCATTTTGTGCCGGGGGATTCGTTATT

MG16 effectors
11797
MG16-3 effector
protein
unknown
MATKKILGLDLGTNSIGWALIETEDSNPKSILAMGSRIVPLSTDDSTQFA

KGQAITKNADRTQKRTARKGLNRYQMRRAMLTEELRRHGMLPERTD

ENIMDLWRLRSDAATDGKQLSLPQIGRVLYHINQKRGYKHSKADNSA

NTKQTKYVEAVNQRYRDIQACHQTIGQYFYEQLLSSAVQTPSGSYYTY

RIKDKVLPREAYIAEFDQIMKVQRVFYPDVLTDELVDTLRNHIIFYQRP

LKSCKHLVSLCEFEKRPFKREDGQIVYSGPKCAPRTSPLAQFCTVWEA

VNNITLTNRQNETFEITQEQRVAMADFLNQHDKMGVKDLQKILGISPK

DGWWAGKAIGKGLKGNTTFTQLREALGNLPNAEHLLKMKLSMVDAA

VDTTTGELIRQVSPQVEEEPLFRLWHLVYSLQNEDELRKALRKQFGID

DEEVLDKLCKIDFVKPGYANKSHKFIRKLLPYLMEGYQYHEACAHIGV

NHSDSLTAEQNAARPLLDKIPLLEKNELRQPVIEKILNQMINVVNALKA

EYGDIDDVRIELARELKSSKDEREAAFKRNNENERQNKIYENRIREYGI

QPSRSRIQKYKMWEESNHLCFYCGKPVNVTDFLAGAEVEIEHIIPQSVL

FDDSYSNKVCACRACNQAKGNLTAREFMEKHSKEEYDSYLRRVDDAF

NAHRISKTKRDHLLWRKEDIPQDFIDRQLLQSQYIAKKAAEILRQGYR

NVYATSGSVTDFLRHQWGYDEILHRLNLPRYQQVEGLTEDVTYDHCG

QEHQQERIKGWTKRLDHRHHAIDALTIALTQQSVIQRLNTLNNSREQ

MFDELGKRTDTPEYTEKRSLLEKWVDAQPHFSVQEVTDKVDGILVSFR

AGKRAATPAKRAVYQNGKRHIVQTGLQVPRGALSEETVYGKLGNKY

VVKYPLGHQSMKMDDIVDPTIREIVRTRLNAFGGKAKDAFAEPLYSDA

AHQMQIKTVRCYTGLQDKAVVPVRFNAQGEPVGFVKMGNNHHIAIYR

DAKGQYQESVVSFWQAVERKRYGIPVVIEQPHEVWDKLINSDNIPQDF

LETLPHDDWQFVVSLQQNEMFILGMDDADFEAAMEQKDYRTLNKYL

YRVQKISSKEYCFRYHTETSVDDKYDGVINKSISMELQKLKRLTSISAFF

SQHPHKVRVNLLGEVSAL

MG86 effectors
11798
MG86-1 effector
protein
unknown
MKKILSFDLGITSIGYSVLTEDEAQKYSLLDYGVSMFDKPTDKDGNSK

KLLHAQALSTKKLYKLRKERKKNLALLFEKYALAKASKLLEQEKKNL

YMYKWQLRAKKVFEERLSIGEIFTILYHIAKHRGYKSLDSGDLLEELC

VELGIKIDVKKEKKDDEKGKIKQALSTIESLRKEYPKKTVAQIIYEVEL

QKERPVFRNHDNYNYMIRREHINDEIATIIRKQKEFGNFENIDSEVFIVD

IIAAIDDQKESTNDMSLFGKCEYYPKEHVAHQYSLLSDIFKMYQAVANI

TFNKEKIKITKEQIRLLTEDFLNKIKKGKSVKELKYKDVRKILKLDESV

KIFNKEDSYQRAGKKVEHTITKFHFVDNLSKIDKSFIEDIFNADESYVL

MREIFDVIHKEKSPKRIYEQLKSKVSSEAVIIDLIRYKKGSSLNISSYAMA

KFLPYFEEGMTLDAIKEKLDLGRKEDYSVYKKGIKYLHISTYEKDDDL

EINNHPVKYVVSAVLRVVKHLHAKHGTFDEIKVESTRELSLNDKVKKE

IDKANKAREKEIEKIISNDEYQKIAKEYGKNIHKYARKILMWEAQERFD

VYSGKSIGIDDIFSNRVDVDHIVPQSLGGLYVQHNLVLVHRDENLQKSN

QLPMNYITDKEAYINRVEHLFSEHKINWKKRKNLLASNLDEIYKDTFES

KDLRATSYIEALTANILKRYYPFIDEKKSVDGSAVRHIQGRATANIRKV

LGVKTKSRESNIHHGVDALLIGVTNPSWLQKLSNIFRENFGKIDDEARK

NIKKALPYIDGVEVKDIVKEIEQKYNSYGEDSIFYKDIWGKAKTVNFW

VSKKPMISKVHKDTIYADKGNGIFTVRESIIAKFINLKITPTTFPEDFMK

KFHKEILEKMYLYKTNSNDVICKIVQQRAEEIKELLWSFEFLDVKNKE

EMQEAKANLESLVHRELFDNNGNVVRKVKFYQTNLTGFKVRGGLAT

KEKTFIGFRAFKKDKKLEYKRIDVSNFEKIKKSNDGSFKVYKNDIVFFV

FDEEKYKGGKIVSFLEDKKMAAFSNPKYPANIQAQPESFLTIFKGKANS

HKQVSVGKAKGIIKLKVDILGNIESYQVLGNAKSKLLDEIKSIVSH

MG86 effector
11799
MG86-1 effector
Nucleotide
unknown
(N20)GUUUUAAUACCCGAAAGGGUAUUAAACUAAGGUCACUUUUUA

sgRNA

sgRNA
(RNA)

GUGGCUGACUUUAGAGUAUGGCUUUGGCUAUACUCCAUUUU

MG94 effector
11800
MG94-1 effector
protein
unknown
MRKKIRYVIGLDIGIASVGWAALLLDENDNVCGIVRAGVHTFDEAVVG

QSKITGAAYRRGYRSGRRSIRRKVNRIQRVKNLLQRLNIISKKDLEEYF

SGAVENIYYLRCAAIQNEPAYILNNKELAQLLIYYAKHRGYKSNTSYEQ

KTDDSKKVLSALSENKKYMLEKGYQTAGEMLYRDEKFRRKRYGSSEE

CELLLVRNSGDDYSHSISRELLVEEVHVIFARQRELGNKLTTKELEDQF

VEIMQSQRNYDEGSGEGSPYGGNLIEKMVGECTFEKGEKRACKASYTS

ERFVLLEKLNHLRIQSKNGDVRALTEEERDAIIKLAYKNKDVKYKALR

TILKLNPDERFGGLTYSRGDIENSTEGKSVFVSLEYWYEIKKVLGLFYD

DLDNEETQQLLDSIGTILTCYKSDDLRRRKFEQLHLEQEKIEHLLALNY

TKFQNLSFKAMKNIMPELEKGLSYTEACSNAGYGDKETIEGKNKYISK

ELLNNTLDSIMNPTVKRAVRRTIRILNELIKQYGSPVEVHVEMARDLTH

SQTVTNKMKKRQDENKAEKEEAKRFICENFGKTEAQVSGKDILRYRL

WKSQNQIDIYSNTMIPVSDILDYEKYEVDHIIPYSCSENDSFNNKMLVRK

KDNQDKKNRTPYEYIGSDEKKWEAFATCANTYVMNYGKRKNMLTKV

PASNTGEWMSRNLNDTRYTTKVVTDLIRKHLKFEAYVDQKRKKHIYPI

NGGITAKLRYEWGLEKDREKSDKHHAQDAVVIACCTDGMIQRLSRQY

MLQEIGIVTWKNHKLVDRRTGEIVEETNLPWECFREEVEMFMADSPE

DYIEKAKKNGYKGEAPKPIFVSRLPQKKTTGKINEDTLRSVRIDSKGKA

RFVNKTKLQDLKLVEVDGKKQIKDYYRPEDDKLLYDKLLERLVKNDD

AKVVFAEPFYKPKKDGSDGPIVRSVKTYGKTVKNQVLVGDGVAERGG

IYRCDVFKRKDEYYAVVVYYRDLYIGNLPNNAAHFDIEMKKGEFEFSL

YKDDLIRFVKDGKEQYAYYKYINANNSQITYTEHDTSKETKCTTIRTLD

KFQKMNVDLLGNIYSSDKEEREWN*

MG94 effector
11801
MG94-1 effector
protein
unknown
KTVKNQVLVGDGVAERGGIYRCDVFKRKDEYYAVVVYYRDLYIGNLP

PI domain

NNAAHFDIEMKKGEFEFSLYKDDLIRFVKDGKEQYAYYKYINANNSQI

TYTEHDTSKETKCTTIRTLDKFQKMNVDLLGNIYSSDKEEREWN*

Number	Date	Country
63237791	Aug 2021	US
63245629	Sep 2021	US
63252956	Oct 2021	US
63282909	Nov 2021	US
63316895	Mar 2022	US
63319681	Mar 2022	US
63322944	Mar 2022	US
63369858	Jul 2022	US

	Number	Date	Country
Parent	PCT/US2022/041755	Aug 2022	WO
Child	18586929		US

ENZYMES WITH RUVC DOMAINS

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (8)

Continuations (1)